Complex	NN	O	O
formation	NN	O	O
induces	NN	O	O
the	NN	O	O
rapid	NN	O	O
degradation	NN	O	O
of	NN	O	O
betacatenin	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
the	NN	O	O
identification	NN	O	O
and	NN	O	O
genomic	NN	O	O
structure	NN	O	O
of	NN	O	O
APC	NN	O	O
homologues	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

We	NN	O	O
calculated	NN	O	O
age	NN	O	O
related	NN	O	O
risks	NN	O	O
of	NN	O	O
all	NN	O	O
,	NN	O	O
colorectal	NN	O	B-Disease
,	NN	O	I-Disease
endometrial	NN	O	I-Disease
,	NN	O	I-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancers	NN	O	I-Disease
in	NN	O	O
nt943	NN	O	O
+	NN	O	O
3	NN	O	O
A	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
T	NN	O	O
MSH2	NN	O	O
mutation	NN	O	O
carriers	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
76	NN	O	O
)	NN	O	O
for	NN	O	O
all	NN	O	O
patients	NN	O	O
and	NN	O	O
for	NN	O	O
men	NN	O	O
and	NN	O	O
women	NN	O	O
separately	NN	O	O
.	NN	O	O

HLA	NN	O	O
histocompatibility	NN	O	O
typing	NN	O	O
of	NN	O	O
the	NN	O	O
family	NN	O	O
members	NN	O	O
did	NN	O	O
not	NN	O	O
demonstrate	NN	O	O
evidence	NN	O	O
for	NN	O	O
genetic	NN	O	O
linkage	NN	O	O
of	NN	O	O
C7	NN	O	B-Disease
deficiency	NN	O	I-Disease
with	NN	O	O
the	NN	O	O
major	NN	O	O
histocompatibility	NN	O	O
loci	NN	O	O
.	NN	O	O

Increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
cancer	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cartilage	NN	O	B-Disease
-	NN	O	I-Disease
hair	NN	O	I-Disease
hypoplasia	NN	O	I-Disease
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
One	NN	O	O
hundred	NN	O	O
twenty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
CHH	NN	O	B-Disease
were	NN	O	O
identified	NN	O	O
through	NN	O	O
2	NN	O	O
countrywide	NN	O	O
epidemiologic	NN	O	O
surveys	NN	O	O
in	NN	O	O
1974	NN	O	O
and	NN	O	O
in	NN	O	O
1986	NN	O	O
.	NN	O	O

Their	NN	O	O
parents	NN	O	O
and	NN	O	O
nonaffected	NN	O	O
siblings	NN	O	O
were	NN	O	O
identified	NN	O	O
through	NN	O	O
the	NN	O	O
Population	NN	O	O
Register	NN	O	O
Center	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	O
statistically	NN	O	O
significant	NN	O	O
excess	NN	O	O
risk	NN	O	O
of	NN	O	O
cancer	NN	O	B-Disease
was	NN	O	O
seen	NN	O	O
among	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
CHH	NN	O	B-Disease
(	NN	O	O
standardized	NN	O	O
incidence	NN	O	O
ratio	NN	O	O
6	NN	O	O
.	NN	O	O
9	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
to	NN	O	O
16	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
mainly	NN	O	O
attributable	NN	O	O
to	NN	O	O
non	NN	O	B-Disease
-	NN	O	I-Disease
Hodgkins	NN	O	I-Disease
lymphoma	NN	O	I-Disease
(	NN	O	O
standardized	NN	O	O
incidence	NN	O	O
ratio	NN	O	O
90	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
18	NN	O	O
to	NN	O	O
264	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
excess	NN	O	O
risk	NN	O	O
of	NN	O	O
basal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
was	NN	O	O
seen	NN	O	O
(	NN	O	O
standardized	NN	O	O
incidence	NN	O	O
ratio	NN	O	O
35	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
7	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
102	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
cancer	NN	O	B-Disease
incidence	NN	O	O
among	NN	O	O
the	NN	O	O
siblings	NN	O	O
or	NN	O	O
the	NN	O	O
parents	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
from	NN	O	O
the	NN	O	O
average	NN	O	O
cancer	NN	O	B-Disease
incidence	NN	O	O
in	NN	O	O
the	NN	O	O
Finnish	NN	O	O
population	NN	O	O
.	NN	O	O

Database	NN	O	O
searches	NN	O	O
and	NN	O	O
analysis	NN	O	O
of	NN	O	O
available	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
sequence	NN	O	O
from	NN	O	O
the	NN	O	O
region	NN	O	O
revealed	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
the	NN	O	O
fibroblast	NN	O	O
growth	NN	O	O
factor	NN	O	O
homologous	NN	O	O
factor	NN	O	O
gene	NN	O	O
,	NN	O	O
FHF2	NN	O	O
,	NN	O	O
within	NN	O	O
the	NN	O	O
duplication	NN	O	O
breakpoint	NN	O	O
interval	NN	O	O
.	NN	O	O

The	NN	O	O
gene	NN	O	O
structure	NN	O	O
of	NN	O	O
FHF2	NN	O	O
was	NN	O	O
determined	NN	O	O
and	NN	O	O
two	NN	O	O
new	NN	O	O
exons	NN	O	O
were	NN	O	O
identified	NN	O	O
,	NN	O	O
including	NN	O	O
a	NN	O	O
new	NN	O	O
5	NN	O	O
end	NN	O	O
exon	NN	O	O
,	NN	O	O
1B	NN	O	O
.	NN	O	O

Northern	NN	O	O
blot	NN	O	O
hybridisation	NN	O	O
showed	NN	O	O
highest	NN	O	O
expression	NN	O	O
in	NN	O	O
brain	NN	O	O
and	NN	O	O
skeletal	NN	O	O
muscle	NN	O	O
.	NN	O	O

Both	NN	O	O
mutations	NN	O	O
were	NN	O	O
predicted	NN	O	O
to	NN	O	O
truncate	NN	O	O
the	NN	O	O
E	NN	O	O
-	NN	O	O
cadherin	NN	O	O
protein	NN	O	O
in	NN	O	O
the	NN	O	O
signal	NN	O	O
peptide	NN	O	O
domain	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
CDH1	NN	O	O
should	NN	O	O
be	NN	O	O
investigated	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
inherited	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
both	NN	O	O
gastric	NN	O	B-Disease
and	NN	O	I-Disease
colorectal	NN	O	I-Disease
cancers	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
has	NN	O	O
implications	NN	O	O
regarding	NN	O	O
the	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
the	NN	O	O
mutant	NN	O	O
allele	NN	O	O
exerts	NN	O	O
its	NN	O	O
effect	NN	O	O
.	NN	O	O

Hereditary	NN	O	B-Disease
hemochromatosis	NN	O	I-Disease
(	NN	O	O
HH	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
common	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
disorder	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
tissue	NN	O	O
iron	NN	O	O
deposition	NN	O	O
secondary	NN	O	O
to	NN	O	O
excessive	NN	O	O
dietary	NN	O	O
iron	NN	O	O
absorption	NN	O	O
.	NN	O	O

We	NN	O	O
recently	NN	O	O
reported	NN	O	O
that	NN	O	O
HFE	NN	O	O
,	NN	O	O
the	NN	O	O
protein	NN	O	O
defective	NN	O	O
in	NN	O	O
HH	NN	O	B-Disease
,	NN	O	O
was	NN	O	O
physically	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
transferrin	NN	O	O
receptor	NN	O	O
(	NN	O	O
TfR	NN	O	O
)	NN	O	O
in	NN	O	O
duodenal	NN	O	O
crypt	NN	O	O
cells	NN	O	O
and	NN	O	O
proposed	NN	O	O
that	NN	O	O
mutations	NN	O	O
in	NN	O	O
HFE	NN	O	O
attenuate	NN	O	O
the	NN	O	O
uptake	NN	O	O
of	NN	O	O
transferrin	NN	O	O
-	NN	O	O
bound	NN	O	O
iron	NN	O	O
from	NN	O	O
plasma	NN	O	O
by	NN	O	O
duodenal	NN	O	O
crypt	NN	O	O
cells	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
transporters	NN	O	O
for	NN	O	O
dietary	NN	O	O
iron	NN	O	O
.	NN	O	O

By	NN	O	O
4	NN	O	O
weeks	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
the	NN	O	O
HFE	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
demonstrated	NN	O	O
iron	NN	O	O
loading	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
HFE	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
littermates	NN	O	O
,	NN	O	O
with	NN	O	O
elevated	NN	O	O
transferrin	NN	O	O
saturations	NN	O	O
(	NN	O	O
68	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
49	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
elevated	NN	O	O
liver	NN	O	O
iron	NN	O	O
concentrations	NN	O	O
(	NN	O	O
985	NN	O	O
micrograms	NN	O	O
vs	NN	O	O
.	NN	O	O
381	NN	O	O
micrograms	NN	O	O
)	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
SEPs	NN	O	O
and	NN	O	O
MEPs	NN	O	O
have	NN	O	O
proved	NN	O	O
useful	NN	O	O
in	NN	O	O
revealing	NN	O	O
signs	NN	O	O
of	NN	O	O
progressively	NN	O	O
severe	NN	O	O
,	NN	O	O
central	NN	O	O
dying	NN	O	B-Disease
-	NN	O	I-Disease
back	NN	O	I-Disease
axonopathy	NN	O	I-Disease
in	NN	O	O
early	NN	O	O
stages	NN	O	O
of	NN	O	O
adult	NN	O	O
-	NN	O	O
onset	NN	O	O
ALD	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
authors	NN	O	O
report	NN	O	O
a	NN	O	O
mutation	NN	O	O
in	NN	O	O
exon	NN	O	O
5	NN	O	O
of	NN	O	O
GCH1	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
adult	NN	O	O
-	NN	O	O
onset	NN	O	O
oromandibular	NN	O	B-Disease
dystonia	NN	O	I-Disease
and	NN	O	O
no	NN	O	O
obvious	NN	O	O
family	NN	O	O
history	NN	O	O
of	NN	O	O
dystonia	NN	O	B-Disease
.	NN	O	O

Germline	NN	O	O
mutations	NN	O	O
of	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
in	NN	O	O
Korean	NN	O	O
familial	NN	O	B-Disease
adenomatous	NN	O	I-Disease
polyposis	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

Germline	NN	O	O
mutations	NN	O	O
were	NN	O	O
identified	NN	O	O
in	NN	O	O
38	NN	O	O
patients	NN	O	O
(	NN	O	O
61	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
initial	NN	O	O
48	NN	O	O
patients	NN	O	O
,	NN	O	O
SSCP	NN	O	O
analysis	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
PTT	NN	O	O
for	NN	O	O
those	NN	O	O
patients	NN	O	O
for	NN	O	O
whom	NN	O	O
no	NN	O	O
detectable	NN	O	O
mutations	NN	O	O
were	NN	O	O
found	NN	O	O
by	NN	O	O
SSCP	NN	O	O
.	NN	O	O

Twenty	NN	O	O
individuals	NN	O	O
were	NN	O	O
heterozygous	NN	O	O
for	NN	O	O
the	NN	O	O
Arg95Stop	NN	O	O
mutation	NN	O	O
.	NN	O	O

7	NN	O	O
%	NN	O	O
(	NN	O	O
20	NN	O	O
/	NN	O	O
300	NN	O	O
)	NN	O	O
.	NN	O	O

N	NN	O	O
.	NN	O	O
,	NN	O	O
Gnirke	NN	O	O
,	NN	O	O
A	NN	O	O
.	NN	O	O
,	NN	O	O
Thomas	NN	O	O
,	NN	O	O
W	NN	O	O
.	NN	O	O
,	NN	O	O
Tsuchihashi	NN	O	O
,	NN	O	O
Z	NN	O	O
.	NN	O	O
,	NN	O	O
Ruddy	NN	O	O
,	NN	O	O
D	NN	O	O
.	NN	O	O

C	NN	O	O
.	NN	O	O
,	NN	O	O
Fullan	NN	O	O
,	NN	O	O
A	NN	O	O
.	NN	O	O
,	NN	O	O
Hinton	NN	O	O
,	NN	O	O
L	NN	O	O
.	NN	O	O

M	NN	O	O
.	NN	O	O
,	NN	O	O
Jones	NN	O	O
,	NN	O	O
N	NN	O	O
.	NN	O	O

L	NN	O	O
.	NN	O	O
,	NN	O	O
Kimmel	NN	O	O
,	NN	O	O
B	NN	O	O
.	NN	O	O

Mutation	NN	O	O
and	NN	O	O
haplotype	NN	O	O
studies	NN	O	O
of	NN	O	O
familial	NN	O	B-Disease
Mediterranean	NN	O	I-Disease
fever	NN	O	I-Disease
reveal	NN	O	O
new	NN	O	O
ancestral	NN	O	O
relationships	NN	O	O
and	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
high	NN	O	O
carrier	NN	O	O
frequency	NN	O	O
with	NN	O	O
reduced	NN	O	O
penetrance	NN	O	O
in	NN	O	O
the	NN	O	O
Ashkenazi	NN	O	O
Jewish	NN	O	O
population	NN	O	O
.	NN	O	O

Among	NN	O	O
90	NN	O	O
symptomatic	NN	O	O
mutation	NN	O	O
-	NN	O	O
positive	NN	O	O
individuals	NN	O	O
,	NN	O	O
11	NN	O	O
mutations	NN	O	O
accounted	NN	O	O
for	NN	O	O
79	NN	O	O
%	NN	O	O
of	NN	O	O
carrier	NN	O	O
chromosomes	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
two	NN	O	O
mutations	NN	O	O
that	NN	O	O
are	NN	O	O
novel	NN	O	O
,	NN	O	O
one	NN	O	O
alters	NN	O	O
the	NN	O	O
same	NN	O	O
residue	NN	O	O
(	NN	O	O
680	NN	O	O
)	NN	O	O
as	NN	O	O
a	NN	O	O
previously	NN	O	O
known	NN	O	O
mutation	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
(	NN	O	O
P369S	NN	O	O
)	NN	O	O
is	NN	O	O
located	NN	O	O
in	NN	O	O
exon	NN	O	O
3	NN	O	O
.	NN	O	O

Consistent	NN	O	O
with	NN	O	O
another	NN	O	O
recent	NN	O	O
report	NN	O	O
,	NN	O	O
the	NN	O	O
E148Q	NN	O	O
mutation	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
of	NN	O	O
several	NN	O	O
ethnicities	NN	O	O
and	NN	O	O
on	NN	O	O
multiple	NN	O	O
microsatellite	NN	O	O
haplotypes	NN	O	O
,	NN	O	O
but	NN	O	O
haplotype	NN	O	O
data	NN	O	O
indicate	NN	O	O
an	NN	O	O
ancestral	NN	O	O
relationships	NN	O	O
between	NN	O	O
non	NN	O	O
-	NN	O	O
Jewish	NN	O	O
Italian	NN	O	O
and	NN	O	O
Ashkenazi	NN	O	O
Jewish	NN	O	O
patients	NN	O	O
with	NN	O	O
FMF	NN	O	B-Disease
and	NN	O	O
other	NN	O	O
affected	NN	O	O
populations	NN	O	O
.	NN	O	O

Autoimmune	NN	O	B-Disease
lymphoproliferative	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
ALPS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
disorder	NN	O	B-Disease
of	NN	O	I-Disease
lymphocyte	NN	O	I-Disease
homeostasis	NN	O	I-Disease
and	NN	O	I-Disease
immunological	NN	O	I-Disease
tolerance	NN	O	I-Disease
.	NN	O	O

Among	NN	O	O
the	NN	O	O
ALPS	NN	O	B-Disease
-	NN	O	O
associated	NN	O	O
Fas	NN	O	O
mutants	NN	O	O
,	NN	O	O
dominant	NN	O	O
inhibition	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
was	NN	O	O
much	NN	O	O
more	NN	O	O
pronounced	NN	O	O
in	NN	O	O
mutants	NN	O	O
affecting	NN	O	O
the	NN	O	O
intracellular	NN	O	O
,	NN	O	O
versus	NN	O	O
extracellular	NN	O	O
,	NN	O	O
portion	NN	O	O
of	NN	O	O
the	NN	O	O
Fas	NN	O	O
receptor	NN	O	O
.	NN	O	O

Significant	NN	O	O
ALPS	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
morbidity	NN	O	O
occurred	NN	O	O
in	NN	O	O
44	NN	O	O
%	NN	O	O
of	NN	O	O
relatives	NN	O	O
with	NN	O	O
intracellular	NN	O	O
mutations	NN	O	O
,	NN	O	O
versus	NN	O	O
0	NN	O	O
%	NN	O	O
of	NN	O	O
relatives	NN	O	O
with	NN	O	O
extracellular	NN	O	O
mutations	NN	O	O
.	NN	O	O

Genetic	NN	O	B-Disease
hemochromatosis	NN	O	I-Disease
(	NN	O	O
GH	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
believed	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
disease	NN	O	O
restricted	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
European	NN	O	O
ancestry	NN	O	O
.	NN	O	O

In	NN	O	O
northwestern	NN	O	O
Europe	NN	O	O
,	NN	O	O
>	NN	O	O
80	NN	O	O
%	NN	O	O
of	NN	O	O
GH	NN	O	B-Disease
patients	NN	O	O
are	NN	O	O
homozygous	NN	O	O
for	NN	O	O
one	NN	O	O
mutation	NN	O	O
,	NN	O	O
the	NN	O	O
substitution	NN	O	O
of	NN	O	O
tyrosine	NN	O	O
for	NN	O	O
cysteine	NN	O	O
at	NN	O	O
position	NN	O	O
282	NN	O	O
(	NN	O	O
C282Y	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
unprocessed	NN	O	O
protein	NN	O	O
.	NN	O	O

The	NN	O	O
distribution	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
mutations	NN	O	O
differ	NN	O	O
,	NN	O	O
C282Y	NN	O	O
being	NN	O	O
limited	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
northwestern	NN	O	O
European	NN	O	O
ancestry	NN	O	O
and	NN	O	O
H63D	NN	O	O
being	NN	O	O
found	NN	O	O
at	NN	O	O
allele	NN	O	O
frequencies	NN	O	O
>	NN	O	O
5	NN	O	O
%	NN	O	O
,	NN	O	O
in	NN	O	O
Europe	NN	O	O
,	NN	O	O
in	NN	O	O
countries	NN	O	O
bordering	NN	O	O
the	NN	O	O
Mediterranean	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
Middle	NN	O	O
East	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
Indian	NN	O	O
subcontinent	NN	O	O
.	NN	O	O

The	NN	O	O
H63D	NN	O	O
mutation	NN	O	O
is	NN	O	O
older	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
occur	NN	O	O
on	NN	O	O
such	NN	O	O
a	NN	O	O
large	NN	O	O
extended	NN	O	O
haplotype	NN	O	O
,	NN	O	O
the	NN	O	O
haplotype	NN	O	O
in	NN	O	O
this	NN	O	O
case	NN	O	O
extending	NN	O	O
<	NN	O	O
/	NN	O	O
=	NN	O	O
700	NN	O	O
kb	NN	O	O
.	NN	O	O

3	NN	O	O
%	NN	O	O
(	NN	O	O
+	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
Greenland	NN	O	O
,	NN	O	O
4	NN	O	O
.	NN	O	O

5	NN	O	O
%	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

The	NN	O	O
high	NN	O	O
prevalence	NN	O	O
of	NN	O	O
HFE	NN	O	O
mutations	NN	O	O
in	NN	O	O
Denmark	NN	O	O
suggests	NN	O	O
that	NN	O	O
population	NN	O	O
screening	NN	O	O
for	NN	O	O
the	NN	O	O
C282Y	NN	O	O
mutation	NN	O	O
could	NN	O	O
be	NN	O	O
highly	NN	O	O
advantageous	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
preventive	NN	O	O
health	NN	O	O
care	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
the	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
alkaptonuria	NN	O	B-Disease
mouse	NN	O	O
model	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
RT	NN	O	O
-	NN	O	O
PCR	NN	O	O
to	NN	O	O
amplify	NN	O	O
the	NN	O	O
Hgd	NN	O	O
cDNA	NN	O	O
from	NN	O	O
Hgd	NN	O	O
(	NN	O	O
aku	NN	O	O
)	NN	O	O
/	NN	O	O
Hgd	NN	O	O
(	NN	O	O
aku	NN	O	O
)	NN	O	O
mice	NN	O	O
.	NN	O	O

Two	NN	O	O
products	NN	O	O
shorter	NN	O	O
than	NN	O	O
the	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
product	NN	O	O
were	NN	O	O
amplified	NN	O	O
.	NN	O	O

Restriction	NN	O	O
mapping	NN	O	O
and	NN	O	O
DNA	NN	O	O
sequencing	NN	O	O
were	NN	O	O
then	NN	O	O
used	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
Hgd	NN	O	O
(	NN	O	O
aku	NN	O	O
)	NN	O	O
mouse	NN	O	O
mutation	NN	O	O
,	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
single	NN	O	O
base	NN	O	O
change	NN	O	O
in	NN	O	O
a	NN	O	O
splice	NN	O	O
donor	NN	O	O
consensus	NN	O	O
sequence	NN	O	O
,	NN	O	O
causing	NN	O	O
exon	NN	O	O
skipping	NN	O	O
and	NN	O	O
frame	NN	O	O
-	NN	O	O
shifted	NN	O	O
products	NN	O	O
.	NN	O	O

The	NN	O	O
locus	NN	O	O
for	NN	O	O
non	NN	O	B-Disease
-	NN	O	I-Disease
syndromic	NN	O	I-Disease
sensorineural	NN	O	I-Disease
hearing	NN	O	I-Disease
loss	NN	O	I-Disease
with	NN	O	O
EVA	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
mapped	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
chromosomal	NN	O	O
region	NN	O	O
,	NN	O	O
7q31	NN	O	O
,	NN	O	O
as	NN	O	O
the	NN	O	O
Pendred	NN	O	B-Disease
syndrome	NN	O	I-Disease
locus	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
seven	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
PDS	NN	O	B-Disease
gene	NN	O	O
(	NN	O	O
PDS	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
gene	NN	O	O
responsible	NN	O	O
for	NN	O	O
Pendred	NN	O	B-Disease
syndrome	NN	O	I-Disease
,	NN	O	O
have	NN	O	O
been	NN	O	O
found	NN	O	O
in	NN	O	O
families	NN	O	O
of	NN	O	O
non	NN	O	B-Disease
-	NN	O	I-Disease
syndromic	NN	O	I-Disease
sensorineural	NN	O	I-Disease
hearing	NN	O	I-Disease
loss	NN	O	I-Disease
with	NN	O	O
EVA	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
provide	NN	O	O
evidence	NN	O	O
that	NN	O	O
mutations	NN	O	O
in	NN	O	O
PDS	NN	O	O
cause	NN	O	O
both	NN	O	O
syndromic	NN	O	B-Disease
and	NN	O	I-Disease
non	NN	O	I-Disease
-	NN	O	I-Disease
syndromic	NN	O	I-Disease
hearing	NN	O	I-Disease
loss	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

Milder	NN	O	O
phenotypes	NN	O	O
such	NN	O	O
as	NN	O	O
adrenomyeloneuropathy	NN	O	B-Disease
and	NN	O	O
Addison	NN	O	B-Disease
disease	NN	O	I-Disease
only	NN	O	O
also	NN	O	O
have	NN	O	O
been	NN	O	O
recognized	NN	O	O
.	NN	O	O

WNT	NN	O	O
signalling	NN	O	O
orchestrates	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
developmental	NN	O	O
programs	NN	O	O
.	NN	O	O

Most	NN	O	O
colon	NN	O	B-Disease
cancers	NN	O	I-Disease
arise	NN	O	O
from	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
gene	NN	O	O
encoding	NN	O	O
adenomatous	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
(	NN	O	O
APC	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
a	NN	O	O
protein	NN	O	O
required	NN	O	O
for	NN	O	O
ubiquitin	NN	O	O
-	NN	O	O
mediated	NN	O	O
degradation	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
catenin	NN	O	O
,	NN	O	O
but	NN	O	O
a	NN	O	O
small	NN	O	O
percentage	NN	O	O
of	NN	O	O
colon	NN	O	B-Disease
and	NN	O	I-Disease
some	NN	O	I-Disease
other	NN	O	I-Disease
cancers	NN	O	I-Disease
harbour	NN	O	O
beta	NN	O	O
-	NN	O	O
catenin	NN	O	O
-	NN	O	O
stabilizing	NN	O	O
mutations	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
discovered	NN	O	O
that	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
expressing	NN	O	O
an	NN	O	O
activated	NN	O	O
beta	NN	O	O
-	NN	O	O
catenin	NN	O	O
are	NN	O	O
predisposed	NN	O	O
to	NN	O	O
developing	NN	O	O
skin	NN	O	B-Disease
tumours	NN	O	I-Disease
resembling	NN	O	O
pilomatricomas	NN	O	B-Disease
.	NN	O	O

Given	NN	O	O
that	NN	O	O
the	NN	O	O
skin	NN	O	O
of	NN	O	O
these	NN	O	O
adult	NN	O	O
mice	NN	O	O
also	NN	O	O
exhibits	NN	O	O
signs	NN	O	O
of	NN	O	O
de	NN	O	O
novo	NN	O	O
hair	NN	O	O
-	NN	O	O
follicle	NN	O	O
morphogenesis	NN	O	O
,	NN	O	O
we	NN	O	O
wondered	NN	O	O
whether	NN	O	O
human	NN	O	O
pilomatricomas	NN	O	B-Disease
might	NN	O	O
originate	NN	O	O
from	NN	O	O
hair	NN	O	O
matrix	NN	O	O
cells	NN	O	O
and	NN	O	O
whether	NN	O	O
they	NN	O	O
might	NN	O	O
possess	NN	O	O
beta	NN	O	O
-	NN	O	O
catenin	NN	O	O
-	NN	O	O
stabilizing	NN	O	O
mutations	NN	O	O
.	NN	O	O

Pendrin	NN	O	O
is	NN	O	O
closely	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
family	NN	O	O
of	NN	O	O
sulfate	NN	O	O
transport	NN	O	O
proteins	NN	O	O
that	NN	O	O
includes	NN	O	O
the	NN	O	O
rat	NN	O	O
sulfate	NN	O	O
-	NN	O	O
anion	NN	O	O
transporter	NN	O	O
(	NN	O	O
encoded	NN	O	O
by	NN	O	O
Sat	NN	O	O
-	NN	O	O
1	NN	O	O
;	NN	O	O
29	NN	O	O
%	NN	O	O
amino	NN	O	O
acid	NN	O	O
sequence	NN	O	O
identity	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
human	NN	O	O
diastrophic	NN	O	B-Disease
dysplasia	NN	O	I-Disease
sulfate	NN	O	O
transporter	NN	O	O
(	NN	O	O
encoded	NN	O	O
by	NN	O	O
DTD	NN	O	O
;	NN	O	O
32	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
human	NN	O	O
sulfate	NN	O	O
transporter	NN	O	O
downregulated	NN	O	O
in	NN	O	O
adenoma	NN	O	B-Disease
(	NN	O	O
encoded	NN	O	O
by	NN	O	O
DRA	NN	O	O
;	NN	O	O
45	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
pendrin	NN	O	O
functions	NN	O	O
as	NN	O	O
a	NN	O	O
transporter	NN	O	O
of	NN	O	O
chloride	NN	O	O
and	NN	O	O
iodide	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
sulfate	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
provide	NN	O	O
insight	NN	O	O
into	NN	O	O
thyroid	NN	O	O
physiology	NN	O	O
and	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
Pendred	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
distribution	NN	O	O
of	NN	O	O
common	NN	O	O
polymorphisms	NN	O	O
was	NN	O	O
determined	NN	O	O
in	NN	O	O
the	NN	O	O
91	NN	O	O
Caucasian	NN	O	O
cancer	NN	O	B-Disease
cases	NN	O	O
in	NN	O	O
this	NN	O	O
series	NN	O	O
and	NN	O	O
24	NN	O	O
sister	NN	O	O
controls	NN	O	O
using	NN	O	O
allele	NN	O	O
-	NN	O	O
specific	NN	O	O
amplification	NN	O	O
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
our	NN	O	O
data	NN	O	O
suggest	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
some	NN	O	O
uncharacterized	NN	O	O
variants	NN	O	O
and	NN	O	O
rare	NN	O	O
forms	NN	O	O
of	NN	O	O
polymorphisms	NN	O	O
in	NN	O	O
determining	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
risk	NN	O	O
,	NN	O	O
and	NN	O	O
highlight	NN	O	O
the	NN	O	O
necessity	NN	O	O
to	NN	O	O
screen	NN	O	O
for	NN	O	O
missense	NN	O	O
alterations	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
truncating	NN	O	O
mutations	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
.	NN	O	O

By	NN	O	O
using	NN	O	O
transient	NN	O	O
and	NN	O	O
stable	NN	O	O
overexpression	NN	O	O
of	NN	O	O
human	NN	O	O
cDNAs	NN	O	O
encoding	NN	O	O
ALDP	NN	O	O
and	NN	O	O
its	NN	O	O
closest	NN	O	O
relative	NN	O	O
ALDRP	NN	O	O
,	NN	O	O
we	NN	O	O
could	NN	O	O
restore	NN	O	O
the	NN	O	O
impaired	NN	O	O
peroxisomal	NN	O	O
beta	NN	O	O
-	NN	O	O
oxidation	NN	O	O
in	NN	O	O
fibroblasts	NN	O	O
of	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
ALD	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

Centrosome	NN	O	O
amplification	NN	O	O
and	NN	O	O
a	NN	O	O
defective	NN	O	O
G2	NN	O	O
-	NN	O	O
M	NN	O	O
cell	NN	O	O
cycle	NN	O	O
checkpoint	NN	O	O
induce	NN	O	O
genetic	NN	O	O
instability	NN	O	O
in	NN	O	O
BRCA1	NN	O	O
exon	NN	O	O
11	NN	O	O
isoform	NN	O	O
-	NN	O	O
deficient	NN	O	O
cells	NN	O	O
.	NN	O	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
mutant	NN	O	O
cells	NN	O	O
maintain	NN	O	O
an	NN	O	O
intact	NN	O	O
G1	NN	O	O
-	NN	O	O
S	NN	O	O
cell	NN	O	O
cycle	NN	O	O
checkpoint	NN	O	O
and	NN	O	O
proliferate	NN	O	O
poorly	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
uncover	NN	O	O
an	NN	O	O
essential	NN	O	O
role	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
in	NN	O	O
maintaining	NN	O	O
genetic	NN	O	O
stability	NN	O	O
through	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
centrosome	NN	O	O
duplication	NN	O	O
and	NN	O	O
the	NN	O	O
G2	NN	O	O
-	NN	O	O
M	NN	O	O
checkpoint	NN	O	O
and	NN	O	O
provide	NN	O	O
a	NN	O	O
molecular	NN	O	O
basis	NN	O	O
for	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
in	NN	O	O
tumorigenesis	NN	O	O
.	NN	O	O
.	NN	O	O

Herein	NN	O	O
we	NN	O	O
describe	NN	O	O
haplotype	NN	O	O
and	NN	O	O
mutational	NN	O	O
analyses	NN	O	O
of	NN	O	O
HGO	NN	O	O
in	NN	O	O
seven	NN	O	O
new	NN	O	O
AKU	NN	O	B-Disease
pedigrees	NN	O	O
.	NN	O	O

Fabry	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
FD	NN	O	B-Disease
)	NN	O	O
(	NN	O	O
angiokeratoma	NN	O	B-Disease
corporis	NN	O	I-Disease
diffusum	NN	O	I-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
inborn	NN	O	I-Disease
error	NN	O	I-Disease
of	NN	O	I-Disease
glycosphingolipid	NN	O	I-Disease
metabolism	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
defects	NN	O	O
in	NN	O	O
the	NN	O	O
lysosomal	NN	O	O
alpha	NN	O	O
-	NN	O	O
galactosidase	NN	O	O
A	NN	O	O
gene	NN	O	O
(	NN	O	O
GLA	NN	O	O
)	NN	O	O
.	NN	O	O

By	NN	O	O
use	NN	O	O
of	NN	O	O
chemical	NN	O	O
cleavage	NN	O	O
of	NN	O	O
mismatches	NN	O	O
adapted	NN	O	O
to	NN	O	O
fluorescence	NN	O	O
-	NN	O	O
based	NN	O	O
detection	NN	O	O
systems	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
characterized	NN	O	O
the	NN	O	O
mutations	NN	O	O
underlying	NN	O	O
alpha	NN	O	B-Disease
-	NN	O	I-Disease
Gal	NN	O	I-Disease
A	NN	O	I-Disease
deficiency	NN	O	I-Disease
in	NN	O	O
16	NN	O	O
individuals	NN	O	O
from	NN	O	O
six	NN	O	O
unrelated	NN	O	O
families	NN	O	O
with	NN	O	O
FD	NN	O	B-Disease
.	NN	O	O

Prenatal	NN	O	O
diagnosis	NN	O	O
by	NN	O	O
FISH	NN	O	O
in	NN	O	O
a	NN	O	O
family	NN	O	O
with	NN	O	O
Pelizaeus	NN	O	B-Disease
-	NN	O	I-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
duplication	NN	O	O
of	NN	O	O
PLP	NN	O	O
gene	NN	O	O
.	NN	O	O

Samples	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
duplication	NN	O	O
of	NN	O	O
the	NN	O	O
PLP	NN	O	O
gene	NN	O	O
,	NN	O	O
by	NN	O	O
interphase	NN	O	O
FISH	NN	O	O
,	NN	O	O
in	NN	O	O
lymphocyte	NN	O	O
preparations	NN	O	O
from	NN	O	O
the	NN	O	O
proband	NN	O	O
,	NN	O	O
his	NN	O	O
aunt	NN	O	O
and	NN	O	O
an	NN	O	O
amniotic	NN	O	O
fluid	NN	O	O
cell	NN	O	O
preparation	NN	O	O
from	NN	O	O
the	NN	O	O
fetus	NN	O	O
.	NN	O	O

The	NN	O	O
proband	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
carry	NN	O	O
the	NN	O	O
duplication	NN	O	O
,	NN	O	O
thus	NN	O	O
confirming	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Pelizaeus	NN	O	B-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
neither	NN	O	O
the	NN	O	O
aunt	NN	O	O
nor	NN	O	O
the	NN	O	O
fetus	NN	O	O
carried	NN	O	O
a	NN	O	O
duplication	NN	O	O
.	NN	O	O
.	NN	O	O

Mutations	NN	O	O
spanning	NN	O	O
the	NN	O	O
emerin	NN	O	O
gene	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
EDMD	NN	O	B-Disease
.	NN	O	O

Microdeletions	NN	O	O
at	NN	O	O
chromosome	NN	O	O
bands	NN	O	O
1q32	NN	O	O
-	NN	O	O
q41	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
Van	NN	O	B-Disease
der	NN	O	I-Disease
Woude	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Van	NN	O	B-Disease
der	NN	O	I-Disease
Woude	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
VWS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
dominant	NN	O	I-Disease
disorder	NN	O	I-Disease
comprising	NN	O	O
cleft	NN	O	B-Disease
lip	NN	O	I-Disease
and	NN	O	O
/	NN	O	O
or	NN	O	O
cleft	NN	O	B-Disease
palate	NN	O	I-Disease
and	NN	O	O
lip	NN	O	B-Disease
pits	NN	O	I-Disease
.	NN	O	O

From	NN	O	O
a	NN	O	O
panel	NN	O	O
of	NN	O	O
37	NN	O	O
unrelated	NN	O	O
individuals	NN	O	O
,	NN	O	O
we	NN	O	O
detected	NN	O	O
an	NN	O	O
allele	NN	O	O
loss	NN	O	O
in	NN	O	O
one	NN	O	O
family	NN	O	O
,	NN	O	O
indicating	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
deletion	NN	O	O
.	NN	O	O

Mutations	NN	O	O
resulting	NN	O	O
in	NN	O	O
defective	NN	O	O
splicing	NN	O	O
constitute	NN	O	O
a	NN	O	O
significant	NN	O	O
proportion	NN	O	O
(	NN	O	O
30	NN	O	O
/	NN	O	O
62	NN	O	O
[	NN	O	O
48	NN	O	O
%	NN	O	O
]	NN	O	O
)	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
series	NN	O	O
of	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
ATM	NN	O	O
gene	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
ataxia	NN	O	B-Disease
-	NN	O	I-Disease
telangiectasia	NN	O	I-Disease
(	NN	O	O
AT	NN	O	B-Disease
)	NN	O	O
that	NN	O	O
were	NN	O	O
detected	NN	O	O
by	NN	O	O
the	NN	O	O
protein	NN	O	O
-	NN	O	O
truncation	NN	O	O
assay	NN	O	O
followed	NN	O	O
by	NN	O	O
sequence	NN	O	O
analysis	NN	O	O
of	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
5	NN	O	O
of	NN	O	O
12	NN	O	O
nonsense	NN	O	O
mutations	NN	O	O
and	NN	O	O
1	NN	O	O
missense	NN	O	O
mutation	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
deletion	NN	O	O
in	NN	O	O
the	NN	O	O
cDNA	NN	O	O
of	NN	O	O
the	NN	O	O
exons	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
mutations	NN	O	O
occurred	NN	O	O
.	NN	O	O

No	NN	O	O
ATM	NN	O	O
protein	NN	O	O
was	NN	O	O
detected	NN	O	O
by	NN	O	O
western	NN	O	O
blotting	NN	O	O
in	NN	O	O
any	NN	O	O
AT	NN	O	B-Disease
cell	NN	O	O
line	NN	O	O
in	NN	O	O
which	NN	O	O
splicing	NN	O	O
mutations	NN	O	O
were	NN	O	O
identified	NN	O	O
.	NN	O	O

Mutation	NN	O	O
analysis	NN	O	O
of	NN	O	O
ACTC	NN	O	O
revealed	NN	O	O
an	NN	O	O
Ala295Ser	NN	O	O
mutation	NN	O	O
in	NN	O	O
exon	NN	O	O
5	NN	O	O
close	NN	O	O
to	NN	O	O
2	NN	O	O
missense	NN	O	O
mutations	NN	O	O
recently	NN	O	O
described	NN	O	O
to	NN	O	O
cause	NN	O	O
the	NN	O	O
inherited	NN	O	O
form	NN	O	O
of	NN	O	O
idiopathic	NN	O	B-Disease
dilated	NN	O	I-Disease
cardiomyopathy	NN	O	I-Disease
(	NN	O	O
IDC	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Of	NN	O	O
16	NN	O	O
oral	NN	O	B-Disease
mucosal	NN	O	I-Disease
lesions	NN	O	I-Disease
studied	NN	O	O
histologically	NN	O	O
,	NN	O	O
15	NN	O	O
represented	NN	O	O
fibroepithelial	NN	O	B-Disease
or	NN	O	I-Disease
epithelial	NN	O	I-Disease
hyperplasias	NN	O	I-Disease
and	NN	O	O
were	NN	O	O
reactive	NN	O	O
in	NN	O	O
nature	NN	O	O
.	NN	O	O

Immunohistochemically	NN	O	O
,	NN	O	O
expression	NN	O	O
of	NN	O	O
AGA	NN	O	O
in	NN	O	O
AGU	NN	O	B-Disease
patients	NN	O	O
mucosal	NN	O	B-Disease
lesions	NN	O	I-Disease
did	NN	O	O
not	NN	O	O
differ	NN	O	O
from	NN	O	O
that	NN	O	O
seen	NN	O	O
in	NN	O	O
corresponding	NN	O	O
lesions	NN	O	O
of	NN	O	O
normal	NN	O	O
subjects	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
one	NN	O	O
frameshift	NN	O	O
mutation	NN	O	O
,	NN	O	O
2799delC	NN	O	O
,	NN	O	O
modifies	NN	O	O
the	NN	O	O
C	NN	O	O
-	NN	O	O
terminal	NN	O	O
part	NN	O	O
of	NN	O	O
OCRL1	NN	O	O
,	NN	O	O
with	NN	O	O
an	NN	O	O
extension	NN	O	O
of	NN	O	O
six	NN	O	O
amino	NN	O	O
acids	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
the	NN	O	O
FMR1	NN	O	O
gene	NN	O	O
and	NN	O	O
the	NN	O	O
repeat	NN	O	O
-	NN	O	O
amplification	NN	O	O
mechanism	NN	O	O
causing	NN	O	O
fragile	NN	O	B-Disease
X	NN	O	I-Disease
syndrome	NN	O	I-Disease
led	NN	O	O
to	NN	O	O
development	NN	O	O
of	NN	O	O
reliable	NN	O	O
DNA	NN	O	O
-	NN	O	O
based	NN	O	O
diagnostic	NN	O	O
methods	NN	O	O
,	NN	O	O
including	NN	O	O
Southern	NN	O	O
blot	NN	O	O
hybridization	NN	O	O
and	NN	O	O
PCR	NN	O	O
.	NN	O	O

Control	NN	O	O
individuals	NN	O	O
showed	NN	O	O
clear	NN	O	O
expression	NN	O	O
of	NN	O	O
FMRP	NN	O	O
in	NN	O	O
nearly	NN	O	O
every	NN	O	O
hair	NN	O	O
root	NN	O	O
,	NN	O	O
whereas	NN	O	O
male	NN	O	O
fragile	NN	O	B-Disease
X	NN	O	I-Disease
patients	NN	O	O
lacked	NN	O	O
expression	NN	O	O
of	NN	O	O
FMRP	NN	O	O
in	NN	O	O
almost	NN	O	O
all	NN	O	O
their	NN	O	O
hair	NN	O	O
roots	NN	O	O
.	NN	O	O

The	NN	O	O
advantages	NN	O	O
of	NN	O	O
this	NN	O	O
test	NN	O	O
are	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
plucking	NN	O	O
of	NN	O	O
hair	NN	O	O
follicles	NN	O	O
does	NN	O	O
no	NN	O	O
appreciable	NN	O	O
harm	NN	O	O
to	NN	O	O
the	NN	O	O
mentally	NN	O	B-Disease
retarded	NN	O	I-Disease
patient	NN	O	O
,	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
hairs	NN	O	O
can	NN	O	O
be	NN	O	O
sent	NN	O	O
in	NN	O	O
a	NN	O	O
simple	NN	O	O
envelope	NN	O	O
to	NN	O	O
a	NN	O	O
diagnostic	NN	O	O
center	NN	O	O
,	NN	O	O
and	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
the	NN	O	O
test	NN	O	O
is	NN	O	O
available	NN	O	O
within	NN	O	O
5	NN	O	O
h	NN	O	O
of	NN	O	O
plucking	NN	O	O
.	NN	O	O

Prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
clusters	NN	O	O
in	NN	O	O
some	NN	O	O
families	NN	O	O
,	NN	O	O
and	NN	O	O
an	NN	O	O
estimated	NN	O	O
5	NN	O	O
%	NN	O	O
-	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
all	NN	O	O
cases	NN	O	O
are	NN	O	O
estimated	NN	O	O
to	NN	O	O
result	NN	O	O
from	NN	O	O
inheritance	NN	O	O
of	NN	O	O
prostate	NN	O	O
cancer	NN	O	O
-	NN	O	O
susceptibility	NN	O	O
genes	NN	O	O
.	NN	O	O

We	NN	O	O
previously	NN	O	O
reported	NN	O	O
evidence	NN	O	O
of	NN	O	O
linkage	NN	O	O
to	NN	O	O
the	NN	O	O
1q24	NN	O	O
-	NN	O	O
25	NN	O	O
region	NN	O	O
(	NN	O	O
HPC1	NN	O	O
)	NN	O	O
in	NN	O	O
91	NN	O	O
North	NN	O	O
American	NN	O	O
and	NN	O	O
Swedish	NN	O	O
families	NN	O	O
each	NN	O	O
with	NN	O	O
multiple	NN	O	O
cases	NN	O	O
of	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
(	NN	O	O
Smith	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O
1996	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
chromosome	NN	O	O
22q11	NN	O	O
region	NN	O	O
is	NN	O	O
susceptible	NN	O	O
to	NN	O	O
rearrangements	NN	O	O
that	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
congenital	NN	O	B-Disease
anomaly	NN	O	I-Disease
disorders	NN	O	I-Disease
and	NN	O	O
malignant	NN	O	B-Disease
tumors	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
high	NN	O	O
prevalence	NN	O	O
of	NN	O	O
the	NN	O	O
disorder	NN	O	O
in	NN	O	O
the	NN	O	O
population	NN	O	O
and	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
most	NN	O	O
cases	NN	O	O
occur	NN	O	O
sporadically	NN	O	O
suggest	NN	O	O
that	NN	O	O
sequences	NN	O	O
at	NN	O	O
or	NN	O	O
near	NN	O	O
the	NN	O	O
breakpoints	NN	O	O
confer	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
chromosome	NN	O	O
rearrangements	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
models	NN	O	O
to	NN	O	O
explain	NN	O	O
how	NN	O	O
the	NN	O	O
LCR22s	NN	O	O
can	NN	O	O
mediate	NN	O	O
different	NN	O	O
homologous	NN	O	O
recombination	NN	O	O
events	NN	O	O
,	NN	O	O
thereby	NN	O	O
generating	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
rearrangements	NN	O	O
that	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
congenital	NN	O	B-Disease
anomaly	NN	O	I-Disease
disorders	NN	O	I-Disease
.	NN	O	O

Three	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
EGR2	NN	O	O
mutations	NN	O	O
are	NN	O	O
dominant	NN	O	O
and	NN	O	O
occur	NN	O	O
within	NN	O	O
the	NN	O	O
zinc	NN	O	O
finger	NN	O	O
DNA	NN	O	O
-	NN	O	O
binding	NN	O	O
domain	NN	O	O
.	NN	O	O

The	NN	O	O
fourth	NN	O	O
mutation	NN	O	O
is	NN	O	O
recessive	NN	O	O
and	NN	O	O
affects	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
domain	NN	O	O
(	NN	O	O
R1	NN	O	O
)	NN	O	O
that	NN	O	O
binds	NN	O	O
the	NN	O	O
NAB	NN	O	O
transcriptional	NN	O	O
co	NN	O	O
-	NN	O	O
repressors	NN	O	O
.	NN	O	O

The	NN	O	O
zinc	NN	O	O
finger	NN	O	O
mutations	NN	O	O
affect	NN	O	O
DNA	NN	O	O
binding	NN	O	O
and	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
residual	NN	O	O
binding	NN	O	O
directly	NN	O	O
correlates	NN	O	O
with	NN	O	O
disease	NN	O	O
severity	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
mosaic	NN	O	O
mice	NN	O	O
showed	NN	O	O
that	NN	O	O
in	NN	O	O
heart	NN	O	O
,	NN	O	O
lung	NN	O	O
,	NN	O	O
kidney	NN	O	O
,	NN	O	O
brain	NN	O	O
,	NN	O	O
and	NN	O	O
liver	NN	O	O
,	NN	O	O
mainly	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
Piga	NN	O	O
is	NN	O	O
active	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
these	NN	O	O
tissues	NN	O	O
require	NN	O	O
GPI	NN	O	O
-	NN	O	O
linked	NN	O	O
proteins	NN	O	O
.	NN	O	O

The	NN	O	O
C282Y	NN	O	O
mutation	NN	O	O
causing	NN	O	O
hereditary	NN	O	B-Disease
hemochromatosis	NN	O	I-Disease
does	NN	O	O
not	NN	O	O
produce	NN	O	O
a	NN	O	O
null	NN	O	O
allele	NN	O	O
.	NN	O	O

Targeted	NN	O	O
mutagenesis	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
produce	NN	O	O
two	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
murine	NN	O	O
hemochromatosis	NN	O	B-Disease
gene	NN	O	O
(	NN	O	O
Hfe	NN	O	O
)	NN	O	O
locus	NN	O	O
.	NN	O	O

Genotype	NN	O	O
-	NN	O	O
phenotype	NN	O	O
analysis	NN	O	O
in	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
Emery	NN	O	I-Disease
-	NN	O	I-Disease
Dreifuss	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
and	NN	O	O
identification	NN	O	O
of	NN	O	O
a	NN	O	O
missense	NN	O	O
mutation	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
milder	NN	O	O
phenotype	NN	O	O
.	NN	O	O

The	NN	O	O
phenotype	NN	O	O
in	NN	O	O
these	NN	O	O
families	NN	O	O
was	NN	O	O
compared	NN	O	O
in	NN	O	O
detail	NN	O	O
with	NN	O	O
the	NN	O	O
clinical	NN	O	O
features	NN	O	O
in	NN	O	O
cases	NN	O	O
with	NN	O	O
typical	NN	O	O
null	NN	O	O
mutations	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
family	NN	O	O
with	NN	O	O
the	NN	O	O
missense	NN	O	O
mutation	NN	O	O
the	NN	O	O
phenotype	NN	O	O
was	NN	O	O
milder	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
have	NN	O	O
diagnostic	NN	O	O
implications	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
pointing	NN	O	O
to	NN	O	O
functionally	NN	O	O
important	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
emerin	NN	O	O
protein	NN	O	O
.	NN	O	O
.	NN	O	O

X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
Emery	NN	O	I-Disease
-	NN	O	I-Disease
Dreifuss	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
EDMD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
relatively	NN	O	O
rare	NN	O	O
benign	NN	O	B-Disease
neuromuscular	NN	O	I-Disease
disorder	NN	O	I-Disease
which	NN	O	O
can	NN	O	O
vary	NN	O	O
remarkably	NN	O	O
in	NN	O	O
onset	NN	O	O
,	NN	O	O
course	NN	O	O
and	NN	O	O
severity	NN	O	O
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
common	NN	O	O
germline	NN	O	O
mutations	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
or	NN	O	O
BRCA2	NN	O	O
in	NN	O	O
Ashkenazi	NN	O	O
Jewish	NN	O	O
men	NN	O	O
predisposed	NN	O	O
them	NN	O	O
to	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
suggests	NN	O	O
that	NN	O	O
unlike	NN	O	O
cases	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancers	NN	O	I-Disease
,	NN	O	O
mutations	NN	O	O
in	NN	O	O
BRCA1	NN	O	O
or	NN	O	O
BRCA2	NN	O	O
do	NN	O	O
not	NN	O	O
significantly	NN	O	O
predispose	NN	O	O
men	NN	O	O
to	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease

A	NN	O	O
major	NN	O	O
function	NN	O	O
of	NN	O	O
APC	NN	O	O
is	NN	O	O
the	NN	O	O
downregulation	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
catenin	NN	O	O
,	NN	O	O
a	NN	O	O
transcription	NN	O	O
-	NN	O	O
activating	NN	O	O
protein	NN	O	O
with	NN	O	O
oncogenic	NN	O	O
potential	NN	O	O
.	NN	O	O

Sulfate	NN	O	O
transport	NN	O	O
is	NN	O	O
not	NN	O	O
impaired	NN	O	O
in	NN	O	O
pendred	NN	O	B-Disease
syndrome	NN	O	I-Disease
thyrocytes	NN	O	O
.	NN	O	O

Sequencing	NN	O	O
of	NN	O	O
the	NN	O	O
index	NN	O	O
patients	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
identified	NN	O	O
four	NN	O	O
new	NN	O	O
dominant	NN	O	O
mutations	NN	O	O
in	NN	O	O
COL2A1	NN	O	O
that	NN	O	O
result	NN	O	O
in	NN	O	O
Kniest	NN	O	B-Disease
dysplasia	NN	O	I-Disease
a	NN	O	O
21	NN	O	O
-	NN	O	O
bp	NN	O	O
deletion	NN	O	O
in	NN	O	O
exon	NN	O	O
16	NN	O	O
,	NN	O	O
an	NN	O	O
18	NN	O	O
-	NN	O	O
bp	NN	O	O
deletion	NN	O	O
in	NN	O	O
exon	NN	O	O
19	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
bp	NN	O	O
deletions	NN	O	O
in	NN	O	O
the	NN	O	O
splice	NN	O	O
donor	NN	O	O
sites	NN	O	O
of	NN	O	O
introns	NN	O	O
14	NN	O	O
and	NN	O	O
20	NN	O	O
.	NN	O	O

A	NN	O	O
previously	NN	O	O
described	NN	O	O
28	NN	O	O
-	NN	O	O
bp	NN	O	O
deletion	NN	O	O
at	NN	O	O
the	NN	O	O
COL2A1	NN	O	O
exon	NN	O	O
12	NN	O	O
-	NN	O	O
intron	NN	O	O
12	NN	O	O
junction	NN	O	O
,	NN	O	O
deleting	NN	O	O
the	NN	O	O
splice	NN	O	O
donor	NN	O	O
site	NN	O	O
,	NN	O	O
was	NN	O	O
identified	NN	O	O
in	NN	O	O
the	NN	O	O
fifth	NN	O	O
case	NN	O	O
.	NN	O	O

Q188R	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
mutation	NN	O	O
in	NN	O	O
European	NN	O	O
populations	NN	O	O
or	NN	O	O
in	NN	O	O
those	NN	O	O
predominantly	NN	O	O
of	NN	O	O
European	NN	O	O
descent	NN	O	O
.	NN	O	O

N314D	NN	O	O
does	NN	O	O
not	NN	O	O
impair	NN	O	O
GALT	NN	O	O
activity	NN	O	O
in	NN	O	O
in	NN	O	O
vitro	NN	O	O
expression	NN	O	O
systems	NN	O	O
.	NN	O	O

The	NN	O	O
considerable	NN	O	O
genetic	NN	O	O
heterogeneity	NN	O	O
documented	NN	O	O
to	NN	O	O
date	NN	O	O
undoubtedly	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
phenotypic	NN	O	O
heterogeneity	NN	O	O
that	NN	O	O
is	NN	O	O
observed	NN	O	O
in	NN	O	O
galactosemia	NN	O	B-Disease
.	NN	O	O

Its	NN	O	O
membrane	NN	O	O
expression	NN	O	O
is	NN	O	O
highly	NN	O	O
regulated	NN	O	O
by	NN	O	O
endocytosis	NN	O	O
and	NN	O	O
trafficking	NN	O	O
through	NN	O	O
the	NN	O	O
secretory	NN	O	O
lysosome	NN	O	O
pathway	NN	O	O
.	NN	O	O

We	NN	O	O
analyzed	NN	O	O
the	NN	O	O
maternal	NN	O	O
status	NN	O	O
of	NN	O	O
56	NN	O	O
cases	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
origin	NN	O	O
of	NN	O	O
both	NN	O	O
types	NN	O	O
of	NN	O	O
PLP	NN	O	O
mutation	NN	O	O
,	NN	O	O
since	NN	O	O
this	NN	O	O
is	NN	O	O
relevant	NN	O	O
to	NN	O	O
genetic	NN	O	O
counseling	NN	O	O
.	NN	O	O

In	NN	O	O
sharp	NN	O	O
contrast	NN	O	O
,	NN	O	O
among	NN	O	O
the	NN	O	O
34	NN	O	O
duplicated	NN	O	O
cases	NN	O	O
,	NN	O	O
91	NN	O	O
%	NN	O	O
of	NN	O	O
mothers	NN	O	O
were	NN	O	O
carriers	NN	O	O
,	NN	O	O
a	NN	O	O
value	NN	O	O
significantly	NN	O	O
(	NN	O	O
chi2	NN	O	O
=	NN	O	O
9	NN	O	O
.	NN	O	O
20	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
in	NN	O	O
favor	NN	O	O
of	NN	O	O
a	NN	O	O
male	NN	O	O
bias	NN	O	O
,	NN	O	O
with	NN	O	O
an	NN	O	O
estimation	NN	O	O
of	NN	O	O
the	NN	O	O
male	NN	O	O
/	NN	O	O
female	NN	O	O
mutation	NN	O	O
frequency	NN	O	O
(	NN	O	O
k	NN	O	O
)	NN	O	O
of	NN	O	O
9	NN	O	O
.	NN	O	O

New	NN	O	O
mutations	NN	O	O
,	NN	O	O
polymorphisms	NN	O	O
,	NN	O	O
and	NN	O	O
rare	NN	O	O
variants	NN	O	O
in	NN	O	O
the	NN	O	O
ATM	NN	O	O
gene	NN	O	O
detected	NN	O	O
by	NN	O	O
a	NN	O	O
novel	NN	O	O
SSCP	NN	O	O
strategy	NN	O	O
.	NN	O	O

This	NN	O	O
deletion	NN	O	O
caused	NN	O	O
a	NN	O	O
frameshift	NN	O	O
in	NN	O	O
translation	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
a	NN	O	O
premature	NN	O	O
stop	NN	O	O
codon	NN	O	O
at	NN	O	O
the	NN	O	O
amino	NN	O	O
acid	NN	O	O
position	NN	O	O
408	NN	O	O
.	NN	O	O

Association	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
with	NN	O	O
the	NN	O	O
hRad50	NN	O	O
-	NN	O	O
hMre11	NN	O	O
-	NN	O	O
p95	NN	O	O
complex	NN	O	O
and	NN	O	O
the	NN	O	O
DNA	NN	O	O
damage	NN	O	O
response	NN	O	O
.	NN	O	O

Formation	NN	O	O
of	NN	O	O
irradiation	NN	O	O
-	NN	O	O
induced	NN	O	O
foci	NN	O	O
positive	NN	O	O
for	NN	O	O
BRCA1	NN	O	O
,	NN	O	O
hRad50	NN	O	O
,	NN	O	O
hMre11	NN	O	O
,	NN	O	O
or	NN	O	O
p95	NN	O	O
was	NN	O	O
dramatically	NN	O	O
reduced	NN	O	O
in	NN	O	O
HCC	NN	O	O
/	NN	O	O
1937	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
cells	NN	O	O
carrying	NN	O	O
a	NN	O	O
homozygous	NN	O	O
mutation	NN	O	O
in	NN	O	O
BRCA1	NN	O	O
but	NN	O	O
was	NN	O	O
restored	NN	O	O
by	NN	O	O
transfection	NN	O	O
of	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
BRCA1	NN	O	O
.	NN	O	O

These	NN	O	O
patients	NN	O	O
are	NN	O	O
considered	NN	O	O
functionally	NN	O	O
hemizygous	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
biochemical	NN	O	O
phenotype	NN	O	O
predicted	NN	O	O
from	NN	O	O
the	NN	O	O
genotype	NN	O	O
in	NN	O	O
functionally	NN	O	O
hemizygous	NN	O	O
patients	NN	O	O
was	NN	O	O
related	NN	O	O
significantly	NN	O	O
to	NN	O	O
the	NN	O	O
assigned	NN	O	O
phenylalanine	NN	O	O
level	NN	O	O
.	NN	O	O

Both	NN	O	O
factors	NN	O	O
depend	NN	O	O
on	NN	O	O
the	NN	O	O
intellectual	NN	O	O
resources	NN	O	O
of	NN	O	O
the	NN	O	O
mother	NN	O	O
with	NN	O	O
PKU	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
significant	NN	O	O
relationship	NN	O	O
among	NN	O	O
genotype	NN	O	O
,	NN	O	O
biochemical	NN	O	O
phenotype	NN	O	O
,	NN	O	O
and	NN	O	O
cognitive	NN	O	O
performance	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
is	NN	O	O
of	NN	O	O
importance	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
an	NN	O	O
optimal	NN	O	O
strategy	NN	O	O
for	NN	O	O
future	NN	O	O
treatment	NN	O	O
of	NN	O	O
females	NN	O	O
with	NN	O	O
PKU	NN	O	B-Disease
who	NN	O	O
plan	NN	O	O
pregnancy	NN	O	O
.	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
the	NN	O	O
characterization	NN	O	O
of	NN	O	O
a	NN	O	O
transgene	NN	O	O
insertion	NN	O	O
(	NN	O	O
Epstein	NN	O	O
-	NN	O	O
Barr	NN	O	O
virus	NN	O	O
Latent	NN	O	O
Membrane	NN	O	O
Protein	NN	O	O
2A	NN	O	O
,	NN	O	O
LMP2A	NN	O	O
)	NN	O	O
into	NN	O	O
mouse	NN	O	O
chromosome	NN	O	O
7C	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
resulted	NN	O	O
in	NN	O	O
mouse	NN	O	O
models	NN	O	O
for	NN	O	O
PWS	NN	O	B-Disease
and	NN	O	O
AS	NN	O	B-Disease
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
sex	NN	O	O
of	NN	O	O
the	NN	O	O
transmitting	NN	O	O
parent	NN	O	O
.	NN	O	O

Linkage	NN	O	O
analysis	NN	O	O
of	NN	O	O
5	NN	O	O
novel	NN	O	O
van	NN	O	B-Disease
der	NN	O	I-Disease
Woude	NN	O	I-Disease
syndrome	NN	O	I-Disease
kindreds	NN	O	O
to	NN	O	O
1q32	NN	O	O
-	NN	O	O
q41	NN	O	O
markers	NN	O	O
further	NN	O	O
supports	NN	O	O
locus	NN	O	O
homogeneity	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
trait	NN	O	O
.	NN	O	O

The	NN	O	O
vWS	NN	O	B-Disease
gene	NN	O	O
has	NN	O	O
been	NN	O	O
assigned	NN	O	O
to	NN	O	O
a	NN	O	O
locus	NN	O	O
in	NN	O	O
1q32	NN	O	O
-	NN	O	O
q41	NN	O	O
by	NN	O	O
linkage	NN	O	O
analysis	NN	O	O
and	NN	O	O
physical	NN	O	O
mapping	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
support	NN	O	O
linkage	NN	O	O
of	NN	O	O
vWS	NN	O	B-Disease
within	NN	O	O
a	NN	O	O
region	NN	O	O
of	NN	O	O
tightly	NN	O	O
linked	NN	O	O
markers	NN	O	O
and	NN	O	O
do	NN	O	O
not	NN	O	O
favour	NN	O	O
locus	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
trait	NN	O	O
.	NN	O	O

The	NN	O	O
Atp7b	NN	O	O
protein	NN	O	O
is	NN	O	O
a	NN	O	O
copper	NN	O	O
-	NN	O	O
transporting	NN	O	O
ATPase	NN	O	O
expressed	NN	O	O
predominantly	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
to	NN	O	O
a	NN	O	O
lesser	NN	O	O
extent	NN	O	O
in	NN	O	O
most	NN	O	O
other	NN	O	O
tissues	NN	O	O
.	NN	O	O

Using	NN	O	O
homologous	NN	O	O
recombination	NN	O	O
to	NN	O	O
disrupt	NN	O	O
the	NN	O	O
normal	NN	O	O
translation	NN	O	O
of	NN	O	O
ATP7B	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
generated	NN	O	O
a	NN	O	O
strain	NN	O	O
of	NN	O	O
mice	NN	O	O
that	NN	O	O
are	NN	O	O
homozygous	NN	O	O
mutants	NN	O	O
(	NN	O	O
null	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
Wilson	NN	O	B-Disease
disease	NN	O	I-Disease
gene	NN	O	O
.	NN	O	O

The	NN	O	O
ATP7B	NN	O	O
null	NN	O	O
mice	NN	O	O
display	NN	O	O
a	NN	O	O
gradual	NN	O	O
accumulation	NN	O	O
of	NN	O	O
hepatic	NN	O	O
copper	NN	O	O
that	NN	O	O
increases	NN	O	O
to	NN	O	O
a	NN	O	O
level	NN	O	O
60	NN	O	O
-	NN	O	O
fold	NN	O	O
greater	NN	O	O
than	NN	O	O
normal	NN	O	O
by	NN	O	O
5	NN	O	O
months	NN	O	O
of	NN	O	O
age	NN	O	O
.	NN	O	O

Segregation	NN	O	O
distortion	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
occur	NN	O	O
in	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
the	NN	O	O
trinucleotide	NN	O	B-Disease
repeat	NN	O	I-Disease
disorders	NN	O	I-Disease
.	NN	O	O

To	NN	O	O
confirm	NN	O	O
these	NN	O	O
results	NN	O	O
,	NN	O	O
sperm	NN	O	O
typing	NN	O	O
analysis	NN	O	O
was	NN	O	O
also	NN	O	O
performed	NN	O	O
using	NN	O	O
a	NN	O	O
polymorphic	NN	O	O
marker	NN	O	O
,	NN	O	O
D14S1050	NN	O	O
,	NN	O	O
closely	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
MJD1	NN	O	O
gene	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
in	NN	O	O
frequency	NN	O	O
of	NN	O	O
these	NN	O	O
two	NN	O	O
alleles	NN	O	O
is	NN	O	O
not	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
8423	NN	O	O
)	NN	O	O
.	NN	O	O

Missense	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
alternative	NN	O	O
splice	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
PAX6	NN	O	O
gene	NN	O	O
in	NN	O	O
eye	NN	O	B-Disease
anomalies	NN	O	I-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
exon	NN	O	O
5a	NN	O	O
appears	NN	O	O
to	NN	O	O
function	NN	O	O
as	NN	O	O
a	NN	O	O
molecular	NN	O	O
switch	NN	O	O
that	NN	O	O
specifies	NN	O	O
target	NN	O	O
genes	NN	O	O
.	NN	O	O

Functional	NN	O	O
analyses	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
V54D	NN	O	O
mutation	NN	O	O
slightly	NN	O	O
increased	NN	O	O
NTS	NN	O	O
binding	NN	O	O
and	NN	O	O
decreased	NN	O	O
CTS	NN	O	O
transactivation	NN	O	O
activity	NN	O	O
to	NN	O	O
almost	NN	O	O
half	NN	O	O
.	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
previously	NN	O	O
reported	NN	O	O
two	NN	O	O
BRCA1	NN	O	O
founder	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
Norwegian	NN	O	O
population	NN	O	O
.	NN	O	O

An	NN	O	O
observed	NN	O	O
excess	NN	O	O
of	NN	O	O
mutation	NN	O	O
carriers	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
accounted	NN	O	O
for	NN	O	O
by	NN	O	O
methodological	NN	O	O
problems	NN	O	O
;	NN	O	O
possible	NN	O	O
explanations	NN	O	O
were	NN	O	O
a	NN	O	O
"	NN	O	O
true	NN	O	O
"	NN	O	O
low	NN	O	O
penetrance	NN	O	O
or	NN	O	O
preferential	NN	O	O
segregation	NN	O	O
.	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
the	NN	O	O
fusion	NN	O	O
protein	NN	O	O
led	NN	O	O
to	NN	O	O
morphological	NN	O	O
transformation	NN	O	O
and	NN	O	O
increased	NN	O	O
growth	NN	O	O
rate	NN	O	O
of	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

Pulse	NN	O	O
-	NN	O	O
chase	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
COLIA1	NN	O	O
/	NN	O	O
PDGFB	NN	O	O
precursor	NN	O	O
was	NN	O	O
processed	NN	O	O
to	NN	O	O
an	NN	O	O
end	NN	O	O
product	NN	O	O
that	NN	O	O
was	NN	O	O
indistinguishable	NN	O	O
from	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
PDGF	NN	O	O
-	NN	O	O
BB	NN	O	O
.	NN	O	O

Most	NN	O	O
of	NN	O	O
the	NN	O	O
nonsense	NN	O	O
,	NN	O	O
frameshift	NN	O	O
and	NN	O	O
splice	NN	O	O
site	NN	O	O
mutations	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
exons	NN	O	O
6	NN	O	O
-	NN	O	O
11	NN	O	O
.	NN	O	O

Mutations	NN	O	O
that	NN	O	O
alter	NN	O	O
splice	NN	O	O
sites	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
synthesis	NN	O	O
of	NN	O	O
several	NN	O	O
types	NN	O	O
of	NN	O	O
mRNAs	NN	O	O
,	NN	O	O
a	NN	O	O
fraction	NN	O	O
of	NN	O	O
which	NN	O	O
represented	NN	O	O
the	NN	O	O
normally	NN	O	O
spliced	NN	O	O
product	NN	O	O
.	NN	O	O

Reduced	NN	O	O
levels	NN	O	O
of	NN	O	O
a	NN	O	O
normal	NN	O	O
-	NN	O	O
size	NN	O	O
WASP	NN	O	O
with	NN	O	O
a	NN	O	O
missense	NN	O	O
mutation	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
two	NN	O	O
individuals	NN	O	O
with	NN	O	O
XLT	NN	O	B-Disease
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
mutation	NN	O	O
analysis	NN	O	O
at	NN	O	O
the	NN	O	O
DNA	NN	O	O
level	NN	O	O
is	NN	O	O
not	NN	O	O
sufficient	NN	O	O
for	NN	O	O
predicting	NN	O	O
clinical	NN	O	O
course	NN	O	O
.	NN	O	O

Aminoglycoside	NN	O	O
antibiotics	NN	O	O
restore	NN	O	O
dystrophin	NN	O	O
function	NN	O	O
to	NN	O	O
skeletal	NN	O	O
muscles	NN	O	O
of	NN	O	O
mdx	NN	O	O
mice	NN	O	O
.	NN	O	O

Exposure	NN	O	O
of	NN	O	O
mdx	NN	O	O
myotubes	NN	O	O
to	NN	O	O
gentamicin	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
localization	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
to	NN	O	O
the	NN	O	O
cell	NN	O	O
membrane	NN	O	O
.	NN	O	O

We	NN	O	O
then	NN	O	O
evaluated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
differing	NN	O	O
dosages	NN	O	O
of	NN	O	O
gentamicin	NN	O	O
on	NN	O	O
expression	NN	O	O
and	NN	O	O
functional	NN	O	O
protection	NN	O	O
of	NN	O	O
the	NN	O	O
muscles	NN	O	O
of	NN	O	O
mdx	NN	O	O
mice	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
provide	NN	O	O
a	NN	O	O
mechanistic	NN	O	O
basis	NN	O	O
for	NN	O	O
the	NN	O	O
A	NN	O	B-Disease
-	NN	O	I-Disease
T	NN	O	I-Disease
phenotype	NN	O	O
and	NN	O	O
lay	NN	O	O
a	NN	O	O
rational	NN	O	O
foundation	NN	O	O
for	NN	O	O
therapeutic	NN	O	O
intervention	NN	O	O
.	NN	O	O
.	NN	O	O

Cleft	NN	O	B-Disease
palate	NN	O	I-Disease
,	NN	O	O
swelling	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
ear	NN	O	I-Disease
pinna	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
hitch	NN	O	B-Disease
hiker	NN	O	I-Disease
thumb	NN	O	I-Disease
were	NN	O	O
absent	NN	O	O
.	NN	O	O

Multiple	NN	O	B-Disease
epiphyseal	NN	O	I-Disease
dysplasia	NN	O	I-Disease
is	NN	O	O
more	NN	O	O
frequently	NN	O	O
caused	NN	O	O
by	NN	O	O
dominant	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
COMP	NN	O	O
(	NN	O	O
EDM1	NN	O	B-Disease
,	NN	O	O
McKusick	NN	O	O
132400	NN	O	O
)	NN	O	O
and	NN	O	O
COL9A2	NN	O	O
genes	NN	O	O
(	NN	O	O
EDM2	NN	O	B-Disease
,	NN	O	O
McKusick	NN	O	O
600204	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
a	NN	O	O
girl	NN	O	O
with	NN	O	O
clinical	NN	O	O
features	NN	O	O
suggesting	NN	O	O
diastrophic	NN	O	B-Disease
dysplasia	NN	O	I-Disease
but	NN	O	O
with	NN	O	O
unusual	NN	O	O
radiographic	NN	O	O
features	NN	O	O
including	NN	O	O
severe	NN	O	O
platyspondyly	NN	O	B-Disease
,	NN	O	O
wide	NN	O	O
metaphyses	NN	O	O
,	NN	O	O
and	NN	O	O
fibular	NN	O	O
overgrowth	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
partially	NN	O	O
reminiscent	NN	O	O
of	NN	O	O
metatropic	NN	O	B-Disease
dysplasia	NN	O	I-Disease
.	NN	O	O

Mxi1	NN	O	O
is	NN	O	O
thought	NN	O	O
to	NN	O	O
negatively	NN	O	O
regulate	NN	O	O
Myc	NN	O	O
function	NN	O	O
and	NN	O	O
may	NN	O	O
therefore	NN	O	O
be	NN	O	O
a	NN	O	O
potential	NN	O	O
tumor	NN	O	B-Disease
suppressor	NN	O	O
gene	NN	O	O
.	NN	O	O

Little	NN	O	O
effort	NN	O	O
has	NN	O	O
yet	NN	O	O
been	NN	O	O
made	NN	O	O
to	NN	O	O
find	NN	O	O
alterations	NN	O	O
involving	NN	O	O
this	NN	O	O
gene	NN	O	O
in	NN	O	O
human	NN	O	O
solid	NN	O	B-Disease
tumors	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
screened	NN	O	O
31	NN	O	O
human	NN	O	O
gastric	NN	O	B-Disease
cancers	NN	O	I-Disease
,	NN	O	O
7	NN	O	O
esophageal	NN	O	B-Disease
cancers	NN	O	I-Disease
,	NN	O	O
85	NN	O	O
bone	NN	O	B-Disease
and	NN	O	I-Disease
soft	NN	O	I-Disease
tissue	NN	O	I-Disease
tumors	NN	O	I-Disease
of	NN	O	O
various	NN	O	O
types	NN	O	O
,	NN	O	O
including	NN	O	O
4	NN	O	O
neurofibrosarcomas	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
also	NN	O	O
examined	NN	O	O
29	NN	O	O
human	NN	O	O
tumor	NN	O	B-Disease
cell	NN	O	O
lines	NN	O	O
consisting	NN	O	O
of	NN	O	O
12	NN	O	O
esophageal	NN	O	B-Disease
cancers	NN	O	I-Disease
,	NN	O	O
7	NN	O	O
glioma	NN	O	B-Disease
/	NN	O	O
glioblastomas	NN	O	B-Disease
and	NN	O	O
10	NN	O	O
others	NN	O	O
for	NN	O	O
Mxi1	NN	O	O
mutations	NN	O	O
in	NN	O	O
exons	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
(	NN	O	O
HLH	NN	O	O
domain	NN	O	O
)	NN	O	O
,	NN	O	O
5	NN	O	O
and	NN	O	O
6	NN	O	O
.	NN	O	O

Missense	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
functional	NN	O	O
domain	NN	O	O
of	NN	O	O
Mxi1	NN	O	O
in	NN	O	O
these	NN	O	O
cases	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
neurofibrosarcoma	NN	O	B-Disease
.	NN	O	O
.	NN	O	O

A	NN	O	O
population	NN	O	O
-	NN	O	O
based	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
clinical	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
hemochromatosis	NN	O	B-Disease
gene	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Hereditary	NN	O	B-Disease
hemochromatosis	NN	O	I-Disease
is	NN	O	O
associated	NN	O	O
with	NN	O	O
homozygosity	NN	O	O
for	NN	O	O
the	NN	O	O
C282Y	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
hemochromatosis	NN	O	B-Disease
(	NN	O	O
HFE	NN	O	O
)	NN	O	O
gene	NN	O	O
on	NN	O	O
chromosome	NN	O	O
6	NN	O	O
,	NN	O	O
elevated	NN	O	O
serum	NN	O	O
transferrin	NN	O	O
saturation	NN	O	O
,	NN	O	O
and	NN	O	O
excess	NN	O	B-Disease
iron	NN	O	I-Disease
deposits	NN	O	I-Disease
throughout	NN	O	O
the	NN	O	O
body	NN	O	O
.	NN	O	O

In	NN	O	O
1994	NN	O	O
,	NN	O	O
we	NN	O	O
obtained	NN	O	O
blood	NN	O	O
samples	NN	O	O
for	NN	O	O
the	NN	O	O
determination	NN	O	O
of	NN	O	O
serum	NN	O	O
transferrin	NN	O	O
saturation	NN	O	O
and	NN	O	O
ferritin	NN	O	O
levels	NN	O	O
and	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
the	NN	O	O
C282Y	NN	O	O
mutation	NN	O	O
and	NN	O	O
the	NN	O	O
H63D	NN	O	O
mutation	NN	O	O
(	NN	O	O
which	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
increased	NN	O	O
hepatic	NN	O	O
iron	NN	O	O
levels	NN	O	O
)	NN	O	O
in	NN	O	O
3011	NN	O	O
unrelated	NN	O	O
white	NN	O	O
adults	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Sixteen	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
percent	NN	O	O
)	NN	O	O
were	NN	O	O
homozygous	NN	O	O
for	NN	O	O
the	NN	O	O
C282Y	NN	O	O
mutation	NN	O	O
,	NN	O	O
and	NN	O	O
424	NN	O	O
(	NN	O	O
14	NN	O	O
.	NN	O	O
1	NN	O	O
percent	NN	O	O
)	NN	O	O
were	NN	O	O
heterozygous	NN	O	O
.	NN	O	O

Four	NN	O	O
of	NN	O	O
the	NN	O	O
homozygous	NN	O	O
subjects	NN	O	O
had	NN	O	O
previously	NN	O	O
been	NN	O	O
given	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
hemochromatosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
12	NN	O	O
had	NN	O	O
not	NN	O	O
.	NN	O	O

Eight	NN	O	O
of	NN	O	O
the	NN	O	O
16	NN	O	O
homozygous	NN	O	O
subjects	NN	O	O
had	NN	O	O
clinical	NN	O	O
findings	NN	O	O
that	NN	O	O
were	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
hereditary	NN	O	B-Disease
hemochromatosis	NN	O	I-Disease
,	NN	O	O
such	NN	O	O
as	NN	O	O
hepatomegaly	NN	O	B-Disease
,	NN	O	O
skin	NN	O	B-Disease
pigmentation	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
arthritis	NN	O	B-Disease
.	NN	O	O

Emerin	NN	O	O
was	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
biopsied	NN	O	O
muscle	NN	O	O
,	NN	O	O
and	NN	O	O
RT	NN	O	O
-	NN	O	O
PCR	NN	O	O
and	NN	O	O
PCR	NN	O	O
-	NN	O	O
based	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
analyses	NN	O	O
of	NN	O	O
the	NN	O	O
emerin	NN	O	O
gene	NN	O	O
demonstrated	NN	O	O
no	NN	O	O
amplification	NN	O	O
product	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
.	NN	O	O

Duchenne	NN	O	B-Disease
/	NN	O	I-Disease
Becker	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
:	NN	O	O
correlation	NN	O	O
of	NN	O	O
phenotype	NN	O	O
by	NN	O	O
electroretinography	NN	O	O
with	NN	O	O
sites	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
mutations	NN	O	O
.	NN	O	O

Genotype	NN	O	O
-	NN	O	O
phenotype	NN	O	O
studies	NN	O	O
of	NN	O	O
mouse	NN	O	O
models	NN	O	O
for	NN	O	O
DMD	NN	O	B-Disease
show	NN	O	O
position	NN	O	O
-	NN	O	O
specific	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
mutations	NN	O	O
upon	NN	O	O
the	NN	O	O
phenotype	NN	O	O
mice	NN	O	O
with	NN	O	O
5	NN	O	O
defects	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
have	NN	O	O
normal	NN	O	O
ERGs	NN	O	O
,	NN	O	O
those	NN	O	O
with	NN	O	O
defects	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
region	NN	O	O
have	NN	O	O
a	NN	O	O
normal	NN	O	O
b	NN	O	O
-	NN	O	O
wave	NN	O	O
amplitude	NN	O	O
associated	NN	O	O
with	NN	O	O
prolonged	NN	O	O
implicit	NN	O	O
times	NN	O	O
for	NN	O	O
both	NN	O	O
the	NN	O	O
b	NN	O	O
-	NN	O	O
wave	NN	O	O
and	NN	O	O
oscillatory	NN	O	O
potentials	NN	O	O
,	NN	O	O
and	NN	O	O
mice	NN	O	O
with	NN	O	O
3	NN	O	O
defects	NN	O	O
have	NN	O	O
a	NN	O	O
phenotype	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
seen	NN	O	O
in	NN	O	O
DMD	NN	O	B-Disease
/	NN	O	O
BMD	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
most	NN	O	O
important	NN	O	O
determinant	NN	O	O
in	NN	O	O
the	NN	O	O
ERG	NN	O	O
b	NN	O	O
-	NN	O	O
wave	NN	O	O
phenotype	NN	O	O
is	NN	O	O
the	NN	O	O
mutation	NN	O	O
position	NN	O	O
,	NN	O	O
rather	NN	O	O
than	NN	O	O
muscle	NN	O	B-Disease
disease	NN	O	I-Disease
severity	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
six	NN	O	O
per	NN	O	O
cent	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
mutations	NN	O	O
5	NN	O	O
of	NN	O	O
the	NN	O	O
Dp260	NN	O	O
transcript	NN	O	O
start	NN	O	O
site	NN	O	O
have	NN	O	O
abnormal	NN	O	O
ERGs	NN	O	O
,	NN	O	O
as	NN	O	O
opposed	NN	O	O
to	NN	O	O
94	NN	O	O
%	NN	O	O
with	NN	O	O
more	NN	O	O
distal	NN	O	O
mutations	NN	O	O
.	NN	O	O

Cis	NN	O	O
and	NN	O	O
trans	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
mutation	NN	O	O
in	NN	O	O
a	NN	O	O
cell	NN	O	O
culture	NN	O	O
model	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
provide	NN	O	O
evidence	NN	O	O
that	NN	O	O
the	NN	O	O
DM	NN	O	B-Disease
mutation	NN	O	O
acts	NN	O	O
in	NN	O	O
cis	NN	O	O
to	NN	O	O
reduce	NN	O	O
protein	NN	O	O
production	NN	O	O
(	NN	O	O
consistent	NN	O	O
with	NN	O	O
DMPK	NN	O	B-Disease
haploinsufficiency	NN	O	I-Disease
)	NN	O	O
and	NN	O	O
in	NN	O	O
trans	NN	O	O
as	NN	O	O
a	NN	O	O
riboregulator	NN	O	O
to	NN	O	O
inhibit	NN	O	O
myogenesis	NN	O	O
.	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
retinas	NN	O	O
of	NN	O	O
nine	NN	O	O
enucleated	NN	O	O
eyes	NN	O	O
from	NN	O	O
males	NN	O	O
with	NN	O	O
Coats	NN	O	B-Disease
disease	NN	O	I-Disease
demonstrated	NN	O	O
in	NN	O	O
one	NN	O	O
a	NN	O	O
somatic	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
NDP	NN	O	O
gene	NN	O	O
which	NN	O	O
was	NN	O	O
not	NN	O	O
present	NN	O	O
within	NN	O	O
non	NN	O	O
-	NN	O	O
retinal	NN	O	O
tissue	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
Turkish	NN	O	O
family	NN	O	O
with	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Li	NN	O	B-Disease
-	NN	O	I-Disease
Fraumeni	NN	O	I-Disease
syndrome	NN	O	I-Disease
,	NN	O	O
we	NN	O	O
analyzed	NN	O	O
the	NN	O	O
mutation	NN	O	O
pattern	NN	O	O
of	NN	O	O
TP53	NN	O	O
,	NN	O	O
P57KIP2	NN	O	O
,	NN	O	O
P15INK4B	NN	O	O
,	NN	O	O
and	NN	O	O
P16INK4A	NN	O	O
in	NN	O	O
the	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
,	NN	O	O
and	NN	O	O
loss	NN	O	O
of	NN	O	O
heterozygosity	NN	O	O
(	NN	O	O
homo	NN	O	O
/	NN	O	O
hemizygous	NN	O	O
deletion	NN	O	O
)	NN	O	O
pattern	NN	O	O
of	NN	O	O
TP53	NN	O	O
and	NN	O	O
P15INK4B	NN	O	O
/	NN	O	O
P16INK4A	NN	O	O
in	NN	O	O
two	NN	O	O
tumor	NN	O	B-Disease
tissues	NN	O	O
.	NN	O	O

Tumor	NN	O	O
tissue	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
propositus	NN	O	O
with	NN	O	O
the	NN	O	O
seminoma	NN	O	B-Disease
revealed	NN	O	O
loss	NN	O	O
of	NN	O	O
heterozygosity	NN	O	O
in	NN	O	O
the	NN	O	O
TP53	NN	O	O
gene	NN	O	O
.	NN	O	O

P16INK4A	NN	O	O
codon	NN	O	O
94	NN	O	O
mutation	NN	O	O
observed	NN	O	O
in	NN	O	O
our	NN	O	O
family	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
mutation	NN	O	O
in	NN	O	O
Li	NN	O	B-Disease
-	NN	O	I-Disease
Fraumeni	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
patient	NN	O	O
who	NN	O	O
showed	NN	O	O
an	NN	O	O
intermediate	NN	O	O
saliva	NN	O	O
/	NN	O	O
serum	NN	O	O
technetium	NN	O	O
ratio	NN	O	O
(	NN	O	O
14	NN	O	O
.	NN	O	O
0	NN	O	O
;	NN	O	O
normal	NN	O	O
,	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
and	NN	O	O
was	NN	O	O
considered	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
partial	NN	O	O
or	NN	O	O
less	NN	O	O
severe	NN	O	O
defect	NN	O	O
in	NN	O	O
the	NN	O	O
previous	NN	O	O
report	NN	O	O
(	NN	O	O
IX	NN	O	O
-	NN	O	O
24	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
a	NN	O	O
NIS	NN	O	O
gene	NN	O	O
mutation	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
now	NN	O	O
possible	NN	O	O
to	NN	O	O
use	NN	O	O
gene	NN	O	O
diagnostics	NN	O	O
of	NN	O	O
this	NN	O	O
unique	NN	O	O
NIS	NN	O	O
mutation	NN	O	O
to	NN	O	O
identify	NN	O	O
patients	NN	O	O
with	NN	O	O
congenital	NN	O	B-Disease
hypothyroidism	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
an	NN	O	O
iodide	NN	O	B-Disease
transport	NN	O	I-Disease
defect	NN	O	I-Disease
in	NN	O	O
this	NN	O	O
family	NN	O	O
and	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
carrier	NN	O	O
state	NN	O	O
of	NN	O	O
potential	NN	O	O
parents	NN	O	O
for	NN	O	O
genetic	NN	O	O
counseling	NN	O	O
and	NN	O	O
arranging	NN	O	O
rapid	NN	O	O
and	NN	O	O
early	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
their	NN	O	O
infants	NN	O	O
.	NN	O	O

Molecular	NN	O	O
analysis	NN	O	O
in	NN	O	O
familial	NN	O	B-Disease
neurohypophyseal	NN	O	I-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
:	NN	O	O
early	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
an	NN	O	O
asymptomatic	NN	O	O
carrier	NN	O	O
.	NN	O	O

Familial	NN	O	B-Disease
neurohypophyseal	NN	O	I-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
(	NN	O	O
FNDI	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
inherited	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
hormone	NN	O	I-Disease
arginine	NN	O	I-Disease
vasopressin	NN	O	I-Disease
(	NN	O	O
AVP	NN	O	O
)	NN	O	O
and	NN	O	O
is	NN	O	O
transmitted	NN	O	O
as	NN	O	O
an	NN	O	O
autosomal	NN	O	O
dominant	NN	O	O
trait	NN	O	O
.	NN	O	O

The	NN	O	O
substitution	NN	O	O
was	NN	O	O
confirmed	NN	O	O
by	NN	O	O
restriction	NN	O	O
endonuclease	NN	O	O
analysis	NN	O	O
and	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
heterozygosis	NN	O	O
.	NN	O	O

The	NN	O	O
alteration	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
second	NN	O	O
exon	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
in	NN	O	O
this	NN	O	O
family	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
disease	NN	O	O
,	NN	O	O
as	NN	O	O
all	NN	O	O
individuals	NN	O	O
harboring	NN	O	O
the	NN	O	O
mutation	NN	O	O
had	NN	O	O
been	NN	O	O
previously	NN	O	O
diagnosed	NN	O	O
or	NN	O	O
have	NN	O	O
eventually	NN	O	O
developed	NN	O	O
FNDI	NN	O	B-Disease
.	NN	O	O

FRDA	NN	O	B-Disease
is	NN	O	O
caused	NN	O	O
by	NN	O	O
a	NN	O	O
GAA	NN	O	O
triplet	NN	O	O
expansion	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
intron	NN	O	O
of	NN	O	O
the	NN	O	O
FRDA	NN	O	B-Disease
gene	NN	O	O
on	NN	O	O
chromosome	NN	O	O
9q13	NN	O	O
in	NN	O	O
97	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
in	NN	O	O
vivo	NN	O	O
evidence	NN	O	O
of	NN	O	O
impaired	NN	O	O
mitochondrial	NN	O	O
respiration	NN	O	O
in	NN	O	O
skeletal	NN	O	O
muscle	NN	O	O
of	NN	O	O
FRDA	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
FRDA	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
nuclear	NN	O	O
-	NN	O	O
encoded	NN	O	O
mitochondrial	NN	O	B-Disease
disorder	NN	O	I-Disease
affecting	NN	O	O
oxidative	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
give	NN	O	O
a	NN	O	O
rationale	NN	O	O
for	NN	O	O
treatments	NN	O	O
aimed	NN	O	O
to	NN	O	O
improve	NN	O	O
mitochondrial	NN	O	O
function	NN	O	O
in	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O
.	NN	O	O

Restriction	NN	O	O
digestion	NN	O	O
following	NN	O	O
PCR	NN	O	O
amplification	NN	O	O
of	NN	O	O
ARG1	NN	O	O
exon	NN	O	O
2	NN	O	O
confirmed	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
the	NN	O	O
mutation	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
mutation	NN	O	O
at	NN	O	O
splice	NN	O	O
donor	NN	O	O
site	NN	O	O
and	NN	O	O
the	NN	O	O
truncation	NN	O	O
of	NN	O	O
mRNA	NN	O	O
were	NN	O	O
identical	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
a	NN	O	O
recently	NN	O	O
reported	NN	O	O
Italian	NN	O	O
patient	NN	O	O
,	NN	O	O
although	NN	O	O
different	NN	O	O
in	NN	O	O
symptomatology	NN	O	O
.	NN	O	O

DNA	NN	O	O
was	NN	O	O
also	NN	O	O
screened	NN	O	O
for	NN	O	O
structural	NN	O	O
rearrangements	NN	O	O
(	NN	O	O
deletions	NN	O	O
and	NN	O	O
duplications	NN	O	O
)	NN	O	O
and	NN	O	O
point	NN	O	O
mutations	NN	O	O
in	NN	O	O
mtDNA	NN	O	O
.	NN	O	O

We	NN	O	O
identified	NN	O	O
24	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
WFS1	NN	O	O
gene	NN	O	O
8	NN	O	O
nonsense	NN	O	O
mutations	NN	O	O
,	NN	O	O
8	NN	O	O
missense	NN	O	O
mutations	NN	O	O
,	NN	O	O
3	NN	O	O
in	NN	O	O
-	NN	O	O
frame	NN	O	O
deletions	NN	O	O
,	NN	O	O
1	NN	O	O
in	NN	O	O
-	NN	O	O
frame	NN	O	O
insertion	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
frameshift	NN	O	O
mutations	NN	O	O
.	NN	O	O

Only	NN	O	O
20	NN	O	O
of	NN	O	O
4000	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
had	NN	O	O
late	NN	O	O
-	NN	O	O
onset	NN	O	O
FMF	NN	O	B-Disease
.	NN	O	O

These	NN	O	O
patients	NN	O	O
were	NN	O	O
mostly	NN	O	O
men	NN	O	O
,	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
North	NN	O	O
African	NN	O	O
origin	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O

001	NN	O	O
001	NN	O	O
.	NN	O	O

001	NN	O	O
.	NN	O	O

A	NN	O	O
highly	NN	O	O
accurate	NN	O	O
,	NN	O	O
low	NN	O	O
cost	NN	O	O
test	NN	O	O
for	NN	O	O
BRCA1	NN	O	O
mutations	NN	O	O
.	NN	O	O

Juvenile	NN	O	B-Disease
retinoschisis	NN	O	I-Disease
is	NN	O	O
an	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
recessive	NN	O	I-Disease
disease	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
XLRS1	NN	O	O
gene	NN	O	O
.	NN	O	O

Mutations	NN	O	O
in	NN	O	O
25	NN	O	O
of	NN	O	O
the	NN	O	O
families	NN	O	O
were	NN	O	O
localized	NN	O	O
to	NN	O	O
exons	NN	O	O
4	NN	O	O
-	NN	O	O
6	NN	O	O
,	NN	O	O
emphasizing	NN	O	O
the	NN	O	O
critical	NN	O	O
functional	NN	O	O
significance	NN	O	O
of	NN	O	O
the	NN	O	O
discoidin	NN	O	O
domain	NN	O	O
of	NN	O	O
the	NN	O	O
XLRS1	NN	O	O
protein	NN	O	O

We	NN	O	O
studied	NN	O	O
whether	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
growth	NN	O	O
hormone	NN	O	O
(	NN	O	O
GH	NN	O	O
)	NN	O	O
treatment	NN	O	O
on	NN	O	O
growth	NN	O	O
and	NN	O	O
body	NN	O	O
composition	NN	O	O
in	NN	O	O
PWS	NN	O	B-Disease
are	NN	O	O
accompanied	NN	O	O
by	NN	O	O
an	NN	O	O
improvement	NN	O	O
in	NN	O	O
respiratory	NN	O	O
function	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Treatment	NN	O	O
of	NN	O	O
children	NN	O	O
with	NN	O	O
Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
PWS	NN	O	B-Disease
)	NN	O	O
seems	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
stimulatory	NN	O	O
effect	NN	O	O
on	NN	O	O
central	NN	O	O
respiratory	NN	O	O
structures	NN	O	O
.	NN	O	O

Haplotype	NN	O	O
analysis	NN	O	O
was	NN	O	O
undertaken	NN	O	O
on	NN	O	O
the	NN	O	O
four	NN	O	O
families	NN	O	O
who	NN	O	O
have	NN	O	O
been	NN	O	O
described	NN	O	O
with	NN	O	O
this	NN	O	O
mutation	NN	O	O
.	NN	O	O

Most	NN	O	O
fragile	NN	O	B-Disease
X	NN	O	I-Disease
syndrome	NN	O	I-Disease
patients	NN	O	O
have	NN	O	O
expansion	NN	O	O
of	NN	O	O
a	NN	O	O
(	NN	O	O
CGG	NN	O	O
)	NN	O	O
(	NN	O	O
n	NN	O	O
)	NN	O	O
sequence	NN	O	O
with	NN	O	O
>	NN	O	O
200	NN	O	O
repeats	NN	O	O
(	NN	O	O
full	NN	O	O
mutation	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
FMR1	NN	O	O
gene	NN	O	O
responsible	NN	O	O
for	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
a	NN	O	O
consistent	NN	O	O
,	NN	O	O
although	NN	O	O
modest	NN	O	O
,	NN	O	O
reactivation	NN	O	O
of	NN	O	O
the	NN	O	O
FMR1	NN	O	O
gene	NN	O	O
with	NN	O	O
4	NN	O	O
-	NN	O	O
phenylbutyrate	NN	O	O
,	NN	O	O
sodium	NN	O	O
butyrate	NN	O	O
and	NN	O	O
trichostatin	NN	O	O
A	NN	O	O
,	NN	O	O
as	NN	O	O
shown	NN	O	O
by	NN	O	O
RT	NN	O	O
-	NN	O	O
PCR	NN	O	O
.	NN	O	O

Spectrum	NN	O	O
of	NN	O	O
hSNF5	NN	O	O
/	NN	O	O
INI1	NN	O	O
somatic	NN	O	O
mutations	NN	O	O
in	NN	O	O
human	NN	O	O
cancer	NN	O	B-Disease
and	NN	O	O
genotype	NN	O	O
-	NN	O	O
phenotype	NN	O	O
correlations	NN	O	O
.	NN	O	O

2	NN	O	O
and	NN	O	O
recently	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
mutated	NN	O	O
in	NN	O	O
malignant	NN	O	B-Disease
rhabdoid	NN	O	I-Disease
tumors	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
hSNF5	NN	O	O
/	NN	O	O
INI1	NN	O	O
point	NN	O	O
mutations	NN	O	O
were	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
breast	NN	O	B-Disease
cancers	NN	O	I-Disease
,	NN	O	O
Wilms	NN	O	B-Disease
tumors	NN	O	I-Disease
,	NN	O	O
gliomas	NN	O	B-Disease
,	NN	O	O
ependymomas	NN	O	B-Disease
,	NN	O	O
sarcomas	NN	O	B-Disease
and	NN	O	O
other	NN	O	O
tumor	NN	O	B-Disease
types	NN	O	O
,	NN	O	O
even	NN	O	O
though	NN	O	O
most	NN	O	O
analyzed	NN	O	O
cases	NN	O	O
harbored	NN	O	O
loss	NN	O	O
of	NN	O	O
heterozygosity	NN	O	O
at	NN	O	O
22q11	NN	O	O
.	NN	O	O

Spinocerebellar	NN	O	B-Disease
ataxia	NN	O	I-Disease
type	NN	O	I-Disease
-	NN	O	I-Disease
3	NN	O	I-Disease
or	NN	O	O
Machado	NN	O	B-Disease
-	NN	O	I-Disease
Joseph	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
SCA3	NN	O	B-Disease
/	NN	O	O
MJD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
CAG	NN	O	B-Disease
/	NN	O	I-Disease
polyglutamine	NN	O	I-Disease
repeat	NN	O	I-Disease
disease	NN	O	I-Disease
family	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
manuscript	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
the	NN	O	O
characterization	NN	O	O
of	NN	O	O
MAGEL2	NN	O	O
and	NN	O	O
its	NN	O	O
mouse	NN	O	O
homologue	NN	O	O
Magel2	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
PAX3	NN	O	O
-	NN	O	O
FKHR	NN	O	O
but	NN	O	O
not	NN	O	O
PAX3	NN	O	O
activated	NN	O	O
a	NN	O	O
myogenic	NN	O	O
transcription	NN	O	O
program	NN	O	O
including	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
transcription	NN	O	O
factors	NN	O	O
MyoD	NN	O	O
,	NN	O	O
Myogenin	NN	O	O
,	NN	O	O
Six1	NN	O	O
,	NN	O	O
and	NN	O	O
Slug	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
battery	NN	O	O
of	NN	O	O
genes	NN	O	O
involved	NN	O	O
in	NN	O	O
several	NN	O	O
aspects	NN	O	O
of	NN	O	O
muscle	NN	O	O
function	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
utilizes	NN	O	O
cDNA	NN	O	O
microarrays	NN	O	O
to	NN	O	O
elucidate	NN	O	O
the	NN	O	O
pattern	NN	O	O
of	NN	O	O
gene	NN	O	O
expression	NN	O	O
induced	NN	O	O
by	NN	O	O
an	NN	O	O
oncogenic	NN	O	O
transcription	NN	O	O
factor	NN	O	O
and	NN	O	O
demonstrates	NN	O	O
the	NN	O	O
profound	NN	O	O
myogenic	NN	O	O
properties	NN	O	O
of	NN	O	O
PAX3	NN	O	O
-	NN	O	O
FKHR	NN	O	O
in	NN	O	O
NIH	NN	O	O
3T3	NN	O	O
cells	NN	O	O
.	NN	O	O
.	NN	O	O

Somatic	NN	O	O
rearrangement	NN	O	O
of	NN	O	O
chromosome	NN	O	O
14	NN	O	O
in	NN	O	O
human	NN	O	O
lymphocytes	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
mutation	NN	O	O
analysis	NN	O	O
of	NN	O	O
individual	NN	O	O
exons	NN	O	O
of	NN	O	O
the	NN	O	O
PDS	NN	O	B-Disease
gene	NN	O	O
in	NN	O	O
one	NN	O	O
Spanish	NN	O	O
family	NN	O	O
that	NN	O	O
shows	NN	O	O
intrafamilial	NN	O	O
variability	NN	O	O
of	NN	O	O
the	NN	O	O
deafness	NN	O	B-Disease
phenotype	NN	O	O
(	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
profound	NN	O	O
and	NN	O	O
one	NN	O	O
with	NN	O	O
moderate	NN	O	O
-	NN	O	O
severe	NN	O	O
deafness	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Sjogren	NN	O	B-Disease
-	NN	O	I-Disease
Larsson	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
SLS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
disorder	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
ichthyosis	NN	O	B-Disease
,	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
spasticity	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
deficient	NN	O	B-Disease
activity	NN	O	I-Disease
of	NN	O	I-Disease
fatty	NN	O	I-Disease
aldehyde	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
(	NN	O	O
FALDH	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
splice	NN	O	O
-	NN	O	O
site	NN	O	O
mutations	NN	O	O
led	NN	O	O
to	NN	O	O
exon	NN	O	O
skipping	NN	O	O
or	NN	O	O
utilization	NN	O	O
of	NN	O	O
cryptic	NN	O	O
acceptor	NN	O	O
-	NN	O	O
splice	NN	O	O
sites	NN	O	O
.	NN	O	O

Confirmation	NN	O	O
of	NN	O	O
linkage	NN	O	O
of	NN	O	O
Van	NN	O	B-Disease
der	NN	O	I-Disease
Woude	NN	O	I-Disease
syndrome	NN	O	I-Disease
to	NN	O	O
chromosome	NN	O	O
1q32	NN	O	O
:	NN	O	O
evidence	NN	O	O
of	NN	O	O
association	NN	O	O
with	NN	O	O
STR	NN	O	O
alleles	NN	O	O
suggests	NN	O	O
possible	NN	O	O
unique	NN	O	O
origin	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
mutation	NN	O	O
.	NN	O	O

All	NN	O	O
families	NN	O	O
showed	NN	O	O
positive	NN	O	O
LOD	NN	O	O
scores	NN	O	O
without	NN	O	O
any	NN	O	O
recombination	NN	O	O
in	NN	O	O
the	NN	O	O
candidate	NN	O	O
region	NN	O	O
.	NN	O	O

87	NN	O	O
87	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
a	NN	O	O
unique	NN	O	O
origin	NN	O	O
for	NN	O	O
a	NN	O	O
mutation	NN	O	O
responsible	NN	O	O
for	NN	O	O
many	NN	O	O
or	NN	O	O
most	NN	O	O
cases	NN	O	O
of	NN	O	O
VWS	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
Sit	NN	O	O
(	NN	O	O
a	NN	O	O
)	NN	O	O
alloantigen	NN	O	O
is	NN	O	O
of	NN	O	O
low	NN	O	O
frequency	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
400	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
German	NN	O	O
population	NN	O	O
.	NN	O	O

A	NN	O	O
major	NN	O	O
gene	NN	O	O
locus	NN	O	O
for	NN	O	O
PLS	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
mapped	NN	O	O
to	NN	O	O
a	NN	O	O
2	NN	O	O
.	NN	O	O

Many	NN	O	O
individuals	NN	O	O
with	NN	O	O
AAPC	NN	O	B-Disease
develop	NN	O	O
relatively	NN	O	O
few	NN	O	O
colorectal	NN	O	B-Disease
polyps	NN	O	I-Disease
but	NN	O	O
are	NN	O	O
still	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
for	NN	O	O
colorectal	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Alstrom	NN	O	B-Disease
syndrome	NN	O	I-Disease
:	NN	O	O
further	NN	O	O
evidence	NN	O	O
for	NN	O	O
linkage	NN	O	O
to	NN	O	O
human	NN	O	O
chromosome	NN	O	O
2p13	NN	O	O
.	NN	O	O

Pair	NN	O	O
-	NN	O	O
wise	NN	O	O
analyses	NN	O	O
resulted	NN	O	O
in	NN	O	O
maximum	NN	O	O
lod	NN	O	O
(	NN	O	O
logarithm	NN	O	O
of	NN	O	O
the	NN	O	O
odds	NN	O	O
ratio	NN	O	O
)	NN	O	O
scores	NN	O	O
of	NN	O	O
3	NN	O	O
.	NN	O	O

84	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O

9	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

16	NN	O	O
for	NN	O	O
marker	NN	O	O
D2S2110	NN	O	O
were	NN	O	O
observed	NN	O	O
,	NN	O	O
further	NN	O	O
supporting	NN	O	O
linkage	NN	O	O
to	NN	O	O
chromosome	NN	O	O
2p13	NN	O	O
.	NN	O	O

A	NN	O	O
widened	NN	O	B-Disease
vestibular	NN	O	I-Disease
aqueduct	NN	O	I-Disease
was	NN	O	O
found	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
computed	NN	O	O
tomography	NN	O	O
(	NN	O	O
CT	NN	O	O
)	NN	O	O
scan	NN	O	O
exploration	NN	O	O
of	NN	O	O
the	NN	O	O
inner	NN	O	O
ear	NN	O	O
.	NN	O	O

Our	NN	O	O
patient	NN	O	O
illustrates	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
investigating	NN	O	O
for	NN	O	O
underlying	NN	O	O
ocular	NN	O	O
and	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
pathology	NN	O	O
whenever	NN	O	O
midline	NN	O	B-Disease
scalp	NN	O	I-Disease
defects	NN	O	I-Disease
are	NN	O	O
present	NN	O	O
.	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
mutant	NN	O	O
hMre11	NN	O	O
proteins	NN	O	O
retain	NN	O	O
some	NN	O	O
ability	NN	O	O
to	NN	O	O
interact	NN	O	O
with	NN	O	O
hRad50	NN	O	O
and	NN	O	O
Nbs1	NN	O	O
,	NN	O	O
formation	NN	O	O
of	NN	O	O
ionizing	NN	O	O
radiation	NN	O	O
-	NN	O	O
induced	NN	O	O
hMre11	NN	O	O
and	NN	O	O
Nbs1	NN	O	O
foci	NN	O	O
was	NN	O	O
absent	NN	O	O
in	NN	O	O
hMRE11	NN	O	O
mutant	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
osteolytic	NN	O	B-Disease
lesions	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
develop	NN	O	O
usually	NN	O	O
in	NN	O	O
the	NN	O	O
long	NN	O	O
bones	NN	O	O
during	NN	O	O
early	NN	O	O
adulthood	NN	O	O
,	NN	O	O
show	NN	O	O
increased	NN	O	O
osteoblast	NN	O	O
and	NN	O	O
osteoclast	NN	O	O
activity	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
When	NN	O	O
expressed	NN	O	O
alone	NN	O	O
in	NN	O	O
Xenopus	NN	O	O
oocytes	NN	O	O
,	NN	O	O
T1620M	NN	O	O
exhibited	NN	O	O
no	NN	O	O
persistent	NN	O	O
currents	NN	O	O
,	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
the	NN	O	O
LQT3	NN	O	B-Disease
mutant	NN	O	O
channels	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
midpoint	NN	O	O
of	NN	O	O
steady	NN	O	O
-	NN	O	O
state	NN	O	O
inactivation	NN	O	O
(	NN	O	O
V	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
shifted	NN	O	O
toward	NN	O	O
more	NN	O	O
positive	NN	O	O
potentials	NN	O	O
than	NN	O	O
for	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
hH1	NN	O	O
.	NN	O	O

In	NN	O	O
hereditary	NN	O	B-Disease
retinoblastoma	NN	O	I-Disease
,	NN	O	O
different	NN	O	O
epidemiological	NN	O	O
studies	NN	O	O
have	NN	O	O
indicated	NN	O	O
a	NN	O	O
preferential	NN	O	O
paternal	NN	O	O
transmission	NN	O	O
of	NN	O	O
mutant	NN	O	O
retinoblastoma	NN	O	B-Disease
alleles	NN	O	O
to	NN	O	O
offspring	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
a	NN	O	O
meiotic	NN	O	O
drive	NN	O	O
.	NN	O	O

The	NN	O	O
segregation	NN	O	O
probability	NN	O	O
of	NN	O	O
mutant	NN	O	O
RB1	NN	O	O
alleles	NN	O	O
in	NN	O	O
sperm	NN	O	O
samples	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
SPERMSEG	NN	O	O
program	NN	O	O
,	NN	O	O
which	NN	O	O
includes	NN	O	O
experimental	NN	O	O
parameters	NN	O	O
,	NN	O	O
recombination	NN	O	O
fractions	NN	O	O
between	NN	O	O
the	NN	O	O
markers	NN	O	O
,	NN	O	O
and	NN	O	O
segregation	NN	O	O
parameters	NN	O	O
.	NN	O	O

Friedreich	NN	O	B-Disease
ataxia	NN	O	I-Disease
:	NN	O	O
an	NN	O	O
overview	NN	O	O
.	NN	O	O

Genomic	NN	O	O
DNA	NN	O	O
was	NN	O	O
isolated	NN	O	O
from	NN	O	O
leukocytes	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
exons	NN	O	O
of	NN	O	O
the	NN	O	O
XLRS1	NN	O	O
gene	NN	O	O
were	NN	O	O
amplified	NN	O	O
by	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
and	NN	O	O
analyzed	NN	O	O
using	NN	O	O
a	NN	O	O
direct	NN	O	O
sequencing	NN	O	O
method	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
discovery	NN	O	O
of	NN	O	O
new	NN	O	O
point	NN	O	O
mutations	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
increases	NN	O	O
the	NN	O	O
available	NN	O	O
information	NN	O	O
regarding	NN	O	O
the	NN	O	O
spectrum	NN	O	O
of	NN	O	O
genetic	NN	O	B-Disease
abnormalities	NN	O	I-Disease
and	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
of	NN	O	O
XLRS	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
limited	NN	O	O
data	NN	O	O
failed	NN	O	O
to	NN	O	O
reveal	NN	O	O
a	NN	O	O
correlation	NN	O	O
between	NN	O	O
mutation	NN	O	O
and	NN	O	O
disease	NN	O	O
phenotype	NN	O	O
.	NN	O	O

The	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
of	NN	O	O
Atm	NN	O	O
-	NN	O	O
null	NN	O	O
mice	NN	O	O
shows	NN	O	O
a	NN	O	O
pronounced	NN	O	O
defect	NN	O	O
in	NN	O	O
apoptosis	NN	O	O
induced	NN	O	O
by	NN	O	O
genotoxic	NN	O	O
stress	NN	O	O
,	NN	O	O
suggesting	NN	O	O
ATM	NN	O	O
functions	NN	O	O
to	NN	O	O
eliminate	NN	O	O
neurons	NN	O	O
with	NN	O	O
excessive	NN	O	O
genomic	NN	O	O
damage	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
the	NN	O	O
death	NN	O	O
effector	NN	O	O
Bax	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
a	NN	O	O
large	NN	O	O
proportion	NN	O	O
of	NN	O	O
Atm	NN	O	O
-	NN	O	O
dependent	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
the	NN	O	O
developing	NN	O	O
CNS	NN	O	O
after	NN	O	O
ionizing	NN	O	O
radiation	NN	O	O
(	NN	O	O
IR	NN	O	O
)	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
a	NN	O	O
shared	NN	O	O
common	NN	O	O
haplotype	NN	O	O
for	NN	O	O
genetic	NN	O	O
loci	NN	O	O
flanking	NN	O	O
the	NN	O	O
cathepsin	NN	O	O
C	NN	O	O
gene	NN	O	O
suggests	NN	O	O
that	NN	O	O
affected	NN	O	O
subjects	NN	O	O
descended	NN	O	O
from	NN	O	O
the	NN	O	O
Cochin	NN	O	O
isolate	NN	O	O
are	NN	O	O
homozygous	NN	O	O
for	NN	O	O
a	NN	O	O
mutation	NN	O	O
inherited	NN	O	O
"	NN	O	O
identical	NN	O	O
by	NN	O	O
descent	NN	O	O
"	NN	O	O
from	NN	O	O
a	NN	O	O
common	NN	O	O
ancestor	NN	O	O
.	NN	O	O

This	NN	O	O
finding	NN	O	O
supports	NN	O	O
simple	NN	O	O
autosomal	NN	O	O
recessive	NN	O	O
inheritance	NN	O	O
for	NN	O	O
HMS	NN	O	B-Disease
in	NN	O	O
these	NN	O	O
families	NN	O	O
.	NN	O	O

A	NN	O	O
high	NN	O	O
percentage	NN	O	O
of	NN	O	O
ATM	NN	O	O
germline	NN	O	O
mutations	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
among	NN	O	O
patients	NN	O	O
with	NN	O	O
sporadic	NN	O	B-Disease
breast	NN	O	I-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Among	NN	O	O
these	NN	O	O
patients	NN	O	O
we	NN	O	O
identified	NN	O	O
seven	NN	O	O
(	NN	O	O
8	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
ATM	NN	O	O
germline	NN	O	O
mutations	NN	O	O
,	NN	O	O
of	NN	O	O
which	NN	O	O
five	NN	O	O
are	NN	O	O
distinct	NN	O	O
.	NN	O	O

The	NN	O	O
specific	NN	O	O
characteristics	NN	O	O
of	NN	O	O
our	NN	O	O
population	NN	O	O
of	NN	O	O
patients	NN	O	O
may	NN	O	O
explain	NN	O	O
why	NN	O	O
such	NN	O	O
a	NN	O	O
high	NN	O	O
frequency	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
in	NN	O	O
other	NN	O	O
series	NN	O	O
.	NN	O	O

Constitutive	NN	O	O
and	NN	O	O
regulated	NN	O	O
modes	NN	O	O
of	NN	O	O
splicing	NN	O	O
produce	NN	O	O
six	NN	O	O
major	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
protein	NN	O	O
kinase	NN	O	O
(	NN	O	O
DMPK	NN	O	O
)	NN	O	O
isoforms	NN	O	O
with	NN	O	O
distinct	NN	O	O
properties	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
eight	NN	O	O
index	NN	O	O
patients	NN	O	O
with	NN	O	O
protein	NN	O	B-Disease
S	NN	O	I-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
PROS1	NN	O	B-Disease
gene	NN	O	I-Disease
defect	NN	O	I-Disease
were	NN	O	O
studied	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
109	NN	O	O
first	NN	O	O
-	NN	O	O
degree	NN	O	O
relatives	NN	O	O
.	NN	O	O

The	NN	O	O
heterozygous	NN	O	O
family	NN	O	O
members	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
the	NN	O	O
ALPS	NN	O	B-Disease
phenotype	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
disease	NN	O	O
-	NN	O	O
causing	NN	O	O
FAS	NN	O	O
mutation	NN	O	O
in	NN	O	O
this	NN	O	O
family	NN	O	O
is	NN	O	O
autosomal	NN	O	O
recessive	NN	O	O
.	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
novel	NN	O	O
imprinted	NN	O	O
transcripts	NN	O	O
in	NN	O	O
the	NN	O	O
Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
Angelman	NN	O	B-Disease
syndrome	NN	O	I-Disease
deletion	NN	O	O
region	NN	O	O
:	NN	O	O
further	NN	O	O
evidence	NN	O	O
for	NN	O	O
regional	NN	O	O
imprinting	NN	O	O
control	NN	O	O
.	NN	O	O

Deletions	NN	O	O
and	NN	O	O
other	NN	O	O
abnormalities	NN	O	O
of	NN	O	O
human	NN	O	O
chromosome	NN	O	O
15q11	NN	O	O
-	NN	O	O
q13	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
two	NN	O	O
developmental	NN	O	O
disorders	NN	O	O
,	NN	O	O
Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
PWS	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
Angelman	NN	O	B-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
AS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

A	NN	O	O
domain	NN	O	O
of	NN	O	O
exclusive	NN	O	O
paternal	NN	O	O
expression	NN	O	O
surrounding	NN	O	O
the	NN	O	O
imprinting	NN	O	O
center	NN	O	O
suggests	NN	O	O
strong	NN	O	O
regional	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
imprinting	NN	O	O
process	NN	O	O
.	NN	O	O

Combined	NN	O	O
analysis	NN	O	O
of	NN	O	O
hereditary	NN	O	B-Disease
prostate	NN	O	I-Disease
cancer	NN	O	I-Disease
linkage	NN	O	O
to	NN	O	O
1q24	NN	O	O
-	NN	O	O
25	NN	O	O
:	NN	O	O
results	NN	O	O
from	NN	O	O
772	NN	O	O
hereditary	NN	O	B-Disease
prostate	NN	O	I-Disease
cancer	NN	O	I-Disease
families	NN	O	O
from	NN	O	O
the	NN	O	O
International	NN	O	O
Consortium	NN	O	O
for	NN	O	O
Prostate	NN	O	B-Disease
Cancer	NN	O	I-Disease
Genetics	NN	O	O
.	NN	O	O

A	NN	O	O
previous	NN	O	O
linkage	NN	O	O
study	NN	O	O
provided	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
-	NN	O	O
susceptibility	NN	O	O
locus	NN	O	O
at	NN	O	O
1q24	NN	O	O
-	NN	O	O
25	NN	O	O
.	NN	O	O

This	NN	O	O
evidence	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
by	NN	O	O
a	NN	O	O
nonparametric	NN	O	O
approach	NN	O	O
,	NN	O	O
presumably	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
extensive	NN	O	O
heterogeneity	NN	O	O
.	NN	O	O

We	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
large	NN	O	O
expansions	NN	O	O
also	NN	O	O
occur	NN	O	O
in	NN	O	O
the	NN	O	O
female	NN	O	O
germline	NN	O	O
and	NN	O	O
that	NN	O	O
a	NN	O	O
negative	NN	O	O
selection	NN	O	O
of	NN	O	O
oocytes	NN	O	O
with	NN	O	O
long	NN	O	O
repeats	NN	O	O
might	NN	O	O
explain	NN	O	O
the	NN	O	O
different	NN	O	O
instability	NN	O	O
behavior	NN	O	O
of	NN	O	O
the	NN	O	O
male	NN	O	O
and	NN	O	O
the	NN	O	O
female	NN	O	O
germlines	NN	O	O
.	NN	O	O
.	NN	O	O

Wilson	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
WD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
disorder	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
copper	NN	O	O
accumulation	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
,	NN	O	O
brain	NN	O	O
,	NN	O	O
kidneys	NN	O	O
,	NN	O	O
and	NN	O	O
corneas	NN	O	O
,	NN	O	O
and	NN	O	O
culminating	NN	O	O
in	NN	O	O
copper	NN	O	O
toxication	NN	O	O
in	NN	O	O
these	NN	O	O
organs	NN	O	O
.	NN	O	O

hCds1	NN	O	O
-	NN	O	O
mediated	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
regulates	NN	O	O
the	NN	O	O
DNA	NN	O	O
damage	NN	O	O
response	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
whether	NN	O	O
BRCA1	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
dispersion	NN	O	O
and	NN	O	O
its	NN	O	O
function	NN	O	O
in	NN	O	O
DNA	NN	O	O
damage	NN	O	O
response	NN	O	O
are	NN	O	O
related	NN	O	O
.	NN	O	O

In	NN	O	O
yeast	NN	O	O
the	NN	O	O
DNA	NN	O	O
damage	NN	O	O
response	NN	O	O
and	NN	O	O
the	NN	O	O
replication	NN	O	O
-	NN	O	O
block	NN	O	O
checkpoint	NN	O	O
are	NN	O	O
mediated	NN	O	O
partly	NN	O	O
through	NN	O	O
the	NN	O	O
Cds1	NN	O	O
kinase	NN	O	O
family	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
gain	NN	O	O
insight	NN	O	O
into	NN	O	O
the	NN	O	O
biology	NN	O	O
of	NN	O	O
the	NN	O	O
MJD1	NN	O	O
/	NN	O	O
SCA3	NN	O	O
gene	NN	O	O
we	NN	O	O
cloned	NN	O	O
the	NN	O	O
rat	NN	O	O
homologue	NN	O	O
and	NN	O	O
studied	NN	O	O
its	NN	O	O
expression	NN	O	O
.	NN	O	O

The	NN	O	O
expression	NN	O	O
pattern	NN	O	O
of	NN	O	O
the	NN	O	O
SCA3	NN	O	O
gene	NN	O	O
in	NN	O	O
various	NN	O	O
rat	NN	O	O
and	NN	O	O
human	NN	O	O
tissues	NN	O	O
was	NN	O	O
investigated	NN	O	O
by	NN	O	O
Northern	NN	O	O
blot	NN	O	O
analyses	NN	O	O
.	NN	O	O

The	NN	O	O
mature	NN	O	O
transcript	NN	O	O
is	NN	O	O
approximately	NN	O	O
6	NN	O	O
kb	NN	O	O
in	NN	O	O
length	NN	O	O
.	NN	O	O

In	NN	O	O
rat	NN	O	O
testis	NN	O	O
,	NN	O	O
a	NN	O	O
smaller	NN	O	O
transcript	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O

Transcription	NN	O	O
of	NN	O	O
rsca3	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
most	NN	O	O
rat	NN	O	O
tissues	NN	O	O
including	NN	O	O
brain	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
emerin	NN	O	O
anchors	NN	O	O
at	NN	O	O
the	NN	O	O
inner	NN	O	O
nuclear	NN	O	O
membrane	NN	O	O
through	NN	O	O
the	NN	O	O
hydrophobic	NN	O	O
stretch	NN	O	O
,	NN	O	O
and	NN	O	O
protrudes	NN	O	O
from	NN	O	O
the	NN	O	O
hydrophilic	NN	O	O
region	NN	O	O
to	NN	O	O
the	NN	O	O
nucleoplasm	NN	O	O
where	NN	O	O
it	NN	O	O
interacts	NN	O	O
with	NN	O	O
the	NN	O	O
nuclear	NN	O	O
lamina	NN	O	O
.	NN	O	O

Locus	NN	O	O
heterogeneity	NN	O	O
in	NN	O	O
Friedreich	NN	O	B-Disease
ataxia	NN	O	I-Disease
.	NN	O	O

Friedreich	NN	O	B-Disease
ataxia	NN	O	I-Disease
(	NN	O	O
FRDA	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
form	NN	O	O
of	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
ataxia	NN	O	I-Disease
.	NN	O	O

Gene	NN	O	O
loci	NN	O	O
in	NN	O	O
the	NN	O	O
X	NN	O	O
-	NN	O	O
linked	NN	O	O
recessive	NN	O	O
forms	NN	O	O
have	NN	O	O
been	NN	O	O
assigned	NN	O	O
to	NN	O	O
Xq13	NN	O	O
.	NN	O	O

1	NN	O	O
in	NN	O	O
the	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
dystonia	NN	O	I-Disease
parkinsonism	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
to	NN	O	O
Xq22	NN	O	O
in	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
sensorineural	NN	O	I-Disease
deafness	NN	O	I-Disease
,	NN	O	O
dystonia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
disease	NN	O	O
genes	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
two	NN	O	O
autosomal	NN	O	O
dominant	NN	O	O
forms	NN	O	O
and	NN	O	O
in	NN	O	O
one	NN	O	O
X	NN	O	O
-	NN	O	O
linked	NN	O	O
recessive	NN	O	O
form	NN	O	O
.	NN	O	O

In	NN	O	O
sensorineural	NN	O	B-Disease
deafness	NN	O	I-Disease
,	NN	O	O
dystonia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
mutations	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
gene	NN	O	O
DDP	NN	O	O
coding	NN	O	O
for	NN	O	O
a	NN	O	O
polypeptide	NN	O	O
of	NN	O	O
unknown	NN	O	O
function	NN	O	O
.	NN	O	O

Several	NN	O	O
distinct	NN	O	O
clinical	NN	O	O
phenotypes	NN	O	O
are	NN	O	O
known	NN	O	O
.	NN	O	O

beta	NN	O	O
-	NN	O	O
galactosidase	NN	O	O
gene	NN	O	O
mutations	NN	O	O
affecting	NN	O	O
the	NN	O	O
lysosomal	NN	O	O
enzyme	NN	O	O
and	NN	O	O
the	NN	O	O
elastin	NN	O	O
-	NN	O	O
binding	NN	O	O
protein	NN	O	O
in	NN	O	O
GM1	NN	O	B-Disease
-	NN	O	I-Disease
gangliosidosis	NN	O	I-Disease
patients	NN	O	O
with	NN	O	O
cardiac	NN	O	B-Disease
involvement	NN	O	I-Disease
.	NN	O	O

Six	NN	O	O
of	NN	O	O
the	NN	O	O
eight	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
infantile	NN	O	O
,	NN	O	O
severe	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
presented	NN	O	O
cardiac	NN	O	B-Disease
involvement	NN	O	I-Disease
,	NN	O	O
a	NN	O	O
feature	NN	O	O
rarely	NN	O	O
associated	NN	O	O
with	NN	O	O
GM1	NN	O	B-Disease
-	NN	O	I-Disease
gangliosidosis	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
all	NN	O	O
other	NN	O	O
patients	NN	O	O
were	NN	O	O
compound	NN	O	O
heterozygous	NN	O	O
for	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
following	NN	O	O
mutations	NN	O	O
R201H	NN	O	O
,	NN	O	O
R482H	NN	O	O
,	NN	O	O
G579D	NN	O	O
,	NN	O	O
IVS8	NN	O	O
+	NN	O	O
2T	NN	O	O
>	NN	O	O
C	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
both	NN	O	O
molecules	NN	O	O
are	NN	O	O
affected	NN	O	O
by	NN	O	O
the	NN	O	O
mutations	NN	O	O
,	NN	O	O
and	NN	O	O
they	NN	O	O
may	NN	O	O
contribute	NN	O	O
differently	NN	O	O
to	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
specific	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
.	NN	O	O
.	NN	O	O

HMGIC	NN	O	O
is	NN	O	O
predominantly	NN	O	O
expressed	NN	O	O
in	NN	O	O
proliferating	NN	O	O
,	NN	O	O
undifferentiated	NN	O	O
mesenchymal	NN	O	O
cells	NN	O	O
and	NN	O	O
is	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
adult	NN	O	O
tissues	NN	O	O
.	NN	O	O

To	NN	O	O
study	NN	O	O
its	NN	O	O
role	NN	O	O
in	NN	O	O
adipogenesis	NN	O	O
and	NN	O	O
obesity	NN	O	B-Disease
,	NN	O	O
we	NN	O	O
examined	NN	O	O
Hmgic	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
adipose	NN	O	O
tissue	NN	O	O
of	NN	O	O
adult	NN	O	O
,	NN	O	O
obese	NN	O	B-Disease
mice	NN	O	O
.	NN	O	O

Our	NN	O	O
studies	NN	O	O
implicate	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
HMGIC	NN	O	O
in	NN	O	O
fat	NN	O	O
-	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
adipose	NN	O	O
-	NN	O	O
specific	NN	O	O
target	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
obesity	NN	O	B-Disease
.	NN	O	O
.	NN	O	O

Molecular	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
genotype	NN	O	O
-	NN	O	O
phenotype	NN	O	O
relationship	NN	O	O
in	NN	O	O
factor	NN	O	B-Disease
X	NN	O	I-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

Missense	NN	O	O
mutations	NN	O	O
were	NN	O	O
studied	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
molecular	NN	O	O
modelling	NN	O	O
,	NN	O	O
whereas	NN	O	O
single	NN	O	O
basepair	NN	O	O
substitutions	NN	O	O
in	NN	O	O
splice	NN	O	O
sites	NN	O	O
and	NN	O	O
the	NN	O	O
5	NN	O	O
flanking	NN	O	O
region	NN	O	O
were	NN	O	O
examined	NN	O	O
by	NN	O	O
in	NN	O	O
vitro	NN	O	O
splicing	NN	O	O
assay	NN	O	O
and	NN	O	O
luciferase	NN	O	O
reporter	NN	O	O
gene	NN	O	O
assay	NN	O	O
respectively	NN	O	O
.	NN	O	O

One	NN	O	O
family	NN	O	O
manifesting	NN	O	O
an	NN	O	O
autosomal	NN	O	O
dominant	NN	O	O
pattern	NN	O	O
of	NN	O	O
inheritance	NN	O	O
possessed	NN	O	O
three	NN	O	O
clinically	NN	O	O
affected	NN	O	O
members	NN	O	O
who	NN	O	O
were	NN	O	O
heterozygous	NN	O	O
for	NN	O	O
a	NN	O	O
splice	NN	O	O
-	NN	O	O
site	NN	O	O
mutation	NN	O	O
that	NN	O	O
was	NN	O	O
predicted	NN	O	O
to	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
a	NN	O	O
truncated	NN	O	O
protein	NN	O	O
product	NN	O	O
.	NN	O	O

By	NN	O	O
contrast	NN	O	O
,	NN	O	O
no	NN	O	O
such	NN	O	O
relationship	NN	O	O
could	NN	O	O
be	NN	O	O
discerned	NN	O	O
between	NN	O	O
laboratory	NN	O	O
phenotype	NN	O	O
and	NN	O	O
polymorphism	NN	O	O
genotype	NN	O	O
.	NN	O	O
.	NN	O	O

Chromosomal	NN	O	O
translocations	NN	O	O
in	NN	O	O
human	NN	O	O
lipomas	NN	O	B-Disease
frequently	NN	O	O
create	NN	O	O
fusion	NN	O	O
transcripts	NN	O	O
encoding	NN	O	O
high	NN	O	O
mobility	NN	O	O
group	NN	O	O
(	NN	O	O
HMG	NN	O	O
)	NN	O	O
I	NN	O	O
-	NN	O	O
C	NN	O	O
DNA	NN	O	O
-	NN	O	O
binding	NN	O	O
domains	NN	O	O
and	NN	O	O
C	NN	O	O
-	NN	O	O
terminal	NN	O	O
sequences	NN	O	O
from	NN	O	O
different	NN	O	O
presumed	NN	O	O
transcription	NN	O	O
factors	NN	O	O
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
potential	NN	O	O
role	NN	O	O
for	NN	O	O
HMG	NN	O	O
I	NN	O	O
-	NN	O	O
C	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
lipomas	NN	O	B-Disease
.	NN	O	O

These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
DNA	NN	O	O
-	NN	O	O
binding	NN	O	O
domains	NN	O	O
of	NN	O	O
HMG	NN	O	O
I	NN	O	O
-	NN	O	O
C	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
a	NN	O	O
C	NN	O	O
-	NN	O	O
terminal	NN	O	O
fusion	NN	O	O
partner	NN	O	O
,	NN	O	O
are	NN	O	O
sufficient	NN	O	O
to	NN	O	O
perturb	NN	O	O
adipogenesis	NN	O	O
and	NN	O	O
predispose	NN	O	O
to	NN	O	O
lipomas	NN	O	B-Disease
.	NN	O	O

These	NN	O	O
observations	NN	O	O
link	NN	O	O
ATM	NN	O	O
and	NN	O	O
p95	NN	O	O
/	NN	O	O
nbs1	NN	O	O
in	NN	O	O
a	NN	O	O
common	NN	O	O
signalling	NN	O	O
pathway	NN	O	O
and	NN	O	O
provide	NN	O	O
an	NN	O	O
explanation	NN	O	O
for	NN	O	O
phenotypic	NN	O	O
similarities	NN	O	O
in	NN	O	O
these	NN	O	O
two	NN	O	O
diseases	NN	O	O
.	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
extracellular	NN	O	O
matrix	NN	O	O
synthesis	NN	O	O
or	NN	O	O
organization	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
development	NN	O	O
of	NN	O	O
the	NN	O	O
ocular	NN	O	O
phenotypes	NN	O	O
.	NN	O	O

Fmr1	NN	O	O
knockout	NN	O	O
mice	NN	O	O
exhibit	NN	O	O
a	NN	O	O
phenotype	NN	O	O
with	NN	O	O
some	NN	O	O
similarities	NN	O	O
to	NN	O	O
humans	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
macroorchidism	NN	O	B-Disease
and	NN	O	O
behavioral	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

Inactivation	NN	O	O
of	NN	O	O
the	NN	O	O
Friedreich	NN	O	B-Disease
ataxia	NN	O	I-Disease
mouse	NN	O	O
gene	NN	O	O
leads	NN	O	O
to	NN	O	O
early	NN	O	O
embryonic	NN	O	B-Disease
lethality	NN	O	I-Disease
without	NN	O	O
iron	NN	O	O
accumulation	NN	O	O
.	NN	O	O

Friedreich	NN	O	B-Disease
ataxia	NN	O	I-Disease
(	NN	O	O
FRDA	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
ataxia	NN	O	I-Disease
,	NN	O	O
is	NN	O	O
caused	NN	O	O
in	NN	O	O
almost	NN	O	O
all	NN	O	O
cases	NN	O	O
by	NN	O	O
homozygous	NN	O	O
intronic	NN	O	O
expansions	NN	O	O
resulting	NN	O	O
in	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
frataxin	NN	O	O
,	NN	O	O
a	NN	O	O
mitochondrial	NN	O	O
protein	NN	O	O
conserved	NN	O	O
through	NN	O	O
evolution	NN	O	O
,	NN	O	O
and	NN	O	O
involved	NN	O	O
in	NN	O	O
mitochondrial	NN	O	O
iron	NN	O	O
homeostasis	NN	O	O
.	NN	O	O

Yeast	NN	O	O
knockout	NN	O	O
models	NN	O	O
,	NN	O	O
and	NN	O	O
histological	NN	O	O
and	NN	O	O
biochemical	NN	O	O
data	NN	O	O
from	NN	O	O
patient	NN	O	O
heart	NN	O	O
biopsies	NN	O	O
or	NN	O	O
autopsies	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
frataxin	NN	O	O
defect	NN	O	O
causes	NN	O	O
a	NN	O	O
specific	NN	O	O
iron	NN	O	B-Disease
-	NN	O	I-Disease
sulfur	NN	O	I-Disease
protein	NN	O	I-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
mitochondrial	NN	O	O
iron	NN	O	O
accumulation	NN	O	O
leading	NN	O	O
to	NN	O	O
the	NN	O	O
pathological	NN	O	O
changes	NN	O	O
.	NN	O	O

To	NN	O	O
study	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
,	NN	O	O
we	NN	O	O
generated	NN	O	O
a	NN	O	O
mouse	NN	O	O
model	NN	O	O
by	NN	O	O
deletion	NN	O	O
of	NN	O	O
exon	NN	O	O
4	NN	O	O
leading	NN	O	O
to	NN	O	O
inactivation	NN	O	O
of	NN	O	O
the	NN	O	O
Frda	NN	O	B-Disease
gene	NN	O	O
product	NN	O	O
.	NN	O	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
homozygous	NN	O	O
deletions	NN	O	O
cause	NN	O	O
embryonic	NN	O	B-Disease
lethality	NN	O	I-Disease
a	NN	O	O
few	NN	O	O
days	NN	O	O
after	NN	O	O
implantation	NN	O	O
,	NN	O	O
demonstrating	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
for	NN	O	O
frataxin	NN	O	O
during	NN	O	O
early	NN	O	O
development	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
milder	NN	O	O
phenotype	NN	O	O
in	NN	O	O
humans	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
residual	NN	O	O
frataxin	NN	O	O
expression	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
expansion	NN	O	O
mutations	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
the	NN	O	O
linkage	NN	O	O
disequilibrium	NN	O	O
(	NN	O	O
LD	NN	O	O
)	NN	O	O
delta	NN	O	O
values	NN	O	O
,	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
Jewish	NN	O	O
European	NN	O	O
N370S	NN	O	O
chromosomes	NN	O	O
had	NN	O	O
greater	NN	O	O
haplotype	NN	O	O
diversity	NN	O	O
and	NN	O	O
less	NN	O	O
LD	NN	O	O
at	NN	O	O
the	NN	O	O
markers	NN	O	O
flanking	NN	O	O
the	NN	O	O
conserved	NN	O	O
haplotype	NN	O	O
than	NN	O	O
did	NN	O	O
the	NN	O	O
AJ	NN	O	O
N370S	NN	O	O
chromosomes	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
are	NN	O	O
interpreted	NN	O	O
as	NN	O	O
suggesting	NN	O	O
some	NN	O	O
degree	NN	O	O
of	NN	O	O
clinical	NN	O	O
and	NN	O	O
genetic	NN	O	O
heterogeneity	NN	O	O
in	NN	O	O
ankylosing	NN	O	B-Disease
spondylitis	NN	O	I-Disease
with	NN	O	O
genes	NN	O	O
for	NN	O	O
psoriasis	NN	O	B-Disease
and	NN	O	O
inflammatory	NN	O	B-Disease
bowel	NN	O	I-Disease
disease	NN	O	I-Disease
being	NN	O	O
important	NN	O	O
in	NN	O	O
some	NN	O	O
individuals	NN	O	O
,	NN	O	O
particularly	NN	O	O
those	NN	O	O
who	NN	O	O
are	NN	O	O
B27	NN	O	O
negative	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
are	NN	O	O
thought	NN	O	O
to	NN	O	O
provide	NN	O	O
evidence	NN	O	O
against	NN	O	O
the	NN	O	O
concept	NN	O	O
that	NN	O	O
the	NN	O	O
gene	NN	O	O
for	NN	O	O
ankylosing	NN	O	B-Disease
spondylitis	NN	O	I-Disease
is	NN	O	O
not	NN	O	O
B27	NN	O	O
but	NN	O	O
a	NN	O	O
closely	NN	O	O
linked	NN	O	O
gene	NN	O	O
and	NN	O	O
favour	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
an	NN	O	O
environmental	NN	O	O
event	NN	O	O
affecting	NN	O	O
approximately	NN	O	O
one	NN	O	O
-	NN	O	O
fifth	NN	O	O
of	NN	O	O
B27	NN	O	O
positive	NN	O	O
males	NN	O	O
to	NN	O	O
result	NN	O	O
in	NN	O	O
disease	NN	O	O
.	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
undertaken	NN	O	O
a	NN	O	O
hospital	NN	O	O
-	NN	O	O
based	NN	O	O
study	NN	O	O
,	NN	O	O
to	NN	O	O
identify	NN	O	O
possible	NN	O	O
BRCA1	NN	O	O
and	NN	O	O
BRCA2	NN	O	O
founder	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
Polish	NN	O	O
population	NN	O	O
.	NN	O	O

Seven	NN	O	O
distinct	NN	O	O
mutations	NN	O	O
were	NN	O	O
identified	NN	O	O
;	NN	O	O
five	NN	O	O
of	NN	O	O
these	NN	O	O
occurred	NN	O	O
in	NN	O	O
two	NN	O	O
or	NN	O	O
more	NN	O	O
families	NN	O	O
.	NN	O	O

In	NN	O	O
total	NN	O	O
,	NN	O	O
recurrent	NN	O	O
mutations	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
33	NN	O	O
(	NN	O	O
94	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
35	NN	O	O
families	NN	O	O
with	NN	O	O
detected	NN	O	O
mutations	NN	O	O
.	NN	O	O

"	NN	O	O
Grandmatrilineal	NN	O	O
"	NN	O	O
inheritance	NN	O	O
occurs	NN	O	O
when	NN	O	O
a	NN	O	O
woman	NN	O	O
with	NN	O	O
deletion	NN	O	O
of	NN	O	O
an	NN	O	O
imprinted	NN	O	O
,	NN	O	O
paternally	NN	O	O
expressed	NN	O	O
gene	NN	O	O
is	NN	O	O
at	NN	O	O
risk	NN	O	O
of	NN	O	O
having	NN	O	O
affected	NN	O	O
grandchildren	NN	O	O
through	NN	O	O
her	NN	O	O
sons	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
also	NN	O	O
examined	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
NKH	NN	O	B-Disease
with	NN	O	O
no	NN	O	O
detectable	NN	O	O
GLDC	NN	O	O
mRNA	NN	O	O
in	NN	O	O
his	NN	O	O
lymphoblasts	NN	O	O
.	NN	O	O

Structural	NN	O	O
information	NN	O	O
of	NN	O	O
GLDC	NN	O	O
and	NN	O	O
psiGLDC	NN	O	O
should	NN	O	O
facilitate	NN	O	O
the	NN	O	O
molecular	NN	O	O
analysis	NN	O	O
of	NN	O	O
NKH	NN	O	B-Disease
.	NN	O	O

De	NN	O	O
novo	NN	O	O
deletions	NN	O	O
of	NN	O	O
SNRPN	NN	O	O
exon	NN	O	O
1	NN	O	O
in	NN	O	O
early	NN	O	O
human	NN	O	O
and	NN	O	O
mouse	NN	O	O
embryos	NN	O	O
result	NN	O	O
in	NN	O	O
a	NN	O	O
paternal	NN	O	O
to	NN	O	O
maternal	NN	O	O
imprint	NN	O	O
switch	NN	O	O
.	NN	O	O

Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
PWS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
neurogenetic	NN	O	B-Disease
disease	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
infantile	NN	O	B-Disease
hypotonia	NN	O	I-Disease
,	NN	O	O
gonadal	NN	O	B-Disease
hypoplasia	NN	O	I-Disease
,	NN	O	O
obsessive	NN	O	O
behaviour	NN	O	O
and	NN	O	O
neonatal	NN	O	O
feeding	NN	O	O
difficulties	NN	O	O
followed	NN	O	O
by	NN	O	O
hyperphagia	NN	O	B-Disease
,	NN	O	O
leading	NN	O	O
to	NN	O	O
profound	NN	O	O
obesity	NN	O	B-Disease
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
a	NN	O	O
PWS	NN	O	B-Disease
family	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
father	NN	O	O
is	NN	O	O
mosaic	NN	O	O
for	NN	O	O
an	NN	O	O
IC	NN	O	O
deletion	NN	O	O
on	NN	O	O
his	NN	O	O
paternal	NN	O	O
chromosome	NN	O	O
.	NN	O	O

We	NN	O	O
,	NN	O	O
and	NN	O	O
others	NN	O	O
,	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
repeat	NN	O	O
expansion	NN	O	O
decreases	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
adjacent	NN	O	O
gene	NN	O	O
SIX5	NN	O	O
(	NN	O	O
refs	NN	O	O
7	NN	O	O
,	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
encodes	NN	O	O
a	NN	O	O
homeodomain	NN	O	O
transcription	NN	O	O
factor	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
SIX5	NN	O	B-Disease
deficiency	NN	O	I-Disease
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
phenotype	NN	O	O
,	NN	O	O
we	NN	O	O
disrupted	NN	O	O
mouse	NN	O	O
Six5	NN	O	O
by	NN	O	O
replacing	NN	O	O
the	NN	O	O
first	NN	O	O
exon	NN	O	O
with	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
galactosidase	NN	O	O
reporter	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
loss	NN	O	O
of	NN	O	O
Dm15	NN	O	O
(	NN	O	O
the	NN	O	O
mouse	NN	O	O
DMPK	NN	O	O
homologue	NN	O	O
)	NN	O	O
in	NN	O	O
mice	NN	O	O
produces	NN	O	O
a	NN	O	O
partial	NN	O	O
DM	NN	O	B-Disease
phenotype	NN	O	O
characterized	NN	O	O
by	NN	O	O
decreased	NN	O	O
development	NN	O	O
of	NN	O	O
skeletal	NN	O	O
muscle	NN	O	O
force	NN	O	O
and	NN	O	O
cardiac	NN	O	B-Disease
conduction	NN	O	I-Disease
disorders	NN	O	I-Disease
.	NN	O	O

As	NN	O	O
ocular	NN	O	O
cataracts	NN	O	B-Disease
are	NN	O	O
a	NN	O	O
characteristic	NN	O	O
feature	NN	O	O
of	NN	O	O
DM	NN	O	B-Disease
,	NN	O	O
these	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
decreased	NN	O	O
SIX5	NN	O	O
transcription	NN	O	O
is	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
aetiology	NN	O	O
of	NN	O	O
DM	NN	O	B-Disease
.	NN	O	O

ATM	NN	O	O
-	NN	O	O
dependent	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
nibrin	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
radiation	NN	O	O
exposure	NN	O	O
.	NN	O	O

ATM	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
nibrin	NN	O	O
does	NN	O	O
not	NN	O	O
affect	NN	O	O
nibrin	NN	O	O
-	NN	O	O
MRE11	NN	O	O
-	NN	O	O
RAD50	NN	O	O
association	NN	O	O
as	NN	O	O
revealed	NN	O	O
by	NN	O	O
radiation	NN	O	O
-	NN	O	O
induced	NN	O	O
foci	NN	O	O
formation	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
The	NN	O	O
study	NN	O	O
was	NN	O	O
restricted	NN	O	O
to	NN	O	O
patients	NN	O	O
of	NN	O	O
Jewish	NN	O	O
origin	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
ease	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
and	NN	O	O
BRCA2	NN	O	O
genotyping	NN	O	O
in	NN	O	O
this	NN	O	O
ethnic	NN	O	O
group	NN	O	O
.	NN	O	O

From	NN	O	O
the	NN	O	O
189	NN	O	O
patients	NN	O	O
who	NN	O	O
identified	NN	O	O
themselves	NN	O	O
as	NN	O	O
Jewish	NN	O	O
,	NN	O	O
88	NN	O	O
hereditary	NN	O	O
cases	NN	O	O
were	NN	O	O
identified	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
germline	NN	O	O
founder	NN	O	O
mutation	NN	O	O
in	NN	O	O
BRCA1	NN	O	O
or	NN	O	O
BRCA2	NN	O	O
.	NN	O	O

CD34	NN	O	O
hematopoietic	NN	O	O
stem	NN	O	O
-	NN	O	O
cell	NN	O	O
cultures	NN	O	O
induced	NN	O	O
toward	NN	O	O
the	NN	O	O
granulocytic	NN	O	O
lineage	NN	O	O
expressed	NN	O	O
MEFV	NN	O	O
at	NN	O	O
the	NN	O	O
myelocyte	NN	O	O
stage	NN	O	O
,	NN	O	O
concurrently	NN	O	O
with	NN	O	O
lineage	NN	O	O
commitment	NN	O	O
.	NN	O	O

MEFV	NN	O	O
was	NN	O	O
also	NN	O	O
expressed	NN	O	O
in	NN	O	O
the	NN	O	O
monocytic	NN	O	O
cell	NN	O	O
lines	NN	O	O
U937	NN	O	O
and	NN	O	O
THP	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

In	NN	O	O
granulocytes	NN	O	O
,	NN	O	O
MEFV	NN	O	O
was	NN	O	O
up	NN	O	O
-	NN	O	O
regulated	NN	O	O
by	NN	O	O
IFN	NN	O	O
-	NN	O	O
gamma	NN	O	O
and	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
IFN	NN	O	O
-	NN	O	O
alpha	NN	O	O
and	NN	O	O
colchicine	NN	O	O
.	NN	O	O

Biochemical	NN	O	O
and	NN	O	O
structural	NN	O	O
analysis	NN	O	O
of	NN	O	O
missense	NN	O	O
mutations	NN	O	O
in	NN	O	O
N	NN	O	O
-	NN	O	O
acetylgalactosamine	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
sulfate	NN	O	O
sulfatase	NN	O	O
causing	NN	O	O
mucopolysaccharidosis	NN	O	B-Disease
IVA	NN	O	I-Disease
phenotypes	NN	O	O
.	NN	O	O

Mucopolysaccharidosis	NN	O	B-Disease
IVA	NN	O	I-Disease
(	NN	O	O
MPS	NN	O	B-Disease
IVA	NN	O	I-Disease
;	NN	O	O
OMIM	NN	O	O
#	NN	O	O
253000	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
lysosomal	NN	O	B-Disease
storage	NN	O	I-Disease
disorder	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
a	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
N	NN	O	I-Disease
-	NN	O	I-Disease
acetylgalactosamine	NN	O	I-Disease
-	NN	O	I-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
sulfate	NN	O	I-Disease
sulfatase	NN	O	I-Disease
(	NN	O	O
GALNS	NN	O	O
)	NN	O	O
,	NN	O	O
has	NN	O	O
variable	NN	O	O
clinical	NN	O	O
phenotypes	NN	O	O
.	NN	O	O

Mutants	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
mild	NN	O	O
phenotype	NN	O	O
had	NN	O	O
a	NN	O	O
considerable	NN	O	O
residual	NN	O	O
activity	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
13	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
GALNS	NN	O	O
activity	NN	O	O
)	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
we	NN	O	O
propose	NN	O	O
that	NN	O	O
there	NN	O	O
are	NN	O	O
at	NN	O	O
least	NN	O	O
three	NN	O	O
different	NN	O	O
reasons	NN	O	O
for	NN	O	O
the	NN	O	O
severe	NN	O	O
phenotype	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
destruction	NN	O	O
of	NN	O	O
the	NN	O	O
hydrophobic	NN	O	O
core	NN	O	O
or	NN	O	O
modification	NN	O	O
of	NN	O	O
the	NN	O	O
packing	NN	O	O
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
removal	NN	O	O
of	NN	O	O
a	NN	O	O
salt	NN	O	O
bridge	NN	O	O
to	NN	O	O
destabilize	NN	O	O
the	NN	O	O
entire	NN	O	O
conformation	NN	O	O
;	NN	O	O
(	NN	O	O
iii	NN	O	O
)	NN	O	O
modification	NN	O	O
of	NN	O	O
the	NN	O	O
active	NN	O	O
site	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
perhaps	NN	O	O
because	NN	O	O
of	NN	O	O
an	NN	O	O
ancient	NN	O	O
frame	NN	O	O
-	NN	O	O
shift	NN	O	O
mutation	NN	O	O
,	NN	O	O
neither	NN	O	O
the	NN	O	O
mouse	NN	O	O
nor	NN	O	O
the	NN	O	O
rat	NN	O	O
protein	NN	O	O
has	NN	O	O
an	NN	O	O
intact	NN	O	O
C	NN	O	O
-	NN	O	O
terminal	NN	O	O
B30	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
first	NN	O	O
family	NN	O	O
,	NN	O	O
the	NN	O	O
extra	NN	O	O
copy	NN	O	O
was	NN	O	O
first	NN	O	O
detected	NN	O	O
by	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
heterozygosity	NN	O	O
of	NN	O	O
the	NN	O	O
AhaII	NN	O	O
dimorphism	NN	O	O
within	NN	O	O
the	NN	O	O
PLP	NN	O	O
gene	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
FISH	NN	O	O
analysis	NN	O	O
showed	NN	O	O
an	NN	O	O
additional	NN	O	O
copy	NN	O	O
of	NN	O	O
PLP	NN	O	O
in	NN	O	O
Xp22	NN	O	O
.	NN	O	O

The	NN	O	O
identification	NN	O	O
of	NN	O	O
three	NN	O	O
separate	NN	O	O
families	NN	O	O
in	NN	O	O
which	NN	O	O
PLP	NN	O	O
is	NN	O	O
duplicated	NN	O	O
at	NN	O	O
a	NN	O	O
noncontiguous	NN	O	O
site	NN	O	O
suggests	NN	O	O
that	NN	O	O
such	NN	O	O
duplications	NN	O	O
could	NN	O	O
be	NN	O	O
a	NN	O	O
relatively	NN	O	O
common	NN	O	O
but	NN	O	O
previously	NN	O	O
undetected	NN	O	O
cause	NN	O	O
of	NN	O	O
genetic	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
exon	NN	O	O
13	NN	O	O
duplication	NN	O	O
in	NN	O	O
the	NN	O	O
BRCA1	NN	O	O
gene	NN	O	O
is	NN	O	O
a	NN	O	O
founder	NN	O	O
mutation	NN	O	O
present	NN	O	O
in	NN	O	O
geographically	NN	O	O
diverse	NN	O	O
populations	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
our	NN	O	O
goal	NN	O	O
was	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
frequency	NN	O	O
and	NN	O	O
geographic	NN	O	O
diversity	NN	O	O
of	NN	O	O
carriers	NN	O	O
of	NN	O	O
this	NN	O	O
duplication	NN	O	O
.	NN	O	O

In	NN	O	O
four	NN	O	O
families	NN	O	O
,	NN	O	O
partial	NN	O	O
deletions	NN	O	O
of	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
exons	NN	O	O
were	NN	O	O
detected	NN	O	O
by	NN	O	O
Southern	NN	O	O
blot	NN	O	O
analysis	NN	O	O
.	NN	O	O

This	NN	O	O
response	NN	O	O
includes	NN	O	O
S	NN	O	O
-	NN	O	O
phase	NN	O	O
checkpoint	NN	O	O
activation	NN	O	O
,	NN	O	O
formation	NN	O	O
of	NN	O	O
the	NN	O	O
NBS1	NN	O	O
/	NN	O	O
Mrel1	NN	O	O
/	NN	O	O
Rad50	NN	O	O
nuclear	NN	O	O
foci	NN	O	O
and	NN	O	O
rescue	NN	O	O
of	NN	O	O
hypersensitivity	NN	O	B-Disease
to	NN	O	I-Disease
ionizing	NN	O	I-Disease
radiation	NN	O	I-Disease
.	NN	O	O

Together	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
biochemical	NN	O	O
link	NN	O	O
between	NN	O	O
cell	NN	O	O
-	NN	O	O
cycle	NN	O	O
checkpoints	NN	O	O
activated	NN	O	O
by	NN	O	O
DNA	NN	O	O
damage	NN	O	O
and	NN	O	O
DNA	NN	O	O
repair	NN	O	O
in	NN	O	O
two	NN	O	O
genetic	NN	O	B-Disease
diseases	NN	O	I-Disease
with	NN	O	O
overlapping	NN	O	O
phenotypes	NN	O	O
.	NN	O	O
.	NN	O	O

Homozygosity	NN	O	O
mapping	NN	O	O
in	NN	O	O
a	NN	O	O
family	NN	O	O
with	NN	O	O
microcephaly	NN	O	B-Disease
,	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
short	NN	O	B-Disease
stature	NN	O	I-Disease
to	NN	O	O
a	NN	O	O
Cohen	NN	O	B-Disease
syndrome	NN	O	I-Disease
region	NN	O	O
on	NN	O	O
8q21	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
8q22	NN	O	O
.	NN	O	O
1	NN	O	O
:	NN	O	O
redefining	NN	O	O
a	NN	O	O
clinical	NN	O	O
entity	NN	O	O
.	NN	O	O

A	NN	O	O
syndrome	NN	O	O
of	NN	O	O
microcephaly	NN	O	B-Disease
,	NN	O	O
progressive	NN	O	O
postnatal	NN	O	B-Disease
growth	NN	O	I-Disease
deficiency	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
was	NN	O	O
observed	NN	O	O
in	NN	O	O
two	NN	O	O
brothers	NN	O	O
and	NN	O	O
their	NN	O	O
cousin	NN	O	O
from	NN	O	O
a	NN	O	O
multiply	NN	O	O
consanguineous	NN	O	O
kindred	NN	O	O
of	NN	O	O
Lebanese	NN	O	O
descent	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
absence	NN	O	O
of	NN	O	O
a	NN	O	O
distinctive	NN	O	O
facial	NN	O	O
appearance	NN	O	O
,	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
short	NN	O	B-Disease
stature	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
initially	NN	O	O
considered	NN	O	O
clinical	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Cohen	NN	O	B-Disease
syndrome	NN	O	I-Disease
was	NN	O	O
withdrawn	NN	O	O
and	NN	O	O
a	NN	O	O
novel	NN	O	O
genetic	NN	O	O
entity	NN	O	O
was	NN	O	O
assumed	NN	O	O
.	NN	O	O

Association	NN	O	O
of	NN	O	O
alleles	NN	O	O
of	NN	O	O
the	NN	O	O
CYP2D6	NN	O	O
gene	NN	O	O
was	NN	O	O
examined	NN	O	O
by	NN	O	O
both	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
and	NN	O	O
within	NN	O	O
-	NN	O	O
family	NN	O	O
means	NN	O	O
.	NN	O	O

For	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
studies	NN	O	O
,	NN	O	O
617	NN	O	O
unrelated	NN	O	O
individuals	NN	O	O
with	NN	O	O
AS	NN	O	B-Disease
(	NN	O	O
361	NN	O	O
probands	NN	O	O
from	NN	O	O
sibling	NN	O	O
-	NN	O	O
pair	NN	O	O
and	NN	O	O
parent	NN	O	O
-	NN	O	O
case	NN	O	O
trio	NN	O	O
families	NN	O	O
and	NN	O	O
256	NN	O	O
unrelated	NN	O	O
non	NN	O	O
-	NN	O	O
familial	NN	O	O
sporadic	NN	O	O
cases	NN	O	O
)	NN	O	O
and	NN	O	O
402	NN	O	O
healthy	NN	O	O
ethnically	NN	O	O
matched	NN	O	O
controls	NN	O	O
were	NN	O	O
employed	NN	O	O
.	NN	O	O

The	NN	O	O
mutations	NN	O	O
associated	NN	O	O
with	NN	O	O
Pendred	NN	O	B-Disease
syndrome	NN	O	I-Disease
have	NN	O	O
complete	NN	O	O
loss	NN	O	O
of	NN	O	O
pendrin	NN	O	O
-	NN	O	O
induced	NN	O	O
chloride	NN	O	O
and	NN	O	O
iodide	NN	O	O
transport	NN	O	O
,	NN	O	O
while	NN	O	O
alleles	NN	O	O
unique	NN	O	O
to	NN	O	O
people	NN	O	O
with	NN	O	O
DFNB4	NN	O	B-Disease
are	NN	O	O
able	NN	O	O
to	NN	O	O
transport	NN	O	O
both	NN	O	O
iodide	NN	O	O
and	NN	O	O
chloride	NN	O	O
,	NN	O	O
albeit	NN	O	O
at	NN	O	O
a	NN	O	O
much	NN	O	O
lower	NN	O	O
level	NN	O	O
than	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
pendrin	NN	O	O
.	NN	O	O

S	NN	O	O
.	NN	O	O

Heterozygous	NN	O	O
mutations	NN	O	O
encoding	NN	O	O
abnormal	NN	O	O
forms	NN	O	O
of	NN	O	O
the	NN	O	O
death	NN	O	O
receptor	NN	O	O
Fas	NN	O	O
dominantly	NN	O	O
interfere	NN	O	O
with	NN	O	O
Fas	NN	O	O
-	NN	O	O
induced	NN	O	O
lymphocyte	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
human	NN	O	O
autoimmune	NN	O	B-Disease
lymphoproliferative	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Determination	NN	O	O
of	NN	O	O
carrier	NN	O	O
status	NN	O	O
for	NN	O	O
the	NN	O	O
Wiskott	NN	O	B-Disease
-	NN	O	I-Disease
Aldrich	NN	O	I-Disease
syndrome	NN	O	I-Disease
by	NN	O	O
flow	NN	O	O
cytometric	NN	O	O
analysis	NN	O	O
of	NN	O	O
Wiskott	NN	O	B-Disease
-	NN	O	I-Disease
Aldrich	NN	O	I-Disease
syndrome	NN	O	I-Disease
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
mononuclear	NN	O	O
cells	NN	O	O
.	NN	O	O

Monocytes	NN	O	O
from	NN	O	O
all	NN	O	O
nine	NN	O	O
WAS	NN	O	B-Disease
carriers	NN	O	O
showed	NN	O	O
varied	NN	O	O
population	NN	O	O
of	NN	O	O
WASPdim	NN	O	O
together	NN	O	O
with	NN	O	O
WASPbright	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
lymphocytes	NN	O	O
from	NN	O	O
all	NN	O	O
the	NN	O	O
carriers	NN	O	O
except	NN	O	O
two	NN	O	O
lacked	NN	O	O
the	NN	O	O
WASPdim	NN	O	O
population	NN	O	O
.	NN	O	O

Restoration	NN	O	O
of	NN	O	O
photoreceptor	NN	O	O
ultrastructure	NN	O	O
and	NN	O	O
function	NN	O	O
in	NN	O	O
retinal	NN	O	B-Disease
degeneration	NN	O	I-Disease
slow	NN	O	O
mice	NN	O	O
by	NN	O	O
gene	NN	O	O
therapy	NN	O	O
.	NN	O	O

Mutations	NN	O	O
in	NN	O	O
Prph2	NN	O	O
have	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
result	NN	O	O
in	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
photoreceptor	NN	O	B-Disease
dystrophies	NN	O	I-Disease
,	NN	O	O
including	NN	O	O
autosomal	NN	O	B-Disease
dominant	NN	O	I-Disease
retinitis	NN	O	I-Disease
pigmentosa	NN	O	I-Disease
and	NN	O	O
macular	NN	O	B-Disease
dystrophy	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
electroretinograms	NN	O	O
(	NN	O	O
ERGs	NN	O	O
)	NN	O	O
of	NN	O	O
Prph2Rd2	NN	O	O
/	NN	O	O
Rd2	NN	O	O
mice	NN	O	O
have	NN	O	O
greatly	NN	O	O
diminished	NN	O	O
a	NN	O	O
-	NN	O	O
wave	NN	O	O
and	NN	O	O
b	NN	O	O
-	NN	O	O
wave	NN	O	O
amplitudes	NN	O	O
,	NN	O	O
which	NN	O	O
decline	NN	O	O
to	NN	O	O
virtually	NN	O	O
undetectable	NN	O	O
concentrations	NN	O	O
by	NN	O	O
two	NN	O	O
months	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
demonstrate	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
that	NN	O	O
a	NN	O	O
complex	NN	O	O
ultrastructural	NN	O	O
cell	NN	O	O
defect	NN	O	O
can	NN	O	O
be	NN	O	O
corrected	NN	O	O
both	NN	O	O
morphologically	NN	O	O
and	NN	O	O
functionally	NN	O	O
by	NN	O	O
in	NN	O	O
vivo	NN	O	O
gene	NN	O	O
transfer	NN	O	O
.	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
86	NN	O	O
%	NN	O	O
of	NN	O	O
afibrinogenemia	NN	O	B-Disease
alleles	NN	O	O
analyzed	NN	O	O
to	NN	O	O
date	NN	O	O
have	NN	O	O
truncating	NN	O	O
mutations	NN	O	O
of	NN	O	O
FGA	NN	O	O
,	NN	O	O
though	NN	O	O
mutations	NN	O	O
in	NN	O	O
all	NN	O	O
3	NN	O	O
fibrinogen	NN	O	O
genes	NN	O	O
,	NN	O	O
FGG	NN	O	O
,	NN	O	O
FGA	NN	O	O
,	NN	O	O
and	NN	O	O
FGB	NN	O	O
,	NN	O	O
might	NN	O	O
be	NN	O	O
predicted	NN	O	O
to	NN	O	O
cause	NN	O	O
congenital	NN	O	B-Disease
afibrinogenemia	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
(	NN	O	O
CTG	NN	O	O
)	NN	O	O
n	NN	O	O
expansion	NN	O	O
in	NN	O	O
the	NN	O	O
3	NN	O	O
UTR	NN	O	O
of	NN	O	O
the	NN	O	O
DMPK	NN	O	O
gene	NN	O	O
causes	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

Affected	NN	O	O
individuals	NN	O	O
exhibit	NN	O	O
neonatal	NN	O	B-Disease
hypotonia	NN	O	I-Disease
,	NN	O	O
developmental	NN	O	B-Disease
delay	NN	O	I-Disease
and	NN	O	O
childhood	NN	O	B-Disease
-	NN	O	I-Disease
onset	NN	O	I-Disease
obesity	NN	O	I-Disease
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
differentiated	NN	O	O
retinoblastoma	NN	O	B-Disease
cells	NN	O	O
(	NN	O	O
Weri	NN	O	O
-	NN	O	O
Rb1	NN	O	O
cells	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
express	NN	O	O
RS1	NN	O	O
mRNA	NN	O	O
and	NN	O	O
to	NN	O	O
release	NN	O	O
retinoschisin	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
retinoschisis	NN	O	I-Disease
is	NN	O	O
caused	NN	O	O
by	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
a	NN	O	O
putative	NN	O	O
secreted	NN	O	O
photoreceptor	NN	O	O
protein	NN	O	O
and	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
example	NN	O	O
of	NN	O	O
a	NN	O	O
secreted	NN	O	O
photo	NN	O	O
-	NN	O	O
receptor	NN	O	O
protein	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
retinal	NN	O	B-Disease
dystrophy	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

Benign	NN	O	B-Disease
familial	NN	O	I-Disease
infantile	NN	O	I-Disease
convulsions	NN	O	I-Disease
(	NN	O	O
BFIC	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
autosomal	NN	O	B-Disease
dominant	NN	O	I-Disease
epilepsy	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

It	NN	O	O
was	NN	O	O
rare	NN	O	O
,	NN	O	O
as	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
controls	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
segregating	NN	O	O
with	NN	O	O
the	NN	O	O
BFIC	NN	O	B-Disease
phenotype	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
mechanism	NN	O	O
for	NN	O	O
AFAP	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
carrying	NN	O	O
a	NN	O	O
mutant	NN	O	O
APC	NN	O	B-Disease
allele	NN	O	O
(	NN	O	O
APC	NN	O	O
(	NN	O	O
AS9	NN	O	O
)	NN	O	O
)	NN	O	O
that	NN	O	O
has	NN	O	O
a	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
alternatively	NN	O	O
spliced	NN	O	O
region	NN	O	O
of	NN	O	O
exon	NN	O	O
9	NN	O	O
.	NN	O	O

Mutation	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
both	NN	O	O
APC	NN	O	O
(	NN	O	O
AS9	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
APC	NN	O	B-Disease
alleles	NN	O	O
were	NN	O	O
somatically	NN	O	O
mutated	NN	O	O
in	NN	O	O
most	NN	O	O
colorectal	NN	O	B-Disease
tumors	NN	O	I-Disease
from	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
pleckstrin	NN	O	O
homology	NN	O	O
(	NN	O	O
PH	NN	O	O
)	NN	O	O
domain	NN	O	O
of	NN	O	O
the	NN	O	O
FGD1	NN	O	O
gene	NN	O	O
in	NN	O	O
an	NN	O	O
Italian	NN	O	O
family	NN	O	O
with	NN	O	O
faciogenital	NN	O	B-Disease
dysplasia	NN	O	I-Disease
(	NN	O	O
Aarskog	NN	O	B-Disease
-	NN	O	I-Disease
Scott	NN	O	I-Disease
syndrome	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

Aarskog	NN	O	B-Disease
-	NN	O	I-Disease
Scott	NN	O	I-Disease
Syndrome	NN	O	I-Disease
(	NN	O	O
AAS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
disorder	NN	O	I-Disease
characterised	NN	O	O
by	NN	O	O
short	NN	O	B-Disease
stature	NN	O	I-Disease
and	NN	O	O
multiple	NN	O	O
facial	NN	O	B-Disease
,	NN	O	I-Disease
limb	NN	O	I-Disease
and	NN	O	I-Disease
genital	NN	O	I-Disease
abnormalities	NN	O	I-Disease
.	NN	O	O

One	NN	O	O
patient	NN	O	O
presented	NN	O	O
a	NN	O	O
mutation	NN	O	O
that	NN	O	O
results	NN	O	O
in	NN	O	O
a	NN	O	O
nucleotide	NN	O	O
change	NN	O	O
in	NN	O	O
exon	NN	O	O
10	NN	O	O
of	NN	O	O
the	NN	O	O
FGD1	NN	O	O
gene	NN	O	O
(	NN	O	O
G2559	NN	O	O
>	NN	O	O
A	NN	O	O
)	NN	O	O
substituting	NN	O	O
a	NN	O	O
Gln	NN	O	O
for	NN	O	O
Arg	NN	O	O
in	NN	O	O
position	NN	O	O
610	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
mutant	NN	O	O
mice	NN	O	O
expressing	NN	O	O
HD	NN	O	B-Disease
repeats	NN	O	O
,	NN	O	O
the	NN	O	O
production	NN	O	O
and	NN	O	O
aggregation	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
terminal	NN	O	O
huntingtin	NN	O	O
fragments	NN	O	O
preferentially	NN	O	O
occur	NN	O	O
in	NN	O	O
HD	NN	O	B-Disease
-	NN	O	O
affected	NN	O	O
neurons	NN	O	O
and	NN	O	O
their	NN	O	O
processes	NN	O	O
and	NN	O	O
axonal	NN	O	O
terminals	NN	O	O
.	NN	O	O

Mass	NN	O	O
spectrometric	NN	O	O
sequencing	NN	O	O
of	NN	O	O
components	NN	O	O
of	NN	O	O
this	NN	O	O
complex	NN	O	O
indicated	NN	O	O
that	NN	O	O
BRCA1	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
SWI	NN	O	O
/	NN	O	O
SNF	NN	O	O
-	NN	O	O
related	NN	O	O
complex	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
p53	NN	O	O
-	NN	O	O
mediated	NN	O	O
stimulation	NN	O	O
of	NN	O	O
transcription	NN	O	O
by	NN	O	O
BRCA1	NN	O	O
was	NN	O	O
completely	NN	O	O
abrogated	NN	O	O
by	NN	O	O
either	NN	O	O
a	NN	O	O
dominant	NN	O	O
-	NN	O	O
negative	NN	O	O
mutant	NN	O	O
of	NN	O	O
BRG1	NN	O	O
or	NN	O	O
the	NN	O	O
cancer	NN	O	B-Disease
-	NN	O	O
causing	NN	O	O
deletion	NN	O	O
in	NN	O	O
exon	NN	O	O
11	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
APC	NN	O	O
enhanced	NN	O	O
the	NN	O	O
GEF	NN	O	O
activity	NN	O	O
of	NN	O	O
Asef	NN	O	O
and	NN	O	O
stimulated	NN	O	O
Asef	NN	O	O
-	NN	O	O
mediated	NN	O	O
cell	NN	O	O
flattening	NN	O	O
,	NN	O	O
membrane	NN	O	O
ruffling	NN	O	O
,	NN	O	O
and	NN	O	O
lamellipodia	NN	O	O
formation	NN	O	O
in	NN	O	O
MDCK	NN	O	O
cells	NN	O	O
.	NN	O	O

Mice	NN	O	O
that	NN	O	O
expressed	NN	O	O
expanded	NN	O	O
CUG	NN	O	O
repeats	NN	O	O
developed	NN	O	O
myotonia	NN	O	B-Disease
and	NN	O	O
myopathy	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
mice	NN	O	O
expressing	NN	O	O
a	NN	O	O
nonexpanded	NN	O	O
repeat	NN	O	O
did	NN	O	O
not	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
transcripts	NN	O	O
with	NN	O	O
expanded	NN	O	O
CUG	NN	O	O
repeats	NN	O	O
are	NN	O	O
sufficient	NN	O	O
to	NN	O	O
generate	NN	O	O
a	NN	O	O
DM	NN	O	B-Disease
phenotype	NN	O	O
.	NN	O	O

Almost	NN	O	O
all	NN	O	O
APC	NN	O	B-Disease
mutations	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
are	NN	O	O
single	NN	O	O
-	NN	O	O
nucleotide	NN	O	O
alterations	NN	O	O
,	NN	O	O
small	NN	O	O
insertions	NN	O	O
,	NN	O	O
or	NN	O	O
small	NN	O	O
deletions	NN	O	O
that	NN	O	O
would	NN	O	O
truncate	NN	O	O
the	NN	O	O
protein	NN	O	O
product	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
.	NN	O	O

These	NN	O	O
rearrangements	NN	O	O
were	NN	O	O
initially	NN	O	O
revealed	NN	O	O
by	NN	O	O
analyzing	NN	O	O
cDNAs	NN	O	O
and	NN	O	O
could	NN	O	O
not	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
by	NN	O	O
using	NN	O	O
mutation	NN	O	O
detection	NN	O	O
methods	NN	O	O
that	NN	O	O
screened	NN	O	O
each	NN	O	O
exon	NN	O	O
individually	NN	O	O
.	NN	O	O

The	NN	O	O
identification	NN	O	O
of	NN	O	O
four	NN	O	O
genomic	NN	O	O
rearrangements	NN	O	O
among	NN	O	O
30	NN	O	O
mutations	NN	O	O
suggests	NN	O	O
that	NN	O	O
genomic	NN	O	O
rearrangements	NN	O	O
are	NN	O	O
frequent	NN	O	O
germline	NN	O	O
APC	NN	O	B-Disease
mutations	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
consequence	NN	O	O
of	NN	O	O
this	NN	O	O
mutation	NN	O	O
is	NN	O	O
an	NN	O	O
amino	NN	O	O
acid	NN	O	O
substitution	NN	O	O
at	NN	O	O
a	NN	O	O
highly	NN	O	O
conserved	NN	O	O
position	NN	O	O
within	NN	O	O
the	NN	O	O
CACNA1A	NN	O	O
gene	NN	O	O
.	NN	O	O

Examination	NN	O	O
of	NN	O	O
plasma	NN	O	O
amino	NN	O	O
acids	NN	O	O
,	NN	O	O
an	NN	O	O
investigation	NN	O	O
not	NN	O	O
previously	NN	O	O
reported	NN	O	O
,	NN	O	O
revealed	NN	O	O
an	NN	O	O
extremely	NN	O	O
low	NN	O	O
plasma	NN	O	O
tryptophan	NN	O	O
level	NN	O	O
,	NN	O	O
a	NN	O	O
finding	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
tryptophan	NN	O	O
in	NN	O	O
albumin	NN	O	O
synthesis	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
mother	NN	O	O
is	NN	O	O
a	NN	O	O
heterozygous	NN	O	O
carrier	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
father	NN	O	O
and	NN	O	O
sister	NN	O	O
seem	NN	O	O
to	NN	O	O
be	NN	O	O
normal	NN	O	O
.	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
disease	NN	O	O
is	NN	O	O
inherited	NN	O	O
in	NN	O	O
an	NN	O	O
autosomal	NN	O	O
recessive	NN	O	O
manner	NN	O	O
and	NN	O	O
that	NN	O	O
lymphocytes	NN	O	O
and	NN	O	O
fibroblasts	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
detect	NN	O	O
carriers	NN	O	O
.	NN	O	O

Glucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
dehydrogenase	NN	O	O
variants	NN	O	O
from	NN	O	O
Italian	NN	O	O
subjects	NN	O	O
associated	NN	O	O
with	NN	O	O
severe	NN	O	B-Disease
neonatal	NN	O	I-Disease
jaundice	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
abnormal	NN	O	O
enzymes	NN	O	O
are	NN	O	O
respectively	NN	O	O
designated	NN	O	O
as	NN	O	O
GdDcbrousse	NN	O	O
-	NN	O	O
like	NN	O	O
,	NN	O	O
GdGallura	NN	O	O
and	NN	O	O
GdAgrigento	NN	O	O
.	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
probands	NN	O	O
,	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
rates	NN	O	O
of	NN	O	O
chromosome	NN	O	O
damage	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
both	NN	O	O
blood	NN	O	O
and	NN	O	O
skin	NN	O	O
.	NN	O	O

Increased	NN	O	O
rates	NN	O	O
of	NN	O	O
chromosome	NN	O	O
damage	NN	O	O
were	NN	O	O
also	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
fibroblasts	NN	O	O
of	NN	O	O
some	NN	O	O
phenotypically	NN	O	O
normal	NN	O	O
family	NN	O	O
members	NN	O	O
(	NN	O	O
obligate	NN	O	O
heterozygotes	NN	O	O
and	NN	O	O
sibs	NN	O	O
)	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
normal	NN	O	O
controls	NN	O	O
.	NN	O	O

Cells	NN	O	O
from	NN	O	O
patient	NN	O	O
1	NN	O	O
had	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
control	NN	O	O
levels	NN	O	O
of	NN	O	O
acid	NN	O	O
lipase	NN	O	O
,	NN	O	O
using	NN	O	O
14C	NN	O	O
-	NN	O	O
triolein	NN	O	O
as	NN	O	O
substrate	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
when	NN	O	O
artificial	NN	O	O
substrates	NN	O	O
(	NN	O	O
esters	NN	O	O
of	NN	O	O
4	NN	O	O
-	NN	O	O
methylumbelliferone	NN	O	O
and	NN	O	O
p	NN	O	O
-	NN	O	O
nitrophenol	NN	O	O
)	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
acid	NN	O	O
lipase	NN	O	O
,	NN	O	O
these	NN	O	O
cells	NN	O	O
had	NN	O	O
30	NN	O	O
%	NN	O	O
of	NN	O	O
control	NN	O	O
levels	NN	O	O
.	NN	O	O

Ataxia	NN	O	B-Disease
-	NN	O	I-Disease
telangiectasia	NN	O	I-Disease
(	NN	O	O
A	NN	O	B-Disease
-	NN	O	I-Disease
T	NN	O	I-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
syndrome	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
a	NN	O	O
greatly	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
malignant	NN	O	B-Disease
neoplasms	NN	O	I-Disease
in	NN	O	O
homozygous	NN	O	O
affected	NN	O	O
individuals	NN	O	O
.	NN	O	O

For	NN	O	O
A	NN	O	B-Disease
-	NN	O	I-Disease
T	NN	O	I-Disease
heterozygotes	NN	O	O
younger	NN	O	O
than	NN	O	O
age	NN	O	O
45	NN	O	O
,	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
dying	NN	O	O
from	NN	O	O
a	NN	O	O
malignant	NN	O	B-Disease
neoplasm	NN	O	I-Disease
was	NN	O	O
estimated	NN	O	O
to	NN	O	O
be	NN	O	O
greater	NN	O	O
than	NN	O	O
5	NN	O	O
times	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
the	NN	O	O
general	NN	O	O
population	NN	O	O
.	NN	O	O

Hitherto	NN	O	O
accepted	NN	O	O
figures	NN	O	O
may	NN	O	O
underestimate	NN	O	O
the	NN	O	O
frequency	NN	O	O
by	NN	O	O
a	NN	O	O
factor	NN	O	O
of	NN	O	O
10	NN	O	O
to	NN	O	O
20	NN	O	O
.	NN	O	O
.	NN	O	O

Analbuminemia	NN	O	B-Disease
in	NN	O	O
an	NN	O	O
American	NN	O	O
Indian	NN	O	O
girl	NN	O	O
.	NN	O	O

The	NN	O	O
pedigree	NN	O	O
and	NN	O	O
clinical	NN	O	O
findings	NN	O	O
were	NN	O	O
compatible	NN	O	O
with	NN	O	O
autosomal	NN	O	O
recessive	NN	O	O
transmission	NN	O	O
of	NN	O	O
analbuminemia	NN	O	B-Disease
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
a	NN	O	O
"	NN	O	O
thalassemia	NN	O	B-Disease
"	NN	O	O
-	NN	O	O
like	NN	O	O
mutation	NN	O	O
for	NN	O	O
this	NN	O	O
disorder	NN	O	O
.	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
each	NN	O	O
mutant	NN	O	O
gene	NN	O	O
provides	NN	O	O
valuable	NN	O	O
information	NN	O	O
as	NN	O	O
to	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
mutation	NN	O	O
that	NN	O	O
occurs	NN	O	O
spontaneously	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
a	NN	O	O
comparison	NN	O	O
of	NN	O	O
the	NN	O	O
data	NN	O	O
suggested	NN	O	O
that	NN	O	O
both	NN	O	O
missense	NN	O	O
and	NN	O	O
synonymous	NN	O	O
mutations	NN	O	O
can	NN	O	O
occur	NN	O	O
at	NN	O	O
any	NN	O	O
coding	NN	O	O
sequence	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
germ	NN	O	O
line	NN	O	O
HPRT	NN	O	O
gene	NN	O	O
,	NN	O	O
but	NN	O	O
that	NN	O	O
a	NN	O	O
limited	NN	O	O
percentage	NN	O	O
of	NN	O	O
all	NN	O	O
the	NN	O	O
missense	NN	O	O
mutations	NN	O	O
cause	NN	O	O
disease	NN	O	O
.	NN	O	O

It	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
typical	NN	O	O
folate	NN	O	O
sensitive	NN	O	O
fragile	NN	O	O
site	NN	O	O
.	NN	O	O

The	NN	O	O
fragile	NN	O	O
site	NN	O	O
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
it	NN	O	O
does	NN	O	O
not	NN	O	O
give	NN	O	O
abnormal	NN	O	O
results	NN	O	O
when	NN	O	O
subjected	NN	O	O
to	NN	O	O
Southern	NN	O	O
analysis	NN	O	O
with	NN	O	O
probe	NN	O	O
pfxa3	NN	O	O
which	NN	O	O
detects	NN	O	O
the	NN	O	O
unstable	NN	O	O
DNA	NN	O	O
sequence	NN	O	O
characteristic	NN	O	O
of	NN	O	O
fragile	NN	O	B-Disease
X	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
mapping	NN	O	O
locates	NN	O	O
the	NN	O	O
fragile	NN	O	O
site	NN	O	O
between	NN	O	O
150	NN	O	O
kb	NN	O	O
and	NN	O	O
600	NN	O	O
kb	NN	O	O
distal	NN	O	O
to	NN	O	O
FRAXA	NN	O	O
.	NN	O	O

Norrie	NN	O	B-Disease
disease	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
human	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
recessive	NN	O	I-Disease
disorder	NN	O	I-Disease
of	NN	O	O
unknown	NN	O	O
etiology	NN	O	O
characterized	NN	O	O
by	NN	O	O
congenital	NN	O	B-Disease
blindness	NN	O	I-Disease
,	NN	O	O
sensory	NN	O	B-Disease
neural	NN	O	I-Disease
deafness	NN	O	I-Disease
and	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
.	NN	O	O

3	NN	O	O
3	NN	O	O
.	NN	O	O

28	NN	O	O
,	NN	O	O
serves	NN	O	O
as	NN	O	O
a	NN	O	O
flanking	NN	O	O
marker	NN	O	O
centromeric	NN	O	O
to	NN	O	O
the	NN	O	O
disease	NN	O	O
gene	NN	O	O
.	NN	O	O

AluR	NN	O	O
.	NN	O	O
centromere	NN	O	O
.	NN	O	O

Together	NN	O	O
these	NN	O	O
data	NN	O	O
define	NN	O	O
the	NN	O	O
obligate	NN	O	O
region	NN	O	O
containing	NN	O	O
the	NN	O	O
NDP	NN	O	O
gene	NN	O	O
to	NN	O	O
a	NN	O	O
chromosomal	NN	O	O
segment	NN	O	O
less	NN	O	O
than	NN	O	O
150	NN	O	O
kb	NN	O	O
.	NN	O	O

Molecular	NN	O	O
basis	NN	O	O
of	NN	O	O
phenylketonuria	NN	O	B-Disease
and	NN	O	O
related	NN	O	O
hyperphenylalaninemias	NN	O	B-Disease
:	NN	O	O
mutations	NN	O	O
and	NN	O	O
polymorphisms	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
phenylalanine	NN	O	O
hydroxylase	NN	O	O
gene	NN	O	O
.	NN	O	O

Mutations	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
phenylalanine	NN	O	O
hydroxylase	NN	O	O
gene	NN	O	O
producing	NN	O	O
phenylketonuria	NN	O	B-Disease
or	NN	O	O
hyperphenylalaninemia	NN	O	B-Disease
have	NN	O	O
now	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
many	NN	O	O
patients	NN	O	O
from	NN	O	O
various	NN	O	O
ethnic	NN	O	O
groups	NN	O	O
.	NN	O	O

One	NN	O	O
splicing	NN	O	O
mutation	NN	O	O
results	NN	O	O
in	NN	O	O
a	NN	O	O
3	NN	O	O
amino	NN	O	O
acid	NN	O	O
in	NN	O	O
-	NN	O	O
frame	NN	O	O
insertion	NN	O	O
.	NN	O	O

About	NN	O	O
half	NN	O	O
of	NN	O	O
all	NN	O	O
missense	NN	O	O
mutations	NN	O	O
have	NN	O	O
been	NN	O	O
examined	NN	O	O
by	NN	O	O
in	NN	O	O
vitro	NN	O	O
expression	NN	O	O
analysis	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
correlation	NN	O	O
has	NN	O	O
been	NN	O	O
observed	NN	O	O
between	NN	O	O
residual	NN	O	O
PAH	NN	O	O
activity	NN	O	O
and	NN	O	O
disease	NN	O	O
phenotype	NN	O	O
.	NN	O	O

Since	NN	O	O
continuing	NN	O	O
advances	NN	O	O
in	NN	O	O
molecular	NN	O	O
methodologies	NN	O	O
have	NN	O	O
dramatically	NN	O	O
accelerated	NN	O	O
the	NN	O	O
rate	NN	O	O
in	NN	O	O
which	NN	O	O
new	NN	O	O
mutations	NN	O	O
are	NN	O	O
being	NN	O	O
identified	NN	O	O
and	NN	O	O
characterized	NN	O	O
,	NN	O	O
this	NN	O	O
register	NN	O	O
of	NN	O	O
mutations	NN	O	O
will	NN	O	O
be	NN	O	O
updated	NN	O	O
periodically	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
genetic	NN	O	B-Disease
defects	NN	O	I-Disease
responsible	NN	O	O
for	NN	O	O
most	NN	O	O
phenylketonuria	NN	O	B-Disease
(	NN	O	O
PKU	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
hyperphenylalaninemia	NN	O	B-Disease
(	NN	O	O
HPA	NN	O	B-Disease
)	NN	O	O
cases	NN	O	O
are	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
phenylalanine	NN	O	O
hydroxylase	NN	O	O
(	NN	O	O
PAH	NN	O	O
)	NN	O	O
gene	NN	O	O
.	NN	O	O

Both	NN	O	O
mutations	NN	O	O
were	NN	O	O
tested	NN	O	O
in	NN	O	O
a	NN	O	O
eukaryotic	NN	O	O
expression	NN	O	O
system	NN	O	O
in	NN	O	O
which	NN	O	O
enzyme	NN	O	O
activities	NN	O	O
of	NN	O	O
different	NN	O	O
mutant	NN	O	O
PAH	NN	O	O
enzymes	NN	O	O
reflect	NN	O	O
the	NN	O	O
relative	NN	O	O
severities	NN	O	O
of	NN	O	O
the	NN	O	O
mutations	NN	O	O
,	NN	O	O
although	NN	O	O
these	NN	O	O
in	NN	O	O
vitro	NN	O	O
activities	NN	O	O
cannot	NN	O	O
be	NN	O	O
translated	NN	O	O
directly	NN	O	O
into	NN	O	O
in	NN	O	O
vivo	NN	O	O
hepatic	NN	O	O
activities	NN	O	O
.	NN	O	O

The	NN	O	O
second	NN	O	O
,	NN	O	O
a	NN	O	O
C	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
T	NN	O	O
transition	NN	O	O
at	NN	O	O
nucleotide	NN	O	O
739	NN	O	O
(	NN	O	O
Arg247Trp	NN	O	O
)	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
by	NN	O	O
Triggs	NN	O	O
-	NN	O	O
Raine	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O

(	NN	O	O
1992	NN	O	O
)	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
clinically	NN	O	O
benign	NN	O	O
"	NN	O	O
pseudodeficient	NN	O	O
"	NN	O	O
allele	NN	O	O
associated	NN	O	O
with	NN	O	O
reduced	NN	O	O
enzyme	NN	O	O
activity	NN	O	O
against	NN	O	O
artificial	NN	O	O
substrate	NN	O	O
.	NN	O	O

A	NN	O	O
mutation	NN	O	O
common	NN	O	O
in	NN	O	O
non	NN	O	O
-	NN	O	O
Jewish	NN	O	O
Tay	NN	O	B-Disease
-	NN	O	I-Disease
Sachs	NN	O	I-Disease
disease	NN	O	I-Disease
:	NN	O	O
frequency	NN	O	O
and	NN	O	O
RNA	NN	O	O
studies	NN	O	O
.	NN	O	O

In	NN	O	O
Finland	NN	O	O
,	NN	O	O
there	NN	O	O
are	NN	O	O
more	NN	O	O
than	NN	O	O
120	NN	O	O
living	NN	O	O
CHM	NN	O	B-Disease
patients	NN	O	O
belonging	NN	O	O
to	NN	O	O
eight	NN	O	O
apparently	NN	O	O
unrelated	NN	O	O
pedigrees	NN	O	O
.	NN	O	O

Molecular	NN	O	O
deletions	NN	O	O
involving	NN	O	O
the	NN	O	O
CHM	NN	O	B-Disease
gene	NN	O	O
have	NN	O	O
been	NN	O	O
detected	NN	O	O
in	NN	O	O
three	NN	O	O
families	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
provide	NN	O	O
additional	NN	O	O
evidence	NN	O	O
for	NN	O	O
the	NN	O	O
pathogenetic	NN	O	O
role	NN	O	O
of	NN	O	O
CHM	NN	O	B-Disease
mutations	NN	O	O
and	NN	O	O
provide	NN	O	O
a	NN	O	O
diagnostic	NN	O	O
tool	NN	O	O
for	NN	O	O
one	NN	O	O
fifth	NN	O	O
of	NN	O	O
the	NN	O	O
worlds	NN	O	O
known	NN	O	O
CHM	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
mutation	NN	O	O
underlying	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
has	NN	O	O
been	NN	O	O
identified	NN	O	O
as	NN	O	O
an	NN	O	O
expansion	NN	O	O
of	NN	O	O
a	NN	O	O
polymorphic	NN	O	O
CTG	NN	O	O
-	NN	O	O
repeat	NN	O	O
in	NN	O	O
a	NN	O	O
gene	NN	O	O
encoding	NN	O	O
protein	NN	O	O
kinase	NN	O	O
activity	NN	O	O
.	NN	O	O

Brain	NN	O	O
and	NN	O	O
heart	NN	O	O
transcripts	NN	O	O
of	NN	O	O
the	NN	O	O
DM	NN	O	O
-	NN	O	O
kinase	NN	O	O
(	NN	O	O
DMR	NN	O	O
-	NN	O	O
B15	NN	O	O
)	NN	O	O
gene	NN	O	O
are	NN	O	O
subject	NN	O	O
to	NN	O	O
alternative	NN	O	O
RNA	NN	O	O
splicing	NN	O	O
in	NN	O	O
both	NN	O	O
human	NN	O	O
and	NN	O	O
mouse	NN	O	O
.	NN	O	O

The	NN	O	O
pattern	NN	O	O
of	NN	O	O
retention	NN	O	O
of	NN	O	O
subclones	NN	O	O
in	NN	O	O
the	NN	O	O
deletion	NN	O	O
patient	NN	O	O
place	NN	O	O
the	NN	O	O
end	NN	O	O
point	NN	O	O
of	NN	O	O
the	NN	O	O
deletion	NN	O	O
within	NN	O	O
30	NN	O	O
-	NN	O	O
130	NN	O	O
kb	NN	O	O
of	NN	O	O
the	NN	O	O
proximal	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
YAC	NN	O	O
.	NN	O	O

The	NN	O	O
frequencies	NN	O	O
of	NN	O	O
the	NN	O	O
G6PD	NN	O	O
A	NN	O	O
and	NN	O	O
of	NN	O	O
the	NN	O	O
G6PD	NN	O	O
A	NN	O	O
-	NN	O	O
genes	NN	O	O
in	NN	O	O
parts	NN	O	O
of	NN	O	O
Africa	NN	O	O
are	NN	O	O
both	NN	O	O
about	NN	O	O
0	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

Comparable	NN	O	O
results	NN	O	O
were	NN	O	O
produced	NN	O	O
when	NN	O	O
the	NN	O	O
replacement	NN	O	O
119	NN	O	O
Gln	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
Glu	NN	O	O
was	NN	O	O
studied	NN	O	O
instead	NN	O	O
of	NN	O	O
126	NN	O	O
Asn	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
Asp	NN	O	O
.	NN	O	O

We	NN	O	O
infer	NN	O	O
that	NN	O	O
the	NN	O	O
coexistence	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
mutations	NN	O	O
is	NN	O	O
responsible	NN	O	O
for	NN	O	O
enzyme	NN	O	B-Disease
deficiency	NN	O	I-Disease
in	NN	O	I-Disease
G6PD	NN	O	I-Disease
A	NN	O	O
-	NN	O	O
because	NN	O	O
they	NN	O	O
act	NN	O	O
synergistically	NN	O	O
in	NN	O	O
causing	NN	O	O
instability	NN	O	O
of	NN	O	O
the	NN	O	O
enzyme	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
loss	NN	O	O
of	NN	O	O
the	NN	O	O
expressed	NN	O	O
paternal	NN	O	O
alleles	NN	O	O
of	NN	O	O
maternally	NN	O	O
imprinted	NN	O	O
genes	NN	O	O
must	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
PWS	NN	O	B-Disease
phenotype	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
mapped	NN	O	O
the	NN	O	O
gene	NN	O	O
encoding	NN	O	O
the	NN	O	O
small	NN	O	O
nuclear	NN	O	O
RNA	NN	O	O
associated	NN	O	O
polypeptide	NN	O	O
SmN	NN	O	O
(	NN	O	O
SNRPN	NN	O	O
)	NN	O	O
to	NN	O	O
human	NN	O	O
chromosome	NN	O	O
15q12	NN	O	O
and	NN	O	O
a	NN	O	O
processed	NN	O	O
pseudogene	NN	O	O
SNRPNP1	NN	O	O
to	NN	O	O
chromosome	NN	O	O
region	NN	O	O
6pter	NN	O	O
-	NN	O	O
p21	NN	O	O
.	NN	O	O

The	NN	O	O
fact	NN	O	O
that	NN	O	O
the	NN	O	O
mouse	NN	O	O
Snrpn	NN	O	O
gene	NN	O	O
is	NN	O	O
maternally	NN	O	O
imprinted	NN	O	O
in	NN	O	O
brain	NN	O	O
suggests	NN	O	O
that	NN	O	O
loss	NN	O	O
of	NN	O	O
the	NN	O	O
paternally	NN	O	O
derived	NN	O	O
SNRPN	NN	O	O
allele	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
PWS	NN	O	B-Disease
phenotype	NN	O	O
.	NN	O	O
.	NN	O	O

Eleven	NN	O	O
of	NN	O	O
12	NN	O	O
infantile	NN	O	O
TSD	NN	O	B-Disease
alleles	NN	O	O
examined	NN	O	O
in	NN	O	O
six	NN	O	O
families	NN	O	O
had	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
hexosaminidase	NN	O	O
A	NN	O	O
(	NN	O	O
Hex	NN	O	O
A	NN	O	O
)	NN	O	O
alpha	NN	O	O
-	NN	O	O
subunit	NN	O	O
exon	NN	O	O
11	NN	O	O
insertion	NN	O	O
mutation	NN	O	O
that	NN	O	O
is	NN	O	O
present	NN	O	O
in	NN	O	O
approximately	NN	O	O
70	NN	O	O
%	NN	O	O
of	NN	O	O
Ashkenazi	NN	O	O
Jewish	NN	O	O
TSD	NN	O	B-Disease
heterozygotes	NN	O	O
.	NN	O	O

The	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
remaining	NN	O	O
allele	NN	O	O
was	NN	O	O
a	NN	O	O
single	NN	O	O
-	NN	O	O
base	NN	O	O
transition	NN	O	O
in	NN	O	O
the	NN	O	O
donor	NN	O	O
splice	NN	O	O
site	NN	O	O
of	NN	O	O
the	NN	O	O
alpha	NN	O	O
-	NN	O	O
subunit	NN	O	O
intron	NN	O	O
9	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
prerequisite	NN	O	O
for	NN	O	O
the	NN	O	O
identification	NN	O	O
of	NN	O	O
point	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
ND	NN	O	B-Disease
gene	NN	O	O
we	NN	O	O
have	NN	O	O
established	NN	O	O
the	NN	O	O
exon	NN	O	O
-	NN	O	O
intron	NN	O	O
structure	NN	O	O
of	NN	O	O
this	NN	O	O
gene	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
predicted	NN	O	O
to	NN	O	O
cause	NN	O	O
a	NN	O	O
very	NN	O	O
premature	NN	O	O
translational	NN	O	O
termination	NN	O	O
accounting	NN	O	O
for	NN	O	O
the	NN	O	O
severe	NN	O	O
phenotype	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
the	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
5	NN	O	O
polymorphisms	NN	O	O
useful	NN	O	O
for	NN	O	O
internal	NN	O	O
control	NN	O	O
.	NN	O	O
.	NN	O	O

Proliferation	NN	O	O
-	NN	O	O
related	NN	O	O
expression	NN	O	O
of	NN	O	O
p19	NN	O	O
/	NN	O	O
nm23	NN	O	O
nucleoside	NN	O	O
diphosphate	NN	O	O
kinase	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
familial	NN	O	B-Disease
adenomatous	NN	O	I-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
(	NN	O	O
FAPC	NN	O	B-Disease
)	NN	O	O
with	NN	O	O
epidermoid	NN	O	B-Disease
cysts	NN	O	I-Disease
,	NN	O	O
osteomata	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
areas	NN	O	O
of	NN	O	O
congenital	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
retinal	NN	O	I-Disease
pigment	NN	O	I-Disease
epithelium	NN	O	I-Disease
(	NN	O	O
CHRPEs	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
a	NN	O	O
male	NN	O	O
patient	NN	O	O
and	NN	O	O
his	NN	O	O
maternal	NN	O	O
aunt	NN	O	O
,	NN	O	O
both	NN	O	O
of	NN	O	O
whom	NN	O	O
suffered	NN	O	O
a	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
degree	NN	O	O
of	NN	O	O
mental	NN	O	B-Disease
handicap	NN	O	I-Disease
.	NN	O	O

As	NN	O	O
expected	NN	O	O
,	NN	O	O
the	NN	O	O
molecular	NN	O	O
analyses	NN	O	O
indicate	NN	O	O
loss	NN	O	O
of	NN	O	O
one	NN	O	O
allele	NN	O	O
at	NN	O	O
the	NN	O	O
MCC	NN	O	O
and	NN	O	O
APC	NN	O	B-Disease
loci	NN	O	O
.	NN	O	O

The	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
is	NN	O	O
located	NN	O	O
within	NN	O	O
band	NN	O	O
5q22	NN	O	O
.	NN	O	O

The	NN	O	O
retinal	NN	O	B-Disease
degeneration	NN	O	I-Disease
mouse	NN	O	O
(	NN	O	O
gene	NN	O	O
symbol	NN	O	O
,	NN	O	O
rd	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
for	NN	O	O
certain	NN	O	O
forms	NN	O	O
of	NN	O	O
human	NN	O	O
hereditary	NN	O	B-Disease
retinopathies	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
have	NN	O	O
determined	NN	O	O
that	NN	O	O
the	NN	O	O
human	NN	O	O
gene	NN	O	O
(	NN	O	O
PDEB	NN	O	O
)	NN	O	O
maps	NN	O	O
to	NN	O	O
4p16	NN	O	O
.	NN	O	O

3	NN	O	O
,	NN	O	O
very	NN	O	O
close	NN	O	O
to	NN	O	O
the	NN	O	O
Huntington	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
HD	NN	O	B-Disease
)	NN	O	O
region	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
his	NN	O	O
T	NN	O	O
lymphocytes	NN	O	O
proliferated	NN	O	O
normally	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
phytohemagglutinin	NN	O	O
,	NN	O	O
concanavalin	NN	O	O
A	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
neuraminidase	NN	O	O
/	NN	O	O
galactose	NN	O	O
oxidase	NN	O	O
.	NN	O	O

Although	NN	O	O
gastric	NN	O	B-Disease
cancer	NN	O	I-Disease
is	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
cancer	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
world	NN	O	O
,	NN	O	O
genetic	NN	O	O
changes	NN	O	O
during	NN	O	O
its	NN	O	O
carcinogenesis	NN	O	O
are	NN	O	O
not	NN	O	O
well	NN	O	O
understood	NN	O	O
.	NN	O	O

Since	NN	O	O
some	NN	O	O
gastric	NN	O	B-Disease
cancers	NN	O	I-Disease
are	NN	O	O
considered	NN	O	O
to	NN	O	O
originate	NN	O	O
from	NN	O	O
the	NN	O	O
intestinal	NN	O	O
metaplasia	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
the	NN	O	O
adenomatous	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
(	NN	O	O
APC	NN	O	B-Disease
)	NN	O	O
gene	NN	O	O
,	NN	O	O
the	NN	O	O
mutation	NN	O	O
of	NN	O	O
which	NN	O	O
causes	NN	O	O
adenomatous	NN	O	B-Disease
polyps	NN	O	I-Disease
in	NN	O	I-Disease
the	NN	O	I-Disease
colon	NN	O	I-Disease
,	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
carcinogenesis	NN	O	O
of	NN	O	O
gastric	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
71	NN	O	O
-	NN	O	O
kilodalton	NN	O	O
protein	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
product	NN	O	O
of	NN	O	O
the	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
gene	NN	O	O
in	NN	O	O
brain	NN	O	O
and	NN	O	O
other	NN	O	O
nonmuscle	NN	O	O
tissues	NN	O	O
.	NN	O	O

Recently	NN	O	O
we	NN	O	O
described	NN	O	O
a	NN	O	O
6	NN	O	O
.	NN	O	O

5	NN	O	O
-	NN	O	O
kb	NN	O	O
mRNA	NN	O	O
encodes	NN	O	O
a	NN	O	O
70	NN	O	O
.	NN	O	O

Correlation	NN	O	O
between	NN	O	O
the	NN	O	O
location	NN	O	O
of	NN	O	O
germ	NN	O	O
-	NN	O	O
line	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
and	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
colorectal	NN	O	B-Disease
polyps	NN	O	I-Disease
in	NN	O	O
familial	NN	O	B-Disease
adenomatous	NN	O	I-Disease
polyposis	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
this	NN	O	O
information	NN	O	O
,	NN	O	O
we	NN	O	O
compared	NN	O	O
the	NN	O	O
location	NN	O	O
of	NN	O	O
germ	NN	O	O
-	NN	O	O
line	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
in	NN	O	O
22	NN	O	O
unrelated	NN	O	O
patients	NN	O	O
(	NN	O	O
12	NN	O	O
of	NN	O	O
whom	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
previously	NN	O	O
)	NN	O	O
with	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
colorectal	NN	O	B-Disease
polyps	NN	O	I-Disease
developed	NN	O	O
in	NN	O	O
FAP	NN	O	B-Disease
patients	NN	O	O
;	NN	O	O
17	NN	O	O
were	NN	O	O
sparse	NN	O	O
types	NN	O	O
and	NN	O	O
five	NN	O	O
were	NN	O	O
profuse	NN	O	O
types	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
mutations	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
C	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
G	NN	O	O
transversion	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
replacement	NN	O	O
of	NN	O	O
Tyr180	NN	O	O
by	NN	O	O
a	NN	O	O
stop	NN	O	O
codon	NN	O	O
.	NN	O	O

4	NN	O	O
%	NN	O	O
(	NN	O	O
7	NN	O	O
of	NN	O	O
94	NN	O	O
)	NN	O	O
were	NN	O	O
A	NN	O	O
to	NN	O	O
G	NN	O	O
mutation	NN	O	O
at	NN	O	O
nt	NN	O	O
493	NN	O	O
,	NN	O	O
7	NN	O	O
.	NN	O	O

DGGE	NN	O	O
analysis	NN	O	O
of	NN	O	O
10	NN	O	O
APC	NN	O	B-Disease
exons	NN	O	O
(	NN	O	O
4	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
9	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
12	NN	O	O
,	NN	O	O
13	NN	O	O
,	NN	O	O
14	NN	O	O
,	NN	O	O
and	NN	O	O
part	NN	O	O
of	NN	O	O
15	NN	O	O
)	NN	O	O
in	NN	O	O
33	NN	O	O
unrelated	NN	O	O
Dutch	NN	O	O
FAP	NN	O	B-Disease
patients	NN	O	O
has	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
identification	NN	O	O
of	NN	O	O
eight	NN	O	O
novel	NN	O	O
germ	NN	O	O
line	NN	O	O
mutations	NN	O	O
resulting	NN	O	O
in	NN	O	O
stop	NN	O	O
codons	NN	O	O
or	NN	O	O
frameshifts	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
an	NN	O	O
extremely	NN	O	O
heterogeneous	NN	O	O
spectrum	NN	O	O
of	NN	O	O
mutations	NN	O	O
spread	NN	O	O
throughout	NN	O	O
the	NN	O	O
entire	NN	O	O
length	NN	O	O
of	NN	O	O
the	NN	O	O
large	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
among	NN	O	O
the	NN	O	O
FAP	NN	O	B-Disease
patients	NN	O	O
indicates	NN	O	O
that	NN	O	O
this	NN	O	O
approach	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
useful	NN	O	O
as	NN	O	O
a	NN	O	O
rapid	NN	O	O
presymptomatic	NN	O	O
diagnostic	NN	O	O
procedure	NN	O	O
in	NN	O	O
a	NN	O	O
routine	NN	O	O
laboratory	NN	O	O
.	NN	O	O

The	NN	O	O
following	NN	O	O
markers	NN	O	O
were	NN	O	O
tested	NN	O	O
C2	NN	O	O
levels	NN	O	O
,	NN	O	O
factor	NN	O	O
B	NN	O	O
polymorphism	NN	O	O
,	NN	O	O
blood	NN	O	O
groups	NN	O	O
,	NN	O	O
and	NN	O	O
enzyme	NN	O	O
typing	NN	O	O
.	NN	O	O

Somatic	NN	O	O
mutations	NN	O	O
of	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
in	NN	O	O
colorectal	NN	O	B-Disease
tumors	NN	O	I-Disease
:	NN	O	O
mutation	NN	O	O
cluster	NN	O	O
region	NN	O	O
in	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
gene	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
loss	NN	O	O
of	NN	O	O
heterozygosity	NN	O	O
(	NN	O	O
LOH	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
locus	NN	O	O
in	NN	O	O
30	NN	O	O
tumors	NN	O	B-Disease
,	NN	O	O
43	NN	O	O
other	NN	O	O
somatic	NN	O	O
mutations	NN	O	O
were	NN	O	O
detected	NN	O	O
.	NN	O	O

Constitutional	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
WT1	NN	O	O
gene	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Denys	NN	O	B-Disease
-	NN	O	I-Disease
Drash	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
have	NN	O	O
analysed	NN	O	O
the	NN	O	O
DNA	NN	O	O
sequence	NN	O	O
in	NN	O	O
constitutional	NN	O	O
cells	NN	O	O
from	NN	O	O
eight	NN	O	O
patients	NN	O	O
and	NN	O	O
have	NN	O	O
shown	NN	O	O
heterozygous	NN	O	O
mutations	NN	O	O
in	NN	O	O
six	NN	O	O
of	NN	O	O
them	NN	O	O
.	NN	O	O

Four	NN	O	O
of	NN	O	O
the	NN	O	O
mutations	NN	O	O
were	NN	O	O
in	NN	O	O
exon	NN	O	O
9	NN	O	O
,	NN	O	O
all	NN	O	O
resulting	NN	O	O
in	NN	O	O
missense	NN	O	O
mutations	NN	O	O
.	NN	O	O

Three	NN	O	O
were	NN	O	O
at	NN	O	O
nucleotide	NN	O	O
position	NN	O	O
1180	NN	O	O
resulting	NN	O	O
in	NN	O	O
an	NN	O	O
arg	NN	O	O
>	NN	O	O
trp	NN	O	O
amino	NN	O	O
acid	NN	O	O
change	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
had	NN	O	O
a	NN	O	O
missense	NN	O	O
mutation	NN	O	O
in	NN	O	O
exon	NN	O	O
8	NN	O	O
,	NN	O	O
converting	NN	O	O
an	NN	O	O
arg	NN	O	O
>	NN	O	O
his	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
base	NN	O	O
pair	NN	O	O
insertion	NN	O	O
at	NN	O	O
nucleotide	NN	O	O
position	NN	O	O
821	NN	O	O
in	NN	O	O
exon	NN	O	O
6	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
a	NN	O	O
premature	NN	O	O
stop	NN	O	O
codon	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
patient	NN	O	O
.	NN	O	O

06	NN	O	O
centimorgans	NN	O	O
(	NN	O	O
or	NN	O	O
about	NN	O	O
60	NN	O	O
kilobases	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
CSF1R	NN	O	O
gene	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
further	NN	O	O
segregation	NN	O	O
analysis	NN	O	O
has	NN	O	O
been	NN	O	O
performed	NN	O	O
using	NN	O	O
a	NN	O	O
newly	NN	O	O
identified	NN	O	O
WAS	NN	O	B-Disease
family	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
an	NN	O	O
additional	NN	O	O
marker	NN	O	O
probe	NN	O	O
,	NN	O	O
HOATL1	NN	O	O
.	NN	O	O

These	NN	O	O
linkage	NN	O	O
data	NN	O	O
narrow	NN	O	O
the	NN	O	O
boundaries	NN	O	O
within	NN	O	O
which	NN	O	O
the	NN	O	O
WAS	NN	O	B-Disease
locus	NN	O	O
maps	NN	O	O
to	NN	O	O
the	NN	O	O
chromosomal	NN	O	O
region	NN	O	O
bracketed	NN	O	O
by	NN	O	O
TIMP	NN	O	O
and	NN	O	O
DXS146	NN	O	O
and	NN	O	O
support	NN	O	O
the	NN	O	O
loci	NN	O	O
order	NN	O	O
Xpter	NN	O	O
-	NN	O	O
DXS7	NN	O	O
-	NN	O	O
TIMP	NN	O	O
-	NN	O	O
(	NN	O	O
OATL1	NN	O	O
,	NN	O	O
WAS	NN	O	O
,	NN	O	O
DXS255	NN	O	O
)	NN	O	O
-	NN	O	O
DXS146	NN	O	O
.	NN	O	O

Reciprocal	NN	O	O
chromosome	NN	O	O
translocations	NN	O	O
are	NN	O	O
common	NN	O	O
de	NN	O	O
novo	NN	O	O
rearrangements	NN	O	O
that	NN	O	O
occur	NN	O	O
randomly	NN	O	O
throughout	NN	O	O
the	NN	O	O
human	NN	O	O
genome	NN	O	O
.	NN	O	O

Most	NN	O	O
likely	NN	O	O
,	NN	O	O
deletion	NN	O	O
and	NN	O	O
translation	NN	O	O
arose	NN	O	O
simultaneously	NN	O	O
from	NN	O	O
a	NN	O	O
complex	NN	O	O
rearrangement	NN	O	O
event	NN	O	O
that	NN	O	O
involves	NN	O	O
three	NN	O	O
chromosomal	NN	O	O
breakpoints	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
the	NN	O	O
X	NN	O	O
-	NN	O	O
derived	NN	O	O
sequence	NN	O	O
GGAATCA	NN	O	O
has	NN	O	O
been	NN	O	O
lost	NN	O	O
in	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
the	NN	O	O
der	NN	O	O
(	NN	O	O
X	NN	O	O
)	NN	O	O
chromosome	NN	O	O
,	NN	O	O
as	NN	O	O
it	NN	O	O
matches	NN	O	O
an	NN	O	O
inverted	NN	O	O
GAATCA	NN	O	O
sequence	NN	O	O
present	NN	O	O
on	NN	O	O
the	NN	O	O
opposite	NN	O	O
strand	NN	O	O
exactly	NN	O	O
at	NN	O	O
the	NN	O	O
other	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
deleted	NN	O	O
5	NN	O	O
-	NN	O	O
kb	NN	O	O
fragment	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
clinical	NN	O	O
,	NN	O	O
cytogenetic	NN	O	O
,	NN	O	O
and	NN	O	O
molecular	NN	O	O
studies	NN	O	O
of	NN	O	O
14	NN	O	O
patients	NN	O	O
with	NN	O	O
DGS	NN	O	B-Disease
.	NN	O	O

Chromosome	NN	O	O
analysis	NN	O	O
,	NN	O	O
utilizing	NN	O	O
high	NN	O	O
-	NN	O	O
resolution	NN	O	O
banding	NN	O	O
techniques	NN	O	O
,	NN	O	O
detected	NN	O	O
interstitial	NN	O	O
deletions	NN	O	O
in	NN	O	O
five	NN	O	O
probands	NN	O	O
and	NN	O	O
was	NN	O	O
inconclusive	NN	O	O
for	NN	O	O
a	NN	O	O
deletion	NN	O	O
in	NN	O	O
three	NN	O	O
probands	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
demonstration	NN	O	O
of	NN	O	O
LOH	NN	O	O
at	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
locus	NN	O	O
in	NN	O	O
adrenocortical	NN	O	B-Disease
tumors	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
this	NN	O	O
mutation	NN	O	O
also	NN	O	O
occurs	NN	O	O
near	NN	O	O
a	NN	O	O
potential	NN	O	O
cryptic	NN	O	O
splice	NN	O	O
acceptor	NN	O	O
site	NN	O	O
,	NN	O	O
raising	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
alternative	NN	O	O
splicing	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
less	NN	O	O
severely	NN	O	O
disrupted	NN	O	O
protein	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
AMELX	NN	O	O
gene	NN	O	O
located	NN	O	O
at	NN	O	O
Xp22	NN	O	O
.	NN	O	O

04	NN	O	O
04	NN	O	O
.	NN	O	O

This	NN	O	O
supports	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
AMELX	NN	O	O
,	NN	O	O
located	NN	O	O
close	NN	O	O
to	NN	O	O
DXS16	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
XAI	NN	O	B-Disease
disease	NN	O	I-Disease
process	NN	O	O
(	NN	O	O
AIH1	NN	O	O
)	NN	O	O
in	NN	O	O
those	NN	O	O
families	NN	O	O
.	NN	O	O

The	NN	O	O
support	NN	O	O
interval	NN	O	O
around	NN	O	O
this	NN	O	O
location	NN	O	O
extended	NN	O	O
about	NN	O	O
8	NN	O	O
cM	NN	O	O
proximal	NN	O	O
to	NN	O	O
DXS92	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
AIH1	NN	O	O
location	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
precisely	NN	O	O
defined	NN	O	O
by	NN	O	O
multipoint	NN	O	O
mapping	NN	O	O
.	NN	O	O

Study	NN	O	O
of	NN	O	O
recombination	NN	O	O
events	NN	O	O
indicated	NN	O	O
that	NN	O	O
AIH1	NN	O	O
lies	NN	O	O
in	NN	O	O
the	NN	O	O
interval	NN	O	O
between	NN	O	O
DXS143	NN	O	O
and	NN	O	O
DXS85	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
significant	NN	O	O
evidence	NN	O	O
against	NN	O	O
linkage	NN	O	O
to	NN	O	O
this	NN	O	O
region	NN	O	O
in	NN	O	O
the	NN	O	O
third	NN	O	O
family	NN	O	O
,	NN	O	O
indicating	NN	O	O
locus	NN	O	O
heterogeneity	NN	O	O
in	NN	O	O
XAI	NN	O	B-Disease
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O
.	NN	O	O

Multiple	NN	O	O
origins	NN	O	O
for	NN	O	O
phenylketonuria	NN	O	B-Disease
in	NN	O	O
Europe	NN	O	O
.	NN	O	O

Phenylketonuria	NN	O	B-Disease
(	NN	O	O
PKU	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
a	NN	O	O
disorder	NN	O	B-Disease
of	NN	O	I-Disease
amino	NN	O	I-Disease
acid	NN	O	I-Disease
metabolism	NN	O	I-Disease
prevalent	NN	O	O
among	NN	O	O
Caucasians	NN	O	O
and	NN	O	O
other	NN	O	O
ethnic	NN	O	O
groups	NN	O	O
,	NN	O	O
is	NN	O	O
caused	NN	O	O
primarily	NN	O	O
by	NN	O	O
a	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
hepatic	NN	O	I-Disease
enzyme	NN	O	I-Disease
phenylalanine	NN	O	I-Disease
hydroxylase	NN	O	I-Disease
(	NN	O	O
PAH	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
cause	NN	O	O
of	NN	O	O
disease	NN	O	O
in	NN	O	O
this	NN	O	O
family	NN	O	O
remains	NN	O	O
unknown	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
this	NN	O	O
rare	NN	O	O
mutation	NN	O	O
and	NN	O	O
PMD	NN	O	B-Disease
is	NN	O	O
intriguing	NN	O	O
.	NN	O	O

Neurological	NN	O	O
mutant	NN	O	O
mice	NN	O	O
can	NN	O	O
often	NN	O	O
provide	NN	O	O
model	NN	O	O
systems	NN	O	O
for	NN	O	O
human	NN	O	O
genetic	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
unexplained	NN	O	O
phenotype	NN	O	O
of	NN	O	O
these	NN	O	O
mutations	NN	O	O
includes	NN	O	O
degeneration	NN	O	B-Disease
and	NN	O	I-Disease
premature	NN	O	I-Disease
cell	NN	O	I-Disease
death	NN	O	I-Disease
of	NN	O	I-Disease
oligodendrocytes	NN	O	I-Disease
with	NN	O	O
associated	NN	O	O
hypomyelination	NN	O	B-Disease
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
a	NN	O	O
new	NN	O	O
mouse	NN	O	O
mutant	NN	O	O
rumpshaker	NN	O	O
is	NN	O	O
defined	NN	O	O
by	NN	O	O
the	NN	O	O
amino	NN	O	O
-	NN	O	O
acid	NN	O	O
substitution	NN	O	O
Ile	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
Thr	NN	O	O
at	NN	O	O
residue	NN	O	O
186	NN	O	O
in	NN	O	O
a	NN	O	O
membrane	NN	O	O
-	NN	O	O
embedded	NN	O	O
domain	NN	O	O
of	NN	O	O
PLP	NN	O	O
.	NN	O	O

Given	NN	O	O
both	NN	O	O
the	NN	O	O
large	NN	O	O
proportion	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
Jewish	NN	O	O
carriers	NN	O	O
with	NN	O	O
this	NN	O	O
allele	NN	O	O
and	NN	O	O
that	NN	O	O
standard	NN	O	O
biochemical	NN	O	O
screening	NN	O	O
cannot	NN	O	O
differentiate	NN	O	O
between	NN	O	O
heterozygotes	NN	O	O
for	NN	O	O
the	NN	O	O
C739	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
T	NN	O	O
mutations	NN	O	O
and	NN	O	O
Tay	NN	O	B-Disease
-	NN	O	I-Disease
Sachs	NN	O	I-Disease
disease	NN	O	I-Disease
carriers	NN	O	O
,	NN	O	O
DNA	NN	O	O
testing	NN	O	O
for	NN	O	O
this	NN	O	O
mutation	NN	O	O
in	NN	O	O
at	NN	O	O
-	NN	O	O
risk	NN	O	O
couples	NN	O	O
is	NN	O	O
essential	NN	O	O
.	NN	O	O

For	NN	O	O
human	NN	O	O
vWF	NN	O	O
,	NN	O	O
this	NN	O	O
interaction	NN	O	O
can	NN	O	O
be	NN	O	O
induced	NN	O	O
in	NN	O	O
vitro	NN	O	O
by	NN	O	O
the	NN	O	O
antibiotic	NN	O	O
ristocetin	NN	O	O
or	NN	O	O
the	NN	O	O
snake	NN	O	O
venom	NN	O	O
protein	NN	O	O
botrocetin	NN	O	O
.	NN	O	O

The	NN	O	O
corresponding	NN	O	O
mutant	NN	O	O
recombinant	NN	O	O
protein	NN	O	O
,	NN	O	O
rvWF	NN	O	O
(	NN	O	O
G561S	NN	O	O
)	NN	O	O
,	NN	O	O
formed	NN	O	O
normal	NN	O	O
multimers	NN	O	O
and	NN	O	O
exhibited	NN	O	O
the	NN	O	O
same	NN	O	O
functional	NN	O	O
defect	NN	O	O
as	NN	O	O
the	NN	O	O
patients	NN	O	O
plasma	NN	O	O
vWF	NN	O	O
,	NN	O	O
confirming	NN	O	O
that	NN	O	O
this	NN	O	O
mutation	NN	O	O
causes	NN	O	O
von	NN	O	B-Disease
Willebrand	NN	O	I-Disease
disease	NN	O	I-Disease
type	NN	O	I-Disease
B	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
normal	NN	O	O
botrocetin	NN	O	O
-	NN	O	O
induced	NN	O	O
binding	NN	O	O
and	NN	O	O
the	NN	O	O
defective	NN	O	O
ristocetin	NN	O	O
-	NN	O	O
induced	NN	O	O
binding	NN	O	O
of	NN	O	O
rvWF	NN	O	O
(	NN	O	O
G561S	NN	O	O
)	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
primary	NN	O	O
defect	NN	O	O
in	NN	O	O
von	NN	O	B-Disease
Willebrand	NN	O	I-Disease
disease	NN	O	I-Disease
type	NN	O	I-Disease
B	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
a	NN	O	O
failure	NN	O	O
of	NN	O	O
normal	NN	O	O
allosteric	NN	O	O
regulation	NN	O	O
of	NN	O	O
the	NN	O	O
glycoprotein	NN	O	O
Ib	NN	O	O
binding	NN	O	O
function	NN	O	O
of	NN	O	O
vWF	NN	O	O
.	NN	O	O
.	NN	O	O

Carriers	NN	O	O
of	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
are	NN	O	O
residents	NN	O	O
of	NN	O	O
11	NN	O	O
villages	NN	O	O
located	NN	O	O
in	NN	O	O
Alasani	NN	O	O
-	NN	O	O
Aphtalan	NN	O	O
valley	NN	O	O
,	NN	O	O
highly	NN	O	O
endemic	NN	O	O
with	NN	O	O
malaria	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
past	NN	O	O
;	NN	O	O
nearly	NN	O	O
all	NN	O	O
marriages	NN	O	O
are	NN	O	O
endogamic	NN	O	O
.	NN	O	O

Resemblance	NN	O	O
of	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
variants	NN	O	O
in	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
and	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
erythrocyte	NN	O	O
enzyme	NN	O	O
activity	NN	O	O
permit	NN	O	O
to	NN	O	O
suggest	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
a	NN	O	O
common	NN	O	O
parental	NN	O	O
mutant	NN	O	O
G6PD	NN	O	O
allele	NN	O	O
distributed	NN	O	O
in	NN	O	O
this	NN	O	O
area	NN	O	O
.	NN	O	O

Hypotonia	NN	O	B-Disease
and	NN	O	O
laxity	NN	O	B-Disease
of	NN	O	I-Disease
joints	NN	O	I-Disease
are	NN	O	O
common	NN	O	O
and	NN	O	O
may	NN	O	O
necessitate	NN	O	O
supportive	NN	O	O
measures	NN	O	O
.	NN	O	O

Unlike	NN	O	O
almost	NN	O	O
all	NN	O	O
other	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
disorders	NN	O	I-Disease
,	NN	O	O
clinical	NN	O	O
expression	NN	O	O
in	NN	O	O
CFND	NN	O	B-Disease
is	NN	O	O
generally	NN	O	O
much	NN	O	O
more	NN	O	O
severe	NN	O	O
in	NN	O	O
females	NN	O	O
than	NN	O	O
in	NN	O	O
males	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
previous	NN	O	O
reports	NN	O	O
of	NN	O	O
this	NN	O	O
condition	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
our	NN	O	O
severely	NN	O	O
affected	NN	O	O
cases	NN	O	O
is	NN	O	O
a	NN	O	O
male	NN	O	O
.	NN	O	O
.	NN	O	O

Cultured	NN	O	O
human	NN	O	O
fibroblasts	NN	O	O
from	NN	O	O
a	NN	O	O
compound	NN	O	O
heterozygote	NN	O	O
for	NN	O	O
this	NN	O	O
transition	NN	O	O
(	NN	O	O
and	NN	O	O
for	NN	O	O
a	NN	O	O
deletion	NN	O	O
mutation	NN	O	O
)	NN	O	O
produce	NN	O	O
no	NN	O	O
detectable	NN	O	O
HEXA	NN	O	O
mRNA	NN	O	O
.	NN	O	O

This	NN	O	O
mutation	NN	O	O
thus	NN	O	O
has	NN	O	O
a	NN	O	O
different	NN	O	O
geographic	NN	O	O
centre	NN	O	O
of	NN	O	O
diffusion	NN	O	O
and	NN	O	O
is	NN	O	O
probably	NN	O	O
less	NN	O	O
common	NN	O	O
than	NN	O	O
the	NN	O	O
exon	NN	O	O
1	NN	O	O
deletion	NN	O	O
TSD	NN	O	B-Disease
mutation	NN	O	O
in	NN	O	O
French	NN	O	O
Canadians	NN	O	O
.	NN	O	O

Neither	NN	O	O
mutation	NN	O	O
has	NN	O	O
been	NN	O	O
detected	NN	O	O
in	NN	O	O
France	NN	O	O
,	NN	O	O
the	NN	O	O
ancestral	NN	O	O
homeland	NN	O	O
of	NN	O	O
French	NN	O	O
Canada	NN	O	O
.	NN	O	O
.	NN	O	O

We	NN	O	O
determined	NN	O	O
the	NN	O	O
AGA	NN	O	O
activity	NN	O	O
in	NN	O	O
cultured	NN	O	O
fibroblasts	NN	O	O
of	NN	O	O
a	NN	O	O
girl	NN	O	O
with	NN	O	O
a	NN	O	O
46	NN	O	O
,	NN	O	O
XX	NN	O	O
,	NN	O	O
del	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
(	NN	O	O
q33	NN	O	O
)	NN	O	O
karyotype	NN	O	O
.	NN	O	O

Resolution	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
loci	NN	O	O
for	NN	O	O
autosomal	NN	O	O
dominant	NN	O	O
aniridia	NN	O	B-Disease
,	NN	O	O
AN1	NN	O	O
and	NN	O	O
AN2	NN	O	O
,	NN	O	O
to	NN	O	O
a	NN	O	O
single	NN	O	O
locus	NN	O	O
on	NN	O	O
chromosome	NN	O	O
11p13	NN	O	O
.	NN	O	O

Markers	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
isolated	NN	O	O
from	NN	O	O
the	NN	O	O
chromosome	NN	O	O
11p13	NN	O	O
region	NN	O	O
were	NN	O	O
then	NN	O	O
analyzed	NN	O	O
in	NN	O	O
this	NN	O	O
aniridia	NN	O	B-Disease
family	NN	O	O
.	NN	O	O

Two	NN	O	O
RFLPs	NN	O	O
at	NN	O	O
the	NN	O	O
D11S323	NN	O	O
locus	NN	O	O
give	NN	O	O
significant	NN	O	O
evidence	NN	O	O
for	NN	O	O
linkage	NN	O	O
.	NN	O	O

97	NN	O	O
at	NN	O	O
theta	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O

2	NN	O	O
gives	NN	O	O
a	NN	O	O
maximum	NN	O	O
lod	NN	O	O
score	NN	O	O
of	NN	O	O
Z	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O

Although	NN	O	O
pyoderma	NN	O	B-Disease
gangrenosum	NN	O	I-Disease
(	NN	O	O
PG	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
often	NN	O	O
associated	NN	O	O
with	NN	O	O
systemic	NN	O	B-Disease
diseases	NN	O	I-Disease
,	NN	O	O
it	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
congenital	NN	O	B-Disease
complement	NN	O	I-Disease
deficiencies	NN	O	I-Disease
.	NN	O	O

Diverse	NN	O	O
point	NN	O	O
mutations	NN	O	O
result	NN	O	O
in	NN	O	O
glucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
dehydrogenase	NN	O	O
(	NN	O	O
G6PD	NN	O	O
)	NN	O	O
polymorphism	NN	O	O
in	NN	O	O
Taiwan	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
the	NN	O	O
gene	NN	O	O
that	NN	O	O
encodes	NN	O	O
human	NN	O	O
G6PD	NN	O	O
has	NN	O	O
been	NN	O	O
cloned	NN	O	O
and	NN	O	O
sequenced	NN	O	O
,	NN	O	O
which	NN	O	O
enables	NN	O	O
us	NN	O	O
to	NN	O	O
examine	NN	O	O
directly	NN	O	O
the	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
G6PD	NN	O	O
at	NN	O	O
the	NN	O	O
DNA	NN	O	O
level	NN	O	O
.	NN	O	O

An	NN	O	O
error	NN	O	O
in	NN	O	O
dystrophin	NN	O	O
mRNA	NN	O	O
processing	NN	O	O
in	NN	O	O
golden	NN	O	B-Disease
retriever	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
,	NN	O	O
an	NN	O	O
animal	NN	O	O
homologue	NN	O	O
of	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
.	NN	O	O

Golden	NN	O	B-Disease
retriever	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
GRMD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
spontaneous	NN	O	O
,	NN	O	O
X	NN	O	O
-	NN	O	O
linked	NN	O	O
,	NN	O	O
progressively	NN	O	O
fatal	NN	O	O
disease	NN	O	O
of	NN	O	O
dogs	NN	O	O
and	NN	O	O
is	NN	O	O
also	NN	O	O
a	NN	O	O
homologue	NN	O	O
of	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DMD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
example	NN	O	O
of	NN	O	O
dystrophin	NN	O	B-Disease
deficiency	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
a	NN	O	O
splice	NN	O	O
-	NN	O	O
site	NN	O	O
mutation	NN	O	O
.	NN	O	O
.	NN	O	O

A	NN	O	O
28	NN	O	O
-	NN	O	O
base	NN	O	O
pair	NN	O	O
gene	NN	O	O
deletion	NN	O	O
causes	NN	O	O
skipping	NN	O	O
of	NN	O	O
exon	NN	O	O
6	NN	O	O
during	NN	O	O
RNA	NN	O	O
splicing	NN	O	O
.	NN	O	O

Both	NN	O	O
galactosemia	NN	O	B-Disease
mutations	NN	O	O
result	NN	O	O
in	NN	O	O
reduced	NN	O	O
enzymatic	NN	O	O
activity	NN	O	O
when	NN	O	O
reconstructed	NN	O	O
in	NN	O	O
the	NN	O	O
cDNA	NN	O	O
and	NN	O	O
overexpressed	NN	O	O
.	NN	O	O

Both	NN	O	O
mutations	NN	O	O
affect	NN	O	O
evolutionarily	NN	O	O
conserved	NN	O	O
residues	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
they	NN	O	O
are	NN	O	O
functionally	NN	O	O
important	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
polymorphism	NN	O	O
occurs	NN	O	O
in	NN	O	O
a	NN	O	O
nonconserved	NN	O	O
domain	NN	O	O
which	NN	O	O
is	NN	O	O
presumably	NN	O	O
not	NN	O	O
critical	NN	O	O
for	NN	O	O
enzymatic	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
F171S	NN	O	O
mutation	NN	O	O
is	NN	O	O
close	NN	O	O
to	NN	O	O
the	NN	O	O
putative	NN	O	O
active	NN	O	O
-	NN	O	O
site	NN	O	O
nucleophile	NN	O	O
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
its	NN	O	O
possible	NN	O	O
role	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
analyzed	NN	O	O
the	NN	O	O
coding	NN	O	O
exons	NN	O	O
of	NN	O	O
the	NN	O	O
Wilms	NN	O	B-Disease
tumor	NN	O	I-Disease
suppressor	NN	O	O
gene	NN	O	O
(	NN	O	O
WT1	NN	O	O
)	NN	O	O
for	NN	O	O
germline	NN	O	O
mutations	NN	O	O
.	NN	O	O

8	NN	O	O
without	NN	O	O
recombination	NN	O	O
.	NN	O	O

Two	NN	O	O
distinct	NN	O	O
mutations	NN	O	O
at	NN	O	O
a	NN	O	O
single	NN	O	O
BamHI	NN	O	O
site	NN	O	O
in	NN	O	O
phenylketonuria	NN	O	B-Disease
.	NN	O	O

New	NN	O	O
RFLPs	NN	O	O
are	NN	O	O
reported	NN	O	O
for	NN	O	O
four	NN	O	O
loci	NN	O	O
.	NN	O	O

The	NN	O	O
map	NN	O	O
integrates	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
resolution	NN	O	O
genetic	NN	O	O
map	NN	O	O
of	NN	O	O
4p16	NN	O	O
into	NN	O	O
a	NN	O	O
continuous	NN	O	O
map	NN	O	O
extending	NN	O	O
to	NN	O	O
4q31	NN	O	O
and	NN	O	O
an	NN	O	O
unlinked	NN	O	O
cluster	NN	O	O
of	NN	O	O
three	NN	O	O
loci	NN	O	O
at	NN	O	O
4q35	NN	O	O
.	NN	O	O

Carrier	NN	O	O
detection	NN	O	O
and	NN	O	O
prenatal	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Pelizaeus	NN	O	B-Disease
-	NN	O	I-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
using	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
anonymous	NN	O	O
DNA	NN	O	O
polymorphisms	NN	O	O
and	NN	O	O
the	NN	O	O
proteolipid	NN	O	O
protein	NN	O	O
(	NN	O	O
PLP	NN	O	O
)	NN	O	O
gene	NN	O	O
cDNA	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
families	NN	O	O
,	NN	O	O
the	NN	O	O
proteolipid	NN	O	O
protein	NN	O	O
(	NN	O	O
PLP	NN	O	O
)	NN	O	O
gene	NN	O	O
in	NN	O	O
the	NN	O	O
single	NN	O	O
affected	NN	O	O
male	NN	O	O
could	NN	O	O
be	NN	O	O
traced	NN	O	O
back	NN	O	O
to	NN	O	O
his	NN	O	O
unaffected	NN	O	O
maternal	NN	O	O
grandfather	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
each	NN	O	O
family	NN	O	O
contains	NN	O	O
a	NN	O	O
new	NN	O	O
mutation	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
deletion	NN	O	O
mutations	NN	O	O
and	NN	O	O
three	NN	O	O
new	NN	O	O
genes	NN	O	O
at	NN	O	O
the	NN	O	O
familial	NN	O	B-Disease
polyposis	NN	O	I-Disease
locus	NN	O	O
.	NN	O	O

Three	NN	O	O
candidate	NN	O	O
genes	NN	O	O
located	NN	O	O
within	NN	O	O
the	NN	O	O
deleted	NN	O	O
region	NN	O	O
were	NN	O	O
ascertained	NN	O	O
and	NN	O	O
a	NN	O	O
previous	NN	O	O
candidate	NN	O	O
gene	NN	O	O
,	NN	O	O
MCC	NN	O	O
,	NN	O	O
was	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
located	NN	O	O
outside	NN	O	O
the	NN	O	O
deleted	NN	O	O
region	NN	O	O
.	NN	O	O

Two	NN	O	O
other	NN	O	O
cDNAs	NN	O	O
,	NN	O	O
DP2	NN	O	O
and	NN	O	O
DP3	NN	O	O
,	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
overlap	NN	O	O
,	NN	O	O
forming	NN	O	O
a	NN	O	O
single	NN	O	O
gene	NN	O	O
,	NN	O	O
DP2	NN	O	O
.	NN	O	O

4	NN	O	O
cM	NN	O	O
including	NN	O	O
and	NN	O	O
surrounding	NN	O	O
the	NN	O	O
SAA	NN	O	O
gene	NN	O	O
cluster	NN	O	O
as	NN	O	O
the	NN	O	O
site	NN	O	O
of	NN	O	O
the	NN	O	O
FMF	NN	O	B-Disease
mutation	NN	O	O
although	NN	O	O
SAA	NN	O	O
proteins	NN	O	O
are	NN	O	O
prominent	NN	O	O
physiologic	NN	O	O
markers	NN	O	O
of	NN	O	O
the	NN	O	O
acute	NN	O	O
attacks	NN	O	O
.	NN	O	O

Rearrangement	NN	O	O
of	NN	O	O
the	NN	O	O
BCL1	NN	O	O
(	NN	O	O
B	NN	O	O
-	NN	O	O
cell	NN	O	O
lymphoma	NN	O	O
1	NN	O	O
)	NN	O	O
region	NN	O	O
on	NN	O	O
chromosome	NN	O	O
11q13	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
highly	NN	O	O
characteristic	NN	O	O
of	NN	O	O
centrocytic	NN	O	B-Disease
lymphoma	NN	O	I-Disease
and	NN	O	O
also	NN	O	O
is	NN	O	O
found	NN	O	O
infrequently	NN	O	O
in	NN	O	O
other	NN	O	O
B	NN	O	B-Disease
-	NN	O	I-Disease
cell	NN	O	I-Disease
neoplasms	NN	O	I-Disease
.	NN	O	O

"	NN	O	O
Its	NN	O	O
overexpression	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
key	NN	O	O
consequence	NN	O	O
of	NN	O	O
rearrangement	NN	O	O
of	NN	O	O
the	NN	O	O
BCL1	NN	O	O
vicinity	NN	O	O
in	NN	O	O
B	NN	O	B-Disease
-	NN	O	I-Disease
cell	NN	O	I-Disease
neoplasms	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
unifying	NN	O	O
pathogenetic	NN	O	O
feature	NN	O	O
in	NN	O	O
centrocytic	NN	O	B-Disease
lymphoma	NN	O	I-Disease
.	NN	O	O

One	NN	O	O
,	NN	O	O
a	NN	O	O
point	NN	O	O
mutation	NN	O	O
in	NN	O	O
exon	NN	O	O
3	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
substitution	NN	O	O
of	NN	O	O
isoleucine	NN	O	O
by	NN	O	O
serine	NN	O	O
.	NN	O	O

Apparently	NN	O	O
normal	NN	O	O
levels	NN	O	O
of	NN	O	O
mRNA	NN	O	O
were	NN	O	O
generated	NN	O	O
from	NN	O	O
this	NN	O	O
allele	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
ARSA	NN	O	O
activity	NN	O	O
or	NN	O	O
immuno	NN	O	O
-	NN	O	O
cross	NN	O	O
-	NN	O	O
reactive	NN	O	O
material	NN	O	O
could	NN	O	O
be	NN	O	O
detected	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
combinations	NN	O	O
with	NN	O	O
other	NN	O	O
MLD	NN	O	B-Disease
mutations	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
point	NN	O	O
mutation	NN	O	O
in	NN	O	O
exon	NN	O	O
3	NN	O	O
does	NN	O	O
result	NN	O	O
in	NN	O	O
some	NN	O	O
residual	NN	O	O
enzyme	NN	O	O
activity	NN	O	O
and	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
late	NN	O	O
-	NN	O	O
onset	NN	O	O
forms	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
.	NN	O	O

Both	NN	O	O
small	NN	O	O
-	NN	O	O
sized	NN	O	O
and	NN	O	O
normal	NN	O	O
-	NN	O	O
sized	NN	O	O
platelets	NN	O	O
were	NN	O	O
present	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
,	NN	O	O
unlike	NN	O	O
the	NN	O	O
vast	NN	O	O
majority	NN	O	O
of	NN	O	O
WAS	NN	O	B-Disease
carriers	NN	O	O
,	NN	O	O
she	NN	O	O
does	NN	O	O
not	NN	O	O
manifest	NN	O	O
nonrandom	NN	O	O
X	NN	O	O
-	NN	O	O
chromosome	NN	O	O
inactivation	NN	O	O
in	NN	O	O
the	NN	O	O
thrombopoietic	NN	O	O
cell	NN	O	O
lineage	NN	O	O
.	NN	O	O

Since	NN	O	O
the	NN	O	O
deletion	NN	O	O
was	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
third	NN	O	O
exon	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
,	NN	O	O
which	NN	O	O
presents	NN	O	O
no	NN	O	O
homology	NN	O	O
with	NN	O	O
other	NN	O	O
hydroxylases	NN	O	O
,	NN	O	O
we	NN	O	O
suggest	NN	O	O
that	NN	O	O
exon	NN	O	O
3	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
specificity	NN	O	O
of	NN	O	O
the	NN	O	O
enzyme	NN	O	O
for	NN	O	O
phenylalanine	NN	O	O
.	NN	O	O

Normotriglyceridemic	NN	O	B-Disease
abetalipoproteinemia	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
rare	NN	O	O
familial	NN	O	B-Disease
disorder	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
an	NN	O	O
isolated	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
apoB	NN	O	I-Disease
-	NN	O	I-Disease
100	NN	O	I-Disease
.	NN	O	O

Normal	NN	O	O
amounts	NN	O	O
of	NN	O	O
liver	NN	O	O
PAH	NN	O	O
protein	NN	O	O
are	NN	O	O
present	NN	O	O
in	NN	O	O
homozygous	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
catalytic	NN	O	O
activity	NN	O	O
can	NN	O	O
be	NN	O	O
detected	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
resolution	NN	O	O
banding	NN	O	O
analysis	NN	O	O
showed	NN	O	O
an	NN	O	O
interstitial	NN	O	O
deletion	NN	O	O
of	NN	O	O
the	NN	O	O
long	NN	O	O
arm	NN	O	O
of	NN	O	O
chromosome	NN	O	O
5	NN	O	O
(	NN	O	O
q22	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
q31	NN	O	O
1	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
q31	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
breakpoints	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
case	NN	O	O
and	NN	O	O
in	NN	O	O
3	NN	O	O
previously	NN	O	O
reported	NN	O	O
5q	NN	O	O
-	NN	O	O
patients	NN	O	O
with	NN	O	O
adenomatous	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
gene	NN	O	O
responsible	NN	O	O
for	NN	O	O
GS	NN	O	B-Disease
/	NN	O	O
or	NN	O	O
familial	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
(	NN	O	O
FPC	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
in	NN	O	O
the	NN	O	O
5q22	NN	O	O
region	NN	O	O
,	NN	O	O
a	NN	O	O
result	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
findings	NN	O	O
of	NN	O	O
linkage	NN	O	O
studies	NN	O	O

Discovery	NN	O	O
of	NN	O	O
other	NN	O	O
cases	NN	O	O
with	NN	O	O
both	NN	O	O
disorders	NN	O	O
may	NN	O	O
provide	NN	O	O
clues	NN	O	O
to	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
both	NN	O	O
conditions	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
mutated	NN	O	O
glutamine	NN	O	O
is	NN	O	O
not	NN	O	O
only	NN	O	O
highly	NN	O	O
conserved	NN	O	O
in	NN	O	O
evolution	NN	O	O
(	NN	O	O
conserved	NN	O	O
also	NN	O	O
in	NN	O	O
Escherichia	NN	O	O
coli	NN	O	O
and	NN	O	O
Saccharomyces	NN	O	O
cerevisiae	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
is	NN	O	O
also	NN	O	O
two	NN	O	O
amino	NN	O	O
acid	NN	O	O
residues	NN	O	O
downstream	NN	O	O
from	NN	O	O
the	NN	O	O
active	NN	O	O
site	NN	O	O
histidine	NN	O	O
-	NN	O	O
proline	NN	O	O
-	NN	O	O
histidine	NN	O	O
triad	NN	O	O
and	NN	O	O
results	NN	O	O
in	NN	O	O
about	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
normal	NN	O	O
enzymatic	NN	O	O
activity	NN	O	O
.	NN	O	O

Electron	NN	O	O
photomicrographs	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
diameters	NN	O	O
of	NN	O	O
particles	NN	O	O
in	NN	O	O
the	NN	O	O
d	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
deleted	NN	O	O
PAH	NN	O	O
gene	NN	O	O
was	NN	O	O
traced	NN	O	O
to	NN	O	O
25	NN	O	O
different	NN	O	O
locations	NN	O	O
throughout	NN	O	O
Yemen	NN	O	O
,	NN	O	O
family	NN	O	O
histories	NN	O	O
and	NN	O	O
official	NN	O	O
documents	NN	O	O
of	NN	O	O
the	NN	O	O
Yemenite	NN	O	O
Jewish	NN	O	O
community	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
common	NN	O	O
ancestor	NN	O	O
of	NN	O	O
all	NN	O	O
the	NN	O	O
carriers	NN	O	O
of	NN	O	O
this	NN	O	O
genetic	NN	O	B-Disease
defect	NN	O	I-Disease
lived	NN	O	O
in	NN	O	O
Sana	NN	O	O
,	NN	O	O
the	NN	O	O
capital	NN	O	O
of	NN	O	O
Yemen	NN	O	O
,	NN	O	O
before	NN	O	O
the	NN	O	O
eighteenth	NN	O	O
century	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
heterozygous	NN	O	O
family	NN	O	O
members	NN	O	O
were	NN	O	O
identified	NN	O	O
by	NN	O	O
reduced	NN	O	O
activity	NN	O	O
of	NN	O	O
AGA	NN	O	O
in	NN	O	O
lymphocytes	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
studied	NN	O	O
the	NN	O	O
genetic	NN	O	O
linkage	NN	O	O
of	NN	O	O
two	NN	O	O
markers	NN	O	O
,	NN	O	O
the	NN	O	O
apolipoprotein	NN	O	O
C1	NN	O	O
(	NN	O	O
APOC1	NN	O	O
)	NN	O	O
gene	NN	O	O
and	NN	O	O
a	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
(	NN	O	O
CYP2A	NN	O	O
)	NN	O	O
gene	NN	O	O
,	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
the	NN	O	O
gene	NN	O	O
for	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
genetic	NN	O	O
heterogeneity	NN	O	O
,	NN	O	O
with	NN	O	O
all	NN	O	O
families	NN	O	O
showing	NN	O	O
linkage	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
chromosome	NN	O	O
5	NN	O	O
marker	NN	O	O
to	NN	O	O
the	NN	O	O
gene	NN	O	O
.	NN	O	O

48	NN	O	O
-	NN	O	O
telomer	NN	O	O
e	NN	O	O
,	NN	O	O
although	NN	O	O
EF5	NN	O	O
.	NN	O	O

No	NN	O	O
recombinants	NN	O	O
were	NN	O	O
identified	NN	O	O
between	NN	O	O
APC	NN	O	O
and	NN	O	O
either	NN	O	O
EF5	NN	O	O
.	NN	O	O

Serum	NN	O	O
amyloid	NN	O	O
A	NN	O	O
and	NN	O	O
P	NN	O	O
protein	NN	O	O
genes	NN	O	O
in	NN	O	O
familial	NN	O	B-Disease
Mediterranean	NN	O	I-Disease
fever	NN	O	I-Disease
.	NN	O	O

To	NN	O	O
test	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
SAA	NN	O	O
and	NN	O	O
APCS	NN	O	O
in	NN	O	O
MEF	NN	O	B-Disease
and	NN	O	O
MEF	NN	O	B-Disease
-	NN	O	I-Disease
amyloidosis	NN	O	I-Disease
,	NN	O	O
we	NN	O	O
studied	NN	O	O
17	NN	O	O
informative	NN	O	O
families	NN	O	O
(	NN	O	O
15	NN	O	O
Armenians	NN	O	O
,	NN	O	O
2	NN	O	O
non	NN	O	O
-	NN	O	O
Ashkenazi	NN	O	O
Jews	NN	O	O
)	NN	O	O
and	NN	O	O
8	NN	O	O
MEF	NN	O	B-Disease
patients	NN	O	O
with	NN	O	O
amyloidosis	NN	O	B-Disease
using	NN	O	O
a	NN	O	O
candidate	NN	O	O
gene	NN	O	O
approach	NN	O	O
.	NN	O	O

Glucose	NN	O	B-Disease
-	NN	O	I-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
(	NN	O	I-Disease
G6PD	NN	O	I-Disease
)	NN	O	I-Disease
deficiency	NN	O	I-Disease
appears	NN	O	O
to	NN	O	O
be	NN	O	O
fairly	NN	O	O
common	NN	O	O
in	NN	O	O
Mexico	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
of	NN	O	O
these	NN	O	O
variants	NN	O	O
,	NN	O	O
believed	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
biochemical	NN	O	O
characterization	NN	O	O
and	NN	O	O
population	NN	O	O
origin	NN	O	O
to	NN	O	O
be	NN	O	O
unique	NN	O	O
,	NN	O	O
have	NN	O	O
the	NN	O	O
G	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
A	NN	O	O
transition	NN	O	O
at	NN	O	O
nucleotide	NN	O	O
202	NN	O	O
and	NN	O	O
the	NN	O	O
A	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
G	NN	O	O
transition	NN	O	O
at	NN	O	O
nucleotide	NN	O	O
376	NN	O	O
,	NN	O	O
mutations	NN	O	O
that	NN	O	O
we	NN	O	O
now	NN	O	O
recognize	NN	O	O
to	NN	O	O
be	NN	O	O
characteristic	NN	O	O
of	NN	O	O
G6PD	NN	O	O
A	NN	O	O
-	NN	O	O
.	NN	O	O

Two	NN	O	O
other	NN	O	O
Mexican	NN	O	O
males	NN	O	O
with	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
the	NN	O	O
same	NN	O	O
mutation	NN	O	O
.	NN	O	O

All	NN	O	O
five	NN	O	O
have	NN	O	O
the	NN	O	O
(	NN	O	O
NlaIII	NN	O	O
/	NN	O	O
FokI	NN	O	O
/	NN	O	O
PvuII	NN	O	O
/	NN	O	O
PstI	NN	O	O
)	NN	O	O
haplotype	NN	O	O
characteristic	NN	O	O
of	NN	O	O
G6PD	NN	O	O
A	NN	O	O
-	NN	O	O
in	NN	O	O
Africa	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
are	NN	O	O
compatible	NN	O	O
with	NN	O	O
this	NN	O	O
hypothesis	NN	O	O
in	NN	O	O
that	NN	O	O
the	NN	O	O
PKU	NN	O	B-Disease
mutation	NN	O	O
might	NN	O	O
have	NN	O	O
occurred	NN	O	O
in	NN	O	O
northern	NN	O	O
Mongoloids	NN	O	O
and	NN	O	O
subsequently	NN	O	O
spread	NN	O	O
to	NN	O	O
the	NN	O	O
Chinese	NN	O	O
and	NN	O	O
Japanese	NN	O	O
populations	NN	O	O
.	NN	O	O

Normal	NN	O	O
glucose	NN	O	O
absorption	NN	O	O
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
Na	NN	O	O
+	NN	O	O
/	NN	O	O
glucose	NN	O	O
cotransporter	NN	O	O
in	NN	O	O
the	NN	O	O
brush	NN	O	O
border	NN	O	O
membrane	NN	O	O
of	NN	O	O
the	NN	O	O
intestinal	NN	O	O
epithelium	NN	O	O
.	NN	O	O

1	NN	O	O
by	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
,	NN	O	O
using	NN	O	O
a	NN	O	O
human	NN	O	O
histidase	NN	O	O
cDNA	NN	O	O
.	NN	O	O

Determination	NN	O	O
of	NN	O	O
the	NN	O	O
mutations	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
17	NN	O	O
subjects	NN	O	O
.	NN	O	O

This	NN	O	O
investigation	NN	O	O
further	NN	O	O
verifies	NN	O	O
this	NN	O	O
heterogeneity	NN	O	O
and	NN	O	O
identifies	NN	O	O
insertions	NN	O	O
,	NN	O	O
deletions	NN	O	O
,	NN	O	O
and	NN	O	O
point	NN	O	O
mutations	NN	O	O
.	NN	O	O

Linkage	NN	O	O
of	NN	O	O
DNA	NN	O	O
markers	NN	O	O
at	NN	O	O
Xq28	NN	O	O
to	NN	O	O
adrenoleukodystrophy	NN	O	B-Disease
and	NN	O	O
adrenomyeloneuropathy	NN	O	B-Disease
present	NN	O	O
within	NN	O	O
the	NN	O	O
same	NN	O	O
family	NN	O	O
.	NN	O	O

The	NN	O	O
pedigree	NN	O	O
clearly	NN	O	O
supported	NN	O	O
the	NN	O	O
X	NN	O	O
-	NN	O	O
linked	NN	O	O
mode	NN	O	O
of	NN	O	O
inheritance	NN	O	O
of	NN	O	O
the	NN	O	O
nonneonatal	NN	O	O
form	NN	O	O
of	NN	O	O
ALD	NN	O	B-Disease
/	NN	O	O
AMN	NN	O	B-Disease
.	NN	O	O

Analysis	NN	O	O
with	NN	O	O
DNA	NN	O	O
markers	NN	O	O
at	NN	O	O
Xq28	NN	O	O
suggested	NN	O	O
segregation	NN	O	O
of	NN	O	O
both	NN	O	O
ALD	NN	O	B-Disease
and	NN	O	O
AMN	NN	O	B-Disease
with	NN	O	O
an	NN	O	O
identical	NN	O	O
haplotype	NN	O	O
.	NN	O	O

It	NN	O	O
showed	NN	O	O
,	NN	O	O
furthermore	NN	O	O
,	NN	O	O
that	NN	O	O
phenotypic	NN	O	O
differences	NN	O	O
between	NN	O	O
ALD	NN	O	B-Disease
and	NN	O	O
AMN	NN	O	B-Disease
are	NN	O	O
not	NN	O	O
necessarily	NN	O	O
the	NN	O	O
consequence	NN	O	O
of	NN	O	O
allelic	NN	O	O
heterogeneity	NN	O	O
due	NN	O	O
to	NN	O	O
different	NN	O	O
mutations	NN	O	O
within	NN	O	O
the	NN	O	O
same	NN	O	O
gene	NN	O	O
.	NN	O	O

Cytogenetic	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
normal	NN	O	O
karyotypes	NN	O	O
,	NN	O	O
eliminating	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
a	NN	O	O
translocation	NN	O	O
affecting	NN	O	O
DMD	NN	O	B-Disease
gene	NN	O	O
function	NN	O	O
.	NN	O	O

No	NN	O	O
pituitary	NN	O	B-Disease
-	NN	O	I-Disease
adrenal	NN	O	I-Disease
abnormality	NN	O	I-Disease
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
carriers	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
people	NN	O	O
with	NN	O	O
ALD	NN	O	B-Disease
and	NN	O	O
AMN	NN	O	B-Disease
may	NN	O	O
have	NN	O	O
subclinical	NN	O	O
partial	NN	O	O
adrenocrotical	NN	O	B-Disease
insufficiency	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
in	NN	O	O
situ	NN	O	O
location	NN	O	O
of	NN	O	O
all	NN	O	O
three	NN	O	O
probes	NN	O	O
is	NN	O	O
9q13	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
-	NN	O	O
q21	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
premature	NN	O	B-Disease
atherosclerosis	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
families	NN	O	O
with	NN	O	O
CETP	NN	O	B-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

12	NN	O	O
(	NN	O	O
D11S144	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
paper	NN	O	O
describes	NN	O	O
further	NN	O	O
mapping	NN	O	O
of	NN	O	O
the	NN	O	O
AT	NN	O	B-Disease
locus	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
a	NN	O	O
panel	NN	O	O
of	NN	O	O
10	NN	O	O
markers	NN	O	O
that	NN	O	O
span	NN	O	O
approximately	NN	O	O
60	NN	O	O
cM	NN	O	O
in	NN	O	O
the	NN	O	O
11q22	NN	O	O
-	NN	O	O
23	NN	O	O
region	NN	O	O
centered	NN	O	O
around	NN	O	O
S144	NN	O	O
and	NN	O	O
THY1	NN	O	O
.	NN	O	O

Location	NN	O	O
scores	NN	O	O
indicate	NN	O	O
that	NN	O	O
three	NN	O	O
contiguous	NN	O	O
subsegments	NN	O	O
within	NN	O	O
the	NN	O	O
[	NN	O	O
S144	NN	O	O
-	NN	O	O
THY1	NN	O	O
]	NN	O	O
segment	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
three	NN	O	O
contiguous	NN	O	O
segments	NN	O	O
telomeric	NN	O	O
to	NN	O	O
THY1	NN	O	O
,	NN	O	O
are	NN	O	O
each	NN	O	O
unlikely	NN	O	O
to	NN	O	O
contain	NN	O	O
the	NN	O	O
AT	NN	O	B-Disease
locus	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
more	NN	O	O
centromeric	NN	O	O
[	NN	O	O
STMY	NN	O	O
-	NN	O	O
S144	NN	O	O
]	NN	O	O
segment	NN	O	O
is	NN	O	O
most	NN	O	O
likely	NN	O	O
to	NN	O	O
contain	NN	O	O
the	NN	O	O
AT	NN	O	B-Disease
locus	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
oligonucleotide	NN	O	O
primer	NN	O	O
sequences	NN	O	O
that	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
amplify	NN	O	O
eight	NN	O	O
exons	NN	O	O
plus	NN	O	O
the	NN	O	O
muscle	NN	O	O
promoter	NN	O	O
of	NN	O	O
the	NN	O	O
dystrophin	NN	O	O
gene	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
multiplex	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	NN	O	O
PCR	NN	O	O
)	NN	O	O
.	NN	O	O

When	NN	O	O
used	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
an	NN	O	O
existing	NN	O	O
primer	NN	O	O
set	NN	O	O
,	NN	O	O
these	NN	O	O
two	NN	O	O
multiplex	NN	O	O
reactions	NN	O	O
detect	NN	O	O
about	NN	O	O
98	NN	O	O
%	NN	O	O
of	NN	O	O
deletions	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Duchenne	NN	O	B-Disease
or	NN	O	I-Disease
Becker	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DMD	NN	O	B-Disease
,	NN	O	O
BMD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Of	NN	O	O
these	NN	O	O
,	NN	O	O
31	NN	O	O
had	NN	O	O
severe	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
,	NN	O	O
nine	NN	O	O
had	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
deficiency	NN	O	O
,	NN	O	O
and	NN	O	O
three	NN	O	O
had	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
deficient	NN	O	O
electrophoretic	NN	O	O
variant	NN	O	O
.	NN	O	O

2	NN	O	O
%	NN	O	O
on	NN	O	O
the	NN	O	O
Ionian	NN	O	O
Coast	NN	O	O
to	NN	O	O
zero	NN	O	O
on	NN	O	O
the	NN	O	O
eastern	NN	O	O
side	NN	O	O
of	NN	O	O
the	NN	O	O
Lucanian	NN	O	O
Apennines	NN	O	O
,	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
inversely	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
distance	NN	O	O
of	NN	O	O
each	NN	O	O
town	NN	O	O
examined	NN	O	O
from	NN	O	O
the	NN	O	O
Ionian	NN	O	O
Coast	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
this	NN	O	O
geographic	NN	O	O
distribution	NN	O	O
may	NN	O	O
reflect	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
gene	NN	O	O
flow	NN	O	O
from	NN	O	O
Greek	NN	O	O
settlers	NN	O	O
.	NN	O	O

To	NN	O	O
ascertain	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanism	NN	O	O
that	NN	O	O
causes	NN	O	O
murine	NN	O	O
C5	NN	O	B-Disease
deficiency	NN	O	I-Disease
,	NN	O	O
genomic	NN	O	O
and	NN	O	O
cDNA	NN	O	O
libraries	NN	O	O
were	NN	O	O
constructed	NN	O	O
from	NN	O	O
mouse	NN	O	O
liver	NN	O	O
DNA	NN	O	O
and	NN	O	O
mRNA	NN	O	O
employing	NN	O	O
the	NN	O	O
congenic	NN	O	O
strains	NN	O	O
B10	NN	O	O
.	NN	O	O

D2	NN	O	O
/	NN	O	O
oSnJ	NN	O	O
,	NN	O	O
and	NN	O	O
four	NN	O	O
C5	NN	O	O
-	NN	O	O
sufficient	NN	O	O
strains	NN	O	O
,	NN	O	O
Balb	NN	O	O
/	NN	O	O
CJ	NN	O	O
,	NN	O	O
C57Bl	NN	O	O
/	NN	O	O
6J	NN	O	O
,	NN	O	O
DBA	NN	O	O
/	NN	O	O
1J	NN	O	O
,	NN	O	O
and	NN	O	O
B10	NN	O	O
.	NN	O	O

D2	NN	O	O
/	NN	O	O
nSnJ	NN	O	O
,	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Phenylketonuria	NN	O	B-Disease
(	NN	O	O
PKU	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
genetic	NN	O	B-Disease
disorder	NN	O	I-Disease
secondary	NN	O	O
to	NN	O	O
a	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
hepatic	NN	O	I-Disease
phenylalanine	NN	O	I-Disease
hydroxylase	NN	O	I-Disease
(	NN	O	O
PAH	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mutation	NN	O	O
is	NN	O	O
present	NN	O	O
in	NN	O	O
two	NN	O	O
of	NN	O	O
nine	NN	O	O
mutant	NN	O	O
haplotype	NN	O	O
4	NN	O	O
alleles	NN	O	O
among	NN	O	O
Eastern	NN	O	O
Europeans	NN	O	O
and	NN	O	O
is	NN	O	O
not	NN	O	O
present	NN	O	O
among	NN	O	O
Western	NN	O	O
Europeans	NN	O	O
and	NN	O	O
Asians	NN	O	O
.	NN	O	O

This	NN	O	O
led	NN	O	O
us	NN	O	O
to	NN	O	O
propose	NN	O	O
that	NN	O	O
a	NN	O	O
single	NN	O	O
DNA	NN	O	O
rearrangement	NN	O	O
could	NN	O	O
underlie	NN	O	O
both	NN	O	O
ALD	NN	O	B-Disease
and	NN	O	O
abnormal	NN	O	B-Disease
color	NN	O	I-Disease
vision	NN	O	I-Disease
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
single	NN	O	O
case	NN	O	O
of	NN	O	O
blue	NN	O	O
cone	NN	O	O
monochromacy	NN	O	O
may	NN	O	O
therefore	NN	O	O
be	NN	O	O
a	NN	O	O
fortuitous	NN	O	O
coincidence	NN	O	O
of	NN	O	O
two	NN	O	O
diseases	NN	O	O
.	NN	O	O
.	NN	O	O

Laser	NN	O	O
cytofluorimetry	NN	O	O
with	NN	O	O
a	NN	O	O
monoclonal	NN	O	O
antibody	NN	O	O
against	NN	O	O
decay	NN	O	O
-	NN	O	O
accelerating	NN	O	O
factor	NN	O	O
(	NN	O	O
DAF	NN	O	O
)	NN	O	O
revealed	NN	O	O
that	NN	O	O
95	NN	O	O
%	NN	O	O
of	NN	O	O
her	NN	O	O
erythrocytes	NN	O	O
were	NN	O	O
DAF	NN	O	O
-	NN	O	O
negative	NN	O	O
.	NN	O	O

Duplicational	NN	O	O
mutation	NN	O	O
at	NN	O	O
the	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
locus	NN	O	O
:	NN	O	O
its	NN	O	O
frequency	NN	O	O
,	NN	O	O
distribution	NN	O	O
,	NN	O	O
origin	NN	O	O
,	NN	O	O
and	NN	O	O
phenotypegenotype	NN	O	O
correlation	NN	O	O
.	NN	O	O

With	NN	O	O
careful	NN	O	O
quantitative	NN	O	O
analysis	NN	O	O
of	NN	O	O
hybridization	NN	O	O
band	NN	O	O
intensity	NN	O	O
,	NN	O	O
10	NN	O	O
cases	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
carry	NN	O	O
a	NN	O	O
duplication	NN	O	O
of	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
,	NN	O	O
a	NN	O	O
frequency	NN	O	O
of	NN	O	O
14	NN	O	O
%	NN	O	O
for	NN	O	O
nondeletion	NN	O	O
cases	NN	O	O
(	NN	O	O
10	NN	O	O
/	NN	O	O
72	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
6	NN	O	O
%	NN	O	O
for	NN	O	O
all	NN	O	O
cases	NN	O	O
(	NN	O	O
10	NN	O	O
/	NN	O	O
181	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
these	NN	O	O
duplications	NN	O	O
has	NN	O	O
been	NN	O	O
characterized	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
published	NN	O	O
exon	NN	O	O
-	NN	O	O
containing	NN	O	O
HindIII	NN	O	O
fragment	NN	O	O
map	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
six	NN	O	O
of	NN	O	O
the	NN	O	O
10	NN	O	O
duplications	NN	O	O
a	NN	O	O
novel	NN	O	O
restriction	NN	O	O
fragment	NN	O	O
that	NN	O	O
spanned	NN	O	O
the	NN	O	O
duplication	NN	O	O
junction	NN	O	O
was	NN	O	O
detected	NN	O	O
.	NN	O	O

Two	NN	O	O
male	NN	O	O
subjects	NN	O	O
are	NN	O	O
described	NN	O	O
,	NN	O	O
with	NN	O	O
unusual	NN	O	O
clinical	NN	O	O
presentations	NN	O	O
and	NN	O	O
with	NN	O	O
hitherto	NN	O	O
undescribed	NN	O	O
G6PD	NN	O	O
variants	NN	O	O
.	NN	O	O

Statistical	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
stage	NN	O	O
mutation	NN	O	O
model	NN	O	O
in	NN	O	O
von	NN	O	B-Disease
Hippel	NN	O	I-Disease
-	NN	O	I-Disease
Lindau	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
in	NN	O	O
sporadic	NN	O	B-Disease
cerebellar	NN	O	I-Disease
haemangioblastoma	NN	O	I-Disease
and	NN	O	O
renal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
recently	NN	O	O
that	NN	O	O
sporadic	NN	O	B-Disease
renal	NN	O	I-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
may	NN	O	O
arise	NN	O	O
from	NN	O	O
a	NN	O	O
two	NN	O	O
stage	NN	O	O
mutation	NN	O	O
process	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
are	NN	O	O
compatible	NN	O	O
with	NN	O	O
the	NN	O	O
VHL	NN	O	B-Disease
gene	NN	O	O
functioning	NN	O	O
as	NN	O	O
a	NN	O	O
recessive	NN	O	O
tumour	NN	O	B-Disease
suppressor	NN	O	O
gene	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
.	NN	O	O

The	NN	O	O
prevention	NN	O	O
of	NN	O	O
Tay	NN	O	B-Disease
-	NN	O	I-Disease
Sachs	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
GM2	NN	O	B-Disease
gangliosidosis	NN	O	I-Disease
,	NN	O	I-Disease
type	NN	O	I-Disease
1	NN	O	I-Disease
)	NN	O	O
depends	NN	O	O
on	NN	O	O
the	NN	O	O
identification	NN	O	O
of	NN	O	O
carriers	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
for	NN	O	O
this	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
disorder	NN	O	I-Disease
.	NN	O	O

RESULTS	NN	O	O
.	NN	O	O

In	NN	O	O
216	NN	O	O
Ashkenazi	NN	O	O
carriers	NN	O	O
identified	NN	O	O
by	NN	O	O
the	NN	O	O
enzyme	NN	O	O
test	NN	O	O
,	NN	O	O
DNA	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
177	NN	O	O
(	NN	O	O
82	NN	O	O
percent	NN	O	O
)	NN	O	O
had	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
identified	NN	O	O
mutations	NN	O	O
.	NN	O	O

The	NN	O	O
increased	NN	O	O
specificity	NN	O	O
and	NN	O	O
predictive	NN	O	O
value	NN	O	O
of	NN	O	O
the	NN	O	O
DNA	NN	O	O
-	NN	O	O
based	NN	O	O
test	NN	O	O
make	NN	O	O
it	NN	O	O
a	NN	O	O
useful	NN	O	O
adjunct	NN	O	O
to	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
tests	NN	O	O
currently	NN	O	O
used	NN	O	O
to	NN	O	O
screen	NN	O	O
for	NN	O	O
carriers	NN	O	O
of	NN	O	O
Tay	NN	O	B-Disease
-	NN	O	I-Disease
Sachs	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
molecular	NN	O	O
basis	NN	O	O
of	NN	O	O
cholesteryl	NN	O	B-Disease
ester	NN	O	I-Disease
transfer	NN	O	I-Disease
protein	NN	O	I-Disease
(	NN	O	I-Disease
CETP	NN	O	I-Disease
)	NN	O	I-Disease
deficiency	NN	O	I-Disease
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
4	NN	O	O
unrelated	NN	O	O
CETP	NN	O	B-Disease
-	NN	O	I-Disease
deficient	NN	O	I-Disease
families	NN	O	O
.	NN	O	O

The	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
was	NN	O	O
amplified	NN	O	O
by	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
,	NN	O	O
using	NN	O	O
two	NN	O	O
oligonucleotide	NN	O	O
primers	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
intron	NN	O	O
12	NN	O	O
and	NN	O	O
14	NN	O	O
of	NN	O	O
the	NN	O	O
CETP	NN	O	O
gene	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
amplified	NN	O	O
products	NN	O	O
were	NN	O	O
directly	NN	O	O
sequenced	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
examined	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
of	NN	O	O
five	NN	O	O
patients	NN	O	O
-	NN	O	O
-	NN	O	O
four	NN	O	O
of	NN	O	O
Spanish	NN	O	O
origin	NN	O	O
and	NN	O	O
one	NN	O	O
of	NN	O	O
Jewish	NN	O	O
origin	NN	O	O
-	NN	O	O
-	NN	O	O
having	NN	O	O
enzymatically	NN	O	O
documented	NN	O	O
G6PD	NN	O	O
Mediterranean	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
with	NN	O	O
two	NN	O	O
exceptions	NN	O	O
,	NN	O	O
frameshift	NN	O	O
deletions	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
resulted	NN	O	O
in	NN	O	O
more	NN	O	O
severe	NN	O	O
phenotype	NN	O	O
than	NN	O	O
did	NN	O	O
in	NN	O	O
-	NN	O	O
frame	NN	O	O
deletions	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
in	NN	O	O
agreement	NN	O	O
with	NN	O	O
recent	NN	O	O
findings	NN	O	O
by	NN	O	O
Baumbach	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O
and	NN	O	O
Koenig	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O
but	NN	O	O
is	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
findings	NN	O	O
,	NN	O	O
by	NN	O	O
Malhotra	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O
at	NN	O	O
the	NN	O	O
5	NN	O	O
'	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
.	NN	O	O

Six	NN	O	O
APOC2	NN	O	O
RFLPs	NN	O	O
(	NN	O	O
TaqI	NN	O	O
,	NN	O	O
BglI	NN	O	O
,	NN	O	O
BanI	NN	O	O
,	NN	O	O
BamHI	NN	O	O
,	NN	O	O
NcoI	NN	O	O
,	NN	O	O
and	NN	O	O
AvaII	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
to	NN	O	O
date	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
demonstrate	NN	O	O
linkage	NN	O	O
disequilibrium	NN	O	O
between	NN	O	O
DM	NN	O	O
and	NN	O	O
APOC2	NN	O	O
in	NN	O	O
our	NN	O	O
French	NN	O	O
-	NN	O	O
Canadian	NN	O	O
population	NN	O	O
(	NN	O	O
standardized	NN	O	O
disequilibrium	NN	O	O
constant	NN	O	O
phi	NN	O	O
=	NN	O	O
.	NN	O	O
22	NN	O	O
,	NN	O	O
chi	NN	O	O
2	NN	O	O
=	NN	O	O
5	NN	O	O
.	NN	O	O
12	NN	O	O
,	NN	O	O
df	NN	O	O
=	NN	O	O
1	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
suggests	NN	O	O
either	NN	O	O
that	NN	O	O
new	NN	O	O
germline	NN	O	O
RB1	NN	O	O
mutations	NN	O	O
arise	NN	O	O
more	NN	O	O
frequently	NN	O	O
during	NN	O	O
spermatogenesis	NN	O	O
than	NN	O	O
during	NN	O	O
oogenesis	NN	O	O
,	NN	O	O
or	NN	O	O
that	NN	O	O
imprinting	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
embryo	NN	O	O
affects	NN	O	O
chromosomal	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
mutation	NN	O	O
.	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
19	NN	O	O
different	NN	O	O
haplotypes	NN	O	O
observed	NN	O	O
,	NN	O	O
5	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
described	NN	O	O
previously	NN	O	O
.	NN	O	O

Huntington	NN	O	B-Disease
disease	NN	O	I-Disease
:	NN	O	O
no	NN	O	O
evidence	NN	O	O
for	NN	O	O
locus	NN	O	O
heterogeneity	NN	O	O
.	NN	O	O

03	NN	O	O
in	NN	O	O
males	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
large	NN	O	O
pedigree	NN	O	O
with	NN	O	O
autosomal	NN	O	O
dominant	NN	O	O
aniridia	NN	O	B-Disease
,	NN	O	O
we	NN	O	O
found	NN	O	O
close	NN	O	O
linkage	NN	O	O
between	NN	O	O
the	NN	O	O
aniridia	NN	O	B-Disease
locus	NN	O	O
AN2	NN	O	O
and	NN	O	O
the	NN	O	O
markers	NN	O	O
catalase	NN	O	O
(	NN	O	O
CAT	NN	O	O
)	NN	O	O
(	NN	O	O
zeta	NN	O	O
=	NN	O	O
7	NN	O	O
.	NN	O	O
27	NN	O	O
at	NN	O	O
theta	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
00	NN	O	O
)	NN	O	O
and	NN	O	O
D11S151	NN	O	O
(	NN	O	O
zeta	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
86	NN	O	O
at	NN	O	O
theta	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
10	NN	O	O
)	NN	O	O
flanking	NN	O	O
the	NN	O	O
AN2	NN	O	O
locus	NN	O	O
on	NN	O	O
11p13	NN	O	O
.	NN	O	O

2	NN	O	O
shows	NN	O	O
that	NN	O	O
the	NN	O	O
DM	NN	O	B-Disease
locus	NN	O	O
is	NN	O	O
distal	NN	O	O
to	NN	O	O
APOC2	NN	O	O
.	NN	O	O

The	NN	O	O
consequences	NN	O	O
of	NN	O	O
this	NN	O	O
probe	NN	O	O
order	NN	O	O
for	NN	O	O
antenatal	NN	O	O
diagnosis	NN	O	O
and	NN	O	O
future	NN	O	O
research	NN	O	O
aiming	NN	O	O
to	NN	O	O
isolate	NN	O	O
the	NN	O	O
gene	NN	O	O
which	NN	O	O
is	NN	O	O
affected	NN	O	O
in	NN	O	O
DM	NN	O	B-Disease
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Each	NN	O	O
of	NN	O	O
four	NN	O	O
germ	NN	O	O
line	NN	O	O
mutations	NN	O	O
involved	NN	O	O
a	NN	O	O
small	NN	O	O
deletion	NN	O	O
or	NN	O	O
duplication	NN	O	O
,	NN	O	O
while	NN	O	O
three	NN	O	O
somatic	NN	O	O
mutations	NN	O	O
were	NN	O	O
point	NN	O	O
mutations	NN	O	O
leading	NN	O	O
to	NN	O	O
splice	NN	O	O
alterations	NN	O	O
and	NN	O	O
loss	NN	O	O
of	NN	O	O
an	NN	O	O
exon	NN	O	O
from	NN	O	O
the	NN	O	O
mature	NN	O	O
RB1	NN	O	O
mRNA	NN	O	O
.	NN	O	O

1	NN	O	O
1	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
features	NN	O	O
were	NN	O	O
similar	NN	O	O
and	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
obvious	NN	O	O
stigmata	NN	O	O
of	NN	O	O
Langer	NN	O	B-Disease
-	NN	O	I-Disease
Giedion	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
LGS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
three	NN	O	O
other	NN	O	O
cases	NN	O	O
reported	NN	O	O
with	NN	O	O
a	NN	O	O
deletion	NN	O	O
of	NN	O	O
chromosome	NN	O	O
8	NN	O	O
at	NN	O	O
approximately	NN	O	O
the	NN	O	O
same	NN	O	O
breakpoint	NN	O	O
,	NN	O	O
one	NN	O	O
without	NN	O	O
LGS	NN	O	B-Disease
and	NN	O	O
some	NN	O	O
similarities	NN	O	O
to	NN	O	O
our	NN	O	O
cases	NN	O	O
,	NN	O	O
the	NN	O	O
other	NN	O	O
two	NN	O	O
with	NN	O	O
LGS	NN	O	B-Disease
.	NN	O	O

Tight	NN	O	O
linkage	NN	O	O
was	NN	O	O
also	NN	O	O
demonstrated	NN	O	O
for	NN	O	O
CKMM	NN	O	O
and	NN	O	O
the	NN	O	O
gene	NN	O	O
for	NN	O	O
apolipoprotein	NN	O	O
C2	NN	O	O
(	NN	O	O
ApoC2	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
identification	NN	O	O
of	NN	O	O
a	NN	O	O
female	NN	O	O
patient	NN	O	O
with	NN	O	O
the	NN	O	O
X	NN	O	O
-	NN	O	O
linked	NN	O	O
recessive	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
hypoxanthine	NN	O	B-Disease
phosphoribosyltransferase	NN	O	I-Disease
[	NN	O	I-Disease
HPRT	NN	O	I-Disease
]	NN	O	I-Disease
deficiency	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

Pelizaeus	NN	O	B-Disease
-	NN	O	I-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
:	NN	O	O
an	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
neurologic	NN	O	I-Disease
disorder	NN	O	I-Disease
of	NN	O	I-Disease
myelin	NN	O	I-Disease
metabolism	NN	O	I-Disease
with	NN	O	O
a	NN	O	O
novel	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
gene	NN	O	O
encoding	NN	O	O
proteolipid	NN	O	O
protein	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
type	NN	O	B-Disease
IIA	NN	O	I-Disease
vWD	NN	O	I-Disease
patients	NN	O	O
,	NN	O	O
two	NN	O	O
different	NN	O	O
but	NN	O	O
adjacent	NN	O	O
missense	NN	O	O
mutations	NN	O	O
were	NN	O	O
identified	NN	O	O
,	NN	O	O
the	NN	O	O
locations	NN	O	O
of	NN	O	O
which	NN	O	O
may	NN	O	O
identify	NN	O	O
an	NN	O	O
important	NN	O	O
vWF	NN	O	O
functional	NN	O	O
domain	NN	O	O
.	NN	O	O

Diagnosis	NN	O	O
was	NN	O	O
established	NN	O	O
by	NN	O	O
haemolytic	NN	O	O
titration	NN	O	O
and	NN	O	O
western	NN	O	O
blotting	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
distinct	NN	O	O
from	NN	O	O
those	NN	O	O
previously	NN	O	O
noted	NN	O	O
in	NN	O	O
abetalipoproteinemia	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
an	NN	O	O
elevated	NN	O	O
level	NN	O	O
of	NN	O	O
hepatic	NN	O	O
apoB	NN	O	O
mRNA	NN	O	O
and	NN	O	O
accumulation	NN	O	O
of	NN	O	O
intracellular	NN	O	O
hepatic	NN	O	O
apoB	NN	O	O
protein	NN	O	O
.	NN	O	O
.	NN	O	O

Spontaneous	NN	O	O
reversion	NN	O	O
of	NN	O	O
novel	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
mutation	NN	O	O
by	NN	O	O
HPRT	NN	O	O
gene	NN	O	O
rearrangement	NN	O	O
.	NN	O	O

Complex	NN	O	B-Disease
glycerol	NN	O	I-Disease
kinase	NN	O	I-Disease
deficiency	NN	O	I-Disease
:	NN	O	O
molecular	NN	O	O
-	NN	O	O
genetic	NN	O	O
,	NN	O	O
cytogenetic	NN	O	O
,	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
of	NN	O	O
five	NN	O	O
Japanese	NN	O	O
patients	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
muscular	NN	O	B-Disease
dystrophy	NN	O	I-Disease
or	NN	O	O
muscle	NN	O	B-Disease
weakness	NN	O	I-Disease
,	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
congenital	NN	O	B-Disease
adrenal	NN	O	I-Disease
hypoplasia	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
glycerol	NN	O	B-Disease
kinase	NN	O	I-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
finding	NN	O	O
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
gene	NN	O	O
coding	NN	O	O
for	NN	O	O
glycerol	NN	O	O
kinase	NN	O	O
(	NN	O	O
GK	NN	O	O
)	NN	O	O
is	NN	O	O
located	NN	O	O
within	NN	O	O
this	NN	O	O
segment	NN	O	O
.	NN	O	O

The	NN	O	O
result	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
and	NN	O	O
results	NN	O	O
of	NN	O	O
previous	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
genes	NN	O	O
for	NN	O	O
ornithine	NN	O	O
transcarbamylase	NN	O	O
(	NN	O	O
OTC	NN	O	O
)	NN	O	O
,	NN	O	O
DMD	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
GK	NN	O	O
and	NN	O	O
putative	NN	O	O
genes	NN	O	O
responsible	NN	O	O
for	NN	O	O
congenital	NN	O	B-Disease
adrenal	NN	O	I-Disease
hypoplasia	NN	O	I-Disease
(	NN	O	O
AHC	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
GTD	NN	O	B-Disease
are	NN	O	O
arranged	NN	O	O
from	NN	O	O
telomere	NN	O	O
to	NN	O	O
centromere	NN	O	O
as	NN	O	O
pter	NN	O	O
-	NN	O	O
-	NN	O	O
GTD	NN	O	O
-	NN	O	O
-	NN	O	O
AHC	NN	O	O
-	NN	O	O
-	NN	O	O
GK	NN	O	O
-	NN	O	O
-	NN	O	O
DMD	NN	O	O
-	NN	O	O
-	NN	O	O
OTC	NN	O	O
-	NN	O	O
-	NN	O	O
cen	NN	O	O

PKU	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
common	NN	O	O
inborn	NN	O	B-Disease
error	NN	O	I-Disease
of	NN	O	I-Disease
amino	NN	O	I-Disease
-	NN	O	I-Disease
acid	NN	O	I-Disease
metabolism	NN	O	I-Disease
in	NN	O	O
caucasian	NN	O	O
populations	NN	O	O
and	NN	O	O
approximately	NN	O	O
1	NN	O	O
in	NN	O	O
50	NN	O	O
individuals	NN	O	O
are	NN	O	O
carriers	NN	O	O
of	NN	O	O
a	NN	O	O
PKU	NN	O	B-Disease
allele	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
locus	NN	O	O
DXYS12	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
closely	NN	O	O
linked	NN	O	O
with	NN	O	O
TCD	NN	O	B-Disease
(	NN	O	O
lod	NN	O	O
3	NN	O	O
.	NN	O	O
31	NN	O	O
at	NN	O	O
0	NN	O	O
recombination	NN	O	O
distance	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
disease	NN	O	O
mainly	NN	O	O
occurs	NN	O	O
in	NN	O	O
three	NN	O	O
large	NN	O	O
kindreds	NN	O	O
in	NN	O	O
remote	NN	O	O
Northern	NN	O	O
Finland	NN	O	O
.	NN	O	O

Given	NN	O	O
that	NN	O	O
at	NN	O	O
least	NN	O	O
105	NN	O	O
female	NN	O	O
meioses	NN	O	O
transmitting	NN	O	O
TCD	NN	O	B-Disease
have	NN	O	O
occurred	NN	O	O
since	NN	O	O
1650	NN	O	O
in	NN	O	O
these	NN	O	O
kindreds	NN	O	O
,	NN	O	O
extremely	NN	O	O
close	NN	O	O
linkage	NN	O	O
between	NN	O	O
TCD	NN	O	B-Disease
,	NN	O	O
DXYS1	NN	O	O
and	NN	O	O
DXYS12	NN	O	O
is	NN	O	O
suggested	NN	O	O
.	NN	O	O

Renal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinomas	NN	O	I-Disease
constitute	NN	O	O
a	NN	O	O
particularly	NN	O	O
frequent	NN	O	O
cause	NN	O	O
of	NN	O	O
death	NN	O	O
in	NN	O	O
this	NN	O	O
disorder	NN	O	O
,	NN	O	O
occurring	NN	O	O
as	NN	O	O
bilateral	NN	O	B-Disease
and	NN	O	I-Disease
multifocal	NN	O	I-Disease
tumours	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
presenting	NN	O	O
at	NN	O	O
an	NN	O	O
earlier	NN	O	O
age	NN	O	O
than	NN	O	O
in	NN	O	O
sporadic	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
familial	NN	O	O
cases	NN	O	O
of	NN	O	O
this	NN	O	O
tumour	NN	O	B-Disease
type	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
that	NN	O	O
the	NN	O	O
VHL	NN	O	B-Disease
gene	NN	O	O
is	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
locus	NN	O	O
encoding	NN	O	O
the	NN	O	O
human	NN	O	O
homologoue	NN	O	O
of	NN	O	O
the	NN	O	O
RAF1	NN	O	O
oncogene	NN	O	O
,	NN	O	O
which	NN	O	O
maps	NN	O	O
to	NN	O	O
chromosome	NN	O	O
3p25	NN	O	O
(	NN	O	O
ref	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

An	NN	O	O
alternative	NN	O	O
or	NN	O	O
prior	NN	O	O
event	NN	O	O
to	NN	O	O
oncogene	NN	O	O
activation	NN	O	O
in	NN	O	O
tumour	NN	O	B-Disease
formation	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
inactivation	NN	O	O
of	NN	O	O
a	NN	O	O
putative	NN	O	O
tumour	NN	O	B-Disease
suppressor	NN	O	O
which	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
both	NN	O	O
the	NN	O	O
inherited	NN	O	B-Disease
and	NN	O	I-Disease
sporadic	NN	O	I-Disease
forms	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
cancer	NN	O	I-Disease
.	NN	O	O

With	NN	O	O
additional	NN	O	O
OCRL	NN	O	B-Disease
families	NN	O	O
made	NN	O	O
informative	NN	O	O
for	NN	O	O
DXS42	NN	O	O
,	NN	O	O
theta	NN	O	O
remained	NN	O	O
0	NN	O	O
with	NN	O	O
z	NN	O	O
=	NN	O	O
6	NN	O	O
.	NN	O	O

Evidence	NN	O	O
for	NN	O	O
placing	NN	O	O
OCRL	NN	O	O
at	NN	O	O
Xq25	NN	O	O
also	NN	O	O
comes	NN	O	O
from	NN	O	O
a	NN	O	O
female	NN	O	O
with	NN	O	O
Lowe	NN	O	B-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
an	NN	O	O
X	NN	O	O
;	NN	O	O
3	NN	O	O
translocation	NN	O	O
.	NN	O	O

Complete	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
hypoxanthine	NN	O	I-Disease
-	NN	O	I-Disease
guanine	NN	O	I-Disease
phosphoribosyltransferase	NN	O	I-Disease
(	NN	O	O
HPRT	NN	O	O
)	NN	O	O
causes	NN	O	O
the	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
molecular	NN	O	O
study	NN	O	O
using	NN	O	O
standard	NN	O	O
methods	NN	O	O
showed	NN	O	O
G6PD	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
to	NN	O	O
have	NN	O	O
normal	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
(	NN	O	O
at	NN	O	O
pH	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
,	NN	O	O
8	NN	O	O
.	NN	O	O
0	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
normal	NN	O	O
apparent	NN	O	O
affinity	NN	O	O
for	NN	O	O
substrates	NN	O	O
(	NN	O	O
Km	NN	O	O
,	NN	O	O
G6P	NN	O	O
and	NN	O	O
NADP	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
slightly	NN	O	O
abnormal	NN	O	O
utilization	NN	O	O
of	NN	O	O
substrate	NN	O	O
analogues	NN	O	O
(	NN	O	O
decreased	NN	O	O
deamino	NN	O	O
-	NN	O	O
NADP	NN	O	O
and	NN	O	O
increased	NN	O	O
2	NN	O	O
-	NN	O	O
deoxyglucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
utilization	NN	O	O
)	NN	O	O
.	NN	O	O

Therefore	NN	O	O
the	NN	O	O
present	NN	O	O
variant	NN	O	O
has	NN	O	O
been	NN	O	O
designated	NN	O	O
G6PD	NN	O	O
Clinic	NN	O	O
to	NN	O	O
distinguish	NN	O	O
it	NN	O	O
from	NN	O	O
other	NN	O	O
G6PD	NN	O	O
variants	NN	O	O
previously	NN	O	O
described	NN	O	O

Cellular	NN	O	O
and	NN	O	O
humoral	NN	O	O
immunity	NN	O	O
were	NN	O	O
normal	NN	O	O
,	NN	O	O
as	NN	O	O
were	NN	O	O
polymorphonuclear	NN	O	O
leukocyte	NN	O	O
chemotaxis	NN	O	O
and	NN	O	O
bactericidal	NN	O	O
activities	NN	O	O
.	NN	O	O

The	NN	O	O
alpha	NN	O	O
1	NN	O	O
-	NN	O	O
protease	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
or	NN	O	O
alpha	NN	O	O
-	NN	O	O
antitrypsin	NN	O	O
(	NN	O	O
AAT	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
major	NN	O	O
plasma	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
leukocyte	NN	O	O
elastase	NN	O	O
and	NN	O	O
bacterial	NN	O	O
proteases	NN	O	O
,	NN	O	O
is	NN	O	O
encoded	NN	O	O
at	NN	O	O
the	NN	O	O
PI	NN	O	O
locus	NN	O	O
on	NN	O	O
chromosome	NN	O	O
14	NN	O	O
(	NN	O	O
14q24	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
q32	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
BMD	NN	O	B-Disease
families	NN	O	O
no	NN	O	O
recombinants	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
16	NN	O	O
informative	NN	O	O
meioses	NN	O	O
studied	NN	O	O
.	NN	O	O

Four	NN	O	O
of	NN	O	O
these	NN	O	O
eight	NN	O	O
sublocalized	NN	O	O
to	NN	O	O
band	NN	O	O
15q11	NN	O	O
.	NN	O	O

The	NN	O	O
breakpoints	NN	O	O
of	NN	O	O
some	NN	O	O
deletions	NN	O	O
are	NN	O	O
delineated	NN	O	O
within	NN	O	O
the	NN	O	O
DXS164	NN	O	O
locus	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
is	NN	O	O
evident	NN	O	O
that	NN	O	O
the	NN	O	O
deletions	NN	O	O
at	NN	O	O
the	NN	O	O
DMD	NN	O	B-Disease
locus	NN	O	O
are	NN	O	O
frequent	NN	O	O
and	NN	O	O
extremely	NN	O	O
large	NN	O	O
.	NN	O	O
.	NN	O	O

How	NN	O	O
the	NN	O	O
resulting	NN	O	O
alterations	NN	O	O
in	NN	O	O
purine	NN	O	O
metabolism	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
severe	NN	O	O
symptoms	NN	O	O
characteristic	NN	O	O
of	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
patients	NN	O	O
is	NN	O	O
still	NN	O	O
not	NN	O	O
understood	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

A	NN	O	O
deletion	NN	O	O
in	NN	O	O
an	NN	O	O
individual	NN	O	O
with	NN	O	O
retinoblastoma	NN	O	B-Disease
was	NN	O	O
reported	NN	O	O
to	NN	O	O
separate	NN	O	O
the	NN	O	O
closely	NN	O	O
linked	NN	O	O
ESD	NN	O	O
and	NN	O	O
retinoblastoma	NN	O	B-Disease
(	NN	O	O
RB1	NN	O	O
)	NN	O	O
loci	NN	O	O
,	NN	O	O
placing	NN	O	O
ESD	NN	O	O
proximal	NN	O	O
to	NN	O	O
RB1	NN	O	O
.	NN	O	O

Deletions	NN	O	O
have	NN	O	O
been	NN	O	O
characterised	NN	O	O
which	NN	O	O
encompass	NN	O	O
either	NN	O	O
the	NN	O	O
pERT87	NN	O	O
(	NN	O	O
DXS164	NN	O	O
)	NN	O	O
locus	NN	O	O
only	NN	O	O
,	NN	O	O
the	NN	O	O
XJ1	NN	O	O
.	NN	O	O

1	NN	O	O
(	NN	O	O
DXS206	NN	O	O
)	NN	O	O
and	NN	O	O
HIP25	NN	O	O
loci	NN	O	O
only	NN	O	O
,	NN	O	O
or	NN	O	O
all	NN	O	O
three	NN	O	O
loci	NN	O	O
.	NN	O	O

Deletions	NN	O	O
specific	NN	O	O
to	NN	O	O
DMD	NN	O	B-Disease
and	NN	O	O
to	NN	O	O
BMD	NN	O	B-Disease
are	NN	O	O
described	NN	O	O
.	NN	O	O

C3	NN	O	O
levels	NN	O	O
in	NN	O	O
family	NN	O	O
members	NN	O	O
(	NN	O	O
seven	NN	O	O
of	NN	O	O
24	NN	O	O
half	NN	O	O
-	NN	O	O
normal	NN	O	O
)	NN	O	O
,	NN	O	O
lack	NN	O	O
of	NN	O	O
anti	NN	O	O
-	NN	O	O
C3	NN	O	O
activity	NN	O	O
,	NN	O	O
normal	NN	O	O
C3b	NN	O	O
-	NN	O	O
INA	NN	O	O
levels	NN	O	O
and	NN	O	O
a	NN	O	O
normal	NN	O	O
rate	NN	O	O
of	NN	O	O
catabolism	NN	O	O
of	NN	O	O
transfused	NN	O	O
C3	NN	O	O
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
deficiency	NN	O	O
was	NN	O	O
inherited	NN	O	O
with	NN	O	O
autosomal	NN	O	O
codominance	NN	O	O
and	NN	O	O
involved	NN	O	O
decreased	NN	O	B-Disease
synthesis	NN	O	I-Disease
of	NN	O	I-Disease
C3	NN	O	I-Disease
.	NN	O	O

Severe	NN	O	B-Disease
von	NN	O	I-Disease
Willebrand	NN	O	I-Disease
disease	NN	O	I-Disease
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
undetectable	NN	O	O
or	NN	O	O
trace	NN	O	O
quantities	NN	O	O
of	NN	O	O
von	NN	O	B-Disease
Willebrand	NN	O	I-Disease
factor	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
tissue	NN	O	O
stores	NN	O	O
.	NN	O	O

The	NN	O	O
hexadecanol	NN	O	O
content	NN	O	O
of	NN	O	O
SLS	NN	O	B-Disease
fibroblasts	NN	O	O
was	NN	O	O
abnormally	NN	O	O
elevated	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
primary	NN	O	O
defect	NN	O	O
in	NN	O	O
SLS	NN	O	B-Disease
is	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
fatty	NN	O	I-Disease
alcohol	NN	O	I-Disease
NAD	NN	O	I-Disease
+	NN	O	I-Disease
oxidoreductase	NN	O	I-Disease
.	NN	O	O

Germinal	NN	O	O
mosaicism	NN	O	O
in	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
studies	NN	O	O
show	NN	O	O
that	NN	O	O
this	NN	O	O
female	NN	O	O
has	NN	O	O
transmitted	NN	O	O
three	NN	O	O
distinct	NN	O	O
types	NN	O	O
of	NN	O	O
X	NN	O	O
chromosome	NN	O	O
to	NN	O	O
her	NN	O	O
offspring	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
the	NN	O	O
murine	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
gene	NN	O	O
in	NN	O	O
muscle	NN	O	O
and	NN	O	O
brain	NN	O	O
.	NN	O	O

Mouse	NN	O	O
Dmd	NN	O	O
mRNA	NN	O	O
was	NN	O	O
detectable	NN	O	O
in	NN	O	O
skeletal	NN	O	O
and	NN	O	O
cardiac	NN	O	O
muscle	NN	O	O
and	NN	O	O
at	NN	O	O
a	NN	O	O
level	NN	O	O
approximately	NN	O	O
90	NN	O	O
percent	NN	O	O
lower	NN	O	O
in	NN	O	O
brain	NN	O	O
.	NN	O	O

Glucose	NN	O	B-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
incidence	NN	O	O
of	NN	O	O
hematologic	NN	O	B-Disease
malignancy	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
have	NN	O	O
evaluated	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
of	NN	O	O
a	NN	O	O
negative	NN	O	O
association	NN	O	O
between	NN	O	O
glucose	NN	O	B-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
(	NN	O	I-Disease
G6PD	NN	O	I-Disease
)	NN	O	I-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
cancer	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
cohort	NN	O	O
of	NN	O	O
481	NN	O	O
Sardinian	NN	O	O
males	NN	O	O
with	NN	O	O
hematological	NN	O	B-Disease
malignancies	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
of	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
patients	NN	O	O
was	NN	O	O
not	NN	O	O
different	NN	O	O
from	NN	O	O
the	NN	O	O
incidence	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
16	NN	O	O
,	NN	O	O
219	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
same	NN	O	O
conclusion	NN	O	O
resulted	NN	O	O
from	NN	O	O
the	NN	O	O
comparison	NN	O	O
of	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
GdB	NN	O	O
gene	NN	O	O
in	NN	O	O
23	NN	O	O
heterozygous	NN	O	O
women	NN	O	O
having	NN	O	O
a	NN	O	O
clonal	NN	O	O
hematologic	NN	O	B-Disease
disease	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
of	NN	O	O
37	NN	O	O
healthy	NN	O	O
heterozygotes	NN	O	O
.	NN	O	O

Many	NN	O	O
individuals	NN	O	O
in	NN	O	O
these	NN	O	O
four	NN	O	O
GS	NN	O	B-Disease
families	NN	O	O
,	NN	O	O
both	NN	O	O
affected	NN	O	O
and	NN	O	O
at	NN	O	O
risk	NN	O	O
,	NN	O	O
have	NN	O	O
osteomatous	NN	O	B-Disease
jaw	NN	O	I-Disease
lesions	NN	O	I-Disease
and	NN	O	O
pigmented	NN	O	B-Disease
ocular	NN	O	I-Disease
fundus	NN	O	I-Disease
lesions	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
change	NN	O	O
,	NN	O	O
the	NN	O	O
substitution	NN	O	O
of	NN	O	O
a	NN	O	O
C	NN	O	O
for	NN	O	O
G	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
nucleotide	NN	O	O
of	NN	O	O
intron	NN	O	O
12	NN	O	O
is	NN	O	O
expected	NN	O	O
to	NN	O	O
result	NN	O	O
in	NN	O	O
defective	NN	O	O
splicing	NN	O	O
of	NN	O	O
the	NN	O	O
messenger	NN	O	O
RNA	NN	O	O
.	NN	O	O

Hemizygous	NN	O	O
,	NN	O	O
heterozygous	NN	O	O
,	NN	O	O
and	NN	O	O
homozygous	NN	O	O
mutants	NN	O	O
have	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
about	NN	O	O
15	NN	O	O
,	NN	O	O
60	NN	O	O
,	NN	O	O
and	NN	O	O
15	NN	O	O
%	NN	O	O
G6PD	NN	O	O
remaining	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
wild	NN	O	O
type	NN	O	O
.	NN	O	O

Diverse	NN	O	O
point	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
glucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
dehydrogenase	NN	O	O
gene	NN	O	O
cause	NN	O	O
enzyme	NN	O	B-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
mild	NN	O	O
or	NN	O	O
severe	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
until	NN	O	O
now	NN	O	O
,	NN	O	O
their	NN	O	O
precise	NN	O	O
molecular	NN	O	O
basis	NN	O	O
has	NN	O	O
remained	NN	O	O
unknown	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
nondeficient	NN	O	O
polymorphic	NN	O	O
African	NN	O	O
variant	NN	O	O
G6PD	NN	O	O
A	NN	O	O
we	NN	O	O
have	NN	O	O
found	NN	O	O
a	NN	O	O
single	NN	O	O
point	NN	O	O
mutation	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
six	NN	O	O
mutants	NN	O	O
investigated	NN	O	O
were	NN	O	O
all	NN	O	O
associated	NN	O	O
with	NN	O	O
enzyme	NN	O	B-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

Single	NN	O	O
point	NN	O	O
mutations	NN	O	O
were	NN	O	O
also	NN	O	O
found	NN	O	O
in	NN	O	O
G6PD	NN	O	O
Metaponto	NN	O	O
(	NN	O	O
Southern	NN	O	O
Italy	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
G6PD	NN	O	O
Ilesha	NN	O	O
(	NN	O	O
Nigeria	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
asymptomatic	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
G6PD	NN	O	O
Chatham	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
an	NN	O	O
Indian	NN	O	O
boy	NN	O	O
with	NN	O	O
neonatal	NN	O	B-Disease
jaundice	NN	O	I-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
diverse	NN	O	O
point	NN	O	O
mutations	NN	O	O
may	NN	O	O
account	NN	O	O
largely	NN	O	O
for	NN	O	O
the	NN	O	O
phenotypic	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

Synthetic	NN	O	O
oligonucleotides	NN	O	O
,	NN	O	O
designed	NN	O	O
to	NN	O	O
discriminate	NN	O	O
between	NN	O	O
APOE	NN	O	O
alleles	NN	O	O
epsilon	NN	O	O
3	NN	O	O
and	NN	O	O
epsilon	NN	O	O
4	NN	O	O
,	NN	O	O
enabled	NN	O	O
us	NN	O	O
to	NN	O	O
distinguish	NN	O	O
heterozygous	NN	O	O
carriers	NN	O	O
in	NN	O	O
a	NN	O	O
hybridization	NN	O	O
assay	NN	O	O
.	NN	O	O

By	NN	O	O
high	NN	O	O
-	NN	O	O
resolution	NN	O	O
banding	NN	O	O
we	NN	O	O
have	NN	O	O
characterized	NN	O	O
the	NN	O	O
deletion	NN	O	O
chromosomes	NN	O	O
as	NN	O	O
del	NN	O	O
(	NN	O	O
X	NN	O	O
)	NN	O	O
(	NN	O	O
q21	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
q21	NN	O	O
1	NN	O	O
-	NN	O	O
q21	NN	O	O
.	NN	O	O
33	NN	O	O
)	NN	O	O
and	NN	O	O
del	NN	O	O
(	NN	O	O
X	NN	O	O
)	NN	O	O
(	NN	O	O
q21	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
q21	NN	O	O
2	NN	O	O
-	NN	O	O
q21	NN	O	O
.	NN	O	O
31	NN	O	O
)	NN	O	O
respectively	NN	O	O
.	NN	O	O

A	NN	O	O
full	NN	O	O
-	NN	O	O
length	NN	O	O
human	NN	O	O
PAH	NN	O	O
cDNA	NN	O	O
sequence	NN	O	O
has	NN	O	O
been	NN	O	O
inserted	NN	O	O
into	NN	O	O
pzip	NN	O	O
-	NN	O	O
neoSV	NN	O	O
(	NN	O	O
X	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
a	NN	O	O
retroviral	NN	O	O
vector	NN	O	O
containing	NN	O	O
the	NN	O	O
bacterial	NN	O	O
neo	NN	O	O
gene	NN	O	O
.	NN	O	O

Infected	NN	O	O
cells	NN	O	O
express	NN	O	O
PAH	NN	O	O
mRNA	NN	O	O
,	NN	O	O
immunoreactive	NN	O	O
PAH	NN	O	O
protein	NN	O	O
,	NN	O	O
and	NN	O	O
exhibit	NN	O	O
pterin	NN	O	O
-	NN	O	O
dependent	NN	O	O
phenylalanine	NN	O	O
hydroxylase	NN	O	O
activity	NN	O	O
.	NN	O	O

The	NN	O	O
recombinant	NN	O	O
virus	NN	O	O
is	NN	O	O
also	NN	O	O
capable	NN	O	O
of	NN	O	O
infecting	NN	O	O
a	NN	O	O
mouse	NN	O	O
hepatoma	NN	O	B-Disease
cell	NN	O	O
line	NN	O	O
that	NN	O	O
does	NN	O	O
not	NN	O	O
normally	NN	O	O
synthesize	NN	O	O
PAH	NN	O	O
.	NN	O	O

PAH	NN	O	O
activity	NN	O	O
is	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
cellular	NN	O	O
extracts	NN	O	O
and	NN	O	O
the	NN	O	O
entire	NN	O	O
hydroxylation	NN	O	O
system	NN	O	O
is	NN	O	O
reconstituted	NN	O	O
in	NN	O	O
the	NN	O	O
hepatoma	NN	O	B-Disease
cells	NN	O	O
infected	NN	O	O
with	NN	O	O
the	NN	O	O
recombinant	NN	O	O
viruses	NN	O	O
.	NN	O	O

Deletions	NN	O	O
of	NN	O	O
a	NN	O	O
DNA	NN	O	O
sequence	NN	O	O
in	NN	O	O
retinoblastomas	NN	O	B-Disease
and	NN	O	O
mesenchymal	NN	O	B-Disease
tumors	NN	O	I-Disease
:	NN	O	O
organization	NN	O	O
of	NN	O	O
the	NN	O	O
sequence	NN	O	O
and	NN	O	O
its	NN	O	O
encoded	NN	O	O
protein	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
reported	NN	O	O
isolation	NN	O	O
of	NN	O	O
a	NN	O	O
cDNA	NN	O	O
fragment	NN	O	O
that	NN	O	O
recognizes	NN	O	O
chromosomal	NN	O	O
sequences	NN	O	O
possessing	NN	O	O
many	NN	O	O
of	NN	O	O
the	NN	O	O
attributes	NN	O	O
of	NN	O	O
the	NN	O	O
retinoblastoma	NN	O	B-Disease
gene	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
RB1	NN	O	O
locus	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
with	NN	O	O
growth	NN	O	O
hormone	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

A	NN	O	O
controlled	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
therapeutic	NN	O	O
trial	NN	O	O
with	NN	O	O
the	NN	O	O
drug	NN	O	O
mazindol	NN	O	O
,	NN	O	O
a	NN	O	O
growth	NN	O	O
hormone	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
a	NN	O	O
pair	NN	O	O
of	NN	O	O
7	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
monozygotic	NN	O	O
twins	NN	O	O
,	NN	O	O
with	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DMD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Identification	NN	O	O
and	NN	O	O
localization	NN	O	O
of	NN	O	O
mutations	NN	O	O
at	NN	O	O
the	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
locus	NN	O	O
by	NN	O	O
ribonuclease	NN	O	O
A	NN	O	O
cleavage	NN	O	O
.	NN	O	O

Many	NN	O	O
mutations	NN	O	O
leading	NN	O	O
to	NN	O	O
human	NN	O	O
disease	NN	O	O
are	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
single	NN	O	O
DNA	NN	O	O
base	NN	O	O
pair	NN	O	O
changes	NN	O	O
that	NN	O	O
cannot	NN	O	O
be	NN	O	O
identified	NN	O	O
by	NN	O	O
Southern	NN	O	O
analysis	NN	O	O
.	NN	O	O

This	NN	O	O
approach	NN	O	O
now	NN	O	O
allows	NN	O	O
HPRT	NN	O	O
mutation	NN	O	O
detection	NN	O	O
in	NN	O	O
50	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
of	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
polyuridylic	NN	O	O
acid	NN	O	O
-	NN	O	O
paper	NN	O	O
affinity	NN	O	O
procedure	NN	O	O
provides	NN	O	O
a	NN	O	O
general	NN	O	O
method	NN	O	O
for	NN	O	O
analysis	NN	O	O
of	NN	O	O
low	NN	O	O
abundance	NN	O	O
messenger	NN	O	O
RNAs	NN	O	O
.	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
G6PD	NN	O	O
Wayne	NN	O	O
underwent	NN	O	O
splenectomy	NN	O	O
and	NN	O	O
no	NN	O	O
objective	NN	O	O
improvement	NN	O	O
was	NN	O	O
noted	NN	O	O
.	NN	O	O

The	NN	O	O
mAb	NN	O	O
L10	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
distribution	NN	O	O
and	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
sialophorin	NN	O	O
,	NN	O	O
the	NN	O	O
heavily	NN	O	O
glycosylated	NN	O	O
surface	NN	O	O
molecule	NN	O	O
that	NN	O	O
is	NN	O	O
deficient	NN	O	O
/	NN	O	O
defective	NN	O	O
in	NN	O	O
lymphocytes	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
immunodeficiency	NN	O	I-Disease
Wiskott	NN	O	I-Disease
-	NN	O	I-Disease
Aldrich	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Dual	NN	O	O
-	NN	O	O
parameter	NN	O	O
FACS	NN	O	O
analysis	NN	O	O
indicated	NN	O	O
that	NN	O	O
sialophorin	NN	O	O
is	NN	O	O
expressed	NN	O	O
on	NN	O	O
CD4	NN	O	O
+	NN	O	O
and	NN	O	O
CD8	NN	O	O
+	NN	O	O
lymphocytes	NN	O	O
,	NN	O	O
on	NN	O	O
a	NN	O	O
subpopulation	NN	O	O
of	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
B	NN	O	O
lymphocytes	NN	O	O
,	NN	O	O
on	NN	O	O
all	NN	O	O
thymocytes	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
a	NN	O	O
subpopulation	NN	O	O
of	NN	O	O
bone	NN	O	O
marrow	NN	O	O
cells	NN	O	O
.	NN	O	O

Functional	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
L10	NN	O	O
mAb	NN	O	O
stimulates	NN	O	O
the	NN	O	O
proliferation	NN	O	O
of	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
T	NN	O	O
lymphocytes	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
stimulation	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
thymidine	NN	O	O
incorporation	NN	O	O
.	NN	O	O

Hypopigmentation	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

On	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
these	NN	O	O
criteria	NN	O	O
,	NN	O	O
48	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
PWS	NN	O	B-Disease
individuals	NN	O	O
were	NN	O	O
hypopigmented	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
for	NN	O	O
the	NN	O	O
hypopigmentation	NN	O	B-Disease
is	NN	O	O
unknown	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
assay	NN	O	O
consisted	NN	O	O
in	NN	O	O
the	NN	O	O
determination	NN	O	O
of	NN	O	O
very	NN	O	O
-	NN	O	O
long	NN	O	O
-	NN	O	O
chain	NN	O	O
fatty	NN	O	O
acids	NN	O	O
in	NN	O	O
lyophilized	NN	O	O
and	NN	O	O
reconstituted	NN	O	O
plasma	NN	O	O
.	NN	O	O

While	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
neurologic	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
leukodystrophy	NN	O	B-Disease
or	NN	O	O
myeloneuropathy	NN	O	B-Disease
)	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
these	NN	O	O
hemizygotes	NN	O	O
,	NN	O	O
adrenocortical	NN	O	B-Disease
insufficiency	NN	O	I-Disease
provoking	NN	O	O
compensatory	NN	O	O
high	NN	O	O
ACTH	NN	O	O
release	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
both	NN	O	O
.	NN	O	O

But	NN	O	O
the	NN	O	O
close	NN	O	O
genetic	NN	O	O
linkage	NN	O	O
of	NN	O	O
mdx	NN	O	O
to	NN	O	O
G6PD	NN	O	O
and	NN	O	O
Hprt	NN	O	O
on	NN	O	O
the	NN	O	O
mouse	NN	O	O
X	NN	O	O
chromosome	NN	O	O
,	NN	O	O
coupled	NN	O	O
with	NN	O	O
its	NN	O	O
comparatively	NN	O	O
mild	NN	O	O
pathology	NN	O	O
,	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
mdx	NN	O	O
mutation	NN	O	O
may	NN	O	O
instead	NN	O	O
correspond	NN	O	O
to	NN	O	O
Emery	NN	O	B-Disease
Dreifuss	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
which	NN	O	O
itself	NN	O	O
is	NN	O	O
closely	NN	O	O
linked	NN	O	O
to	NN	O	O
DNA	NN	O	O
markers	NN	O	O
at	NN	O	O
Xq28	NN	O	O
-	NN	O	O
qter	NN	O	O
in	NN	O	O
the	NN	O	O
region	NN	O	O
of	NN	O	O
G6PD	NN	O	O
on	NN	O	O
the	NN	O	O
human	NN	O	O
X	NN	O	O
chromosome	NN	O	O
.	NN	O	O

Recent	NN	O	O
progress	NN	O	O
has	NN	O	O
resulted	NN	O	O
in	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
mutated	NN	O	O
in	NN	O	O
Duchenne	NN	O	B-Disease
and	NN	O	I-Disease
the	NN	O	I-Disease
milder	NN	O	I-Disease
Becker	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophies	NN	O	I-Disease
being	NN	O	O
cloned	NN	O	O
and	NN	O	O
has	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
gene	NN	O	O
itself	NN	O	O
extends	NN	O	O
over	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
to	NN	O	O
2	NN	O	O
,	NN	O	O
000	NN	O	O
kilobases	NN	O	O
(	NN	O	O
kb	NN	O	O
)	NN	O	O
.	NN	O	O

Conservation	NN	O	O
of	NN	O	O
the	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
gene	NN	O	O
in	NN	O	O
mice	NN	O	O
and	NN	O	O
humans	NN	O	O
.	NN	O	O

Familial	NN	O	O
Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
with	NN	O	O
apparently	NN	O	O
normal	NN	O	O
chromosomes	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
4	NN	O	O
sibs	NN	O	O
(	NN	O	O
2F	NN	O	O
,	NN	O	O
2M	NN	O	O
)	NN	O	O
with	NN	O	O
Prader	NN	O	B-Disease
-	NN	O	I-Disease
Willi	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
PWS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Diagnosis	NN	O	O
was	NN	O	O
made	NN	O	O
clinically	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
history	NN	O	O
,	NN	O	O
behavior	NN	O	O
,	NN	O	O
and	NN	O	O
physical	NN	O	O
findings	NN	O	O
in	NN	O	O
3	NN	O	O
of	NN	O	O
the	NN	O	O
sibs	NN	O	O
.	NN	O	O

The	NN	O	O
implications	NN	O	O
of	NN	O	O
this	NN	O	O
unusual	NN	O	O
familial	NN	O	O
occurrence	NN	O	O
for	NN	O	O
our	NN	O	O
understanding	NN	O	O
of	NN	O	O
PWS	NN	O	B-Disease
are	NN	O	O
discussed	NN	O	O
.	NN	O	O
.	NN	O	O

Nebulin	NN	O	O
and	NN	O	O
titin	NN	O	O
expression	NN	O	O
in	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
appears	NN	O	O
normal	NN	O	O
.	NN	O	O

Monoclonal	NN	O	O
antibodies	NN	O	O
which	NN	O	O
recognize	NN	O	O
different	NN	O	O
epitopes	NN	O	O
on	NN	O	O
either	NN	O	O
titin	NN	O	O
or	NN	O	O
nebulin	NN	O	O
show	NN	O	O
normal	NN	O	O
staining	NN	O	O
patterns	NN	O	O
on	NN	O	O
frozen	NN	O	O
sections	NN	O	O
of	NN	O	O
three	NN	O	O
muscle	NN	O	O
biopsies	NN	O	O
of	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DMD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Heterozygous	NN	O	B-Disease
C2	NN	O	I-Disease
deficiency	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
angioedema	NN	O	B-Disease
,	NN	O	O
myasthenia	NN	O	B-Disease
gravis	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
systemic	NN	O	B-Disease
lupus	NN	O	I-Disease
erythematosus	NN	O	I-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
it	NN	O	O
appears	NN	O	O
that	NN	O	O
C3	NN	O	B-Disease
deficiency	NN	O	I-Disease
in	NN	O	O
Brittany	NN	O	O
spaniel	NN	O	O
dogs	NN	O	O
not	NN	O	O
only	NN	O	O
shares	NN	O	O
biochemical	NN	O	O
and	NN	O	O
clinical	NN	O	O
features	NN	O	O
with	NN	O	O
C3	NN	O	B-Disease
deficiency	NN	O	I-Disease
in	NN	O	O
humans	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
shares	NN	O	O
some	NN	O	O
genetic	NN	O	O
characteristics	NN	O	O
with	NN	O	O
the	NN	O	O
human	NN	O	O
disorder	NN	O	O
.	NN	O	O
.	NN	O	O

Regional	NN	O	O
mapping	NN	O	O
of	NN	O	O
the	NN	O	O
phenylalanine	NN	O	O
hydroxylase	NN	O	O
gene	NN	O	O
and	NN	O	O
the	NN	O	O
phenylketonuria	NN	O	B-Disease
locus	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
genome	NN	O	O
.	NN	O	O

Heterogeneity	NN	O	O
of	NN	O	O
type	NN	O	B-Disease
I	NN	O	I-Disease
von	NN	O	I-Disease
Willebrand	NN	O	I-Disease
disease	NN	O	I-Disease
:	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
subgroup	NN	O	O
with	NN	O	O
an	NN	O	O
abnormal	NN	O	O
von	NN	O	B-Disease
Willebrand	NN	O	I-Disease
factor	NN	O	O
.	NN	O	O

For	NN	O	O
17	NN	O	O
patients	NN	O	O
(	NN	O	O
13	NN	O	O
kindreds	NN	O	O
)	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
these	NN	O	O
criteria	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
studied	NN	O	O
the	NN	O	O
platelet	NN	O	O
contents	NN	O	O
of	NN	O	O
vWF	NN	O	O
Ag	NN	O	O
and	NN	O	O
RiCof	NN	O	O
and	NN	O	O
the	NN	O	O
changes	NN	O	O
of	NN	O	O
these	NN	O	O
in	NN	O	O
plasma	NN	O	O
after	NN	O	O
DDAVP	NN	O	O
infusion	NN	O	O
.	NN	O	O

In	NN	O	O
three	NN	O	O
additional	NN	O	O
kindreds	NN	O	O
,	NN	O	O
platelets	NN	O	O
contained	NN	O	O
normal	NN	O	O
concentrations	NN	O	O
of	NN	O	O
vWF	NN	O	O
Ag	NN	O	O
,	NN	O	O
but	NN	O	O
RiCof	NN	O	O
was	NN	O	O
very	NN	O	O
low	NN	O	O
(	NN	O	O
platelet	NN	O	O
discordant	NN	O	O
)	NN	O	O
;	NN	O	O
even	NN	O	O
though	NN	O	O
a	NN	O	O
complete	NN	O	O
set	NN	O	O
of	NN	O	O
multimers	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
platelets	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
relatively	NN	O	O
small	NN	O	O
amount	NN	O	O
of	NN	O	O
large	NN	O	O
multimers	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
brought	NN	O	O
together	NN	O	O
information	NN	O	O
on	NN	O	O
864	NN	O	O
affected	NN	O	O
individuals	NN	O	O
in	NN	O	O
164	NN	O	O
families	NN	O	O
(	NN	O	O
including	NN	O	O
three	NN	O	O
new	NN	O	O
pedigrees	NN	O	O
)	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
137	NN	O	O
year	NN	O	O
period	NN	O	O
since	NN	O	O
1845	NN	O	O
when	NN	O	O
Demarquay	NN	O	O
first	NN	O	O
described	NN	O	O
a	NN	O	O
family	NN	O	O
with	NN	O	O
what	NN	O	O
was	NN	O	O
later	NN	O	O
called	NN	O	O
van	NN	O	B-Disease
der	NN	O	I-Disease
Woude	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
VWS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Lip	NN	O	B-Disease
pits	NN	O	I-Disease
also	NN	O	O
are	NN	O	O
equally	NN	O	O
distributed	NN	O	O
between	NN	O	O
the	NN	O	O
sexes	NN	O	O
.	NN	O	O

Affected	NN	O	O
males	NN	O	O
and	NN	O	O
females	NN	O	O
are	NN	O	O
equally	NN	O	O
likely	NN	O	O
to	NN	O	O
transmit	NN	O	O
VWS	NN	O	B-Disease
.	NN	O	O

45	NN	O	O
%	NN	O	O
;	NN	O	O
that	NN	O	O
of	NN	O	O
transmitting	NN	O	O
lower	NN	O	O
lip	NN	O	B-Disease
pits	NN	O	I-Disease
is	NN	O	O
23	NN	O	O
.	NN	O	O

Hereditary	NN	O	B-Disease
C7	NN	O	I-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
simultaneous	NN	O	O
occurrence	NN	O	O
of	NN	O	O
two	NN	O	O
hereditary	NN	O	O
complement	NN	O	B-Disease
deficiencies	NN	O	I-Disease
(	NN	O	I-Disease
C2	NN	O	I-Disease
and	NN	O	I-Disease
C7	NN	O	I-Disease
)	NN	O	I-Disease
was	NN	O	O
discovered	NN	O	O
in	NN	O	O
one	NN	O	O
family	NN	O	O
of	NN	O	O
this	NN	O	O
remarkable	NN	O	O
kindred	NN	O	O
.	NN	O	O
.	NN	O	O

Genetic	NN	O	O
defect	NN	O	B-Disease
in	NN	O	I-Disease
secretion	NN	O	I-Disease
of	NN	O	I-Disease
complement	NN	O	I-Disease
C5	NN	O	I-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

We	NN	O	O
recently	NN	O	O
reported	NN	O	O
that	NN	O	O
mouse	NN	O	O
(	NN	O	O
CD	NN	O	O
.	NN	O	O
1	NN	O	O
strain	NN	O	O
)	NN	O	O
peritoneal	NN	O	O
cells	NN	O	O
in	NN	O	O
culture	NN	O	O
synthesise	NN	O	O
and	NN	O	O
secrete	NN	O	O
a	NN	O	O
single	NN	O	O
chain	NN	O	O
precursor	NN	O	O
,	NN	O	O
pro	NN	O	O
-	NN	O	O
C5	NN	O	O
(	NN	O	O
MW	NN	O	O
approximately	NN	O	O
210	NN	O	O
,	NN	O	O
000	NN	O	O
)	NN	O	O
,	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
-	NN	O	O
chain	NN	O	O
(	NN	O	O
alpha	NN	O	O
chain	NN	O	O
,	NN	O	O
125	NN	O	O
,	NN	O	O
000	NN	O	O
and	NN	O	O
beta	NN	O	O
chain	NN	O	O
83	NN	O	O
,	NN	O	O
000	NN	O	O
MW	NN	O	O
)	NN	O	O
C5	NN	O	O
protein6	NN	O	O
.	NN	O	O

Radiolabelled	NN	O	O
precursor	NN	O	O
C5	NN	O	O
was	NN	O	O
contained	NN	O	O
within	NN	O	O
the	NN	O	O
cells	NN	O	O
and	NN	O	O
was	NN	O	O
secreted	NN	O	O
into	NN	O	O
the	NN	O	O
tissue	NN	O	O
culture	NN	O	O
media	NN	O	O
.	NN	O	O

Clinical	NN	O	O
,	NN	O	O
genetic	NN	O	O
and	NN	O	O
immunologic	NN	O	O
studies	NN	O	O
in	NN	O	O
a	NN	O	O
large	NN	O	O
kindred	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
two	NN	O	O
of	NN	O	O
32	NN	O	O
other	NN	O	O
family	NN	O	O
members	NN	O	O
from	NN	O	O
three	NN	O	O
generations	NN	O	O
had	NN	O	O
depressed	NN	O	O
whole	NN	O	O
hemolytic	NN	O	O
complement	NN	O	O
levels	NN	O	O
.	NN	O	O

No	NN	O	O
linkage	NN	O	O
for	NN	O	O
C5	NN	O	B-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
the	NN	O	O
A	NN	O	O
or	NN	O	O
B	NN	O	O
loci	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
histocompatibility	NN	O	O
complex	NN	O	O
could	NN	O	O
be	NN	O	O
found	NN	O	O
.	NN	O	O

6	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
TRIS	NN	O	O
-	NN	O	O
hydrochloride	NN	O	O
buffer	NN	O	O
system	NN	O	O
at	NN	O	O
pH	NN	O	O
8	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
,	NN	O	O
H	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
activity	NN	O	O
of	NN	O	O
HPRT	NN	O	O
in	NN	O	O
the	NN	O	O
lysates	NN	O	O
of	NN	O	O
erythrocytes	NN	O	O
and	NN	O	O
cultured	NN	O	O
fibroblasts	NN	O	O
when	NN	O	O
analyzed	NN	O	O
in	NN	O	O
the	NN	O	O
usual	NN	O	O
manner	NN	O	O
.	NN	O	O

The	NN	O	O
genes	NN	O	O
for	NN	O	O
Becker	NN	O	B-Disease
and	NN	O	I-Disease
Duchenne	NN	O	I-Disease
dystrophies	NN	O	I-Disease
must	NN	O	O
therefore	NN	O	O
be	NN	O	O
closely	NN	O	O
linked	NN	O	O
,	NN	O	O
if	NN	O	O
not	NN	O	O
allelic	NN	O	O
,	NN	O	O
and	NN	O	O
any	NN	O	O
future	NN	O	O
DNA	NN	O	O
probes	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
practical	NN	O	O
use	NN	O	O
in	NN	O	O
one	NN	O	O
disorder	NN	O	O
should	NN	O	O
be	NN	O	O
equally	NN	O	O
applicable	NN	O	O
to	NN	O	O
the	NN	O	O
other	NN	O	O
.	NN	O	O

Partial	NN	O	O
HPRT	NN	O	B-Disease
deficiencies	NN	O	I-Disease
are	NN	O	O
associated	NN	O	O
with	NN	O	O
gouty	NN	O	B-Disease
arthritis	NN	O	I-Disease
,	NN	O	O
while	NN	O	O
absence	NN	O	O
of	NN	O	O
activity	NN	O	O
results	NN	O	O
in	NN	O	O
Lesch	NN	O	B-Disease
-	NN	O	I-Disease
Nyhan	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
L	NN	O	B-Disease
-	NN	O	I-Disease
N	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

L	NN	O	B-Disease
-	NN	O	I-Disease
N	NN	O	I-Disease
patients	NN	O	O
fail	NN	O	O
to	NN	O	O
reproduce	NN	O	O
and	NN	O	O
the	NN	O	O
heterozygous	NN	O	O
state	NN	O	O
appears	NN	O	O
to	NN	O	O
confer	NN	O	O
no	NN	O	O
selective	NN	O	O
advantage	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
Haldanes	NN	O	O
principle	NN	O	O
predicts	NN	O	O
that	NN	O	O
new	NN	O	O
mutations	NN	O	O
at	NN	O	O
the	NN	O	O
hprt	NN	O	O
locus	NN	O	O
must	NN	O	O
occur	NN	O	O
frequently	NN	O	O
in	NN	O	O
order	NN	O	O
for	NN	O	O
L	NN	O	B-Disease
-	NN	O	I-Disease
N	NN	O	I-Disease
syndrome	NN	O	I-Disease
to	NN	O	O
be	NN	O	O
maintained	NN	O	O
in	NN	O	O
the	NN	O	O
population	NN	O	O
.	NN	O	O

Allelic	NN	O	O
exclusion	NN	O	O
of	NN	O	O
glucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
dehydrogenase	NN	O	O
in	NN	O	O
platelets	NN	O	O
and	NN	O	O
T	NN	O	O
lymphocytes	NN	O	O
from	NN	O	O
a	NN	O	O
Wiskott	NN	O	B-Disease
-	NN	O	I-Disease
Aldrich	NN	O	I-Disease
syndrome	NN	O	I-Disease
carrier	NN	O	O
.	NN	O	O

With	NN	O	O
her	NN	O	O
it	NN	O	O
became	NN	O	O
possible	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
allelic	NN	O	O
exclusion	NN	O	O
occurs	NN	O	O
in	NN	O	O
particular	NN	O	O
cell	NN	O	O
-	NN	O	O
types	NN	O	O
of	NN	O	O
the	NN	O	O
WAS	NN	O	B-Disease
carrier	NN	O	O
.	NN	O	O

This	NN	O	O
family	NN	O	O
study	NN	O	O
provides	NN	O	O
further	NN	O	O
support	NN	O	O
for	NN	O	O
the	NN	O	O
proposal	NN	O	O
that	NN	O	O
C3	NN	O	B-Disease
deficiency	NN	O	I-Disease
predisposes	NN	O	O
to	NN	O	O
nephritis	NN	O	B-Disease
.	NN	O	O
.	NN	O	O

Study	NN	O	O
in	NN	O	O
Northern	NN	O	O
Algeria	NN	O	O
with	NN	O	O
description	NN	O	O
of	NN	O	O
five	NN	O	O
new	NN	O	O
variants	NN	O	O
.	NN	O	O

Glucose	NN	O	B-Disease
-	NN	O	I-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
(	NN	O	I-Disease
G6PD	NN	O	I-Disease
)	NN	O	I-Disease
deficiency	NN	O	I-Disease
was	NN	O	O
found	NN	O	O
in	NN	O	O
3	NN	O	O
.	NN	O	O

2	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
male	NN	O	O
population	NN	O	O
living	NN	O	O
in	NN	O	O
the	NN	O	O
urban	NN	O	O
area	NN	O	O
of	NN	O	O
Algiers	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
nine	NN	O	O
families	NN	O	O
.	NN	O	O

Strikingly	NN	O	O
,	NN	O	O
the	NN	O	O
common	NN	O	O
Mediterranean	NN	O	O
variant	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
.	NN	O	O

The	NN	O	O
Kabyle	NN	O	O
variant	NN	O	O
may	NN	O	O
be	NN	O	O
common	NN	O	O
in	NN	O	O
this	NN	O	O
country	NN	O	O
.	NN	O	O

Glucose	NN	O	B-Disease
-	NN	O	I-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
deficiency	NN	O	I-Disease
inhibits	NN	O	O
in	NN	O	O
vitro	NN	O	O
growth	NN	O	O
of	NN	O	O
Plasmodium	NN	O	O
falciparum	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
may	NN	O	O
confer	NN	O	O
a	NN	O	O
selective	NN	O	O
advantage	NN	O	O
in	NN	O	O
a	NN	O	O
malarious	NN	O	B-Disease
area	NN	O	O
;	NN	O	O
the	NN	O	O
female	NN	O	O
heterozygote	NN	O	O
may	NN	O	O
be	NN	O	O
at	NN	O	O
a	NN	O	O
particular	NN	O	O
advantage	NN	O	O
because	NN	O	O
resistance	NN	O	O
to	NN	O	O
malaria	NN	O	B-Disease
equals	NN	O	O
that	NN	O	O
of	NN	O	O
male	NN	O	O
hemizygotes	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
fatal	NN	O	B-Disease
hemolysis	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
less	NN	O	O
.	NN	O	O

[	NN	O	O
Gd	NN	O	O
-	NN	O	O
allele	NN	O	O
distribution	NN	O	O
patterns	NN	O	O
in	NN	O	O
Azerbaijan	NN	O	O
.	NN	O	O
III	NN	O	O
.	NN	O	O
The	NN	O	O
identification	NN	O	O
of	NN	O	O
mutant	NN	O	O
forms	NN	O	O
of	NN	O	O
glucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
dehydrogenase	NN	O	O
]	NN	O	O

Comparison	NN	O	O
of	NN	O	O
G6PD	NN	O	O
spectra	NN	O	O
in	NN	O	O
two	NN	O	O
subpopulations	NN	O	O
and	NN	O	O
in	NN	O	O
a	NN	O	O
mixed	NN	O	O
group	NN	O	O
permits	NN	O	O
to	NN	O	O
make	NN	O	O
a	NN	O	O
conclusion	NN	O	O
about	NN	O	O
existence	NN	O	O
of	NN	O	O
common	NN	O	O
and	NN	O	O
rare	NN	O	O
G6PD	NN	O	O
alleles	NN	O	O
in	NN	O	O
examined	NN	O	O
population	NN	O	O
.	NN	O	O

Among	NN	O	O
7	NN	O	O
samples	NN	O	O
of	NN	O	O
G6PD	NN	O	O
with	NN	O	O
normal	NN	O	O
and	NN	O	O
increased	NN	O	O
activity	NN	O	O
two	NN	O	O
new	NN	O	O
variants	NN	O	O
of	NN	O	O
IV	NN	O	O
class	NN	O	O
-	NN	O	O
-	NN	O	O
Nukha	NN	O	O
and	NN	O	O
Bash	NN	O	O
-	NN	O	O
Kungut	NN	O	O
-	NN	O	O
-	NN	O	O
were	NN	O	O
found	NN	O	O
.	NN	O	O
.	NN	O	O

Adrenoleukodystrophy	NN	O	B-Disease
(	NN	O	O
ALD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
genetically	NN	O	O
determined	NN	O	O
disorder	NN	O	O
associated	NN	O	O
with	NN	O	O
progressive	NN	O	B-Disease
central	NN	O	I-Disease
demyelination	NN	O	I-Disease
and	NN	O	O
adrenal	NN	O	B-Disease
cortical	NN	O	I-Disease
insufficiency	NN	O	I-Disease
.	NN	O	O

Of	NN	O	O
these	NN	O	O
,	NN	O	O
G6PD	NN	O	O
Mediterranean	NN	O	O
type	NN	O	O
was	NN	O	O
a	NN	O	O
polymorphic	NN	O	O
variant	NN	O	O
and	NN	O	O
G6PD	NN	O	O
Corinth	NN	O	O
occurred	NN	O	O
with	NN	O	O
high	NN	O	O
frequency	NN	O	O
.	NN	O	O

Two	NN	O	O
new	NN	O	O
variants	NN	O	O
were	NN	O	O
identified	NN	O	O
-	NN	O	O
G6PD	NN	O	O
Rudosem	NN	O	O
and	NN	O	O
G6PD	NN	O	O
Nedelino	NN	O	O
.	NN	O	O

Here	NN	O	O
prediction	NN	O	O
and	NN	O	O
exclusion	NN	O	O
of	NN	O	O
DMD	NN	O	B-Disease
gene	NN	O	O
transmission	NN	O	O
may	NN	O	O
be	NN	O	O
possible	NN	O	O
,	NN	O	O
the	NN	O	O
accuracy	NN	O	O
being	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
closeness	NN	O	O
of	NN	O	O
the	NN	O	O
linkage	NN	O	O
of	NN	O	O
the	NN	O	O
DNA	NN	O	O
marker	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
to	NN	O	O
the	NN	O	O
DMD	NN	O	B-Disease
gene	NN	O	O
;	NN	O	O
an	NN	O	O
illustrative	NN	O	O
case	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
segregation	NN	O	O
analyses	NN	O	O
in	NN	O	O
75	NN	O	O
families	NN	O	O
where	NN	O	O
the	NN	O	O
proband	NN	O	O
had	NN	O	O
ankylosing	NN	O	B-Disease
spondylitis	NN	O	I-Disease
,	NN	O	O
are	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
were	NN	O	O
in	NN	O	O
agreement	NN	O	O
with	NN	O	O
our	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
ankylosing	NN	O	B-Disease
spondylitis	NN	O	I-Disease
is	NN	O	O
part	NN	O	O
of	NN	O	O
a	NN	O	O
syndrome	NN	O	O
where	NN	O	O
different	NN	O	O
genetic	NN	O	O
factors	NN	O	O
interact	NN	O	O
.	NN	O	O

TSD	NN	O	B-Disease
carrier	NN	O	O
frequencies	NN	O	O
were	NN	O	O
then	NN	O	O
examined	NN	O	O
by	NN	O	O
single	NN	O	O
country	NN	O	O
and	NN	O	O
single	NN	O	O
region	NN	O	O
of	NN	O	O
origin	NN	O	O
in	NN	O	O
28	NN	O	O
,	NN	O	O
029	NN	O	O
Jews	NN	O	O
within	NN	O	O
this	NN	O	O
sample	NN	O	O
for	NN	O	O
whom	NN	O	O
such	NN	O	O
data	NN	O	O
were	NN	O	O
available	NN	O	O
for	NN	O	O
analysis	NN	O	O
.	NN	O	O

Severe	NN	O	B-Disease
-	NN	O	I-Disease
glucose	NN	O	I-Disease
-	NN	O	I-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
(	NN	O	I-Disease
G6PD	NN	O	I-Disease
)	NN	O	I-Disease
deficiency	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
,	NN	O	O
granulocyte	NN	O	B-Disease
dysfunction	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
increased	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
infections	NN	O	O
:	NN	O	O
description	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
molecular	NN	O	O
variant	NN	O	O
(	NN	O	O
G6PD	NN	O	O
Barcelona	NN	O	O
)	NN	O	O
.	NN	O	O

G6PD	NN	O	O
activity	NN	O	O
was	NN	O	O
absent	NN	O	O
in	NN	O	O
patients	NN	O	O
red	NN	O	O
cells	NN	O	O
and	NN	O	O
was	NN	O	O
about	NN	O	O
2	NN	O	O
%	NN	O	O
of	NN	O	O
normal	NN	O	O
in	NN	O	O
leukocytes	NN	O	O
.	NN	O	O

Other	NN	O	O
tests	NN	O	O
showed	NN	O	O
the	NN	O	O
patients	NN	O	O
granulocytes	NN	O	O
to	NN	O	O
engulf	NN	O	O
latex	NN	O	O
particles	NN	O	O
normally	NN	O	O
,	NN	O	O
but	NN	O	O
to	NN	O	O
have	NN	O	O
impaired	NN	O	O
reduction	NN	O	O
of	NN	O	O
nitroblue	NN	O	O
tetrazolium	NN	O	O
and	NN	O	O
ferricytochrome	NN	O	O
-	NN	O	O
c	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
reduced	NN	O	O
iodination	NN	O	O
.	NN	O	O

Possible	NN	O	O
mechanisms	NN	O	O
for	NN	O	O
the	NN	O	O
severe	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
G6PD	NN	O	I-Disease
in	NN	O	O
erythrocytes	NN	O	O
and	NN	O	O
granulocytes	NN	O	O
was	NN	O	O
investigated	NN	O	O
by	NN	O	O
studies	NN	O	O
on	NN	O	O
the	NN	O	O
immunologic	NN	O	O
specific	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
mutant	NN	O	O
enzyme	NN	O	O
.	NN	O	O

Biochemical	NN	O	O
characterization	NN	O	O
of	NN	O	O
G6PD	NN	O	O
purified	NN	O	O
from	NN	O	O
these	NN	O	O
subjects	NN	O	O
has	NN	O	O
revealed	NN	O	O
13	NN	O	O
new	NN	O	O
variants	NN	O	O
and	NN	O	O
several	NN	O	O
copies	NN	O	O
of	NN	O	O
previously	NN	O	O
described	NN	O	O
forms	NN	O	O
of	NN	O	O
G6PD	NN	O	O
.	NN	O	O

Glucose	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
phosphate	NN	O	O
dehydrogenase	NN	O	O
(	NN	O	O
G6PD	NN	O	O
)	NN	O	O
;	NN	O	O
EC	NN	O	O
1	NN	O	O
.	NN	O	O

(	NN	O	O
3	NN	O	O
)	NN	O	O
Favism	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
observed	NN	O	O
associated	NN	O	O
with	NN	O	O
all	NN	O	O
kinds	NN	O	O
of	NN	O	O
variants	NN	O	O
described	NN	O	O
here	NN	O	O
.	NN	O	O

The	NN	O	O
enzymatic	NN	O	O
characteristics	NN	O	O
were	NN	O	O
examined	NN	O	O
when	NN	O	O
he	NN	O	O
was	NN	O	O
5	NN	O	O
years	NN	O	O
old	NN	O	O
,	NN	O	O
and	NN	O	O
his	NN	O	O
G6PD	NN	O	O
showed	NN	O	O
faster	NN	O	O
-	NN	O	O
than	NN	O	O
-	NN	O	O
normal	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
,	NN	O	O
low	NN	O	O
Km	NN	O	O
G6P	NN	O	O
,	NN	O	O
high	NN	O	O
Km	NN	O	O
NADP	NN	O	O
,	NN	O	O
low	NN	O	O
Ki	NN	O	O
NADPH	NN	O	O
,	NN	O	O
normal	NN	O	O
utilization	NN	O	O
of	NN	O	O
substrate	NN	O	O
analogues	NN	O	O
,	NN	O	O
heat	NN	O	O
instability	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
normal	NN	O	O
pH	NN	O	O
optimum	NN	O	O
curve	NN	O	O
.	NN	O	O

Adrenoleukodystrophy	NN	O	B-Disease
:	NN	O	O
increased	NN	O	O
plasma	NN	O	O
content	NN	O	O
of	NN	O	O
saturated	NN	O	O
very	NN	O	O
long	NN	O	O
chain	NN	O	O
fatty	NN	O	O
acids	NN	O	O
.	NN	O	O

0063	NN	O	O
%	NN	O	O
of	NN	O	O
total	NN	O	O
fatty	NN	O	O
acids	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
HDL	NN	O	O
-	NN	O	O
cholesterol	NN	O	O
concentration	NN	O	O
in	NN	O	O
the	NN	O	O
CTX	NN	O	B-Disease
plasmas	NN	O	O
was	NN	O	O
14	NN	O	O
.	NN	O	O

The	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
lipoprotein	NN	O	O
distribution	NN	O	O
profile	NN	O	O
and	NN	O	O
composition	NN	O	O
of	NN	O	O
the	NN	O	O
plasma	NN	O	O
HDL	NN	O	O
result	NN	O	O
from	NN	O	O
metabolic	NN	O	O
defects	NN	O	O
that	NN	O	O
are	NN	O	O
not	NN	O	O
understood	NN	O	O
but	NN	O	O
may	NN	O	O
be	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
genetic	NN	O	B-Disease
defect	NN	O	I-Disease
in	NN	O	O
bile	NN	O	O
acid	NN	O	O
synthesis	NN	O	O
in	NN	O	O
CTX	NN	O	B-Disease
.	NN	O	O

Since	NN	O	O
there	NN	O	O
are	NN	O	O
differences	NN	O	O
in	NN	O	O
expression	NN	O	O
in	NN	O	O
this	NN	O	O
disease	NN	O	O
,	NN	O	O
we	NN	O	O
recommend	NN	O	O
cholestanol	NN	O	O
study	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
undiagnosed	NN	O	O
cataract	NN	O	B-Disease
or	NN	O	O
tendinous	NN	O	B-Disease
xanthomas	NN	O	I-Disease
in	NN	O	O
childhood	NN	O	O
or	NN	O	O
early	NN	O	O
adolescence	NN	O	O
.	NN	O	O

These	NN	O	O
and	NN	O	O
other	NN	O	O
variants	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
which	NN	O	O
must	NN	O	O
thus	NN	O	O
far	NN	O	O
be	NN	O	O
regarded	NN	O	O
as	NN	O	O
sporadic	NN	O	O
,	NN	O	O
are	NN	O	O
found	NN	O	O
to	NN	O	O
map	NN	O	O
in	NN	O	O
parts	NN	O	O
of	NN	O	O
Italy	NN	O	O
where	NN	O	O
common	NN	O	O
types	NN	O	O
of	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
are	NN	O	O
also	NN	O	O
prevalent	NN	O	O
.	NN	O	O
.	NN	O	O

Corinth	NN	O	O
-	NN	O	O
like	NN	O	O
and	NN	O	O
Fayoum	NN	O	O
-	NN	O	O
like	NN	O	O
variants	NN	O	O
were	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
;	NN	O	O
Mediterranean	NN	O	O
,	NN	O	O
Ohut	NN	O	O
II	NN	O	O
,	NN	O	O
Kilgore	NN	O	O
,	NN	O	O
Boston	NN	O	O
,	NN	O	O
Poznan	NN	O	O
,	NN	O	O
and	NN	O	O
Panay	NN	O	O
variants	NN	O	O
and	NN	O	O
two	NN	O	O
new	NN	O	O
variants	NN	O	O
,	NN	O	O
Petrich	NN	O	O
and	NN	O	O
Gotze	NN	O	O
Delchev	NN	O	O
,	NN	O	O
were	NN	O	O
each	NN	O	O
found	NN	O	O
in	NN	O	O
one	NN	O	O
or	NN	O	O
two	NN	O	O
carriers	NN	O	O
.	NN	O	O

Nephropathy	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
Wiskott	NN	O	B-Disease
-	NN	O	I-Disease
Aldrich	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
new	NN	O	O
CT	NN	O	O
pattern	NN	O	O
in	NN	O	O
adrenoleukodystrophy	NN	O	B-Disease
.	NN	O	O

Four	NN	O	O
new	NN	O	O
G6PD	NN	O	O
variants	NN	O	O
have	NN	O	O
been	NN	O	O
characterized	NN	O	O
in	NN	O	O
individuals	NN	O	O
from	NN	O	O
Papua	NN	O	O
New	NN	O	O
Guinea	NN	O	O
.	NN	O	O

Glucose	NN	O	B-Disease
-	NN	O	I-Disease
6	NN	O	I-Disease
-	NN	O	I-Disease
phosphate	NN	O	I-Disease
dehydrogenase	NN	O	I-Disease
(	NN	O	I-Disease
G6PD	NN	O	I-Disease
)	NN	O	I-Disease
deficiency	NN	O	I-Disease
in	NN	O	O
RBCs	NN	O	O
was	NN	O	O
found	NN	O	O
significantly	NN	O	O
more	NN	O	O
frequently	NN	O	O
in	NN	O	O
210	NN	O	O
male	NN	O	O
cataractous	NN	O	B-Disease
patients	NN	O	O
than	NN	O	O
in	NN	O	O
672	NN	O	O
control	NN	O	O
subjects	NN	O	O
of	NN	O	O
Sardinian	NN	O	O
origin	NN	O	O
.	NN	O	O

beta	NN	O	O
-	NN	O	O
Oxidation	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
chain	NN	O	O
fatty	NN	O	O
acids	NN	O	O
provides	NN	O	O
the	NN	O	O
major	NN	O	O
source	NN	O	O
of	NN	O	O
energy	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
isolated	NN	O	O
the	NN	O	O
human	NN	O	O
VLCAD	NN	O	O
cDNA	NN	O	O
and	NN	O	O
gene	NN	O	O
and	NN	O	O
determined	NN	O	O
the	NN	O	O
complete	NN	O	O
nucleotide	NN	O	O
sequences	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
,	NN	O	O
a	NN	O	O
homozygous	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
consensus	NN	O	O
dinucleotide	NN	O	O
of	NN	O	O
the	NN	O	O
donor	NN	O	O
splice	NN	O	O
site	NN	O	O
(	NN	O	O
g	NN	O	O
+	NN	O	O
1	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
a	NN	O	O
)	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
universal	NN	O	O
skipping	NN	O	O
of	NN	O	O
the	NN	O	O
prior	NN	O	O
exon	NN	O	O
(	NN	O	O
exon	NN	O	O
11	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
initial	NN	O	O
delineation	NN	O	O
of	NN	O	O
human	NN	O	O
mutations	NN	O	O
in	NN	O	O
VLCAD	NN	O	O
suggests	NN	O	O
that	NN	O	O
VLCAD	NN	O	B-Disease
deficiency	NN	O	I-Disease
reduces	NN	O	O
myocardial	NN	O	O
fatty	NN	O	O
acid	NN	O	O
beta	NN	O	O
-	NN	O	O
oxidation	NN	O	O
and	NN	O	O
energy	NN	O	O
production	NN	O	O
and	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
cardiomyopathy	NN	O	B-Disease
and	NN	O	O
sudden	NN	O	B-Disease
death	NN	O	I-Disease
in	NN	O	O
childhood	NN	O	O
.	NN	O	O

ATP7B	NN	O	O
,	NN	O	O
the	NN	O	O
gene	NN	O	O
altered	NN	O	O
in	NN	O	O
Wilson	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
WD	NN	O	B-Disease
)	NN	O	O
patients	NN	O	O
,	NN	O	O
lies	NN	O	O
in	NN	O	O
a	NN	O	O
block	NN	O	O
of	NN	O	O
homology	NN	O	O
shared	NN	O	O
between	NN	O	O
human	NN	O	O
chromosome	NN	O	O
13q14	NN	O	O
and	NN	O	O
the	NN	O	O
central	NN	O	O
region	NN	O	O
of	NN	O	O
mouse	NN	O	O
chromosome	NN	O	O
14	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
80	NN	O	O
interspecific	NN	O	O
backcross	NN	O	O
offspring	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
position	NN	O	O
Atp7b	NN	O	O
close	NN	O	O
to	NN	O	O
D8Mit3	NN	O	O
and	NN	O	O
another	NN	O	O
ATPase	NN	O	O
locus	NN	O	O
,	NN	O	O
Atp4b	NN	O	O
,	NN	O	O
on	NN	O	O
mouse	NN	O	O
chromosome	NN	O	O
8	NN	O	O
.	NN	O	O

ATP4B	NN	O	O
lies	NN	O	O
in	NN	O	O
13q34	NN	O	O
and	NN	O	O
is	NN	O	O
separated	NN	O	O
from	NN	O	O
ATP7B	NN	O	O
by	NN	O	O
several	NN	O	O
loci	NN	O	O
whose	NN	O	O
mouse	NN	O	O
homologues	NN	O	O
map	NN	O	O
to	NN	O	O
mouse	NN	O	O
chromosome	NN	O	O
14	NN	O	O
.	NN	O	O

Mutations	NN	O	O
in	NN	O	O
the	NN	O	O
BRCA1	NN	O	O
gene	NN	O	O
,	NN	O	O
discovered	NN	O	O
in	NN	O	O
1994	NN	O	O
,	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
80	NN	O	O
-	NN	O	O
90	NN	O	O
%	NN	O	O
lifetime	NN	O	O
risk	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
observed	NN	O	O
a	NN	O	O
significant	NN	O	O
correlation	NN	O	O
between	NN	O	O
the	NN	O	O
location	NN	O	O
of	NN	O	O
the	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
gene	NN	O	O
and	NN	O	O
the	NN	O	O
ratio	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
to	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
incidence	NN	O	O
within	NN	O	O
each	NN	O	O
family	NN	O	O
.	NN	O	O

The	NN	O	O
trinucleotide	NN	O	O
expansion	NN	O	O
mutation	NN	O	O
causing	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
is	NN	O	O
in	NN	O	O
the	NN	O	O
3	NN	O	O
untranslated	NN	O	O
region	NN	O	O
of	NN	O	O
a	NN	O	O
protein	NN	O	O
kinase	NN	O	O
gene	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
use	NN	O	O
muscle	NN	O	O
biopsies	NN	O	O
from	NN	O	O
classical	NN	O	O
adult	NN	O	O
-	NN	O	O
onset	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
patients	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
accumulation	NN	O	O
of	NN	O	O
transcripts	NN	O	O
from	NN	O	O
both	NN	O	O
the	NN	O	O
normal	NN	O	O
and	NN	O	O
expanded	NN	O	O
DM	NN	O	B-Disease
kinase	NN	O	O
genes	NN	O	O
in	NN	O	O
patient	NN	O	O
muscle	NN	O	O
,	NN	O	O
and	NN	O	O
compare	NN	O	O
the	NN	O	O
results	NN	O	O
to	NN	O	O
normal	NN	O	O
and	NN	O	O
myopathic	NN	O	B-Disease
controls	NN	O	O
.	NN	O	O

The	NN	O	O
ability	NN	O	O
of	NN	O	O
the	NN	O	O
expansion	NN	O	O
mutation	NN	O	O
to	NN	O	O
alter	NN	O	O
accumulation	NN	O	O
of	NN	O	O
poly	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
+	NN	O	O
RNA	NN	O	O
in	NN	O	O
trans	NN	O	O
suggests	NN	O	O
that	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
the	NN	O	O
first	NN	O	O
example	NN	O	O
of	NN	O	O
a	NN	O	O
dominant	NN	O	O
-	NN	O	O
negative	NN	O	O
mutation	NN	O	O
manifested	NN	O	O
at	NN	O	O
the	NN	O	O
RNA	NN	O	O
level	NN	O	O
.	NN	O	O
.	NN	O	O

This	NN	O	O
protein	NN	O	O
contains	NN	O	O
a	NN	O	O
zinc	NN	O	O
finger	NN	O	O
domain	NN	O	O
in	NN	O	O
its	NN	O	O
amino	NN	O	O
-	NN	O	O
terminal	NN	O	O
region	NN	O	O
,	NN	O	O
but	NN	O	O
is	NN	O	O
otherwise	NN	O	O
unrelated	NN	O	O
to	NN	O	O
previously	NN	O	O
described	NN	O	O
proteins	NN	O	O
.	NN	O	O

We	NN	O	O
speculate	NN	O	O
that	NN	O	O
classic	NN	O	B-Disease
galactosemia	NN	O	I-Disease
mutations	NN	O	O
appear	NN	O	O
to	NN	O	O
differ	NN	O	O
between	NN	O	O
Japanese	NN	O	O
and	NN	O	O
Caucasian	NN	O	O
patients	NN	O	O
.	NN	O	O

Our	NN	O	O
limited	NN	O	O
data	NN	O	O
set	NN	O	O
on	NN	O	O
galactosemia	NN	O	B-Disease
mutations	NN	O	O
in	NN	O	O
Japanese	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
N314D	NN	O	O
GALT	NN	O	O
mutation	NN	O	O
encoding	NN	O	O
the	NN	O	O
Duarte	NN	O	O
variant	NN	O	O
arose	NN	O	O
before	NN	O	O
Asian	NN	O	O
and	NN	O	O
Caucasian	NN	O	O
people	NN	O	O
diverged	NN	O	O
and	NN	O	O
that	NN	O	O
classic	NN	O	B-Disease
galactosemia	NN	O	I-Disease
mutations	NN	O	O
arose	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
accumulated	NN	O	O
after	NN	O	O
the	NN	O	O
divergence	NN	O	O
of	NN	O	O
Asian	NN	O	O
and	NN	O	O
Caucasian	NN	O	O
populations	NN	O	O
.	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
four	NN	O	O
different	NN	O	O
mutations	NN	O	O
identified	NN	O	O
,	NN	O	O
one	NN	O	O
was	NN	O	O
identical	NN	O	O
to	NN	O	O
a	NN	O	O
previously	NN	O	O
reported	NN	O	O
mutation	NN	O	O
(	NN	O	O
C	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
T	NN	O	O
transition	NN	O	O
at	NN	O	O
codon	NN	O	O
240	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
three	NN	O	O
were	NN	O	O
novel	NN	O	O
two	NN	O	O
in	NN	O	O
the	NN	O	O
glycine	NN	O	O
-	NN	O	O
rich	NN	O	O
region	NN	O	O
and	NN	O	O
one	NN	O	O
in	NN	O	O
the	NN	O	O
proline	NN	O	O
/	NN	O	O
serine	NN	O	O
/	NN	O	O
threonine	NN	O	O
-	NN	O	O
rich	NN	O	O
(	NN	O	O
PST	NN	O	O
)	NN	O	O
region	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
mutation	NN	O	O
stats	NN	O	O
of	NN	O	O
individuals	NN	O	O
unselected	NN	O	O
for	NN	O	O
breast	NN	O	B-Disease
or	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
has	NN	O	O
not	NN	O	O
been	NN	O	O
determined	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
whether	NN	O	O
mutations	NN	O	O
in	NN	O	O
such	NN	O	O
individuals	NN	O	O
confer	NN	O	O
the	NN	O	O
same	NN	O	O
risk	NN	O	O
of	NN	O	O
cancer	NN	O	B-Disease
as	NN	O	O
in	NN	O	O
individuals	NN	O	O
from	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
families	NN	O	O
studied	NN	O	O
so	NN	O	O
far	NN	O	O
.	NN	O	O

Following	NN	O	O
the	NN	O	O
finding	NN	O	O
of	NN	O	O
a	NN	O	O
185delAG	NN	O	O
frameshift	NN	O	O
mutation	NN	O	O
in	NN	O	O
several	NN	O	O
Ashkenazi	NN	O	O
Jewish	NN	O	O
breast	NN	O	O
/	NN	O	O
ovarian	NN	O	O
families	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
determined	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
this	NN	O	O
mutation	NN	O	O
in	NN	O	O
858	NN	O	O
Ashkenazim	NN	O	O
seeking	NN	O	O
genetic	NN	O	O
testing	NN	O	O
for	NN	O	O
conditions	NN	O	O
unrelated	NN	O	O
to	NN	O	O
cancer	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
in	NN	O	O
815	NN	O	O
reference	NN	O	O
individuals	NN	O	O
not	NN	O	O
selected	NN	O	O
for	NN	O	O
ethnic	NN	O	O
origin	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
one	NN	O	O
in	NN	O	O
a	NN	O	O
hundred	NN	O	O
women	NN	O	O
of	NN	O	O
Ashkenazi	NN	O	O
descent	NN	O	O
may	NN	O	O
be	NN	O	O
at	NN	O	O
especially	NN	O	O
high	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
/	NN	O	I-Disease
or	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Huntingtin	NN	O	O
appears	NN	O	O
to	NN	O	O
particularly	NN	O	O
associate	NN	O	O
with	NN	O	O
microtubules	NN	O	O
,	NN	O	O
although	NN	O	O
some	NN	O	O
is	NN	O	O
also	NN	O	O
associated	NN	O	O
with	NN	O	O
synaptic	NN	O	O
vesicles	NN	O	O
.	NN	O	O

ADCA	NN	O	B-Disease
type	NN	O	I-Disease
I	NN	O	I-Disease
patients	NN	O	O
from	NN	O	O
families	NN	O	O
segregating	NN	O	O
SCA3	NN	O	B-Disease
share	NN	O	O
clinical	NN	O	O
features	NN	O	O
in	NN	O	O
common	NN	O	O
with	NN	O	O
those	NN	O	O
with	NN	O	O
Machado	NN	O	B-Disease
-	NN	O	I-Disease
Joseph	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
MJD	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
the	NN	O	O
gene	NN	O	O
of	NN	O	O
which	NN	O	O
maps	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
region	NN	O	O
.	NN	O	O

Pelizaeus	NN	O	B-Disease
-	NN	O	I-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
rare	NN	O	B-Disease
,	NN	O	I-Disease
sex	NN	O	I-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
recessive	NN	O	I-Disease
,	NN	O	I-Disease
dysmyelinating	NN	O	I-Disease
disease	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
central	NN	O	I-Disease
nervous	NN	O	I-Disease
system	NN	O	I-Disease
that	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
myelin	NN	O	O
proteolipid	NN	O	O
protein	NN	O	O
(	NN	O	O
PLP	NN	O	O
)	NN	O	O
gene	NN	O	O
.	NN	O	O

Only	NN	O	O
25	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
studied	NN	O	O
with	NN	O	O
Pelizaeus	NN	O	B-Disease
-	NN	O	I-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
have	NN	O	O
exonic	NN	O	O
mutations	NN	O	O
in	NN	O	O
this	NN	O	O
gene	NN	O	O
,	NN	O	O
the	NN	O	O
underlying	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
in	NN	O	O
the	NN	O	O
remaining	NN	O	O
patients	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

Besides	NN	O	O
the	NN	O	O
classic	NN	O	O
WAS	NN	O	B-Disease
phenotype	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
congenital	NN	O	B-Disease
X	NN	O	I-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
thrombocytopenia	NN	O	I-Disease
(	NN	O	O
XLT	NN	O	B-Disease
)	NN	O	O
who	NN	O	O
have	NN	O	O
small	NN	O	O
platelets	NN	O	O
but	NN	O	O
only	NN	O	O
transient	NN	O	O
eczema	NN	O	B-Disease
,	NN	O	O
if	NN	O	O
any	NN	O	O
,	NN	O	O
and	NN	O	O
minimal	NN	O	O
immune	NN	O	B-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

Myotonia	NN	O	B-Disease
levior	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
chloride	NN	O	B-Disease
channel	NN	O	I-Disease
disorder	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
group	NN	O	O
of	NN	O	O
dominant	NN	O	B-Disease
non	NN	O	I-Disease
-	NN	O	I-Disease
dystrophic	NN	O	I-Disease
myotonias	NN	O	I-Disease
,	NN	O	O
comprising	NN	O	O
disorders	NN	O	O
characterized	NN	O	O
by	NN	O	O
clinically	NN	O	O
similar	NN	O	O
forms	NN	O	O
of	NN	O	O
myogenic	NN	O	O
muscle	NN	O	O
stiffness	NN	O	O
,	NN	O	O
is	NN	O	O
genetically	NN	O	O
inhomogeneous	NN	O	O
.	NN	O	O

Dominant	NN	O	B-Disease
myotonia	NN	O	I-Disease
congenita	NN	O	I-Disease
(	NN	O	O
Thomsens	NN	O	B-Disease
disease	NN	O	I-Disease
)	NN	O	O
is	NN	O	O
linked	NN	O	O
to	NN	O	O
CLCN1	NN	O	O
,	NN	O	O
the	NN	O	O
gene	NN	O	O
encoding	NN	O	O
the	NN	O	O
major	NN	O	O
muscle	NN	O	O
chloride	NN	O	O
channel	NN	O	O
,	NN	O	O
localized	NN	O	O
on	NN	O	O
chromosome	NN	O	O
7q35	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
CLCN1	NN	O	O
Gln	NN	O	O
-	NN	O	O
552	NN	O	O
-	NN	O	O
Arg	NN	O	O
substitution	NN	O	O
for	NN	O	O
a	NN	O	O
family	NN	O	O
with	NN	O	O
dominant	NN	O	O
inheritance	NN	O	O
previously	NN	O	O
diagnosed	NN	O	O
to	NN	O	O
have	NN	O	O
myotonia	NN	O	B-Disease
levior	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
5	NN	O	O
kb	NN	O	O
DNA	NN	O	O
sequence	NN	O	O
deletion	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
its	NN	O	O
endpoints	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
and	NN	O	O
third	NN	O	O
introns	NN	O	O
.	NN	O	O

Characterisation	NN	O	O
of	NN	O	O
molecular	NN	O	O
defects	NN	O	O
in	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
amelogenesis	NN	O	I-Disease
imperfecta	NN	O	I-Disease
(	NN	O	O
AIH1	NN	O	O
)	NN	O	O
.	NN	O	O

Frequency	NN	O	O
of	NN	O	O
exon	NN	O	O
15	NN	O	O
missense	NN	O	O
mutation	NN	O	O
(	NN	O	O
442D	NN	O	O
:	NN	O	O
G	NN	O	O
)	NN	O	O
in	NN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
transfer	NN	O	O
protein	NN	O	O
gene	NN	O	O
in	NN	O	O
hyperalphalipoproteinemic	NN	O	B-Disease
Japanese	NN	O	O
subjects	NN	O	O
.	NN	O	O

0049	NN	O	O
in	NN	O	O
the	NN	O	O
Japanese	NN	O	O
general	NN	O	O
population	NN	O	O
.	NN	O	O

Among	NN	O	O
117	NN	O	O
Japanese	NN	O	O
hyperalphalipoproteinemic	NN	O	B-Disease
subjects	NN	O	O
(	NN	O	O
HDL	NN	O	O
-	NN	O	O
cholesterol	NN	O	O
;	NN	O	O
116	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
S	NN	O	O
.	NN	O	O
D	NN	O	O
.	NN	O	O
)	NN	O	O
without	NN	O	O
the	NN	O	O
intron	NN	O	O
14	NN	O	O
splice	NN	O	O
defect	NN	O	O
,	NN	O	O
three	NN	O	O
homozygotes	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
34	NN	O	O
heterozygotes	NN	O	O
(	NN	O	O
29	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
the	NN	O	O
442D	NN	O	O
G	NN	O	O
mutation	NN	O	O
.	NN	O	O

Mucopolysaccharidosis	NN	O	B-Disease
type	NN	O	I-Disease
IVA	NN	O	I-Disease
:	NN	O	O
common	NN	O	O
double	NN	O	O
deletion	NN	O	O
in	NN	O	O
the	NN	O	O
N	NN	O	O
-	NN	O	O
acetylgalactosamine	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
sulfatase	NN	O	O
gene	NN	O	O
(	NN	O	O
GALNS	NN	O	O
)	NN	O	O
.	NN	O	O

0	NN	O	O
kb	NN	O	O
in	NN	O	O
the	NN	O	O
GALNS	NN	O	O
gene	NN	O	O
,	NN	O	O
including	NN	O	O
some	NN	O	O
exons	NN	O	O
.	NN	O	O

0	NN	O	O
-	NN	O	O
kb	NN	O	O
deletion	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
deletion	NN	O	O
resulted	NN	O	O
from	NN	O	O
an	NN	O	O
Alu	NN	O	O
-	NN	O	O
Alu	NN	O	O
recombination	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
6	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
documentation	NN	O	O
of	NN	O	O
a	NN	O	O
common	NN	O	O
double	NN	O	O
deletion	NN	O	O
a	NN	O	O
gene	NN	O	O
that	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
member	NN	O	O
of	NN	O	O
a	NN	O	O
gene	NN	O	O
cluster	NN	O	O
.	NN	O	O

We	NN	O	O
analyzed	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
from	NN	O	O
one	NN	O	O
affected	NN	O	O
individual	NN	O	O
from	NN	O	O
each	NN	O	O
of	NN	O	O
24	NN	O	O
families	NN	O	O
with	NN	O	O
at	NN	O	O
least	NN	O	O
three	NN	O	O
cases	NN	O	O
of	NN	O	O
ovarian	NN	O	B-Disease
or	NN	O	I-Disease
breast	NN	O	I-Disease
cancer	NN	O	I-Disease
,	NN	O	O
using	NN	O	O
SSCP	NN	O	O
assays	NN	O	O
.	NN	O	O

Variant	NN	O	O
SSCP	NN	O	O
bands	NN	O	O
were	NN	O	O
subcloned	NN	O	O
and	NN	O	O
sequenced	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
two	NN	O	O
large	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
studies	NN	O	O
of	NN	O	O
over	NN	O	O
2	NN	O	O
,	NN	O	O
000	NN	O	O
African	NN	O	O
children	NN	O	O
,	NN	O	O
the	NN	O	O
common	NN	O	O
African	NN	O	O
form	NN	O	O
of	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
(	NN	O	O
G6PD	NN	O	B-Disease
A	NN	O	I-Disease
-	NN	O	I-Disease
)	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
46	NN	O	O
-	NN	O	O
58	NN	O	O
%	NN	O	O
reduction	NN	O	O
in	NN	O	O
risk	NN	O	O
of	NN	O	O
severe	NN	O	O
malaria	NN	O	B-Disease
for	NN	O	O
both	NN	O	O
female	NN	O	O
heterozygotes	NN	O	O
and	NN	O	O
male	NN	O	O
hemizygotes	NN	O	O
.	NN	O	O

A	NN	O	O
mathematical	NN	O	O
model	NN	O	O
incorporating	NN	O	O
the	NN	O	O
measured	NN	O	O
selective	NN	O	O
advantage	NN	O	O
against	NN	O	O
malaria	NN	O	B-Disease
suggests	NN	O	O
that	NN	O	O
a	NN	O	O
counterbalancing	NN	O	O
selective	NN	O	O
disadvantage	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
this	NN	O	O
enzyme	NN	O	B-Disease
deficiency	NN	O	I-Disease
,	NN	O	O
has	NN	O	O
retarded	NN	O	O
its	NN	O	O
rise	NN	O	O
in	NN	O	O
frequency	NN	O	O
in	NN	O	O
malaria	NN	O	B-Disease
-	NN	O	O
endemic	NN	O	O
regions	NN	O	O
.	NN	O	O

The	NN	O	O
PAX3	NN	O	O
/	NN	O	O
FKHR	NN	O	O
fusion	NN	O	O
gene	NN	O	O
,	NN	O	O
formed	NN	O	O
by	NN	O	O
a	NN	O	O
t	NN	O	O
(	NN	O	O
2	NN	O	O
;	NN	O	O
13	NN	O	O
)	NN	O	O
(	NN	O	O
q35	NN	O	O
;	NN	O	O
q14	NN	O	O
)	NN	O	O
in	NN	O	O
alveolar	NN	O	B-Disease
rhabdomyosarcoma	NN	O	I-Disease
,	NN	O	O
encodes	NN	O	O
a	NN	O	O
hybrid	NN	O	O
protein	NN	O	O
that	NN	O	O
contains	NN	O	O
both	NN	O	O
PAX3	NN	O	O
DNA	NN	O	O
binding	NN	O	O
domains	NN	O	O
,	NN	O	O
the	NN	O	O
paired	NN	O	O
box	NN	O	O
and	NN	O	O
homeodomain	NN	O	O
,	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
bisected	NN	O	O
DNA	NN	O	O
binding	NN	O	O
domain	NN	O	O
of	NN	O	O
FKHR	NN	O	O
,	NN	O	O
a	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
forkhead	NN	O	O
family	NN	O	O
of	NN	O	O
transcription	NN	O	O
factors	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
PAX3	NN	O	O
and	NN	O	O
PAX3	NN	O	O
/	NN	O	O
FKHR	NN	O	O
display	NN	O	O
similar	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
identical	NN	O	O
transactivation	NN	O	O
activities	NN	O	O
when	NN	O	O
tested	NN	O	O
with	NN	O	O
model	NN	O	O
Pax	NN	O	O
recognition	NN	O	O
sequences	NN	O	O
.	NN	O	O

The	NN	O	O
same	NN	O	O
mutation	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
one	NN	O	O
additional	NN	O	O
melanoma	NN	O	B-Disease
among	NN	O	O
28	NN	O	O
melanomas	NN	O	B-Disease
analyzed	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
we	NN	O	O
were	NN	O	O
able	NN	O	O
to	NN	O	O
amplify	NN	O	O
the	NN	O	O
remaining	NN	O	O
coding	NN	O	O
region	NN	O	O
by	NN	O	O
RT	NN	O	O
-	NN	O	O
PCR	NN	O	O
using	NN	O	O
lymphocyte	NN	O	O
RNA	NN	O	O
.	NN	O	O

PCR	NN	O	O
-	NN	O	O
amplified	NN	O	O
VLCAD	NN	O	O
cDNAs	NN	O	O
were	NN	O	O
sequenced	NN	O	O
in	NN	O	O
cultured	NN	O	O
fibroblasts	NN	O	O
from	NN	O	O
two	NN	O	O
VLCAD	NN	O	B-Disease
-	NN	O	I-Disease
deficient	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

In	NN	O	O
patient	NN	O	O
fibroblasts	NN	O	O
,	NN	O	O
raising	NN	O	O
VLCAD	NN	O	O
activity	NN	O	O
to	NN	O	O
approximately	NN	O	O
20	NN	O	O
%	NN	O	O
of	NN	O	O
normal	NN	O	O
control	NN	O	O
fibroblast	NN	O	O
activity	NN	O	O
raised	NN	O	O
palmitic	NN	O	O
acid	NN	O	O
beta	NN	O	O
-	NN	O	O
oxidation	NN	O	O
flux	NN	O	O
to	NN	O	O
the	NN	O	O
level	NN	O	O
found	NN	O	O
in	NN	O	O
control	NN	O	O
fibroblasts	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
offer	NN	O	O
important	NN	O	O
information	NN	O	O
for	NN	O	O
the	NN	O	O
rational	NN	O	O
design	NN	O	O
of	NN	O	O
future	NN	O	O
somatic	NN	O	O
gene	NN	O	O
therapy	NN	O	O
for	NN	O	O
VLCAD	NN	O	B-Disease
deficiency	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

MRI	NN	O	O
lesions	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
impaired	NN	O	O
psychometric	NN	O	O
performance	NN	O	O
,	NN	O	O
but	NN	O	O
MRI	NN	O	O
and	NN	O	O
molecular	NN	O	O
findings	NN	O	O
were	NN	O	O
only	NN	O	O
weakly	NN	O	O
related	NN	O	O
.	NN	O	O

Quantification	NN	O	O
of	NN	O	O
CTG	NN	O	O
repeat	NN	O	O
size	NN	O	O
may	NN	O	O
allow	NN	O	O
an	NN	O	O
early	NN	O	O
estimate	NN	O	O
on	NN	O	O
the	NN	O	O
probability	NN	O	O
of	NN	O	O
brain	NN	O	O
involvement	NN	O	O
in	NN	O	O
DM	NN	O	B-Disease
;	NN	O	O
cognitive	NN	O	B-Disease
dysfunction	NN	O	I-Disease
is	NN	O	O
associated	NN	O	O
with	NN	O	O
white	NN	O	B-Disease
matter	NN	O	I-Disease
lesions	NN	O	I-Disease
and	NN	O	O
cerebral	NN	O	B-Disease
atrophy	NN	O	I-Disease
later	NN	O	O
on	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
family	NN	O	O
of	NN	O	O
the	NN	O	O
propositus	NN	O	O
had	NN	O	O
a	NN	O	O
strong	NN	O	O
history	NN	O	O
of	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
there	NN	O	O
was	NN	O	O
an	NN	O	O
intrafamilial	NN	O	O
pathological	NN	O	O
expansion	NN	O	O
of	NN	O	O
the	NN	O	O
responsible	NN	O	O
CTG	NN	O	O
repeat	NN	O	O
between	NN	O	O
the	NN	O	O
mildly	NN	O	O
affected	NN	O	O
mother	NN	O	O
(	NN	O	O
160	NN	O	O
repeats	NN	O	O
;	NN	O	O
normal	NN	O	O
27	NN	O	O
repeats	NN	O	O
)	NN	O	O
and	NN	O	O
her	NN	O	O
more	NN	O	O
severely	NN	O	O
affected	NN	O	O
son	NN	O	O
(	NN	O	O
650	NN	O	O
repeats	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
his	NN	O	O
sister	NN	O	O
(	NN	O	O
650	NN	O	O
repeats	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
propositus	NN	O	O
was	NN	O	O
an	NN	O	O
isolated	NN	O	O
case	NN	O	O
of	NN	O	O
Duchenne	NN	O	B-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
with	NN	O	O
marked	NN	O	O
dystrophin	NN	O	B-Disease
deficiency	NN	O	I-Disease
in	NN	O	O
muscle	NN	O	O
biopsy	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
other	NN	O	O
interpretations	NN	O	O
are	NN	O	O
possible	NN	O	O
.	NN	O	O

Twelve	NN	O	O
percent	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
revertant	NN	O	O
fibers	NN	O	O
as	NN	O	O
observed	NN	O	O
by	NN	O	O
immunohistochemistry	NN	O	O
could	NN	O	O
be	NN	O	O
sufficient	NN	O	O
to	NN	O	O
ameliorate	NN	O	O
typical	NN	O	O
DMD	NN	O	B-Disease
clinical	NN	O	O
severity	NN	O	O
,	NN	O	O
or	NN	O	O
the	NN	O	O
patient	NN	O	O
may	NN	O	O
present	NN	O	O
a	NN	O	O
somatic	NN	O	O
mosaic	NN	O	O
.	NN	O	O

To	NN	O	O
this	NN	O	O
end	NN	O	O
,	NN	O	O
we	NN	O	O
performed	NN	O	O
a	NN	O	O
linkage	NN	O	O
study	NN	O	O
with	NN	O	O
59	NN	O	O
consecutively	NN	O	O
collected	NN	O	O
Dutch	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
families	NN	O	O
,	NN	O	O
including	NN	O	O
16	NN	O	O
with	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Neither	NN	O	O
Hdh	NN	O	O
nor	NN	O	O
the	NN	O	O
HD	NN	O	B-Disease
gene	NN	O	O
have	NN	O	O
typical	NN	O	O
TATA	NN	O	O
or	NN	O	O
CCAAT	NN	O	O
elements	NN	O	O
,	NN	O	O
but	NN	O	O
both	NN	O	O
show	NN	O	O
one	NN	O	O
putative	NN	O	O
AP2	NN	O	O
binding	NN	O	O
site	NN	O	O
and	NN	O	O
numerous	NN	O	O
potential	NN	O	O
Sp1	NN	O	O
binding	NN	O	O
sites	NN	O	O
.	NN	O	O

The	NN	O	O
protein	NN	O	O
deficient	NN	O	O
in	NN	O	O
Lowe	NN	O	B-Disease
syndrome	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
phosphatidylinositol	NN	O	O
-	NN	O	O
4	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
bisphosphate	NN	O	O
5	NN	O	O
-	NN	O	O
phosphatase	NN	O	O
.	NN	O	O

We	NN	O	O
engineered	NN	O	O
a	NN	O	O
construct	NN	O	O
of	NN	O	O
the	NN	O	O
OCRL	NN	O	O
cDNA	NN	O	O
that	NN	O	O
encodes	NN	O	O
amino	NN	O	O
acids	NN	O	O
homologous	NN	O	O
to	NN	O	O
the	NN	O	O
platelet	NN	O	O
5	NN	O	O
-	NN	O	O
phosphatase	NN	O	O
for	NN	O	O
expression	NN	O	O
in	NN	O	O
baculovirus	NN	O	O
-	NN	O	O
infected	NN	O	O
Sf9	NN	O	O
insect	NN	O	O
cells	NN	O	O
.	NN	O	O

Most	NN	O	O
important	NN	O	O
,	NN	O	O
the	NN	O	O
enzyme	NN	O	O
converts	NN	O	O
phosphatidylinositol	NN	O	O
4	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
bisphosphate	NN	O	O
to	NN	O	O
phosphatidylinositol	NN	O	O
4	NN	O	O
-	NN	O	O
phosphate	NN	O	O
.	NN	O	O

The	NN	O	O
striking	NN	O	O
linkage	NN	O	O
disequilibrium	NN	O	O
between	NN	O	O
specific	NN	O	O
alleles	NN	O	O
at	NN	O	O
the	NN	O	O
Alu	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
Alu	NN	O	O
(	NN	O	O
ins	NN	O	O
)	NN	O	O
and	NN	O	O
Alu	NN	O	O
(	NN	O	O
del	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
HinfI	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
HinfI	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
HinfI	NN	O	O
-	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
CTG	NN	O	O
repeat	NN	O	O
polymorphism	NN	O	O
seen	NN	O	O
in	NN	O	O
Caucasoid	NN	O	O
(	NN	O	O
Europeans	NN	O	O
and	NN	O	O
Canadians	NN	O	O
)	NN	O	O
populations	NN	O	O
was	NN	O	O
also	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
South	NN	O	O
African	NN	O	O
Negroid	NN	O	O
population	NN	O	O
.	NN	O	O

Numerous	NN	O	O
haplotypes	NN	O	O
,	NN	O	O
not	NN	O	O
previously	NN	O	O
described	NN	O	O
in	NN	O	O
Europeans	NN	O	O
,	NN	O	O
were	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
found	NN	O	O
.	NN	O	O

It	NN	O	O
thus	NN	O	O
seems	NN	O	O
likely	NN	O	O
that	NN	O	O
only	NN	O	O
a	NN	O	O
small	NN	O	O
number	NN	O	O
of	NN	O	O
these	NN	O	O
"	NN	O	O
African	NN	O	O
"	NN	O	O
chromosomes	NN	O	O
were	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
progenitors	NN	O	O
of	NN	O	O
all	NN	O	O
non	NN	O	O
-	NN	O	O
African	NN	O	O
peoples	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
provide	NN	O	O
support	NN	O	O
for	NN	O	O
the	NN	O	O
"	NN	O	O
out	NN	O	O
of	NN	O	O
Africa	NN	O	O
"	NN	O	O
model	NN	O	O
for	NN	O	O
the	NN	O	O
origin	NN	O	O
of	NN	O	O
modern	NN	O	O
humans	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
rare	NN	O	O
ancestral	NN	O	O
DM	NN	O	B-Disease
mutation	NN	O	O
event	NN	O	O
may	NN	O	O
have	NN	O	O
occurred	NN	O	O
after	NN	O	O
the	NN	O	O
migration	NN	O	O
from	NN	O	O
Africa	NN	O	O
,	NN	O	O
hence	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
DM	NN	O	B-Disease
in	NN	O	O
sub	NN	O	O
-	NN	O	O
Saharan	NN	O	O
Negroid	NN	O	O
peoples	NN	O	O
.	NN	O	O
.	NN	O	O

A	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
family	NN	O	O
is	NN	O	O
described	NN	O	O
in	NN	O	O
which	NN	O	O
discordant	NN	O	O
DM	NN	O	B-Disease
phenotypes	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
children	NN	O	O
of	NN	O	O
two	NN	O	O
affected	NN	O	O
sisters	NN	O	O
with	NN	O	O
similar	NN	O	O
CTG	NN	O	O
expansion	NN	O	O
and	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
.	NN	O	O

The	NN	O	O
enzyme	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
catalyze	NN	O	O
the	NN	O	O
major	NN	O	O
part	NN	O	O
of	NN	O	O
mitochondrial	NN	O	O
palmitoylcoenzyme	NN	O	O
A	NN	O	O
dehydrogenation	NN	O	O
in	NN	O	O
liver	NN	O	O
,	NN	O	O
heart	NN	O	O
,	NN	O	O
skeletal	NN	O	O
muscle	NN	O	O
,	NN	O	O
and	NN	O	O
skin	NN	O	O
fibroblasts	NN	O	O
(	NN	O	O
89	NN	O	O
-	NN	O	O
97	NN	O	O
,	NN	O	O
86	NN	O	O
-	NN	O	O
99	NN	O	O
,	NN	O	O
96	NN	O	O
-	NN	O	O
99	NN	O	O
,	NN	O	O
and	NN	O	O
78	NN	O	O
-	NN	O	O
87	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Biological	NN	O	O
properties	NN	O	O
of	NN	O	O
C5	NN	O	B-Disease
-	NN	O	I-Disease
deficient	NN	O	I-Disease
human	NN	O	O
serum	NN	O	O
.	NN	O	O

The	NN	O	O
probands	NN	O	O
serum	NN	O	O
was	NN	O	O
incapable	NN	O	O
of	NN	O	O
mediating	NN	O	O
lysis	NN	O	O
of	NN	O	O
erythrocytes	NN	O	O
from	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
paroxysmal	NN	O	B-Disease
nocturnal	NN	O	I-Disease
hemoglobinuria	NN	O	I-Disease
in	NN	O	O
both	NN	O	O
the	NN	O	O
sucrose	NN	O	O
hemolysia	NN	O	O
and	NN	O	O
acid	NN	O	O
hemolysis	NN	O	O
tests	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
lacked	NN	O	O
bactericidal	NN	O	O
activity	NN	O	O
against	NN	O	O
sensitized	NN	O	O
or	NN	O	O
unsensitized	NN	O	O
Salmonella	NN	O	O
typhi	NN	O	O
.	NN	O	O

Cells	NN	O	O
from	NN	O	O
many	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
are	NN	O	O
deficient	NN	O	O
in	NN	O	O
the	NN	O	O
import	NN	O	O
of	NN	O	O
PTS1	NN	O	O
-	NN	O	O
containing	NN	O	O
proteins	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
causes	NN	O	O
of	NN	O	O
the	NN	O	O
protein	NN	O	O
-	NN	O	O
import	NN	O	O
defect	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
are	NN	O	O
unknown	NN	O	O
.	NN	O	O

Antibodies	NN	O	O
to	NN	O	O
the	NN	O	O
human	NN	O	O
PTS1R	NN	O	O
recognize	NN	O	O
this	NN	O	O
protein	NN	O	O
in	NN	O	O
human	NN	O	O
,	NN	O	O
monkey	NN	O	O
,	NN	O	O
rat	NN	O	O
,	NN	O	O
and	NN	O	O
hamster	NN	O	O
cells	NN	O	O
.	NN	O	O

Spectrum	NN	O	O
of	NN	O	O
germline	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
RB1	NN	O	O
gene	NN	O	O
:	NN	O	O
a	NN	O	O
study	NN	O	O
of	NN	O	O
232	NN	O	O
patients	NN	O	O
with	NN	O	O
hereditary	NN	O	B-Disease
and	NN	O	I-Disease
non	NN	O	I-Disease
hereditary	NN	O	I-Disease
retinoblastoma	NN	O	I-Disease
.	NN	O	O

Germline	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
RB1	NN	O	O
gene	NN	O	O
confer	NN	O	O
hereditary	NN	O	O
predisposition	NN	O	O
to	NN	O	O
retinoblastoma	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
range	NN	O	O
of	NN	O	O
frequency	NN	O	O
of	NN	O	O
detection	NN	O	O
of	NN	O	O
germline	NN	O	O
mutations	NN	O	O
is	NN	O	O
about	NN	O	O
20	NN	O	O
%	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
other	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
inactivation	NN	O	O
of	NN	O	O
RB1	NN	O	O
should	NN	O	O
be	NN	O	O
involved	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
the	NN	O	O
PAX6	NN	O	O
gene	NN	O	O
on	NN	O	O
the	NN	O	O
rearranged	NN	O	O
chromosome	NN	O	O
11	NN	O	O
is	NN	O	O
in	NN	O	O
an	NN	O	O
inappropriate	NN	O	O
chromatin	NN	O	O
environment	NN	O	O
for	NN	O	O
normal	NN	O	O
expression	NN	O	O
and	NN	O	O
therefore	NN	O	O
that	NN	O	O
a	NN	O	O
position	NN	O	O
effect	NN	O	O
is	NN	O	O
the	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
of	NN	O	O
disease	NN	O	O
in	NN	O	O
these	NN	O	O
families	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
BRCA1	NN	O	O
gene	NN	O	O
on	NN	O	O
chromosome	NN	O	O
17q21	NN	O	O
is	NN	O	O
responsible	NN	O	O
for	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
dominant	NN	O	I-Disease
syndrome	NN	O	I-Disease
of	NN	O	O
increased	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
but	NN	O	O
no	NN	O	O
somatic	NN	O	O
mutations	NN	O	O
in	NN	O	O
tumours	NN	O	B-Disease
have	NN	O	O
yet	NN	O	O
been	NN	O	O
described	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
support	NN	O	O
a	NN	O	O
tumour	NN	O	B-Disease
suppressor	NN	O	O
mechanism	NN	O	O
for	NN	O	O
BRCA1	NN	O	O
;	NN	O	O
somatic	NN	O	O
mutations	NN	O	O
and	NN	O	O
LOH	NN	O	O
may	NN	O	O
result	NN	O	O
in	NN	O	O
inactivation	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
in	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
small	NN	O	O
number	NN	O	O
of	NN	O	O
ovarian	NN	O	B-Disease
cancers	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

BRCA1	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
are	NN	O	O
markedly	NN	O	O
decreased	NN	O	O
during	NN	O	O
the	NN	O	O
transition	NN	O	O
from	NN	O	O
carcinoma	NN	O	B-Disease
in	NN	O	I-Disease
situ	NN	O	I-Disease
to	NN	O	O
invasive	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
BRCA1	NN	O	O
may	NN	O	O
normally	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
negative	NN	O	O
regulator	NN	O	O
of	NN	O	O
mammary	NN	O	O
epithelial	NN	O	O
cell	NN	O	O
growth	NN	O	O
whose	NN	O	O
function	NN	O	O
is	NN	O	O
compromised	NN	O	O
in	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
either	NN	O	O
by	NN	O	O
direct	NN	O	O
mutation	NN	O	O
or	NN	O	O
alterations	NN	O	O
in	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O
.	NN	O	O

Five	NN	O	O
of	NN	O	O
nine	NN	O	O
siblings	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
,	NN	O	O
comprising	NN	O	O
two	NN	O	O
cerebral	NN	O	B-Disease
ALD	NN	O	I-Disease
,	NN	O	O
one	NN	O	O
adrenomyeloneuropathy	NN	O	B-Disease
,	NN	O	O
one	NN	O	O
Addison	NN	O	B-Disease
only	NN	O	I-Disease
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
symptomatic	NN	O	O
mother	NN	O	O
(	NN	O	O
all	NN	O	O
accumulating	NN	O	O
very	NN	O	O
long	NN	O	O
chain	NN	O	O
fatty	NN	O	O
acids	NN	O	O
)	NN	O	O
carried	NN	O	O
this	NN	O	O
mutation	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
unaffected	NN	O	O
persons	NN	O	O
,	NN	O	O
in	NN	O	O
five	NN	O	O
unrelated	NN	O	O
ALD	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
twenty	NN	O	O
controls	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
this	NN	O	O
missense	NN	O	O
mutation	NN	O	O
generated	NN	O	O
the	NN	O	O
disease	NN	O	O
per	NN	O	O
se	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
metabolic	NN	O	O
defect	NN	O	O
;	NN	O	O
the	NN	O	O
different	NN	O	O
phenotypes	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
must	NN	O	O
have	NN	O	O
originated	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
additional	NN	O	O
pathogenetic	NN	O	O
factors	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
mutation	NN	O	O
of	NN	O	O
the	NN	O	O
initiation	NN	O	O
codon	NN	O	O
would	NN	O	O
cause	NN	O	O
the	NN	O	O
failure	NN	O	O
of	NN	O	O
ND	NN	O	B-Disease
gene	NN	O	O
expression	NN	O	O
or	NN	O	O
a	NN	O	O
defect	NN	O	O
in	NN	O	O
translation	NN	O	O
thereby	NN	O	O
truncating	NN	O	O
the	NN	O	O
amino	NN	O	O
terminus	NN	O	O
of	NN	O	O
ND	NN	O	B-Disease
protein	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
rarity	NN	O	O
and	NN	O	O
marked	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
ND	NN	O	B-Disease
gene	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
apparently	NN	O	O
unrelated	NN	O	O
Japanese	NN	O	O
families	NN	O	O
who	NN	O	O
have	NN	O	O
lived	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
area	NN	O	O
for	NN	O	O
over	NN	O	O
two	NN	O	O
centuries	NN	O	O
presumably	NN	O	O
share	NN	O	O
the	NN	O	O
origin	NN	O	O
of	NN	O	O
the	NN	O	O
mutation	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
same	NN	O	O
allele	NN	O	O
for	NN	O	O
D14S280	NN	O	O
segregates	NN	O	O
with	NN	O	O
the	NN	O	O
disease	NN	O	O
locus	NN	O	O
in	NN	O	O
the	NN	O	O
three	NN	O	O
kindreds	NN	O	O
.	NN	O	O

The	NN	O	O
breast	NN	O	B-Disease
-	NN	O	I-Disease
ovary	NN	O	I-Disease
cancer	NN	O	I-Disease
-	NN	O	I-Disease
family	NN	O	I-Disease
syndrome	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
dominant	NN	O	O
predisposition	NN	O	O
to	NN	O	O
cancer	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
breast	NN	O	I-Disease
and	NN	O	I-Disease
ovaries	NN	O	I-Disease
which	NN	O	O
has	NN	O	O
been	NN	O	O
mapped	NN	O	O
to	NN	O	O
chromosome	NN	O	O
region	NN	O	O
17q12	NN	O	O
-	NN	O	O
q21	NN	O	O
.	NN	O	O

This	NN	O	O
enzyme	NN	O	O
catalyses	NN	O	O
the	NN	O	O
first	NN	O	O
step	NN	O	O
of	NN	O	O
metabolism	NN	O	O
of	NN	O	O
dietary	NN	O	O
fructose	NN	O	O
,	NN	O	O
conversion	NN	O	O
of	NN	O	O
fructose	NN	O	O
to	NN	O	O
fructose	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
phosphate	NN	O	O
.	NN	O	O

Neither	NN	O	O
mutation	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
a	NN	O	O
sample	NN	O	O
of	NN	O	O
52	NN	O	O
unrelated	NN	O	O
control	NN	O	O
individuals	NN	O	O
.	NN	O	O

An	NN	O	O
additional	NN	O	O
conservative	NN	O	O
amino	NN	O	O
acid	NN	O	O
change	NN	O	O
(	NN	O	O
Val49IIe	NN	O	O
)	NN	O	O
was	NN	O	O
present	NN	O	O
on	NN	O	O
the	NN	O	O
KHK	NN	O	O
allele	NN	O	O
bearing	NN	O	O
Ala43Thr	NN	O	O

This	NN	O	O
complex	NN	O	O
allele	NN	O	O
is	NN	O	O
presumed	NN	O	O
to	NN	O	O
have	NN	O	O
formed	NN	O	O
by	NN	O	O
recombination	NN	O	O
(	NN	O	O
crossover	NN	O	O
,	NN	O	O
fusion	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
structural	NN	O	O
gene	NN	O	O
with	NN	O	O
the	NN	O	O
pseudogene	NN	O	O
,	NN	O	O
which	NN	O	O
contains	NN	O	O
the	NN	O	O
mutated	NN	O	O
sequences	NN	O	O
.	NN	O	O

Both	NN	O	O
parents	NN	O	O
were	NN	O	O
carriers	NN	O	O
of	NN	O	O
the	NN	O	O
recombination	NN	O	O
.	NN	O	O

A	NN	O	O
previous	NN	O	O
conceptus	NN	O	O
in	NN	O	O
this	NN	O	O
family	NN	O	O
was	NN	O	O
stillborn	NN	O	B-Disease
at	NN	O	O
36	NN	O	O
weeks	NN	O	O
,	NN	O	O
with	NN	O	O
features	NN	O	O
of	NN	O	O
severe	NN	O	O
type	NN	O	B-Disease
II	NN	O	I-Disease
GD	NN	O	I-Disease
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Another	NN	O	O
mutation	NN	O	O
,	NN	O	O
PD	NN	O	O
,	NN	O	O
leads	NN	O	O
to	NN	O	O
the	NN	O	O
deficiency	NN	O	O
of	NN	O	O
the	NN	O	O
enzyme	NN	O	O
in	NN	O	O
vitro	NN	O	O
(	NN	O	O
pseudodeficiency	NN	O	O
)	NN	O	O
without	NN	O	O
any	NN	O	O
known	NN	O	O
clinical	NN	O	O
effect	NN	O	O
.	NN	O	O

In	NN	O	O
Israel	NN	O	O
,	NN	O	O
late	NN	O	O
infantile	NN	O	O
MLD	NN	O	B-Disease
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
very	NN	O	O
frequent	NN	O	O
in	NN	O	O
a	NN	O	O
small	NN	O	O
Jewish	NN	O	O
isolate	NN	O	O
,	NN	O	O
the	NN	O	O
Habbanite	NN	O	O
Jews	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
75	NN	O	O
live	NN	O	O
births	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mutation	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
DNA	NN	O	O
from	NN	O	O
either	NN	O	O
of	NN	O	O
the	NN	O	O
clinically	NN	O	O
unaffected	NN	O	O
parents	NN	O	O
of	NN	O	O
the	NN	O	O
proband	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
point	NN	O	O
mutations	NN	O	O
which	NN	O	O
result	NN	O	O
in	NN	O	O
single	NN	O	O
amino	NN	O	O
acid	NN	O	O
substitutions	NN	O	O
can	NN	O	O
produce	NN	O	O
Kniest	NN	O	B-Disease
dysplasia	NN	O	I-Disease
and	NN	O	O
further	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
alteration	NN	O	O
of	NN	O	O
a	NN	O	O
domain	NN	O	O
,	NN	O	O
which	NN	O	O
includes	NN	O	O
the	NN	O	O
region	NN	O	O
encoded	NN	O	O
by	NN	O	O
exon	NN	O	O
12	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
type	NN	O	O
II	NN	O	O
collagen	NN	O	O
protein	NN	O	O
leads	NN	O	O
to	NN	O	O
this	NN	O	O
disorder	NN	O	O
.	NN	O	O
.	NN	O	O

Mutations	NN	O	O
in	NN	O	O
the	NN	O	O
BRCA1	NN	O	O
gene	NN	O	O
in	NN	O	O
families	NN	O	O
with	NN	O	O
early	NN	O	O
-	NN	O	O
onset	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
analysed	NN	O	O
50	NN	O	O
probands	NN	O	O
with	NN	O	O
a	NN	O	O
family	NN	O	O
history	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
/	NN	O	I-Disease
or	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
for	NN	O	O
germline	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
coding	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
BRCA1	NN	O	O
candidate	NN	O	O
gene	NN	O	O
,	NN	O	O
using	NN	O	O
single	NN	O	O
-	NN	O	O
strand	NN	O	O
conformation	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
SSCP	NN	O	O
)	NN	O	O
analysis	NN	O	O
on	NN	O	O
PCR	NN	O	O
-	NN	O	O
amplified	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
two	NN	O	O
missense	NN	O	O
mutations	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
which	NN	O	O
changes	NN	O	O
the	NN	O	O
final	NN	O	O
cysteine	NN	O	O
of	NN	O	O
the	NN	O	O
BRCA1	NN	O	O
zinc	NN	O	O
finger	NN	O	O
motif	NN	O	O
to	NN	O	O
glycine	NN	O	O
.	NN	O	O

The	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
mutations	NN	O	O
,	NN	O	O
coupled	NN	O	O
with	NN	O	O
the	NN	O	O
large	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
,	NN	O	O
indicates	NN	O	O
that	NN	O	O
clinical	NN	O	O
application	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
mutation	NN	O	O
testing	NN	O	O
will	NN	O	O
be	NN	O	O
technically	NN	O	O
challenging	NN	O	O
.	NN	O	O
.	NN	O	O

We	NN	O	O
provide	NN	O	O
genetic	NN	O	O
evidence	NN	O	O
supporting	NN	O	O
the	NN	O	O
identity	NN	O	O
of	NN	O	O
the	NN	O	O
candidate	NN	O	O
gene	NN	O	O
for	NN	O	O
BRCA1	NN	O	O
through	NN	O	O
the	NN	O	O
characterization	NN	O	O
of	NN	O	O
germline	NN	O	O
mutations	NN	O	O
in	NN	O	O
63	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
patients	NN	O	O
and	NN	O	O
10	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
patients	NN	O	O
in	NN	O	O
ten	NN	O	O
families	NN	O	O
with	NN	O	O
cancer	NN	O	B-Disease
linked	NN	O	O
to	NN	O	O
chromosome	NN	O	O
17q21	NN	O	O
.	NN	O	O

In	NN	O	O
clones	NN	O	O
and	NN	O	O
subclones	NN	O	O
derived	NN	O	O
serially	NN	O	O
from	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
cell	NN	O	O
lines	NN	O	O
(	NN	O	O
2774	NN	O	O
;	NN	O	O
serous	NN	O	B-Disease
cystadenocarcinoma	NN	O	I-Disease
)	NN	O	O
,	NN	O	O
a	NN	O	O
very	NN	O	O
high	NN	O	O
proportion	NN	O	O
of	NN	O	O
microsatellites	NN	O	O
distributed	NN	O	O
in	NN	O	O
many	NN	O	O
different	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
genome	NN	O	O
change	NN	O	O
their	NN	O	O
size	NN	O	O
in	NN	O	O
a	NN	O	O
mercurial	NN	O	O
fashion	NN	O	O
.	NN	O	O

BRCA1	NN	O	O
mutations	NN	O	O
in	NN	O	O
primary	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
carcinomas	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
have	NN	O	O
constructed	NN	O	O
a	NN	O	O
physical	NN	O	O
map	NN	O	O
of	NN	O	O
a	NN	O	O
4	NN	O	O
cM	NN	O	O
region	NN	O	O
on	NN	O	O
chromosome	NN	O	O
17q12	NN	O	O
-	NN	O	O
21	NN	O	O
that	NN	O	O
contains	NN	O	O
the	NN	O	O
hereditary	NN	O	B-Disease
breast	NN	O	I-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
gene	NN	O	O
BRCA1	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
localized	NN	O	O
more	NN	O	O
than	NN	O	O
20	NN	O	O
genes	NN	O	O
on	NN	O	O
this	NN	O	O
map	NN	O	O
,	NN	O	O
ten	NN	O	O
of	NN	O	O
which	NN	O	O
had	NN	O	O
not	NN	O	O
been	NN	O	O
mapped	NN	O	O
to	NN	O	O
the	NN	O	O
region	NN	O	O
previously	NN	O	O
,	NN	O	O
and	NN	O	O
have	NN	O	O
isolated	NN	O	O
30	NN	O	O
cDNA	NN	O	O
clones	NN	O	O
representing	NN	O	O
partial	NN	O	O
sequences	NN	O	O
of	NN	O	O
as	NN	O	O
yet	NN	O	O
unidentified	NN	O	O
genes	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
recently	NN	O	O
identified	NN	O	O
by	NN	O	O
positional	NN	O	O
cloning	NN	O	O
the	NN	O	O
gene	NN	O	O
responsible	NN	O	O
for	NN	O	O
ALD	NN	O	B-Disease
,	NN	O	O
located	NN	O	O
in	NN	O	O
Xq28	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
reported	NN	O	O
the	NN	O	O
cloning	NN	O	O
of	NN	O	O
Hdh	NN	O	O
,	NN	O	O
the	NN	O	O
murine	NN	O	O
homologue	NN	O	O
of	NN	O	O
IT15	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
using	NN	O	O
an	NN	O	O
interspecific	NN	O	O
backcross	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
mapped	NN	O	O
both	NN	O	O
Hdh	NN	O	O
and	NN	O	O
the	NN	O	O
mouse	NN	O	O
homologue	NN	O	O
of	NN	O	O
human	NN	O	O
alpha	NN	O	O
-	NN	O	O
adducin	NN	O	O
(	NN	O	O
Add1	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
membrane	NN	O	O
-	NN	O	O
associated	NN	O	O
cytoskeletal	NN	O	O
protein	NN	O	O
gene	NN	O	O
.	NN	O	O

Further	NN	O	O
mapping	NN	O	O
studies	NN	O	O
of	NN	O	O
humans	NN	O	O
,	NN	O	O
mice	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
mammalian	NN	O	O
species	NN	O	O
should	NN	O	O
reveal	NN	O	O
the	NN	O	O
nature	NN	O	O
of	NN	O	O
the	NN	O	O
rearrangements	NN	O	O
affecting	NN	O	O
this	NN	O	O
chromosomal	NN	O	O
segment	NN	O	O
during	NN	O	O
mammalian	NN	O	O
evolution	NN	O	O
.	NN	O	O
.	NN	O	O

Two	NN	O	O
other	NN	O	O
mutations	NN	O	O
were	NN	O	O
identified	NN	O	O
by	NN	O	O
DNA	NN	O	O
sequencing	NN	O	O
or	NN	O	O
primer	NN	O	O
-	NN	O	O
mediated	NN	O	O
restriction	NN	O	O
map	NN	O	O
modification	NN	O	O
of	NN	O	O
PCR	NN	O	O
products	NN	O	O
a	NN	O	O
novel	NN	O	O
intron	NN	O	O
14	NN	O	O
splice	NN	O	O
donor	NN	O	O
site	NN	O	O
mutation	NN	O	O
caused	NN	O	O
by	NN	O	O
a	NN	O	O
T	NN	O	O
insertion	NN	O	O
at	NN	O	O
position	NN	O	O
+	NN	O	O
3	NN	O	O
from	NN	O	O
the	NN	O	O
exon14	NN	O	O
/	NN	O	O
intron14	NN	O	O
boundary	NN	O	O
(	NN	O	O
Int14	NN	O	O
T	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
missense	NN	O	O
mutation	NN	O	O
(	NN	O	O
Asp442	NN	O	O
to	NN	O	O
Gly	NN	O	O
)	NN	O	O
within	NN	O	O
exon	NN	O	O
15	NN	O	O
(	NN	O	O
D442G	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
D442G	NN	O	O
and	NN	O	O
Int14	NN	O	O
A	NN	O	O
mutations	NN	O	O
were	NN	O	O
highly	NN	O	O
prevalent	NN	O	O
in	NN	O	O
subjects	NN	O	O
with	NN	O	O
HDL	NN	O	O
-	NN	O	O
C	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
with	NN	O	O
combined	NN	O	O
allele	NN	O	O
frequencies	NN	O	O
of	NN	O	O
9	NN	O	O
%	NN	O	O
,	NN	O	O
12	NN	O	O
%	NN	O	O
,	NN	O	O
21	NN	O	O
%	NN	O	O
and	NN	O	O
43	NN	O	O
%	NN	O	O
for	NN	O	O
HDL	NN	O	O
-	NN	O	O
C	NN	O	O
60	NN	O	O
-	NN	O	O
79	NN	O	O
,	NN	O	O
80	NN	O	O
-	NN	O	O
99	NN	O	O
,	NN	O	O
100	NN	O	O
-	NN	O	O
119	NN	O	O
,	NN	O	O
and	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
prevalences	NN	O	O
of	NN	O	O
the	NN	O	O
D442G	NN	O	O
and	NN	O	O
Int14	NN	O	O
A	NN	O	O
mutations	NN	O	O
were	NN	O	O
extremely	NN	O	O
high	NN	O	O
in	NN	O	O
a	NN	O	O
general	NN	O	O
sample	NN	O	O
of	NN	O	O
Japanese	NN	O	O
men	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
236	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
heterozygote	NN	O	O
frequencies	NN	O	O
of	NN	O	O
7	NN	O	O
%	NN	O	O
and	NN	O	O
2	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
47	NN	O	O
D442G	NN	O	O
heterozygotes	NN	O	O
,	NN	O	O
mean	NN	O	O
HDL	NN	O	O
-	NN	O	O
C	NN	O	O
levels	NN	O	O
were	NN	O	O
91	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
23	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
similar	NN	O	O
to	NN	O	O
the	NN	O	O
level	NN	O	O
in	NN	O	O
D442G	NN	O	O
homozygotes	NN	O	O
,	NN	O	O
and	NN	O	O
significantly	NN	O	O
greater	NN	O	O
than	NN	O	O
mean	NN	O	O
HDL	NN	O	O
-	NN	O	O
C	NN	O	O
levels	NN	O	O
in	NN	O	O
Int14	NN	O	O
A	NN	O	O
heterozygotes	NN	O	O
(	NN	O	O
69	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
D442G	NN	O	O
mutation	NN	O	O
acts	NN	O	O
differently	NN	O	O
to	NN	O	O
the	NN	O	O
null	NN	O	O
mutations	NN	O	O
with	NN	O	O
weaker	NN	O	O
effects	NN	O	O
on	NN	O	O
HDL	NN	O	O
in	NN	O	O
the	NN	O	O
homozygous	NN	O	O
state	NN	O	O
and	NN	O	O
stronger	NN	O	O
effects	NN	O	O
in	NN	O	O
the	NN	O	O
heterozygotes	NN	O	O
,	NN	O	O
suggesting	NN	O	O
dominant	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
partially	NN	O	O
defective	NN	O	O
allele	NN	O	O
.	NN	O	O

The	NN	O	O
sera	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
apparently	NN	O	O
more	NN	O	O
"	NN	O	O
anti	NN	O	O
-	NN	O	O
atherogenic	NN	O	O
"	NN	O	O
than	NN	O	O
those	NN	O	O
after	NN	O	O
CDCA	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
of	NN	O	O
7	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
disease	NN	O	O
was	NN	O	O
arrested	NN	O	O
,	NN	O	O
but	NN	O	O
dramatic	NN	O	O
effects	NN	O	O
on	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
,	NN	O	O
xanthoma	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
findings	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
found	NN	O	O
after	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O

In	NN	O	O
the	NN	O	O
remaining	NN	O	O
11	NN	O	O
Danish	NN	O	O
and	NN	O	O
Swedish	NN	O	O
families	NN	O	O
at	NN	O	O
least	NN	O	O
8	NN	O	O
causative	NN	O	O
mutations	NN	O	O
were	NN	O	O
found	NN	O	O
by	NN	O	O
PCR	NN	O	O
-	NN	O	O
SSCP	NN	O	O
analysis	NN	O	O
and	NN	O	O
direct	NN	O	O
sequencing	NN	O	O
.	NN	O	O

These	NN	O	O
percentages	NN	O	O
differ	NN	O	O
significantly	NN	O	O
from	NN	O	O
previous	NN	O	O
reports	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
25	NN	O	O
to	NN	O	O
28	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
developed	NN	O	O
AMN	NN	O	B-Disease
and	NN	O	O
53	NN	O	O
to	NN	O	O
57	NN	O	O
%	NN	O	O
CCALD	NN	O	B-Disease
or	NN	O	O
AdolCALD	NN	O	B-Disease
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
-	NN	O	O
-	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
the	NN	O	O
Netherlands	NN	O	O
-	NN	O	O
-	NN	O	O
AMN	NN	O	B-Disease
may	NN	O	O
be	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
phenotype	NN	O	O
of	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
ALD	NN	O	I-Disease
.	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
thus	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
ALD	NN	O	B-Disease
gene	NN	O	O
encodes	NN	O	O
an	NN	O	O
80	NN	O	O
kDa	NN	O	O
membrane	NN	O	O
protein	NN	O	O
.	NN	O	O
.	NN	O	O

X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
spastic	NN	O	I-Disease
paraplegia	NN	O	I-Disease
and	NN	O	O
Pelizaeus	NN	O	B-Disease
-	NN	O	I-Disease
Merzbacher	NN	O	I-Disease
disease	NN	O	I-Disease
are	NN	O	O
allelic	NN	O	B-Disease
disorders	NN	O	I-Disease
at	NN	O	O
the	NN	O	O
proteolipid	NN	O	O
protein	NN	O	O
locus	NN	O	O
.	NN	O	O

While	NN	O	O
narrowing	NN	O	O
the	NN	O	O
genetic	NN	O	O
interval	NN	O	O
containing	NN	O	O
SPG2	NN	O	O
in	NN	O	O
a	NN	O	O
large	NN	O	O
pedigree	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
PLP	NN	O	O
was	NN	O	O
the	NN	O	O
closest	NN	O	O
marker	NN	O	O
to	NN	O	O
the	NN	O	O
disease	NN	O	O
locus	NN	O	O
,	NN	O	O
implicating	NN	O	O
PLP	NN	O	O
as	NN	O	O
a	NN	O	O
possible	NN	O	O
candidate	NN	O	O
gene	NN	O	O
.	NN	O	O

It	NN	O	O
appears	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
that	NN	O	O
SPG2	NN	O	O
and	NN	O	O
PMD	NN	O	B-Disease
are	NN	O	O
allelic	NN	O	B-Disease
disorders	NN	O	I-Disease

Canavan	NN	O	B-Disease
disease	NN	O	I-Disease
is	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
leukodystrophy	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
the	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
aspartoacylase	NN	O	I-Disease
(	NN	O	O
ASPA	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
splice	NN	O	O
-	NN	O	O
site	NN	O	O
mutation	NN	O	O
would	NN	O	O
lead	NN	O	O
to	NN	O	O
skipping	NN	O	O
of	NN	O	O
exon	NN	O	O
3	NN	O	O
,	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
frameshift	NN	O	O
,	NN	O	O
and	NN	O	O
thus	NN	O	O
would	NN	O	O
produce	NN	O	O
aberrant	NN	O	O
ASPA	NN	O	O
.	NN	O	O

Intelligence	NN	O	O
quotient	NN	O	O
profile	NN	O	O
in	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
,	NN	O	O
intergenerational	NN	O	O
deficit	NN	O	O
,	NN	O	O
and	NN	O	O
correlation	NN	O	O
with	NN	O	O
CTG	NN	O	O
amplification	NN	O	O
.	NN	O	O

Scaled	NN	O	O
scores	NN	O	O
from	NN	O	O
the	NN	O	O
assessment	NN	O	O
were	NN	O	O
converted	NN	O	O
into	NN	O	O
an	NN	O	O
intelligence	NN	O	O
quotient	NN	O	O
(	NN	O	O
IQ	NN	O	O
)	NN	O	O
estimation	NN	O	O
on	NN	O	O
each	NN	O	O
person	NN	O	O
.	NN	O	O

Significant	NN	O	O
IQ	NN	O	O
differences	NN	O	O
were	NN	O	O
found	NN	O	O
between	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
all	NN	O	O
55	NN	O	O
DM	NN	O	B-Disease
subjects	NN	O	O
(	NN	O	O
mean	NN	O	O
90	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
SD	NN	O	O
16	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
31	NN	O	O
controls	NN	O	O
(	NN	O	O
102	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
SD	NN	O	O
9	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
sex	NN	O	O
differences	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
15	NN	O	O
affected	NN	O	O
parents	NN	O	O
(	NN	O	O
99	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
SD	NN	O	O
12	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
affected	NN	O	O
children	NN	O	O
(	NN	O	O
88	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
SD	NN	O	O
17	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
where	NN	O	O
significance	NN	O	O
was	NN	O	O
dependent	NN	O	O
on	NN	O	O
parental	NN	O	O
sex	NN	O	O
being	NN	O	O
female	NN	O	O
;	NN	O	O
and	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
15	NN	O	O
pairs	NN	O	O
of	NN	O	O
affected	NN	O	O
sibs	NN	O	O
(	NN	O	O
89	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
SD	NN	O	O
13	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
normal	NN	O	O
sibs	NN	O	O
(	NN	O	O
100	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
SD	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

Adenomatous	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
cytogenetic	NN	O	O
deletion	NN	O	O
of	NN	O	O
chromosome	NN	O	O
5	NN	O	O
resulting	NN	O	O
from	NN	O	O
a	NN	O	O
maternal	NN	O	O
intrachromosomal	NN	O	O
insertion	NN	O	O
.	NN	O	O

Familial	NN	O	B-Disease
male	NN	O	I-Disease
breast	NN	O	I-Disease
cancer	NN	O	I-Disease
is	NN	O	O
not	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
BRCA1	NN	O	O
locus	NN	O	O
on	NN	O	O
chromosome	NN	O	O
17q	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
additional	NN	O	O
pedigrees	NN	O	O
that	NN	O	O
include	NN	O	O
cases	NN	O	O
of	NN	O	O
male	NN	O	B-Disease
breast	NN	O	I-Disease
cancer	NN	O	I-Disease
may	NN	O	O
therefore	NN	O	O
facilitate	NN	O	O
the	NN	O	O
mapping	NN	O	O
and	NN	O	O
isolation	NN	O	O
of	NN	O	O
this	NN	O	O
gene	NN	O	O
.	NN	O	O

The	NN	O	O
EWS	NN	O	O
gene	NN	O	O
,	NN	O	O
involved	NN	O	O
in	NN	O	O
Ewing	NN	O	B-Disease
family	NN	O	I-Disease
of	NN	O	I-Disease
tumors	NN	O	I-Disease
,	NN	O	O
malignant	NN	O	B-Disease
melanoma	NN	O	I-Disease
of	NN	O	I-Disease
soft	NN	O	I-Disease
parts	NN	O	I-Disease
and	NN	O	O
desmoplastic	NN	O	B-Disease
small	NN	O	I-Disease
round	NN	O	I-Disease
cell	NN	O	I-Disease
tumors	NN	O	I-Disease
,	NN	O	O
codes	NN	O	O
for	NN	O	O
an	NN	O	O
RNA	NN	O	O
binding	NN	O	O
protein	NN	O	O
with	NN	O	O
novel	NN	O	O
regulatory	NN	O	O
domains	NN	O	O
.	NN	O	O

To	NN	O	O
better	NN	O	O
understand	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
EWS	NN	O	O
protein	NN	O	O
,	NN	O	O
we	NN	O	O
cloned	NN	O	O
the	NN	O	O
EWS	NN	O	O
cDNA	NN	O	O
.	NN	O	O

Both	NN	O	O
alternatively	NN	O	O
spliced	NN	O	O
transcripts	NN	O	O
,	NN	O	O
EWS	NN	O	O
and	NN	O	O
EWS	NN	O	O
-	NN	O	O
b	NN	O	O
,	NN	O	O
are	NN	O	O
expressed	NN	O	O
in	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
EWS	NN	O	O
-	NN	O	O
b	NN	O	O
protein	NN	O	O
binds	NN	O	O
to	NN	O	O
RNA	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
,	NN	O	O
specifically	NN	O	O
,	NN	O	O
to	NN	O	O
poly	NN	O	O
G	NN	O	O
and	NN	O	O
poly	NN	O	O
U	NN	O	O
.	NN	O	O

Thus	NN	O	O
the	NN	O	O
amino	NN	O	O
terminal	NN	O	O
domain	NN	O	O
of	NN	O	O
EWS	NN	O	O
(	NN	O	O
NTD	NN	O	O
-	NN	O	O
EWS	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
chromosome	NN	O	O
translocation	NN	O	O
may	NN	O	O
regulate	NN	O	O
the	NN	O	O
specificity	NN	O	O
of	NN	O	O
RNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
of	NN	O	O
EWS	NN	O	O
.	NN	O	O

Canavan	NN	O	B-Disease
disease	NN	O	I-Disease
:	NN	O	O
genomic	NN	O	O
organization	NN	O	O
and	NN	O	O
localization	NN	O	O
of	NN	O	O
human	NN	O	O
ASPA	NN	O	O
to	NN	O	O
17p13	NN	O	O
-	NN	O	O
ter	NN	O	O
and	NN	O	O
conservation	NN	O	O
of	NN	O	O
the	NN	O	O
ASPA	NN	O	O
gene	NN	O	O
during	NN	O	O
evolution	NN	O	O
.	NN	O	O

Human	NN	O	O
aspartoacylase	NN	O	O
is	NN	O	O
coded	NN	O	O
by	NN	O	O
six	NN	O	O
exons	NN	O	O
intervened	NN	O	O
by	NN	O	O
five	NN	O	O
introns	NN	O	O
.	NN	O	O

The	NN	O	O
exon	NN	O	O
/	NN	O	O
intron	NN	O	O
splice	NN	O	O
junction	NN	O	O
sites	NN	O	O
follow	NN	O	O
the	NN	O	O
gt	NN	O	O
/	NN	O	O
ag	NN	O	O
consensus	NN	O	O
sequence	NN	O	O
rule	NN	O	O
.	NN	O	O

Southern	NN	O	O
blot	NN	O	O
analysis	NN	O	O
of	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
from	NN	O	O
human	NN	O	O
/	NN	O	O
mouse	NN	O	O
somatic	NN	O	O
cell	NN	O	O
hybrid	NN	O	O
cell	NN	O	O
lines	NN	O	O
localized	NN	O	O
ASPA	NN	O	O
to	NN	O	O
human	NN	O	O
chromosome	NN	O	O
17	NN	O	O
.	NN	O	O

The	NN	O	O
specificity	NN	O	O
of	NN	O	O
cross	NN	O	O
-	NN	O	O
species	NN	O	O
hybridization	NN	O	O
of	NN	O	O
coding	NN	O	O
sequences	NN	O	O
suggests	NN	O	O
that	NN	O	O
aspartoacylase	NN	O	O
has	NN	O	O
been	NN	O	O
conserved	NN	O	O
during	NN	O	O
evolution	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
clinical	NN	O	O
status	NN	O	O
of	NN	O	O
patients	NN	O	O
cannot	NN	O	O
be	NN	O	O
unambiguously	NN	O	O
ascertained	NN	O	O
solely	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
CTG	NN	O	O
repeats	NN	O	O
.	NN	O	O

Beyond	NN	O	O
0	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
this	NN	O	O
analysis	NN	O	O
reveals	NN	O	O
a	NN	O	O
significant	NN	O	O
excess	NN	O	O
of	NN	O	O
transmitting	NN	O	O
grandfathers	NN	O	O
partially	NN	O	O
accounted	NN	O	O
for	NN	O	O
by	NN	O	O
increased	NN	O	O
fertility	NN	O	O
in	NN	O	O
affected	NN	O	O
males	NN	O	O

Metachromatic	NN	O	B-Disease
leukodystrophy	NN	O	I-Disease
(	NN	O	O
MLD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
lysosomal	NN	O	I-Disease
storage	NN	O	I-Disease
disorder	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
a	NN	O	O
deficiency	NN	O	B-Disease
of	NN	O	I-Disease
arylsulfatase	NN	O	I-Disease
A	NN	O	I-Disease
(	NN	O	O
ARSA	NN	O	O
;	NN	O	O
EC	NN	O	O
3	NN	O	O
.	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
8	NN	O	O
ARSA	NN	O	O
exons	NN	O	O
and	NN	O	O
adjacent	NN	O	O
intron	NN	O	O
boundaries	NN	O	O
from	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
late	NN	O	B-Disease
-	NN	O	I-Disease
infantile	NN	O	I-Disease
metachromatic	NN	O	I-Disease
leukodystrophy	NN	O	I-Disease
were	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	NN	O	O
PCR	NN	O	O
)	NN	O	O
amplified	NN	O	O
in	NN	O	O
seven	NN	O	O
discrete	NN	O	O
reactions	NN	O	O
.	NN	O	O

Two	NN	O	O
mutations	NN	O	O
involved	NN	O	O
C	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
T	NN	O	O
transitions	NN	O	O
in	NN	O	O
CGAarg	NN	O	O
codons	NN	O	O
in	NN	O	O
exons	NN	O	O
9	NN	O	O
and	NN	O	O
11	NN	O	O
.	NN	O	O

Two	NN	O	O
subjects	NN	O	O
shared	NN	O	O
a	NN	O	O
G	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
A	NN	O	O
transition	NN	O	O
at	NN	O	O
position	NN	O	O
+	NN	O	O
5	NN	O	O
of	NN	O	O
the	NN	O	O
donor	NN	O	O
splice	NN	O	O
site	NN	O	O
consensus	NN	O	O
sequence	NN	O	O
of	NN	O	O
intron	NN	O	O
10	NN	O	O
.	NN	O	O

Also	NN	O	O
in	NN	O	O
two	NN	O	O
subjects	NN	O	O
an	NN	O	O
A	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
T	NN	O	O
transversion	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
stopcodon	NN	O	O
of	NN	O	O
the	NN	O	O
PROS1	NN	O	O
gene	NN	O	O
;	NN	O	O
this	NN	O	O
transversion	NN	O	O
predicts	NN	O	O
a	NN	O	O
protein	NN	O	O
S	NN	O	O
molecule	NN	O	O
that	NN	O	O
is	NN	O	O
extended	NN	O	O
by	NN	O	O
14	NN	O	O
amino	NN	O	O
acids	NN	O	O
.	NN	O	O

In	NN	O	O
56	NN	O	O
of	NN	O	O
the	NN	O	O
95	NN	O	O
pairs	NN	O	O
,	NN	O	O
clinical	NN	O	O
data	NN	O	O
allowed	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
their	NN	O	O
anticipation	NN	O	O
status	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
intergenerational	NN	O	O
contractions	NN	O	O
of	NN	O	O
the	NN	O	O
CTG	NN	O	O
repeat	NN	O	O
in	NN	O	O
leukocyte	NN	O	O
DNA	NN	O	O
frequently	NN	O	O
accompanies	NN	O	O
apparent	NN	O	O
anticipation	NN	O	O
,	NN	O	O
especially	NN	O	O
when	NN	O	O
DM	NN	O	B-Disease
is	NN	O	O
maternally	NN	O	O
transmitted	NN	O	O
,	NN	O	O
and	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
paternal	NN	O	O
origin	NN	O	O
of	NN	O	O
the	NN	O	O
repeat	NN	O	O
and	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
the	NN	O	O
repeat	NN	O	O
contraction	NN	O	O
in	NN	O	O
a	NN	O	O
sibling	NN	O	O
increase	NN	O	O
the	NN	O	O
probability	NN	O	O
of	NN	O	O
the	NN	O	O
CTG	NN	O	O
repeat	NN	O	O
contraction	NN	O	O

Myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
caused	NN	O	O
by	NN	O	O
abnormal	NN	O	O
expansion	NN	O	O
of	NN	O	O
a	NN	O	O
polymorphic	NN	O	O
(	NN	O	O
CTG	NN	O	O
)	NN	O	O
n	NN	O	O
repeat	NN	O	O
,	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
DM	NN	O	B-Disease
protein	NN	O	O
kinase	NN	O	O
gene	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
male	NN	O	O
patients	NN	O	O
with	NN	O	O
large	NN	O	O
allele	NN	O	O
expansions	NN	O	O
in	NN	O	O
blood	NN	O	O
(	NN	O	O
>	NN	O	O
700	NN	O	O
CTGs	NN	O	O
)	NN	O	O
had	NN	O	O
similar	NN	O	O
or	NN	O	O
smaller	NN	O	O
repeats	NN	O	O
in	NN	O	O
sperm	NN	O	O
,	NN	O	O
when	NN	O	O
detectable	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
DM	NN	O	B-Disease
patients	NN	O	O
can	NN	O	O
be	NN	O	O
considered	NN	O	O
gonosomal	NN	O	O
mosaics	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O

Most	NN	O	O
remarkably	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
multiple	NN	O	O
cases	NN	O	O
where	NN	O	O
the	NN	O	O
length	NN	O	O
distributions	NN	O	O
of	NN	O	O
intermediate	NN	O	O
-	NN	O	O
or	NN	O	O
small	NN	O	O
-	NN	O	O
sized	NN	O	O
alleles	NN	O	O
in	NN	O	O
fathers	NN	O	O
sperm	NN	O	O
were	NN	O	O
significantly	NN	O	O
different	NN	O	O
from	NN	O	O
that	NN	O	O
in	NN	O	O
their	NN	O	O
offsprings	NN	O	O
blood	NN	O	O
.	NN	O	O

A	NN	O	O
model	NN	O	O
explaining	NN	O	O
mitotic	NN	O	O
instability	NN	O	O
and	NN	O	O
sex	NN	O	O
-	NN	O	O
dependent	NN	O	O
segregation	NN	O	O
phenomena	NN	O	O
in	NN	O	O
DM	NN	O	B-Disease
manifestation	NN	O	O
is	NN	O	O
discussed	NN	O	O

Germline	NN	O	O
mutation	NN	O	O
in	NN	O	O
APC	NN	O	O
at	NN	O	O
5q21	NN	O	O
-	NN	O	O
22	NN	O	O
results	NN	O	O
in	NN	O	O
the	NN	O	O
dominantly	NN	O	O
inherited	NN	O	O
syndrome	NN	O	O
adenomatous	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
(	NN	O	O
APC	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Somatic	NN	O	O
mutation	NN	O	O
in	NN	O	O
this	NN	O	O
gene	NN	O	O
is	NN	O	O
an	NN	O	O
early	NN	O	O
event	NN	O	O
in	NN	O	O
colorectal	NN	O	O
tumourigenesis	NN	O	O
.	NN	O	O

Both	NN	O	O
types	NN	O	O
of	NN	O	O
mutation	NN	O	O
are	NN	O	O
concentrated	NN	O	O
in	NN	O	O
the	NN	O	O
5	NN	O	O
half	NN	O	O
of	NN	O	O
exon	NN	O	O
15	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
majority	NN	O	O
(	NN	O	O
18	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
individuals	NN	O	O
with	NN	O	O
normal	NN	O	O
sized	NN	O	O
alleles	NN	O	O
represent	NN	O	O
misdiagnosis	NN	O	O
,	NN	O	O
sample	NN	O	O
mix	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
or	NN	O	O
clerical	NN	O	O
error	NN	O	O
.	NN	O	O

Frequent	NN	O	O
detection	NN	O	O
of	NN	O	O
codon	NN	O	O
877	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
androgen	NN	O	O
receptor	NN	O	O
gene	NN	O	O
in	NN	O	O
advanced	NN	O	B-Disease
prostate	NN	O	I-Disease
cancers	NN	O	I-Disease
.	NN	O	O

Patients	NN	O	O
excrete	NN	O	O
large	NN	O	O
amounts	NN	O	O
of	NN	O	O
homogentisic	NN	O	O
acid	NN	O	O
in	NN	O	O
their	NN	O	O
urine	NN	O	O
and	NN	O	O
a	NN	O	O
black	NN	O	O
ochronotic	NN	O	O
pigment	NN	O	O
is	NN	O	O
deposited	NN	O	O
in	NN	O	O
their	NN	O	O
cartilage	NN	O	O
and	NN	O	O
collagenous	NN	O	O
tissues	NN	O	O
.	NN	O	O

Considering	NN	O	O
conserved	NN	O	O
synteny	NN	O	O
,	NN	O	O
we	NN	O	O
were	NN	O	O
able	NN	O	O
to	NN	O	O
map	NN	O	O
the	NN	O	O
human	NN	O	O
gene	NN	O	O
to	NN	O	O
chromosome	NN	O	O
3q	NN	O	O
in	NN	O	O
six	NN	O	O
alkaptonuria	NN	O	B-Disease
pedigrees	NN	O	O
of	NN	O	O
Slovak	NN	O	O
origin	NN	O	O
.	NN	O	O
.	NN	O	O

Intestinal	NN	O	O
uptake	NN	O	O
of	NN	O	O
dietary	NN	O	O
glucose	NN	O	O
and	NN	O	O
galactose	NN	O	O
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
SGLT1	NN	O	O
Na	NN	O	O
+	NN	O	O
/	NN	O	O
glucose	NN	O	O
cotransporter	NN	O	O
of	NN	O	O
the	NN	O	O
brush	NN	O	O
border	NN	O	O
.	NN	O	O

Four	NN	O	O
novel	NN	O	O
PEPD	NN	O	O
alleles	NN	O	O
causing	NN	O	O
prolidase	NN	O	B-Disease
deficiency	NN	O	I-Disease
.	NN	O	O

Mutations	NN	O	O
at	NN	O	O
the	NN	O	O
PEPD	NN	O	O
locus	NN	O	O
cause	NN	O	O
prolidase	NN	O	B-Disease
deficiency	NN	O	I-Disease
(	NN	O	O
McKusick	NN	O	O
170100	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
rare	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
disorder	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
iminodipeptiduria	NN	O	B-Disease
,	NN	O	O
skin	NN	O	B-Disease
ulcers	NN	O	I-Disease
,	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
recurrent	NN	O	O
infections	NN	O	O
.	NN	O	O

Intronic	NN	O	O
sequences	NN	O	O
flanking	NN	O	O
exons	NN	O	O
5	NN	O	O
and	NN	O	O
7	NN	O	O
were	NN	O	O
identified	NN	O	O
using	NN	O	O
inverse	NN	O	O
PCR	NN	O	O
followed	NN	O	O
by	NN	O	O
direct	NN	O	O
sequencing	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
we	NN	O	O
attempt	NN	O	O
to	NN	O	O
begin	NN	O	O
the	NN	O	O
process	NN	O	O
of	NN	O	O
describing	NN	O	O
these	NN	O	O
alleles	NN	O	O
and	NN	O	O
cataloging	NN	O	O
their	NN	O	O
phenotypic	NN	O	O
expression	NN	O	O
.	NN	O	O
.	NN	O	O

SETTING	NN	O	O
University	NN	O	O
medical	NN	O	O
centers	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
mother	NN	O	O
presented	NN	O	O
at	NN	O	O
age	NN	O	O
63	NN	O	O
years	NN	O	O
with	NN	O	O
a	NN	O	O
profoundly	NN	O	O
abnormal	NN	O	O
electroretinogram	NN	O	O
(	NN	O	O
ERG	NN	O	O
)	NN	O	O
and	NN	O	O
adult	NN	O	O
-	NN	O	O
onset	NN	O	O
retinitis	NN	O	B-Disease
pigmentosa	NN	O	I-Disease
that	NN	O	O
progressed	NN	O	O
dramatically	NN	O	O
over	NN	O	O
12	NN	O	O
years	NN	O	O
,	NN	O	O
with	NN	O	O
marked	NN	O	O
loss	NN	O	O
of	NN	O	O
peripheral	NN	O	O
visual	NN	O	O
field	NN	O	O
.	NN	O	O

The	NN	O	O
son	NN	O	O
had	NN	O	O
onset	NN	O	O
of	NN	O	O
macular	NN	O	B-Disease
degeneration	NN	O	I-Disease
at	NN	O	O
age	NN	O	O
44	NN	O	O
years	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
autosomal	NN	O	B-Disease
recessive	NN	O	I-Disease
disease	NN	O	I-Disease
glucose	NN	O	I-Disease
/	NN	O	I-Disease
galactose	NN	O	I-Disease
malabsorption	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
underlying	NN	O	O
cause	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
missense	NN	O	O
mutation	NN	O	O
in	NN	O	O
SGLT1	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
Asp28	NN	O	O
-	NN	O	O
-	NN	O	O
>	NN	O	O
Asn	NN	O	O
change	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
vitro	NN	O	O
to	NN	O	O
eliminate	NN	O	O
SGLT1	NN	O	O
transport	NN	O	O
activity	NN	O	O
.	NN	O	O

Restriction	NN	O	O
of	NN	O	O
ocular	NN	O	O
fundus	NN	O	O
lesions	NN	O	O
to	NN	O	O
a	NN	O	O
specific	NN	O	O
subgroup	NN	O	O
of	NN	O	O
APC	NN	O	B-Disease
mutations	NN	O	O
in	NN	O	O
adenomatous	NN	O	B-Disease
polyposis	NN	O	I-Disease
coli	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

Ocular	NN	O	O
examination	NN	O	O
revealed	NN	O	O
that	NN	O	O
patients	NN	O	O
expressing	NN	O	O
CHRPE	NN	O	B-Disease
tend	NN	O	O
to	NN	O	O
cluster	NN	O	O
within	NN	O	O
specific	NN	O	O
families	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
wanted	NN	O	O
to	NN	O	O
determined	NN	O	O
whether	NN	O	O
there	NN	O	O
were	NN	O	O
similar	NN	O	O
ERG	NN	O	O
findings	NN	O	O
in	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
for	NN	O	O
DMD	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
mdx	NN	O	O
mouse	NN	O	O
.	NN	O	O

The	NN	O	O
dystrophin	NN	O	O
gene	NN	O	O
was	NN	O	O
analyzed	NN	O	O
by	NN	O	O
Southern	NN	O	O
blot	NN	O	O
hybridization	NN	O	O
.	NN	O	O

The	NN	O	O
ERGs	NN	O	O
of	NN	O	O
the	NN	O	O
mdx	NN	O	O
mice	NN	O	O
were	NN	O	O
normal	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
from	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
mice	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
.	NN	O	O

The	NN	O	O
ERG	NN	O	O
shows	NN	O	O
promise	NN	O	O
of	NN	O	O
becoming	NN	O	O
a	NN	O	O
noninvasive	NN	O	O
diagnostic	NN	O	O
tool	NN	O	O
for	NN	O	O
DMD	NN	O	B-Disease
and	NN	O	O
its	NN	O	O
milder	NN	O	O
allelic	NN	O	O
forms	NN	O	O
.	NN	O	O
.	NN	O	O

Association	NN	O	O
of	NN	O	O
the	NN	O	O
APC	NN	O	B-Disease
tumor	NN	O	I-Disease
suppressor	NN	O	O
protein	NN	O	O
with	NN	O	O
catenins	NN	O	O
.	NN	O	O

Differences	NN	O	O
between	NN	O	O
the	NN	O	O
methylation	NN	O	O
patterns	NN	O	O
of	NN	O	O
the	NN	O	O
region	NN	O	O
of	NN	O	O
chromosome	NN	O	O
15q11	NN	O	O
-	NN	O	O
13	NN	O	O
which	NN	O	O
hybridizes	NN	O	O
to	NN	O	O
the	NN	O	O
highly	NN	O	O
conserved	NN	O	O
DNA	NN	O	O
,	NN	O	O
DN34	NN	O	O
,	NN	O	O
in	NN	O	O
normal	NN	O	O
individuals	NN	O	O
and	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
AS	NN	O	B-Disease
and	NN	O	O
PWS	NN	O	B-Disease
have	NN	O	O
been	NN	O	O
described	NN	O	O
.	NN	O	O

In	NN	O	O
51	NN	O	O
families	NN	O	O
with	NN	O	O
Wilson	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
we	NN	O	O
have	NN	O	O
studied	NN	O	O
DNA	NN	O	O
haplotypes	NN	O	O
of	NN	O	O
dinucleotide	NN	O	O
repeat	NN	O	O
polymorphisms	NN	O	O
(	NN	O	O
CA	NN	O	O
repeats	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
13q14	NN	O	O
.	NN	O	O

3	NN	O	O
region	NN	O	O
,	NN	O	O
to	NN	O	O
examine	NN	O	O
these	NN	O	O
markers	NN	O	O
for	NN	O	O
association	NN	O	O
with	NN	O	O
the	NN	O	O
Wilson	NN	O	B-Disease
disease	NN	O	I-Disease
gene	NN	O	O
(	NN	O	O
WND	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

5	NN	O	O
Mb	NN	O	O
in	NN	O	O
length	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
metabolism	NN	O	O
of	NN	O	O
the	NN	O	O
HDL	NN	O	O
apolipoproteins	NN	O	O
(	NN	O	O
apo	NN	O	O
)	NN	O	O
apoA	NN	O	O
-	NN	O	O
I	NN	O	O
and	NN	O	O
apoA	NN	O	O
-	NN	O	O
II	NN	O	O
in	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
five	NN	O	O
patients	NN	O	O
with	NN	O	O
LCAT	NN	O	B-Disease
deficiency	NN	O	I-Disease
,	NN	O	O
one	NN	O	O
with	NN	O	O
classic	NN	O	B-Disease
LCAT	NN	O	I-Disease
deficiency	NN	O	I-Disease
and	NN	O	O
four	NN	O	O
with	NN	O	O
Fish	NN	O	B-Disease
-	NN	O	I-Disease
eye	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

08	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O

27	NN	O	O
d	NN	O	O
(	NN	O	O
controls	NN	O	O
4	NN	O	O
.	NN	O	O
74	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
65	NN	O	O
days	NN	O	O
)	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
residence	NN	O	O
time	NN	O	O
of	NN	O	O
apoA	NN	O	O
-	NN	O	O
II	NN	O	O
was	NN	O	O
even	NN	O	O
shorter	NN	O	O
at	NN	O	O
1	NN	O	O
.	NN	O	O

66	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O

Macular	NN	O	B-Disease
dystrophy	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
mutations	NN	O	O
at	NN	O	O
codon	NN	O	O
172	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
retinal	NN	O	B-Disease
degeneration	NN	O	I-Disease
slow	NN	O	O
gene	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
report	NN	O	O
,	NN	O	O
66	NN	O	O
hemochromatosis	NN	O	B-Disease
families	NN	O	O
yielding	NN	O	O
151	NN	O	O
hemochromatosis	NN	O	B-Disease
chromosomes	NN	O	O
and	NN	O	O
182	NN	O	O
normal	NN	O	O
chromosomes	NN	O	O
were	NN	O	O
RFLP	NN	O	O
-	NN	O	O
typed	NN	O	O
with	NN	O	O
a	NN	O	O
battery	NN	O	O
of	NN	O	O
probes	NN	O	O
,	NN	O	O
including	NN	O	O
two	NN	O	O
newly	NN	O	O
derived	NN	O	O
polymorphic	NN	O	O
markers	NN	O	O
from	NN	O	O
the	NN	O	O
6	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
support	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
HFE	NN	O	O
resides	NN	O	O
within	NN	O	O
the	NN	O	O
400	NN	O	O
-	NN	O	O
kb	NN	O	O
expanse	NN	O	O
of	NN	O	O
DNA	NN	O	O
between	NN	O	O
i97	NN	O	O
and	NN	O	O
HLA	NN	O	O
-	NN	O	O
F	NN	O	O
.	NN	O	O

Alternatively	NN	O	O
,	NN	O	O
the	NN	O	O
very	NN	O	O
tight	NN	O	O
association	NN	O	O
of	NN	O	O
HLA	NN	O	O
-	NN	O	O
A3	NN	O	O
and	NN	O	O
allele	NN	O	O
1	NN	O	O
of	NN	O	O
the	NN	O	O
6	NN	O	O
.	NN	O	O

The	NN	O	O
DNA	NN	O	O
sequence	NN	O	O
in	NN	O	O
the	NN	O	O
5	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
has	NN	O	O
features	NN	O	O
of	NN	O	O
a	NN	O	O
CpG	NN	O	O
-	NN	O	O
rich	NN	O	O
island	NN	O	O
and	NN	O	O
lacks	NN	O	O
canonical	NN	O	O
promoter	NN	O	O
elements	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
TATA	NN	O	O
and	NN	O	O
CCAAT	NN	O	O
consensus	NN	O	O
sequences	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
now	NN	O	O
tested	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
blind	NN	O	O
study	NN	O	O
,	NN	O	O
26	NN	O	O
American	NN	O	O
TSD	NN	O	B-Disease
carriers	NN	O	O
and	NN	O	O
28	NN	O	O
non	NN	O	O
-	NN	O	O
carriers	NN	O	O
who	NN	O	O
have	NN	O	O
British	NN	O	O
ancestry	NN	O	O
for	NN	O	O
the	NN	O	O
intron	NN	O	O
9	NN	O	O
splice	NN	O	O
site	NN	O	O
mutation	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
remaining	NN	O	O
two	NN	O	O
-	NN	O	O
thirds	NN	O	O
of	NN	O	O
the	NN	O	O
tumors	NN	O	B-Disease
only	NN	O	O
one	NN	O	O
mutation	NN	O	O
was	NN	O	O
found	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
loss	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
heterozygosity	NN	O	O
theory	NN	O	O
of	NN	O	O
tumorigenesis	NN	O	O
.	NN	O	O

The	NN	O	O
PAX6	NN	O	O
gene	NN	O	O
was	NN	O	O
isolated	NN	O	O
as	NN	O	O
a	NN	O	O
candidate	NN	O	O
aniridia	NN	O	B-Disease
gene	NN	O	O
by	NN	O	O
positional	NN	O	O
cloning	NN	O	O
from	NN	O	O
the	NN	O	O
smallest	NN	O	O
region	NN	O	O
of	NN	O	O
overlap	NN	O	O
of	NN	O	O
aniridia	NN	O	B-Disease
-	NN	O	O
associated	NN	O	O
deletions	NN	O	O
.	NN	O	O

The	NN	O	O
definition	NN	O	O
of	NN	O	O
the	NN	O	O
carrier	NN	O	O
status	NN	O	O
in	NN	O	O
two	NN	O	O
possible	NN	O	O
carriers	NN	O	O
led	NN	O	O
us	NN	O	O
to	NN	O	O
give	NN	O	O
accurate	NN	O	O
genetic	NN	O	O
counselling	NN	O	O
and	NN	O	O
to	NN	O	O
prevent	NN	O	O
the	NN	O	O
birth	NN	O	O
of	NN	O	O
an	NN	O	O
affected	NN	O	O
boy	NN	O	O
.	NN	O	O

Mutations	NN	O	O
in	NN	O	O
the	NN	O	O
EDH17B2	NN	O	O
gene	NN	O	O
,	NN	O	O
therefore	NN	O	O
do	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
hereditary	NN	O	B-Disease
breast	NN	O	I-Disease
-	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Cholesteryl	NN	O	O
ester	NN	O	O
transfer	NN	O	O
protein	NN	O	O
(	NN	O	O
CETP	NN	O	O
;	NN	O	O
476	NN	O	O
amino	NN	O	O
acids	NN	O	O
)	NN	O	O
transfers	NN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
from	NN	O	O
HDL	NN	O	O
to	NN	O	O
other	NN	O	O
lipoproteins	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
two	NN	O	O
probands	NN	O	O
with	NN	O	O
a	NN	O	O
CETP	NN	O	O
missense	NN	O	O
mutation	NN	O	O
(	NN	O	O
442	NN	O	O
D	NN	O	O
G	NN	O	O
)	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
coexpression	NN	O	O
of	NN	O	O
wild	NN	O	O
type	NN	O	O
and	NN	O	O
mutant	NN	O	O
cDNAs	NN	O	O
leads	NN	O	O
to	NN	O	O
inhibition	NN	O	O
of	NN	O	O
wild	NN	O	O
type	NN	O	O
secretion	NN	O	O
and	NN	O	O
activity	NN	O	O
.	NN	O	O

Central	NN	O	B-Disease
nervous	NN	O	I-Disease
system	NN	O	I-Disease
demyelination	NN	O	I-Disease
progresses	NN	O	O
rapidly	NN	O	O
and	NN	O	O
death	NN	O	O
occurs	NN	O	O
within	NN	O	O
a	NN	O	O
few	NN	O	O
years	NN	O	O
.	NN	O	O

AMN	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
milder	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
with	NN	O	O
onset	NN	O	O
at	NN	O	O
15	NN	O	O
-	NN	O	O
30	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
and	NN	O	O
a	NN	O	O
more	NN	O	O
progressive	NN	O	O
course	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
mice	NN	O	O
manifest	NN	O	O
several	NN	O	O
characteristics	NN	O	O
that	NN	O	O
are	NN	O	O
occasionally	NN	O	O
observed	NN	O	O
in	NN	O	O
human	NN	O	O
hypobetalipoproteinemia	NN	O	B-Disease
,	NN	O	O
including	NN	O	O
reduced	NN	O	O
plasma	NN	O	O
triglyceride	NN	O	O
concentrations	NN	O	O
,	NN	O	O
fasting	NN	O	O
chylomicronemia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
reduced	NN	O	O
high	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
.	NN	O	O

DNA	NN	O	O
samples	NN	O	O
were	NN	O	O
obtained	NN	O	O
from	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
of	NN	O	O
these	NN	O	O
individuals	NN	O	O
for	NN	O	O
sequencing	NN	O	O
using	NN	O	O
a	NN	O	O
direct	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	NN	O	O
PCR	NN	O	O
)	NN	O	O
sequencing	NN	O	O
procedure	NN	O	O
.	NN	O	O

Employing	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	NN	O	O
PCR	NN	O	O
)	NN	O	O
,	NN	O	O
single	NN	O	O
strand	NN	O	O
conformation	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
SSCP	NN	O	O
)	NN	O	O
analysis	NN	O	O
,	NN	O	O
and	NN	O	O
direct	NN	O	O
DNA	NN	O	O
sequencing	NN	O	O
,	NN	O	O
different	NN	O	O
mutations	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
6	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
mutation	NN	O	O
causing	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
has	NN	O	O
recently	NN	O	O
been	NN	O	O
identified	NN	O	O
as	NN	O	O
an	NN	O	O
unstable	NN	O	O
CTG	NN	O	O
trinucleotide	NN	O	O
repeat	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
3	NN	O	O
untranslated	NN	O	O
region	NN	O	O
of	NN	O	O
a	NN	O	O
gene	NN	O	O
encoding	NN	O	O
for	NN	O	O
a	NN	O	O
protein	NN	O	O
with	NN	O	O
putative	NN	O	O
serine	NN	O	O
-	NN	O	O
threonine	NN	O	O
protein	NN	O	O
kinase	NN	O	O
activity	NN	O	O
.	NN	O	O

Autosomal	NN	O	O
recessive	NN	O	O
transmission	NN	O	O
of	NN	O	O
hemophilia	NN	O	B-Disease
A	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
a	NN	O	O
von	NN	O	B-Disease
Willebrand	NN	O	I-Disease
factor	NN	O	O
mutation	NN	O	O
.	NN	O	O

The	NN	O	O
family	NN	O	O
we	NN	O	O
describe	NN	O	O
demonstrates	NN	O	O
the	NN	O	O
recessive	NN	O	O
inheritance	NN	O	O
of	NN	O	O
a	NN	O	O
recently	NN	O	O
recognized	NN	O	O
class	NN	O	O
of	NN	O	O
genetic	NN	O	O
bleeding	NN	O	O
disorders	NN	O	O
,	NN	O	O
we	NN	O	O
call	NN	O	O
"	NN	O	O
autosomal	NN	O	O
hemophilia	NN	O	B-Disease
.	NN	O	O

Somatic	NN	O	O
von	NN	O	B-Disease
Hippel	NN	O	I-Disease
-	NN	O	I-Disease
Lindau	NN	O	I-Disease
mutation	NN	O	O
in	NN	O	O
clear	NN	O	O
cell	NN	O	O
papillary	NN	O	B-Disease
cystadenoma	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
epididymis	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
findings	NN	O	O
therefore	NN	O	O
confirm	NN	O	O
the	NN	O	O
association	NN	O	O
of	NN	O	O
WAS	NN	O	B-Disease
with	NN	O	O
WASP	NN	O	O
mutation	NN	O	O
and	NN	O	O
identify	NN	O	O
WASP	NN	O	O
mutation	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
for	NN	O	O
isolated	NN	O	O
congenital	NN	O	B-Disease
thrombocytopenia	NN	O	I-Disease
in	NN	O	O
males	NN	O	O
.	NN	O	O

While	NN	O	O
the	NN	O	O
WASP	NN	O	O
gene	NN	O	O
defects	NN	O	O
responsible	NN	O	O
for	NN	O	O
isolated	NN	O	B-Disease
thrombocytopenia	NN	O	I-Disease
and	NN	O	O
other	NN	O	O
mild	NN	O	O
presentations	NN	O	O
of	NN	O	O
WAS	NN	O	B-Disease
do	NN	O	O
not	NN	O	O
appear	NN	O	O
distinct	NN	O	O
from	NN	O	O
those	NN	O	O
resulting	NN	O	O
in	NN	O	O
severe	NN	O	O
WAS	NN	O	B-Disease
,	NN	O	O
these	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
analysis	NN	O	O
of	NN	O	O
WASP	NN	O	O
gene	NN	O	O
mutation	NN	O	O
provides	NN	O	O
a	NN	O	O
valuable	NN	O	O
tool	NN	O	O
for	NN	O	O
distinguishing	NN	O	O
the	NN	O	O
spectrum	NN	O	O
of	NN	O	O
WAS	NN	O	B-Disease
patients	NN	O	O
and	NN	O	O
the	NN	O	O
subset	NN	O	O
of	NN	O	O
males	NN	O	O
with	NN	O	O
isolated	NN	O	B-Disease
thrombocytopenia	NN	O	I-Disease
who	NN	O	O
represent	NN	O	O
mild	NN	O	O
cases	NN	O	O
of	NN	O	O
WAS	NN	O	B-Disease
.	NN	O	O
.	NN	O	O

WASP	NN	O	O
gene	NN	O	O
mutations	NN	O	O
in	NN	O	O
Wiskott	NN	O	B-Disease
-	NN	O	I-Disease
Aldrich	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
X	NN	O	B-Disease
-	NN	O	I-Disease
linked	NN	O	I-Disease
thrombocytopenia	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
WASP	NN	O	O
gene	NN	O	O
has	NN	O	O
been	NN	O	O
recently	NN	O	O
cloned	NN	O	O
from	NN	O	O
Xp11	NN	O	O
.	NN	O	O

First	NN	O	O
,	NN	O	O
MJD	NN	O	B-Disease
is	NN	O	O
associated	NN	O	O
with	NN	O	O
expansion	NN	O	O
fo	NN	O	O
the	NN	O	O
array	NN	O	O
from	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
of	NN	O	O
14	NN	O	O
-	NN	O	O
37	NN	O	O
repeats	NN	O	O
to	NN	O	O
68	NN	O	O
-	NN	O	O
84	NN	O	O
repeats	NN	O	O
in	NN	O	O
most	NN	O	O
Japanese	NN	O	O
and	NN	O	O
Caucasian	NN	O	O
subjects	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
subjects	NN	O	O
were	NN	O	O
observed	NN	O	O
with	NN	O	O
expansions	NN	O	O
intermediate	NN	O	O
in	NN	O	O
size	NN	O	O
between	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
normal	NN	O	O
and	NN	O	O
MJD	NN	O	B-Disease
affected	NN	O	O
groups	NN	O	O
.	NN	O	O

A	NN	O	O
4	NN	O	O
-	NN	O	O
megabase	NN	O	O
YAC	NN	O	O
contig	NN	O	O
that	NN	O	O
spans	NN	O	O
the	NN	O	O
Langer	NN	O	B-Disease
-	NN	O	I-Disease
Giedion	NN	O	I-Disease
syndrome	NN	O	I-Disease
region	NN	O	O
on	NN	O	O
human	NN	O	O
chromosome	NN	O	O
8q24	NN	O	O
.	NN	O	O
1	NN	O	O
:	NN	O	O
use	NN	O	O
in	NN	O	O
refining	NN	O	O
the	NN	O	O
location	NN	O	O
of	NN	O	O
the	NN	O	O
trichorhinophalangeal	NN	O	B-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
multiple	NN	O	O
exostoses	NN	O	O
genes	NN	O	O
(	NN	O	O
TRPS1	NN	O	O
and	NN	O	O
EXT1	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
.	NN	O	O

Genomic	NN	O	O
DNA	NN	O	O
was	NN	O	O
studied	NN	O	O
for	NN	O	O
BRCA1	NN	O	O
mutations	NN	O	O
by	NN	O	O
analysis	NN	O	O
involving	NN	O	O
single	NN	O	O
-	NN	O	O
strand	NN	O	O
conformation	NN	O	O
polymorphisms	NN	O	O
and	NN	O	O
with	NN	O	O
allele	NN	O	O
-	NN	O	O
specific	NN	O	O
assays	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
.	NN	O	O

Two	NN	O	O
of	NN	O	O
the	NN	O	O
mutations	NN	O	O
and	NN	O	O
three	NN	O	O
of	NN	O	O
the	NN	O	O
rare	NN	O	O
sequence	NN	O	O
variants	NN	O	O
were	NN	O	O
found	NN	O	O
among	NN	O	O
the	NN	O	O
39	NN	O	O
women	NN	O	O
who	NN	O	O
reported	NN	O	O
no	NN	O	O
family	NN	O	O
history	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
or	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
results	NN	O	O
represent	NN	O	O
a	NN	O	O
minimal	NN	O	O
estimate	NN	O	O
of	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
mutations	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
.	NN	O	O

Expressivity	NN	O	O
of	NN	O	O
185delAG	NN	O	O
in	NN	O	O
these	NN	O	O
families	NN	O	O
varied	NN	O	O
,	NN	O	O
from	NN	O	O
early	NN	O	O
-	NN	O	O
onset	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
without	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Mutation	NN	O	O
4184delTCAA	NN	O	O
occurred	NN	O	O
independently	NN	O	O
in	NN	O	O
two	NN	O	O
families	NN	O	O
.	NN	O	O

Overall	NN	O	O
in	NN	O	O
our	NN	O	O
series	NN	O	O
,	NN	O	O
BRCA1	NN	O	O
mutations	NN	O	O
have	NN	O	O
been	NN	O	O
detected	NN	O	O
in	NN	O	O
26	NN	O	O
families	NN	O	O
16	NN	O	O
with	NN	O	O
positive	NN	O	O
BRCA1	NN	O	O
lod	NN	O	O
scores	NN	O	O
,	NN	O	O
7	NN	O	O
with	NN	O	O
negative	NN	O	O
lod	NN	O	O
scores	NN	O	O
(	NN	O	O
reflecting	NN	O	O
multiple	NN	O	O
sporadic	NN	O	O
breast	NN	O	B-Disease
cancers	NN	O	I-Disease
)	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
not	NN	O	O
tested	NN	O	O
for	NN	O	O
linkage	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
G6PD	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
studied	NN	O	O
several	NN	O	O
different	NN	O	O
Indian	NN	O	O
populations	NN	O	O
by	NN	O	O
screening	NN	O	O
for	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
,	NN	O	O
followed	NN	O	O
by	NN	O	O
molecular	NN	O	O
analysis	NN	O	O
of	NN	O	O
deficient	NN	O	O
alleles	NN	O	O
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
of	NN	O	O
G6PD	NN	O	B-Disease
deficiency	NN	O	I-Disease
varies	NN	O	O
between	NN	O	O
3	NN	O	O
%	NN	O	O
and	NN	O	O
15	NN	O	O
%	NN	O	O
in	NN	O	O
different	NN	O	O
tribal	NN	O	O
and	NN	O	O
urban	NN	O	O
groups	NN	O	O
.	NN	O	O

This	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
the	NN	O	O
alanine	NN	O	O
residue	NN	O	O
that	NN	O	O
is	NN	O	O
replaced	NN	O	O
by	NN	O	O
glycine	NN	O	O
is	NN	O	O
part	NN	O	O
of	NN	O	O
a	NN	O	O
putative	NN	O	O
coenzyme	NN	O	O
-	NN	O	O
binding	NN	O	O
site	NN	O	O
.	NN	O	O
.	NN	O	O

Evidence	NN	O	O
for	NN	O	O
linkage	NN	O	O
of	NN	O	O
bipolar	NN	O	B-Disease
disorder	NN	O	I-Disease
to	NN	O	O
chromosome	NN	O	O
18	NN	O	O
with	NN	O	O
a	NN	O	O
parent	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
origin	NN	O	O
effect	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
pedigrees	NN	O	O
,	NN	O	O
the	NN	O	O
greatest	NN	O	O
allele	NN	O	O
sharing	NN	O	O
(	NN	O	O
81	NN	O	O
%	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
00002	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
highest	NN	O	O
LOD	NN	O	O
score	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
51	NN	O	O
;	NN	O	O
phi	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
were	NN	O	O
observed	NN	O	O
at	NN	O	O
D18S41	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
provide	NN	O	O
further	NN	O	O
support	NN	O	O
for	NN	O	O
linkage	NN	O	O
of	NN	O	O
BPAD	NN	O	B-Disease
to	NN	O	O
chromosome	NN	O	O
18	NN	O	O
and	NN	O	O
the	NN	O	O
first	NN	O	O
molecular	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
parent	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
origin	NN	O	O
effect	NN	O	O
operating	NN	O	O
in	NN	O	O
this	NN	O	O
disorder	NN	O	O
.	NN	O	O

A	NN	O	O
prevalent	NN	O	O
mutation	NN	O	O
for	NN	O	O
galactosemia	NN	O	B-Disease
among	NN	O	O
black	NN	O	O
Americans	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
define	NN	O	O
the	NN	O	O
mutation	NN	O	O
causing	NN	O	O
galactosemia	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
of	NN	O	O
black	NN	O	O
American	NN	O	O
origin	NN	O	O
who	NN	O	O
have	NN	O	O
no	NN	O	O
galactose	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
phosphate	NN	O	O
uridyltransferase	NN	O	O
(	NN	O	O
GALT	NN	O	O
)	NN	O	O
activity	NN	O	O
in	NN	O	O
erythrocytes	NN	O	O
but	NN	O	O
good	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
We	NN	O	O
found	NN	O	O
a	NN	O	O
48	NN	O	O
%	NN	O	O
prevalence	NN	O	O
of	NN	O	O
the	NN	O	O
S135L	NN	O	O
mutation	NN	O	O
among	NN	O	O
17	NN	O	O
black	NN	O	O
American	NN	O	O
patients	NN	O	O
with	NN	O	O
classic	NN	O	B-Disease
galactosemia	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
1	NN	O	O
%	NN	O	O
prevalence	NN	O	O
in	NN	O	O
a	NN	O	O
population	NN	O	O
of	NN	O	O
50	NN	O	O
black	NN	O	O
Americans	NN	O	O
without	NN	O	O
galactosemia	NN	O	B-Disease
.	NN	O	O

Because	NN	O	O
GALT	NN	O	O
activity	NN	O	O
varies	NN	O	O
in	NN	O	O
different	NN	O	O
tissues	NN	O	O
of	NN	O	O
patients	NN	O	O
homozygous	NN	O	O
for	NN	O	O
S135L	NN	O	O
,	NN	O	O
they	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
better	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
than	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
homozygous	NN	O	O
for	NN	O	O
Q188R	NN	O	O
when	NN	O	O
both	NN	O	O
are	NN	O	O
treated	NN	O	O
from	NN	O	O
infancy	NN	O	O
.	NN	O	O
.	NN	O	O

A	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
mutations	NN	O	O
in	NN	O	O
20	NN	O	O
breast	NN	O	B-Disease
-	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
families	NN	O	O
.	NN	O	O

BRCA1	NN	O	O
mutations	NN	O	O
cosegregating	NN	O	O
with	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
susceptibility	NN	O	O
were	NN	O	O
identified	NN	O	O
in	NN	O	O
16	NN	O	O
families	NN	O	O
,	NN	O	O
including	NN	O	O
1	NN	O	O
family	NN	O	O
with	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
male	NN	O	B-Disease
breast	NN	O	I-Disease
cancer	NN	O	I-Disease
.	NN	O	O

To	NN	O	O
examine	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
in	NN	O	O
normal	NN	O	O
tissue	NN	O	O
growth	NN	O	O
and	NN	O	O
differentiation	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
generate	NN	O	O
a	NN	O	O
potential	NN	O	O
model	NN	O	O
for	NN	O	O
the	NN	O	O
cancer	NN	O	B-Disease
susceptibility	NN	O	O
associated	NN	O	O
with	NN	O	O
loss	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
function	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
created	NN	O	O
a	NN	O	O
mouse	NN	O	O
line	NN	O	O
carrying	NN	O	O
a	NN	O	O
mutation	NN	O	O
in	NN	O	O
one	NN	O	O
Brca1	NN	O	O
allele	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
neuroepithelium	NN	O	O
in	NN	O	O
Brca1	NN	O	B-Disease
-	NN	O	I-Disease
deficient	NN	O	I-Disease
embryos	NN	O	O
appeared	NN	O	O
disorganized	NN	O	O
,	NN	O	O
with	NN	O	O
signs	NN	O	O
of	NN	O	O
both	NN	O	O
rapid	NN	O	O
proliferation	NN	O	O
and	NN	O	O
excessive	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O
.	NN	O	O

It	NN	O	O
leads	NN	O	O
to	NN	O	O
demyelination	NN	O	B-Disease
in	NN	O	I-Disease
the	NN	O	I-Disease
central	NN	O	I-Disease
and	NN	O	I-Disease
peripheral	NN	O	I-Disease
nervous	NN	O	I-Disease
system	NN	O	I-Disease
.	NN	O	O

Defective	NN	O	O
beta	NN	O	O
-	NN	O	O
oxidation	NN	O	O
of	NN	O	O
saturated	NN	O	O
very	NN	O	O
long	NN	O	O
chain	NN	O	O
fatty	NN	O	O
acids	NN	O	O
(	NN	O	O
VLCFAs	NN	O	O
;	NN	O	O
C22	NN	O	O
0	NN	O	O
-	NN	O	O
C26	NN	O	O
0	NN	O	O
)	NN	O	O
in	NN	O	O
peroxisomes	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
lead	NN	O	O
to	NN	O	O
an	NN	O	O
accumulation	NN	O	O
of	NN	O	O
VLCFAs	NN	O	O
in	NN	O	O
leukoid	NN	O	O
areas	NN	O	O
of	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
,	NN	O	O
peripheral	NN	O	O
nerves	NN	O	O
,	NN	O	O
adrenal	NN	O	O
gland	NN	O	O
,	NN	O	O
and	NN	O	O
blood	NN	O	O
.	NN	O	O

The	NN	O	O
mutations	NN	O	O
were	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
ALD	NN	O	B-Disease
gene	NN	O	O
of	NN	O	O
30	NN	O	O
healthy	NN	O	O
persons	NN	O	O
.	NN	O	O
.	NN	O	O

The	NN	O	O
recently	NN	O	O
cloned	NN	O	O
human	NN	O	O
breast	NN	O	B-Disease
and	NN	O	I-Disease
ovarian	NN	O	I-Disease
cancer	NN	O	I-Disease
susceptibility	NN	O	O
gene	NN	O	O
,	NN	O	O
BRCA1	NN	O	O
,	NN	O	O
is	NN	O	O
located	NN	O	O
on	NN	O	O
human	NN	O	O
chromosome	NN	O	O
17q21	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
isolated	NN	O	O
murine	NN	O	O
genomic	NN	O	O
clones	NN	O	O
containing	NN	O	O
Brca1	NN	O	O
as	NN	O	O
a	NN	O	O
first	NN	O	O
step	NN	O	O
in	NN	O	O
generating	NN	O	O
a	NN	O	O
mouse	NN	O	O
model	NN	O	O
for	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
BRCA1	NN	O	O
function	NN	O	O
.	NN	O	O

A	NN	O	O
mouse	NN	O	O
genomic	NN	O	O
library	NN	O	O
was	NN	O	O
screened	NN	O	O
using	NN	O	O
probes	NN	O	O
corresponding	NN	O	O
to	NN	O	O
exon	NN	O	O
11	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
BRCA1	NN	O	O
gene	NN	O	O
.	NN	O	O

Atelosteogenesis	NN	O	B-Disease
type	NN	O	I-Disease
II	NN	O	I-Disease
is	NN	O	O
caused	NN	O	O
by	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
diastrophic	NN	O	B-Disease
dysplasia	NN	O	I-Disease
sulfate	NN	O	O
-	NN	O	O
transporter	NN	O	O
gene	NN	O	O
(	NN	O	O
DTDST	NN	O	O
)	NN	O	O
:	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
phenotypic	NN	O	O
series	NN	O	O
involving	NN	O	O
three	NN	O	O
chondrodysplasias	NN	O	B-Disease
.	NN	O	O

Atelosteogenesis	NN	O	B-Disease
type	NN	O	I-Disease
II	NN	O	I-Disease
(	NN	O	O
AO	NN	O	B-Disease
II	NN	O	I-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
neonatally	NN	O	O
lethal	NN	O	O
chondrodysplasia	NN	O	B-Disease
whose	NN	O	O
clinical	NN	O	O
and	NN	O	O
histological	NN	O	O
characteristics	NN	O	O
resemble	NN	O	O
those	NN	O	O
of	NN	O	O
another	NN	O	O
chondrodysplasia	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
much	NN	O	O
less	NN	O	O
severe	NN	O	O
diastrophic	NN	O	B-Disease
dysplasia	NN	O	I-Disease
(	NN	O	O
DTD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
AOII	NN	O	B-Disease
patients	NN	O	O
also	NN	O	O
have	NN	O	O
DTDST	NN	O	O
mutations	NN	O	O
,	NN	O	O
which	NN	O	O
lead	NN	O	O
to	NN	O	O
defective	NN	O	O
uptake	NN	O	O
of	NN	O	O
inorganic	NN	O	O
sulfate	NN	O	O
and	NN	O	O
insufficient	NN	O	O
sulfation	NN	O	O
of	NN	O	O
macromolecules	NN	O	O
by	NN	O	O
patient	NN	O	O
mesenchymal	NN	O	O
cells	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Together	NN	O	O
with	NN	O	O
our	NN	O	O
recent	NN	O	O
observation	NN	O	O
that	NN	O	O
a	NN	O	O
third	NN	O	O
even	NN	O	O
more	NN	O	O
severe	NN	O	O
chondrodysplasia	NN	O	B-Disease
,	NN	O	O
achondrogenesis	NN	O	O
type	NN	O	O
IB	NN	O	O
,	NN	O	O
is	NN	O	O
also	NN	O	O
caused	NN	O	O
by	NN	O	O
mutations	NN	O	O
in	NN	O	O
DTDST	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
phenotypic	NN	O	O
series	NN	O	O
of	NN	O	O
three	NN	O	O
chondrodysplasias	NN	O	B-Disease
of	NN	O	O
increasing	NN	O	O
severity	NN	O	O
caused	NN	O	O
by	NN	O	O
lesions	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
sulfate	NN	O	O
-	NN	O	O
transporter	NN	O	O
gene	NN	O	O
.	NN	O	O

Emerin	NN	O	B-Disease
deficiency	NN	O	I-Disease
at	NN	O	O
the	NN	O	O
nuclear	NN	O	O
membrane	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Emery	NN	O	B-Disease
-	NN	O	I-Disease
Dreifuss	NN	O	I-Disease
muscular	NN	O	I-Disease
dystrophy	NN	O	I-Disease
.	NN	O	O

Development	NN	O	O
of	NN	O	O
MCF	NN	O	B-Disease
-	NN	O	I-Disease
7	NN	O	I-Disease
tumours	NN	O	I-Disease
in	NN	O	O
nude	NN	O	O
mice	NN	O	O
is	NN	O	O
inhibited	NN	O	O
when	NN	O	O
MCF	NN	O	O
-	NN	O	O
7	NN	O	O
cells	NN	O	O
are	NN	O	O
transfected	NN	O	O
with	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
mutant	NN	O	O
,	NN	O	O
BRCA1	NN	O	O
.	NN	O	O

Most	NN	O	O
importantly	NN	O	O
,	NN	O	O
among	NN	O	O
mice	NN	O	O
with	NN	O	O
established	NN	O	O
MCF	NN	O	B-Disease
-	NN	O	I-Disease
7	NN	O	I-Disease
tumours	NN	O	I-Disease
,	NN	O	O
peritoneal	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
retroviral	NN	O	O
vector	NN	O	O
expressing	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
BRCA1	NN	O	O
significantly	NN	O	O
inhibits	NN	O	O
tumour	NN	O	B-Disease
growth	NN	O	O
and	NN	O	O
increased	NN	O	O
survival	NN	O	O
.	NN	O	O
.	NN	O	O

